<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>400</serviceExecutionTime><Trial id="103306"><TitleDisplay>Effect of NTCP*2 Polymorphism on Rosuvastatin Pharmacokinetics in Healthy Chinese Han Males</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ChiCTR-RO-12002886</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rosuvastatin</Name><Drug id="12420">rosuvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12420">rosuvastatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1033512">Central South University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12420" type="Drug"><TargetEntity id="243619" type="siDrug">Rosuvastatin calcium</TargetEntity></SourceEntity><SourceEntity id="1033512" type="Company"><TargetEntity id="5035525210" type="organizationId">Central South University</TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1033512">Central South University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2659">Cardioprotectant</Class><Class id="2667">Antiarteriosclerotic</Class><Class id="7018">Antihypertriglyceridemic agent</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>17</PatientCountEnrollment><DateStart>2011-06-01T00:00:00Z</DateStart><DateEnd type="estimated">2012-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-09-07T09:08:42Z</DateChangeLast><DateAdded>2013-01-04T11:58:52Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Institute of Clinical Pharmacology Centre South University</Affiliation><Email>hhzhou2003@163.com</Email><Name>Honghao Zhou</Name><Phone>+86 0731-84805380</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Genotype of NTCP*2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Genotype of CYP2C9*3, OATP1B1*5, BCRP 421CA&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Plasma drug concentration</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to explore the effect of NTCP*2 polymorphism on &lt;ulink linkType="Drug" linkID="12420"&gt;rosuvastatin&lt;/ulink&gt; pharmacokinetics in healthy Chinese Han subjects [&lt;ulink linkType="Reference" linkID="1353641"&gt;1353641&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive &lt;ulink linkType="Drug" linkID="12420"&gt;rosuvastatin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1353641"&gt;1353641&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Institute of Clinical Pharmacology Centre South University</Name><Address1>Changsha</Address1><Address2>Hunan</Address2><CountrySubDivision>Hunan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-01-04T11:58:52Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="114648"><TitleDisplay>Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study</TitleDisplay><TitleOfficial>Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">2008P000561</Identifier><Identifier type="NCT">NCT01806532</Identifier></Identifiers><Indications><Indication id="8">Respiratory distress syndrome</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>18F-FDG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET-CT</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="8" type="ciIndication"><TargetEntity id="10038687" type="MEDDRA"/><TargetEntity id="1146" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2008-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-11T11:34:48Z</DateChangeLast><DateAdded>2013-03-11T07:04:44Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Massachusetts General Hospital</Affiliation><Name>Marcos Vidal Melo</Name></Contact><Contact type="Public contact"><Email>VidalMelo.Marcos@mgh.harvard.edu</Email><Name>Marcos Vidal Melo, MD, PhD</Name><Phone>617-726-8980</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Group 1&lt;ul&gt;&lt;li&gt;Mechanically ventilated patients scheduled to undergo a CT scanning for their routine             clinical care&lt;/li&gt;&lt;li&gt;Mechanical ventilation of &gt; 24 h&lt;/li&gt;&lt;li&gt;A&amp;lt; 15 days of mechanical ventilation if patient presents ALI/ARDS (in order to             exclude the late, fibrotic, stage of ARDS)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Group 2&lt;ul&gt;&lt;li&gt;Mechanically ventilated patients with a diagnosis of sepsis&lt;/li&gt;&lt;li&gt;A 96 h of mechanical ventilation&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 18 years&lt;/li&gt;&lt;li&gt;Hemodynamic instability, defined as: systolic blood pressure (SBP)&amp;lt; 90 mmHg without             the use of vasopressors or inotropic agents. Patients             on vasopressors, with the exception of: dopamine up to a dose of 3 microg/kg/min, or             norepinephrine up to 4 microg/min, or neosynephrine up to 40 microg/min are excluded from the study&lt;/li&gt;&lt;li&gt;Hypoxemia, defined as: PaO2&amp;lt; 70 mmHg on an inspired oxygen fraction (FiO2) &gt;/= 0.9; FiO2 &gt;/= 0.8 at baseline&lt;/li&gt;&lt;li&gt;Hemodynamic and/or respiratory instability (as defined, respectively, in 2 and 3), that develop when the patient is mobilized during routine nursing care such as repositioning/washing the patient or changing their bed linens&lt;/li&gt;&lt;li&gt;Hemodynamic and/or respiratory instability (as defined, respectively, in 2 and 3),             that develop when the patient is mobilized during routine nursing care&lt;/li&gt;&lt;li&gt;Patients must be deemed by the treating clinical staff to be able to tolerate leaving the ICU for 90 min (40 to 60 min imaging time + 30 min safety margin). Treating MD, RT, and RN must all agree that the patient is stable for transport&lt;/li&gt;&lt;li&gt;Any acute or chronic condition which, in the opinion of the investigator, might             confound the imaging measurements (such as, but not limited to, severe bronchospasm,             pulmonary infection, and lung tumor)&lt;/li&gt;&lt;li&gt;'Air leaks'; requiring tube thoracostomy (eg, pneumothorax, bronchopleural fistula)&lt;/li&gt;&lt;li&gt;Pregnancy (since this is a study which would expose a fetus to radiation risk)&lt;/li&gt;&lt;li&gt;Patients who have neither an arterial nor a central venous line at the time of the             enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Regional 18F-FDG activity: each patient will undergo PET-CT scans and the regional 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) activity will be measured. This is a measure of regional neutrophil metabolic activity and is used to assess inflammation in the lung. The degree of inflammation will be related to the regional expansion of the lung, as measured by CT scan</Description><Timeframe>Day of imaging</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this study is to investigate acute respiratory distress syndrome (ARDS) with      positron emission tomography (PET) imaging and to examine the distribution of inflammation,      as measured by neutrophil metabolic activity.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Adult intensive care patients with acute respiratory distress syndrome (ARDS) requiring mechanical ventilation who have been on the ventilator for more than 24 h and imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan  will be included.  &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Massachusetts General Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>VidalMelo.Marcos@mgh.harvard.edu</Email><Name>Marcos Vidal Melo, MD, PhD</Name><Phone>617-726-8980</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other respiratory disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18269">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16709">Subjects with acute respiratory distress syndrome</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01806532</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other respiratory disease" id="43449"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other respiratory disease" id="43465"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other respiratory disease" id="32992"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other respiratory disease" id="33139">Subjects under mechanical ventilation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other respiratory disease" id="33141"><Criterion>Subjects with acute respiratory distress syndrome (ARDS)</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other respiratory disease" id="24054"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other respiratory disease" id="24668">Subjects with infectious diseases/disorders</SubCriterion><SubCriterion disease="Other respiratory disease" id="24669">Subjects with malignancy/Neoplasia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other respiratory disease" id="24309"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24672"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="27749"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-03-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-11T07:04:44Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-06-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="115797"><TitleDisplay>An open-label, comparative, sequential study of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>abciximab</Name><Drug id="2745">abciximab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>eptifibatide</Name><Drug id="3359">eptifibatide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2745">abciximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1017805">Baystate Health System Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3359">eptifibatide</Drug><IndicationsPioneer/><Companies><Company><Company id="1017805">Baystate Health System Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2745" type="Drug"><TargetEntity id="130762" type="siDrug">Abciximab</TargetEntity></SourceEntity><SourceEntity id="3359" type="Drug"><TargetEntity id="190747" type="siDrug">Eptifibatide</TargetEntity></SourceEntity><SourceEntity id="1017805" type="Company"><TargetEntity id="4296517828" type="organizationId">Baystate Health Inc</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"/><TargetEntity id="D003327" type="MeSH"/><TargetEntity id="-1572475765" type="omicsDisease"/><TargetEntity id="221" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1017805">Baystate Health System Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="402">GP IIb IIIa antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="180">Antibody fragment</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="127">Cell culture</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="80">Peptide</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>620</PatientCountEnrollment><PatientCountEvaluable>620</PatientCountEvaluable><DateStart>2003-01-31T00:00:00Z</DateStart><DateChangeLast>2013-03-13T11:14:11Z</DateChangeLast><DateAdded>2013-03-13T11:14:11Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult patients undergoing percutaneous coronary interventions&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was an open-label, comparative, sequential study of &lt;ulink linkType="Drug" linkID="3359"&gt;eptifibatide&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt; for patients undergoing percutaneous coronary intervention [&lt;ulink linkType="Reference" linkID="1381559"&gt;1381559&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results published in January 2003 showed that  similar in-hospital and 30-day outcomes for &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;- and &lt;ulink linkType="Drug" linkID="3359"&gt;eptifibatide&lt;/ulink&gt; -treated patients undergoing percutaneous coronary interventions [&lt;ulink linkType="Reference" linkID="1381559"&gt;1381559&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were divided into two groups.&lt;br/&gt;Group A patients received &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;, 0.25 mg/kg i.v. bolus followed by 0.125 microg/kg.min i.v. infusion over 12 h + heparin, 70 U/kg i.v. bolus + [if stent implantation] clopidogrel, 75 mg/d for 30 d (n = 319). &lt;br/&gt;Group B patients received  &lt;ulink linkType="Drug" linkID="3359"&gt;eptifibatide&lt;/ulink&gt;, 180 microg/kg i.v. bolus followed by  2.0 microg/kg.min over 18-24 h + heparin, 70 U/kg  [&lt;ulink linkType="Reference" linkID="1381559"&gt;1381559&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-13T11:14:11Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="116327"><TitleDisplay>Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy</TitleDisplay><TitleOfficial>Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">SS001</Identifier><Identifier type="NCT">NCT01810237</Identifier></Identifiers><Indications><Indication id="325">Thromboembolism</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>dabigatran etexilate</Name><Drug id="24343">dabigatran etexilate</Drug></Intervention><Intervention type="InterventionPrimary"><Name>warfarin</Name><Drug id="44375">warfarin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="24343">dabigatran etexilate</Drug><IndicationsPioneer/><Companies><Company><Company id="1109134">Nova Scotia Health Authority</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44375">warfarin</Drug><IndicationsPioneer/><Companies><Company><Company id="1109134">Nova Scotia Health Authority</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="24343" type="Drug"><TargetEntity id="305702" type="siDrug">Dabigatran etexilate mesilate</TargetEntity></SourceEntity><SourceEntity id="44375" type="Drug"><TargetEntity id="91527" type="siDrug">Warfarin sodium</TargetEntity></SourceEntity><SourceEntity id="1109134" type="Company"><TargetEntity id="5045948977" type="organizationId">Nova Scotia Health Authority</TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"/><TargetEntity id="-338631668" type="omicsDisease"/><TargetEntity id="306" type="siCondition"/></SourceEntity><SourceEntity id="10583" type="Action"><TargetEntity id="2845" type="Mechanism">Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors</TargetEntity><TargetEntity id="6689" type="Mechanism">Vitamin K Epoxide Reductase (VKER, VKOR) (Bacterial) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="111" type="Action"><TargetEntity id="502" type="Mechanism">Thrombin Inhibitors</TargetEntity><TargetEntity id="4384" type="Mechanism">Anti-Thrombin</TargetEntity></SourceEntity><SourceEntity id="11192" type="Action"><TargetEntity id="1024" type="Mechanism">PAR1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="113" type="Action"><TargetEntity id="1624" type="Mechanism">Anti-Factor IXa</TargetEntity><TargetEntity id="2667" type="Mechanism">Coagulation Factor IXa Inhibitors</TargetEntity><TargetEntity id="3316" type="Mechanism">Anti-Factor IX</TargetEntity></SourceEntity><SourceEntity id="114" type="Action"><TargetEntity id="3317" type="Mechanism">Anti-Factor VII</TargetEntity></SourceEntity><SourceEntity id="119" type="Action"><TargetEntity id="5807" type="Mechanism">Anti-Factor X</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1109134">Nova Scotia Health Authority</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10583">Vitamin K epoxide reductase inhibitor</Action><Action id="111">Factor IIa antagonist</Action><Action id="11192">Protease-activated receptor-1 antagonist</Action><Action id="113">Factor IX antagonist</Action><Action id="114">Factor VII antagonist</Action><Action id="119">Factor X antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="449">Antiarrhythmic agent</Class><Class id="659">Coagulation inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Prevention</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2013-03-31T00:00:00Z</DateStart><DateEnd type="actual">2013-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:02:09Z</DateChangeLast><DateAdded>2013-03-19T11:37:29Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Low risk status VTE&lt;/li&gt;&lt;li&gt;Chronic&lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; therapy of at least 12 months duration with target INR of 2.0 to 3.0&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Increased risk of bleeding:&lt;ul&gt;&lt;li&gt;Bleeding requiring transfusion in last 12 months&lt;/li&gt;&lt;li&gt;History of hemorrhagic stroke or intracranial hemorrhage&lt;/li&gt;&lt;li&gt;Recent gastrointestinal             bleeding (&amp;lt; 6 months)&lt;/li&gt;&lt;li&gt;History of a bleeding disorder&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Pregnant, breast-feeding or planning to become pregnant or breast-feed&lt;/li&gt;&lt;li&gt;Inhibitors allergy/sensitivity to&lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Creatinine clearance&amp;lt; 30 ml/min&lt;/li&gt;&lt;li&gt;Concomitant treatment with strong P-glycoprotein&lt;/li&gt;&lt;li&gt;Known thrombophilia including factor V Leiden mutation, prothrombin gene mutation,             antithrombin deficiency, protein C deficiency, protein S deficiency, and             antiphospholipid antibody syndrome&lt;/li&gt;&lt;li&gt;Inability to provide written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Validation of a novel  dabigatran based peri-operative bridging anticoagulation protocol  for patients on chronic warfarin therapy</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objectives of the study were: &lt;br/&gt;To find out if  using &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; bridging would result in consistent therapeutic anticoagulation and the           percentage of patients  who would become sub-therapeutic on &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; once &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; is           stopped.&lt;br/&gt;To find out the incidence of bleeding events with the use of &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; overlapped with           &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; for bridging.&lt;br/&gt;To find out the cost benefit of using &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; instead of dalteparin for bridging           anticoagulation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study population would include low risk patients on long-term &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; therapy for venous      thromboembolic disease (VTE) followed by the hematology anticoagulation clinic. Low risk      would be defined as status &amp;gt; 12 months post-thromboembolic event.&lt;/para&gt;&lt;para&gt;Patients would be identified by performing a manual search of the anticoagulation clinic      database to identify patients on long-term &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; therapy (&amp;gt; 12 months). The results would      be gleaned to identify patients who meet the inclusion criteria.&lt;/para&gt;&lt;para&gt;Patients would then be contacted via phone by one of the anticoagulation clinic personnel who      would be known to the patient and familiar with their history. If the patient was interested      in participating in the study they would be asked to come in for an assessment to elucidate      whether they meet inclusion criteria. The coordinator would discuss the      study principles, goals, and risks. If the patients were interested in the study informed consent      would be obtained by the study coordinator, If the patients were not interested in participating in      the study they would be excluded.&lt;/para&gt;&lt;para&gt;All patients enrolled in the study would undergo a planned sham surgery bridging protocol.      This would take place for all patients over a 2 week period, which is the study period. &lt;/para&gt;&lt;para&gt;On day -5, patients would stop taking their &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;. They would have a baseline complete blood count (CBC),  international normalized ratio (INR),      activated partial thromboplastin time (aPTT), and thrombin time (TT) drawn. Patients would have      an INR, aPTT and TT drawn daily for the duration of the study period, except the sham      surgery day and the following day, until day +5 post the sham surgery day or longer until      the INR is 2. If INR = 2 by day -2 after stopping the &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;, vitamin K would be      administered orally to help reversing the INR to normal. When the INR falls to &amp;lt; 2.0,      po &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; would be started at a therapeutic dose of 150 mg bid. This would      continue until the sham surgery day. On the evening of the sham surgery day, &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; will      be restarted at twice the patient's maintenance dose to a maximum of 10 mg po.      &lt;ulink linkType="Drug" linkID="24343"&gt;Dabigatran&lt;/ulink&gt; would be decreased to a prophylactic dose of 150 mg po daily. &lt;ulink linkType="Drug" linkID="44375"&gt;Warfarin&lt;/ulink&gt; dosing      would be adjusted for each patient based on the day +2 INR. &lt;ulink linkType="Drug" linkID="24343"&gt;Dabigatran&lt;/ulink&gt; prophylaxis would      continue until the INR is &gt;/= 2.0, at which point it would be discontinued      and &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; maintained.  The INR would be checked the day after &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; was discontinued.&lt;/para&gt;&lt;para&gt;Basic demographic information would be collected from the study participants including age      and sex. Patient's weight, medical history, current medications, and indication for      long-term &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; therapy would be recorded.&lt;/para&gt;&lt;para&gt;Safety reporting: the study would closely follow laboratory testing as it relates to      coagulation status (INR, pTT, PTT, and CBC).  All serious adverse events would be captured      and appropriately assessed by the principal investigator as to causality and expectedness.&lt;/para&gt;&lt;para&gt;Should any serious unexpected adverse drug reactions occur, it would be reported to Health      Canada in accordance with the regulations amending the food and  drug regulations (1024 -      clinical trials), section C.05.014.&lt;br/&gt;Where it is neither fatal nor life-threatening, within 15 days after becoming aware of           the information&lt;br/&gt;Where it is fatal or life-threatening, immediately where possible and, in any event,           within 7 days after becoming aware of the information, and&lt;br/&gt;Within 8 days after having informed Health Canada of the adverse drug reaction (ADR), submit as complete a           report as possible which includes an assessment of the importance and implication of           any findings.&lt;/para&gt;&lt;para&gt;All serious unexpected adverse drug reactions (and other safety events as applicable) will      be reported to the Capital Health research ethics board.&lt;/para&gt;&lt;para&gt;To address the primary objective, the study would look at the percentage of patients in      the cohort of 40 who have normal INR, on day 0 (sham surgery day) and thus would be ready to      proceed with surgical intervention. Simple statistics would be used to calculate this      percentage.&lt;br/&gt;For patients who do not have corrected INR on day 0, and thus would have surgery delayed, a      multivariate analysis to elucidate which factors contribute to insufficient normalization of      bleeding tests would be performed.&lt;br/&gt;An      exploratory analysis would be performed to see if patients will be under-anticoagulated in the post-operative period.&lt;br/&gt;A cost analysis will be performed comparing this &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran&lt;/ulink&gt; based bridging protocol      with the current standard of care, a dalteparin based bridging protocol.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was withdrawn as no patients were recruited.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Thrombosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7310">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7343">Subjects on Prior/Concurrent Drug Therapies for Thrombosis</PatientSegment><SubSegments><SubSegment id="7349">Subjects on prior/concurrent combination therapy for thrombosis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01810237</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10315"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thrombosis" id="28003"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="28006">Cost-Benefit Analysis (CBA)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thrombosis" id="5930"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Thrombosis" id="5993"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="5995">Subjects on prior/concurrent anticoagulants</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7578"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7579">Subjects co-morbid with cerebrovascular disease/stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7587"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7596"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7598">Subjects with abnormal coagulation factor levels</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7616"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7617">Subjects with hypersensitivity/contraindications to anticoagulant drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7652"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7824"><Criterion>Subjects with Treatment Related Complications</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7825">Subjects with bleeding manifestations</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-02-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-19T11:37:29Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="120432"><TitleDisplay>Comparison of Four Fixed Dose Combinations Versus Standard Treatment With Separate Anti-TB Drugs for Treatment of Pulmonary Tuberculosis</TitleDisplay><TitleOfficial>A two-arm single-blind randomised comparison of four Fixed Dose Combinations versus standard treatment with separate anti-TB drugs for treatment of pulmonary tuberculosis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN95204603</Identifier><Identifier type="Trial Acronym">4FDC</Identifier></Identifiers><Indications><Indication id="221">Mycobacterium tuberculosis infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid</Name></Intervention><Intervention type="InterventionPrimary"><Name>rifampicin+isoniazid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>ethambutol</Name></Intervention><Intervention type="InterventionControl"><Name>isoniazid</Name></Intervention><Intervention type="InterventionControl"><Name>pyrazinamide</Name></Intervention><Intervention type="InterventionControl"><Name>rifampicin</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1081279" type="Company"><TargetEntity id="5000001086" type="organizationId">United Nations Development Programme</TargetEntity></SourceEntity><SourceEntity id="1086429" type="Company"><TargetEntity id="5040925227" type="organizationId">World Bank Group</TargetEntity></SourceEntity><SourceEntity id="20947" type="Company"><TargetEntity id="5001188676" type="organizationId">World Health Organization</TargetEntity></SourceEntity><SourceEntity id="221" type="ciIndication"><TargetEntity id="A15" type="ICD10"/><TargetEntity id="10044755" type="MEDDRA"/><TargetEntity id="D014376" type="MeSH"/><TargetEntity id="3389" type="ORPHANET"/><TargetEntity id="-1043612885" type="omicsDisease"/><TargetEntity id="843" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1081279">United Nations Development Program</Company><Company id="1086429">The World Bank</Company><Company id="20947">World Health Organization</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>1000</PatientCountEnrollment><DateStart>2007-01-15T00:00:00Z</DateStart><DateEnd type="actual">2011-12-28T00:00:00Z</DateEnd><DateChangeLast>2018-06-09T05:22:36Z</DateChangeLast><DateAdded>2013-04-12T09:48:30Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Medical Co-ordinator, German Leprosy and Tuberculosis Relief Association, 35 Hill View, Independence Layout, Enugu, 100004, Nigeria</Affiliation><Name>Joseph Chukwu</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with newly diagnosed pulmonary tuberculosis (with or without pleural effusion) will be admitted to the study provided they fulfill the following criteria:&lt;ul&gt;&lt;li&gt;A total of two sputum specimens positive for tubercle bacilli on direct smear microscopy. A patient is considered smear positive if:&lt;ul&gt;&lt;li&gt;A total of two out of three consecutive sputum smears are read as positive&lt;/li&gt;&lt;li&gt;A total of wo out of five are read as positive in the event that only one of the first three smear is positive, in which case the patient will be asked for two more specimens: one morning and one spot&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No history of previous anti-tuberculosis chemotherapy, or antiretroviral therapy&lt;/li&gt;&lt;li&gt;Aged 18 years and over&lt;/li&gt;&lt;li&gt;A firm home address and intent to remain there during the entire treatment and follow up period&lt;/li&gt;&lt;li&gt;Informed consent to participate in the study&lt;/li&gt;&lt;li&gt;Weight between 40.00   and 70.00 kg inclusive&lt;/li&gt;&lt;li&gt;Acceptance of human immunodeficiency virus (HIV) counselling and testing&lt;/li&gt;&lt;li&gt;CD4  &gt;/= 220 cells/microl blood if the patient is HIV positive in Nigeria&lt;/li&gt;&lt;li&gt;CD4&amp;gt; 350 cells/microl blood if the patient is HIV positive In Ethiopia&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Positive urinary pregnancy test or obviously pregnant on physical examination&lt;/li&gt;&lt;li&gt;Additional extrapulmonary TB (eg, bone, meningeal, peritoneal or miliary)&lt;/li&gt;&lt;li&gt;Bblurred vision, red-green color blindness and poor visual acuity any active hepatic diseases&lt;/li&gt;&lt;li&gt;Evidence (laboratory and/or clinical history) of pre-existing non-tuberculous disease likely to affect the response to, or assessment of, treatment:&lt;ul&gt;&lt;li&gt;Diabetes mellitus&lt;/li&gt;&lt;li&gt;Liver impairment&lt;/li&gt;&lt;li&gt;Renal impairment&lt;/li&gt;&lt;li&gt;Peripheral neuropathy&lt;/li&gt;&lt;li&gt;Terminal illness such as malignancy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Requirement for hospitalization for any reason other than directly observed treatment (DOT)&lt;/li&gt;&lt;li&gt;Concomitant immunosuppressive treatment during the whole study period&lt;/li&gt;&lt;li&gt;Psychiatric illness, alcohol or drug abuse likely to lead to uncooperative behavior&lt;/li&gt;&lt;li&gt;Patients on antiretroviral treatment during TB treatment period&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cure rates at end of treatment</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cure rates in HIV positive TB patients</Description></Measure><Measure><Description>Early response rates: proportion of patients with negative culture results</Description><Timeframe>At 8 weeks after initiation of therapy</Timeframe></Measure><Measure><Description>Proportion of patients with relapses. A relapse is a patient previously treated for tuberculosis who has met the case definition of cure (as defined above) and been declared cured by a physician and who has now been diagnosed with bacteriologically positive (two positive smears and culture positive) tuberculosis. If there is discordance between smear and culture results, a clinical decision will be made regarding further management: smear positive, culture negative, and smear negative and culture positive</Description><Timeframe>During the 72 weeks follow up period after the end of treatment</Timeframe></Measure><Measure><Description>Proportion of patients with clinical deterioration of pulmonary tuberculosis with the need for hospitalization</Description></Measure><Measure><Description>Proportion of patients with serious adverse events any time during chemotherapy</Description></Measure><Measure><Description>Proportion of patients with any adverse events during chemotherapy</Description></Measure><Measure><Description>Proportion of patients completing treatment (defined as patients who achieved a total of 54 out of 56 doses in the first eight weeks of treatment and 107 out of 112 doses at a daily rate during the subsequent 16 weeks of treatment) within each group (96% doses taken considered as completed in intensive and maintenance phases)</Description></Measure><Measure><Description>Proportion of patients who developed multi-drug-resitant (MDR)-TB</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, single-blind study was to compare a four fixed dose combinations versus standard treatment with separate anti-TB drugs for treatment of pulmonary tuberculosis. The study hypothesis was that the cure rate when taking four fixed -dose combinations would not inferior to the standard treatment with separate anti-TB drugs for treatment of pulmonary tuberculosis (TB) [&lt;ulink linkType="Reference" linkID="1402749"&gt;1402749&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients in the test arm would receive  ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid  (275 + 400 + 150 +  75 mg) followed by rifampicin + isoniazid (150 + 75 mg). The control arm patients would receive loose formulations of ethambutol (400 mg), rifampicin (450 mg), isoniazid (225 mg), pyrazinamide (400 mg) followed by loose formulations of rifampicin (150 mg), isoniazid (225 mg) and isoniazid (100 mg) [&lt;ulink linkType="Reference" linkID="1402749"&gt;1402749&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Ethiopia"><Sites><Site><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Nigeria"><Sites><Site><Name>German Leprosy &amp; Tuberculosis Relief Association</Name><Contacts/></Site><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7085">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7382">Subjects with opportunistic/other infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Mycobacterium tuberculosis infection</Disease><PatientSegments><PatientSegment><PatientSegment id="8589">Subjects with Pulmonary Tuberculosis</PatientSegment><SubSegments><SubSegment id="8593">Subjects with sputum/smear positive pulmonary tuberculosis</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8601">Subjects with Newly Diagnosed Tuberculosis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN95204603</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Mycobacterium tuberculosis infection" id="15041"><Endpoint>Assessment of Microbiological Response</Endpoint><SubEndpoints><SubEndpoint disease="Mycobacterium tuberculosis infection" id="15046">Bacteriological cure</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="HIV infection" id="9211"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9247">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Mycobacterium tuberculosis infection" id="15041"><Endpoint>Assessment of Microbiological Response</Endpoint><SubEndpoints><SubEndpoint disease="Mycobacterium tuberculosis infection" id="15042">Sputum culture conversion</SubEndpoint><SubEndpoint disease="Mycobacterium tuberculosis infection" id="15046">Bacteriological cure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Mycobacterium tuberculosis infection" id="15051"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mycobacterium tuberculosis infection" id="15053"><Endpoint>Assessment of Anti-microbial Resistance</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mycobacterium tuberculosis infection" id="15054"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Mycobacterium tuberculosis infection" id="15055">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5297"><Criterion>Subjects with Opportunistic/Other Infections</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5425">Subjects with mycobacterium infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5322"><Criterion>Subjects with Protocol Specified CD4+ T Cell Counts </Criterion></Inclusion><Inclusion disease="Mycobacterium tuberculosis infection" id="14260"><Criterion>Subjects with Pulmonary Tuberculosis</Criterion><SubCriteria><SubCriterion disease="Mycobacterium tuberculosis infection" id="14264">Subjects with sputum/smear positive pulmonary tuberculosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mycobacterium tuberculosis infection" id="14287"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6820"><Criterion>Subjects with Opportunistic/Other Infections</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6952">Subjects with tuberculosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6834"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6843"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6845">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6848"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6850"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="HIV infection" id="6859"><Criterion>Pregnant or Breast Feeding Subjects</Criterion></Exclusion><Exclusion disease="HIV infection" id="6866"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6941">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6874"><Criterion>Subjects on Prior/Concurrent Antiretroviral Drugs</Criterion></Exclusion><Exclusion disease="HIV infection" id="6892"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6963">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6944"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6945">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11668"><Criterion>Subjects With Extrapulmonary Tuberculosis</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11674"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11676"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11677"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11678"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11681"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11684"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11685"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="HIV infection" id="25989"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6833">Subjects co-morbid with peripheral neuropathy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2011-12-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>59.45 Months</EnrollmentPeriod><EnrollmentRate>16.82 Patients/Month</EnrollmentRate><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-12T09:48:30Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="121560"><TitleDisplay>Prevention of Myeloid Leukemias in Children with Down's Syndrome and Transient Myeloproliferative Disorder</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN54575263</Identifier><Identifier type="Trial Acronym">TMD Prevention 2007</Identifier></Identifiers><Indications><Indication id="104">Down syndrome</Indication><Indication id="273">Myeloproliferative disorder</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cytarabine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1004516" type="Company"><TargetEntity id="5035524398" type="organizationId">Deutsche Forschungsgemeinschaft eV</TargetEntity></SourceEntity><SourceEntity id="28959" type="Company"><TargetEntity id="5001340035" type="organizationId">Hannover Medical School</TargetEntity></SourceEntity><SourceEntity id="104" type="ciIndication"><TargetEntity id="Q90" type="ICD10"/><TargetEntity id="758.0" type="ICD9"/><TargetEntity id="D004314" type="MeSH"/><TargetEntity id="870" type="ORPHANET"/><TargetEntity id="-1866573417" type="omicsDisease"/><TargetEntity id="1105" type="siCondition"/></SourceEntity><SourceEntity id="273" type="ciIndication"><TargetEntity id="10028576" type="MEDDRA"/><TargetEntity id="D009196" type="MeSH"/><TargetEntity id="-1904668786" type="omicsDisease"/><TargetEntity id="1247" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="28959">Hannover Medical School</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1004516">Deutsche Forschungsgemeinschaft (DFG)</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Historical Control</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2007-04-30T00:00:00Z</DateStart><DateChangeLast>2018-08-23T11:24:01Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Pediatric Hematology/OncologyHannover Medical SchoolCarl-Neuberg-Str. 1, Hannover, 30625, Germany</Affiliation><Email>reinhardt.dirk@mh-hannover.de</Email><Name>Dirk Reinhardt</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;TMD with GATA1s mutation and myeloproliferation (&gt; 5% blasts in peripheral blood or bone marrow)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;No consent&lt;/li&gt;&lt;li&gt;No trisomy 21&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Reduction of Down's syndrome myeloid leukemia (DS-ML) risk in children with TMD from 22 to 7%</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>GATA1s negativity (sensitivity 10-3/-4)</Description><Timeframe>At week 12</Timeframe></Measure><Measure><Description>Assessment of safety: serious sdverse events (SAE)/suspected unexpected serious adverse reaction (SUSAR) reporting system, long-term follow-up of late adverse effects, data monitoring committee</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to prevent myeloid leukemias in children with Down's syndrome and transient myeloproliferative disorder [&lt;ulink linkType="Reference" linkID="1405896"&gt;1405896&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Chidren  with persisting GATA1s clone would receive   low-dose cytarabine treatment [&lt;ulink linkType="Reference" linkID="1405896"&gt;1405896&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Czech Republic"><Sites><Site><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Address1>Hamburg</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Slovakia"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3973">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3986">Pediatric Leukemia Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12847">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-878803722" id="19443">GATA1_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myeloproliferative disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="10132">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN54575263</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Myeloproliferative disorder" id="14232"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19418"><Endpoint>Assessment of Tumor Related Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="8071"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8076">Assessment of gene mutations</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8079">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myeloproliferative disorder" id="14255"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myeloproliferative disorder" id="14280"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Myeloproliferative disorder" id="14284">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19374"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19375">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="5031"><Criterion>Subjects with Other Bone Marrow Disorders</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5033">Subjects co-morbid with myeloproliferative disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8754"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13369"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13374">At risk of developing Hematological cancers</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="124801"><TitleDisplay>Phase I Trial of VLP Vaccine</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="153">Hepatitis C virus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>VLP HCV vaccine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1036328" type="Company"><TargetEntity id="4296171343" type="organizationId">Bangi Inc</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"/><TargetEntity id="D019698" type="MeSH"/><TargetEntity id="-776640207" type="omicsDisease"/><TargetEntity id="430" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1036328">Compass Biotechnologies Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><DateChangeLast>2014-03-25T06:05:53Z</DateChangeLast><DateAdded>2013-04-29T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with chronic HCV infection&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>To study the efficacy of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to study the efficacy of the virus like particles (VLP) vaccine as a potential anti-viral immunotherapy for treating chronic hepatitis C virus (HCV) infection   [&lt;ulink linkType="Reference" linkID="1410543"&gt;1410543&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive VLP vaccine as a potential anti-viral immunotherapy for treating chronic hepatitis C virus (HCV) infection  [&lt;ulink linkType="Reference" linkID="1410543"&gt;1410543&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis C virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="461">Subjects with Chronic Hepatitis C Infection</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries/><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatitis C virus infection" id="6858"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatitis C virus infection" id="1751"><Criterion>Subjects with Chronic Hepatitis C Infection</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="131219"><TitleDisplay>Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients</TitleDisplay><TitleOfficial>Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients. A Randomized, Controlled Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01853709</Identifier><Identifier type="Organisational Study">CSPT-END-DIG-2012</Identifier></Identifiers><Indications><Indication id="3010">Colonoscopy</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Education</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>apple juice</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bisacodyl</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>olive oil</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>polyethylene glycol (PEG)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1081359" type="Company"><TargetEntity id="4296856223" type="organizationId">Corporacio Sanitaria Parc Tauli de Sabadell</TargetEntity></SourceEntity><SourceEntity id="3010" type="ciIndication"><TargetEntity id="10010007" type="MEDDRA"/><TargetEntity id="D003113" type="MeSH"/><TargetEntity id="-132434084" type="omicsDisease"/><TargetEntity id="3335" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1081359">Corporacion Parc Tauli</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>162</PatientCountEnrollment><DateStart>2013-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2013-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-07-04T16:12:07Z</DateChangeLast><DateAdded>2013-05-17T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>fjunquera@tauli.cat</Email><Name>Flix Junquera, PhD</Name><Phone>34937458320</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Hospitalized patients who undergo a non-urgent colonoscopy&lt;/li&gt;&lt;li&gt;Patients who give informed consent to participate in the study&lt;/li&gt;&lt;li&gt;Patients  &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Patients who undergo total colonoscopy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Non compliance with the 48 h diet prescribed&lt;/li&gt;&lt;li&gt;The endoscopy planned is a rectosigmoidoscopy&lt;/li&gt;&lt;li&gt;Previous colonic surgery&lt;/li&gt;&lt;li&gt;Mental/cognitive impairment preventing the study assessments&lt;/li&gt;&lt;li&gt;Severe renal failure&lt;/li&gt;&lt;li&gt;Electrolytic disbalance (hyponatremia, hypokaliemia, hyperphosphatemia, hypocalcemia and hypomagnesemia)&lt;/li&gt;&lt;li&gt;Intestinal obstruction, perforation or toxic megacolon&lt;/li&gt;&lt;li&gt;Pregnant or nursing women&lt;/li&gt;&lt;li&gt;Allergy/intolerance to PEG, bisacodyl or adjuvants&lt;/li&gt;&lt;li&gt;No informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percentage of patients with adequate bowel preparation: adequate bowel preparation is defined as a preparation which allows exploring the whole colonic mucose and detecting flat lesions (rating as good or excellent in the Boston Bowel preparation scale)</Description><Timeframe>At the time of performing the colonoscopy</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Complications during and after the procedure</Description><Timeframe>Up to 24 h after colonoscopy</Timeframe></Measure><Measure><Description>Doses of sedation needed during the colonoscopy: final dose will be calculated at the end of the procedure</Description><Timeframe>During the colonoscopy process</Timeframe></Measure><Measure><Description>Endoscopic findings</Description><Timeframe>During the colonoscopy</Timeframe></Measure><Measure><Description>Percentage of complete/incomplete colonoscopies and reprogramming: evaluation of incomplete or inadequate bowel preparation will be assessed after performing the colonoscopy</Description><Timeframe>After the colonoscopy</Timeframe></Measure><Measure><Description>Percentage of patients with adequate bowel preparation by bowel segments: the boston scale will be assessed by the investigators during the procedure</Description><Timeframe>At the time of performing the colonoscopy</Timeframe></Measure><Measure><Description>Tolerance to the colonoscopy: tolerance to the colonoscopy will be measured by VAS during the colonoscopy, 30 min after colonoscopy and 24 h after colonoscopy</Description><Timeframe>From colonoscopy up to 24 h after colonoscopy</Timeframe></Measure><Measure><Description>Tolerance to the preparation</Description><Timeframe>Up to 48 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to compare the efficacy of a multidisciplinary approach (education,      fiber free diet, polyethylene glycol (PEG) 2l, and adjuvant bisacodyl + olive oil) versus a      conventional approach (fiber free diet + PEG  4l  in split doses ) in cleaning the colon of      hospitalized patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This trial consists of two treatment arms:&lt;br/&gt;Arm I: patients in this arm recieve education, fiber free diet, bisacodyl: 10 mg, 2 days before the procedure; 20 mg the day before the procedure and 10 mg, 3 h before the procedure, adjuvants: olive oil (60 ml)/apple juice (200 ml) and PEG: 1 l the night before the procedure and 1 l, 3 h before the procedure.&lt;br/&gt;Arm II: patients in this arm receive education, fiber free diet and  polyethylene glycol (PEG): 2 l the night before the procedure and  2 l, 3 h before the procedure.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Hospital de Sabadell</Name><Address1>Sabadell</Address1><Address2>Barcelona</Address2><Address3>08208</Address3><CountrySubDivision>Barcelona</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Felix Junquera</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01853709</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Anticipated">2013-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-04-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="136932"><TitleDisplay>Amiloride as adjunctive treatment for drug-resistant adult epilepsy: a prospective, open-label study in China</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR-ONC-13003234</Identifier></Identifiers><Indications><Indication id="119">Epilepsy</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>amiloride</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1063031" type="Company"><TargetEntity id="5036351861" type="organizationId">First Affiliated Hospital of the Fourth Military Medical University</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"/><TargetEntity id="345" type="ICD9"/><TargetEntity id="10015037" type="MEDDRA"/><TargetEntity id="D004827" type="MeSH"/><TargetEntity id="-2005570698" type="omicsDisease"/><TargetEntity id="115" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor/><CompaniesCollaborator><Company id="1063031">Xijing Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2013-06-01T00:00:00Z</DateStart><DateEnd type="estimated">2013-12-31T00:00:00Z</DateEnd><DateChangeLast>2014-03-14T14:35:48Z</DateChangeLast><DateAdded>2013-06-04T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Fourth Military Medical University</Affiliation><Email>jiangwen@fmmu.edu.cn</Email><Name>Wen Jiang</Name><Phone>+86 13991905538</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of cryptogenic or symptomatic epilepsy by clinical and electroencephalogram assessment&lt;/li&gt;&lt;li&gt;Failure of adequate trials of at least two tolerated and appropriately chosen AEDs (whether as monotherapy or in combination), ie, more than one seizure/month in the previous 6 months&lt;/li&gt;&lt;li&gt;Informed consent from parents and/or caregivers, who had to be able to administer the study drug and record seizures in a diary&lt;/li&gt;&lt;li&gt;Age between 16 to 45 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Non-epileptic seizures&lt;/li&gt;&lt;li&gt;Progressive neurological disease or intracranial lesion&lt;/li&gt;&lt;li&gt;Generalized tonic-clonic status epilepticus during the past 6 months&lt;/li&gt;&lt;li&gt;Use of at least one other anti epileptic drugs (AEDs), but no more than three, at baseline&lt;/li&gt;&lt;li&gt;Female patients of child bearing age were required not to be pregnant&lt;/li&gt;&lt;li&gt;Poor compliance from parents/caregivers&lt;/li&gt;&lt;li&gt;Treated with traditional Chinese medicine&lt;/li&gt;&lt;li&gt;Hyperkalemia, acidosis, hyponatremia, no urine, liver and kidney dysfunction, diabetes mellitus&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Seizure frequency</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this prospective, open-label, observational trial was to test the efficacy and tolerability of amiloride in drug-resistant adult epilepsy [&lt;ulink linkType="Reference" linkID="1432922"&gt;1432922&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive amiloride [&lt;ulink linkType="Reference" linkID="1432922"&gt;1432922&lt;/ulink&gt;]. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Xijing Hospital, Fourth Military Medical University</Name><Address2>Shaanxi</Address2><CountrySubDivision>Shaanxi</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Epilepsy</Disease><PatientSegments><PatientSegment><PatientSegment id="10316">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10327">Subjects with Medically Intractable Epilepsy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR-ONC-13003234</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Epilepsy" id="17057"><Endpoint>Assessment of Seizure Activity</Endpoint><SubEndpoints><SubEndpoint disease="Epilepsy" id="17058">Assessment of seizure frequency</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Epilepsy" id="15260"><Criterion>Subjects with Epilepsy based on Etiology of Seizures</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15262">Subjects with symptomatic epilepsy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15318"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Epilepsy" id="15345"><Criterion>Subjects with Medically Intractable Epilepsy</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Epilepsy" id="12677"><Criterion>Subjects with Diagnosis of Epilepsy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12679">Subjects with generalized epilepsy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12701"><Criterion>Subjects with Status Epilepticus</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12708"><Criterion>Subjects with Non-Epileptic Seizures</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12709"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12710">Subjects with other central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Epilepsy" id="12717">Subjects co-morbid with metabolic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12748"><Criterion>Subjects with History/ Scheduled to receive Anti-epileptic Therapy</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12764"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Epilepsy" id="26310"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12730">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Epilepsy" id="12731">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-06-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="161168"><TitleDisplay>Effect of analgesia using buccal fentanyl versus diclofenac suppository for extracorporeal shock wave lithotripsy</TitleDisplay><TitleOfficial>Open-label, randomized, controlled study of efficacy of buccal fentanyl versus diclofenac suppository analgesia for extracorporeal shock wave lithotripsy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN75580529</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fentanyl</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>diclofenac suppository</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1070671" type="Company"><TargetEntity id="5037613722" type="organizationId">Bedford Hospitals NHS Trust</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1070671">Bedford Hospital Nhs Trust</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2012-08-01T00:00:00Z</DateStart><DateEnd type="actual">2013-03-01T00:00:00Z</DateEnd><DateChangeLast>2018-05-19T04:02:33Z</DateChangeLast><DateAdded>2013-11-19T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Bedford Hospital NHS Trust Urology Department MK42 9DJ Bedford United Kingdom</Affiliation><Name>Aasem Chaudry</Name></Contact><Contact type="Public contact"><Affiliation>CH de Blois; Blois; 41000; France</Affiliation><Email>elyamaa@ch-blois.fr</Email><Name>Abderrazak Yamani</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients undergoing extracorporeal shock wave lithotripsy in Bedford Hospital NHS Trust&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients refusal to be included in the trial&lt;/li&gt;&lt;li&gt;Allergy or adverse reaction to fentanyl or diclifenac&lt;/li&gt;&lt;li&gt;Contraindications to fentanyl or diclofenac&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain: measured on Visual Analogue Scale score (0 = No pain, 10 = Unbearable pain)</Description></Measure><Measure><Description>Presence of adverse reactions to buccal fentanyl or oral diclofenac</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to assess the efficacy of buccal fentanyl use as analgesia for extracorporeal shock wave lithotripsy [&lt;ulink linkType="Reference" linkID="1500690"&gt;1500690&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a randomized, single-blind, controlled trial comparing two interventions - buccal fentanyl versus oral diclofenac analgesia for ESWL. One group would receive 100 microg of buccal fentanyl and second group would receive 100 mg of po diclofenac.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Bedford Hospital NHS Trust</Name><Contacts/></Site><Site><Contacts/></Site><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8425">Subjects in need of Procedural Analgesia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN75580529</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22141"><Criterion>Subjects in Need of Procedural Analgesia</Criterion></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20179"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2013-03-01T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.03 Months</EnrollmentPeriod><EnrollmentRate>14.22 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-11-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="165615"><TitleDisplay>Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons</TitleDisplay><TitleOfficial>Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00409981</Identifier><Identifier type="Organisational Study">BMT - PAC 2</Identifier><Identifier type="Trial Acronym">PACCOCATH  ISR II</Identifier></Identifiers><Indications><Indication id="330">Restenosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>paclitaxel coated balloon catheter</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1038495" type="Company"><TargetEntity id="5045067917" type="organizationId">Universitaetsklinikum des Saarlandes</TargetEntity></SourceEntity><SourceEntity id="330" type="ciIndication"><TargetEntity id="228" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="1038495">Saarland University Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>56</PatientCountEnrollment><DateStart>2004-07-31T00:00:00Z</DateStart><DateEnd type="actual">2006-06-30T00:00:00Z</DateEnd><DateChangeLast>2014-01-03T09:21:13Z</DateChangeLast><DateAdded>2014-01-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Saarland, Germany</Affiliation><Name>Bruno Scheller, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt; 18 years&lt;/li&gt;&lt;li&gt;Clinical evidence of stable or unstable angina or a positive functional study&lt;/li&gt;&lt;li&gt;Single, restenotic lesion in a stented coronary artery (allowed are multiple lesions but only the target lesion is amenable for percutaneous intervention, ie no staged procedures involving non-target lesions)&lt;/li&gt;&lt;li&gt;Diameter stenosis&amp;gt; 70% (visual estimate)&lt;/li&gt;&lt;li&gt;Stented segment length&amp;lt; 30 mm&lt;/li&gt;&lt;li&gt;Vessel diameter &gt;/= 2.5 mm&lt;/li&gt;&lt;li&gt;Female patients can enter this study if they are post-menopausal for at least two years or have undergone hysterectomy or sterilization&lt;/li&gt;&lt;li&gt;Signed patient informed consent form&lt;/li&gt;&lt;li&gt;Patients and treating physicians agree that the patient will return for all required post procedure follow-up assessments as defined in the clinical protocol&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Left ventricular ejection fraction of&amp;lt; 30%&lt;/li&gt;&lt;li&gt;Target lesion/vessel with any of the following characteristics: clear angiographic calcification in the target lesion or &gt; mild calcification in the proximal vessel (minimally radiopaque densities that are discrete and non-linear). Visible thrombus proximal to the lesion&lt;/li&gt;&lt;li&gt;Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, abciximab,&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, or a sensitivity to contrast media which cannot be adequately pre-medicated.&lt;/li&gt;&lt;li&gt;Other medical illness (ie, cancer, liver disease or congestive heart failure) that may require cytostatic or radiation therapy causing the subject to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (ie,&amp;lt; two years)&lt;/li&gt;&lt;li&gt;Severe chronic renal insufficiency&lt;/li&gt;&lt;li&gt;Significant gastrointestinal (GI) bleed within the past six months. History of bleeding diathesis or coagulopathy or will refuse blood transfusions&lt;/li&gt;&lt;li&gt;Extensive peripheral vascular disease that precludes safe six French sheath insertion and/or requires additional anti-platelet and/or anti-coagulation treatment&lt;/li&gt;&lt;li&gt;Participating in another device or drug study within the last 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Angiographic late lumen loss</Description><Timeframe>After 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Binary restenosis rate</Description></Measure><Measure><Description>Major adverse cardiac events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a randomized, double-blinded German multicenter trial on the      efficacy and tolerance of a &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; coated balloon catheter in coronary in-stent      restenosis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to      percutaneous transluminal coronary angioplasty(rePTCA) of in-stent restenosis (ISR) either using the coated PTCA balloon (&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; - 3 microg/mm(2) balloon surface) or a      non-coated balloon of the same type (n = 56 patients). Balloon inflation time would be 60 s in      both cases.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>I. Medizinische Klinik, Universitaetsklinikum</Name><Address1>Mannheim</Address1><Address3>68167</Address3><Contacts/></Site><Site><Name>Kardiologie, Campus Mitte, Charite</Name><Address1>Berlin</Address1><Address3>10117</Address3><Contacts/></Site><Site><Name>Kardiologie, Campus Virchow-Klinikum, Charite</Name><Address1>Berlin</Address1><Address3>13353</Address3><Contacts/></Site><Site><Name>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</Name><Address1>Homburg / Saar</Address1><Address2>Saarland</Address2><Address3>66421</Address3><CountrySubDivision>Saarland</CountrySubDivision><Contacts/></Site><Site><Name>Medizinische Universittsklinik III, Abt. Kardiologie und Angiologie</Name><Address1>Freiburg</Address1><Address3>79106</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="182">Subjects with Angina</PatientSegment><SubSegments><SubSegment id="188">Subjects with Stable Angina</SubSegment><SubSegment id="3729">Subjects with unstable angina</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><SubSegments><SubSegment id="205">Subjects with restenosis after angioplasty with stent</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00409981</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2542"><Endpoint>Assessment of Stenosis/Restenosis</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2551">In-segment late loss/In-lesion late loss</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2554">Minimal luminal diameter</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2619">Assessment of major adverse cardiac events (MACEs)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2542"><Endpoint>Assessment of Stenosis/Restenosis</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2545">Binary restenosis rates</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Coronary artery disease" id="2512"><Endpoint>Assessment of Thrombotic/Thromboembolic Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2516">Nonfatal cerebral infarction /Ischemic stroke</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Coronary artery disease" id="2571"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2703">Assessment of target lesion revascularization (TLR)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1085"><Criterion>Subjects with angina</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1091">Subjects with stable angina / angina pectoris / exertional angina</SubCriterion><SubCriterion disease="Coronary artery disease" id="1092">Unstable angina (Braunwald Classification)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1222">Stenosis of target lesion is  50% &amp;  100 by visual estimate</SubCriterion><SubCriterion disease="Coronary artery disease" id="1224">Target reference vessel dimensions suitable for stent placement</SubCriterion><SubCriterion disease="Coronary artery disease" id="1227">Total occlusion length as specified by the protocol</SubCriterion><SubCriterion disease="Coronary artery disease" id="1263">In-stent restenosis</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1609"><Criterion>Subjects with Specific Coronary Angiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1616">Calcified lesions</SubCriterion><SubCriterion disease="Coronary artery disease" id="1634">Thrombus in target vessel</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1646"><Criterion>Subjects with Thromboembolic Events</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1648">Subjects with peripheral vascular disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1662">Subjects co-morbid with congestive heart failure (Killip class II-IV/NYHA Class II-IV)/Failure of the right ventricle/Decompensated heart failure</SubCriterion><SubCriterion disease="Coronary artery disease" id="1667">Severe left ventricular dysfunction /abnormal left ventricular ejection fraction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1696"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1702">Subjects with renal failure/renal insufficiency</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1740"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1742">Subjects with bleeding disorders/bleeding diathesis/hemorrhagic diathesis /hematopoietic disease/coagulopathy</SubCriterion><SubCriterion disease="Coronary artery disease" id="1744">Subjects co-morbid with coagulation disorder/dysfunction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1793"><Criterion>Subjects on Cardiovascular Treatment</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1806">Antiplatelet therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="5591"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="25865"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5589">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26158"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1805">Anticoagulant therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="18568"><TitleDisplay>Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites</TitleDisplay><TitleOfficial>A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">IP-REM-AC-02-US</Identifier><Identifier type="NCT">NCT00326885</Identifier></Identifiers><Indications><Indication id="2204">Ascites</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>catumaxomab</Name><Drug id="50340">catumaxomab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="50340">catumaxomab</Drug><IndicationsPioneer/><Companies><Company><Company id="1011051">Neovii Biotech GmbH</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="50340" type="Drug"><TargetEntity id="402346" type="siDrug">Catumaxomab</TargetEntity></SourceEntity><SourceEntity id="1011051" type="Company"><TargetEntity id="4295966349" type="organizationId">Neovii Biotech GmbH</TargetEntity></SourceEntity><SourceEntity id="2204" type="ciIndication"><TargetEntity id="R18" type="ICD10"/><TargetEntity id="789.5" type="ICD9"/><TargetEntity id="10003445" type="MEDDRA"/><TargetEntity id="D001201" type="MeSH"/><TargetEntity id="-1050760240" type="omicsDisease"/><TargetEntity id="417" type="siCondition"/></SourceEntity><SourceEntity id="14553" type="Action"><TargetEntity id="6810" type="Mechanism">Drugs Targeting Epithelial Cell Adhesion Molecule (EPCAM)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>18</NumberOfSites><CompaniesSponsor><Company id="1011051">Neovii Biotech GmbH</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="14553">EpCAM modulator</Action><Action id="5023">CD3 modulator</Action><Action id="5072">Immunoglobulin gamma Fc receptor III agonist</Action><Action id="5117">Immunoglobulin gamma Fc receptor II agonist</Action><Action id="5258">Immunoglobulin gamma Fc receptor I agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="7747">Leukocyte stimulator</Class><Class id="7761">T-lymphocyte stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="740">Infusion</Technology><Technology id="649">Intraperitoneal formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="167">Monoclonal antibody murine</Technology><Technology id="170">Multivalent monoclonal antibody</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>32</PatientCountEnrollment><PatientCountEvaluable>32</PatientCountEvaluable><DateStart>2006-06-30T00:00:00Z</DateStart><DateEnd type="actual">2010-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-18T02:11:17Z</DateChangeLast><DateAdded>2008-07-08T13:49:30Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Stanford University Hospital and Clinics, Department of Obstetrics and Gynecology</Affiliation><Name>Jonathan Berek</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Signed and dated informed consent&lt;/li&gt;&lt;li&gt;Histologically confirmed diagnosis of epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer; any stage at diagnosis (International Federation of Gynecology and Obstetrics [FIGO] stages I to IV)&lt;/li&gt;&lt;li&gt;Progression on or&amp;lt;/= 12 months after primary platinum-based systemic or intraperitoneal (IP) chemotherapy OR relapse following reinduction &gt;/= 12 months after primary chemotherapy&lt;/li&gt;&lt;li&gt;Have refused, failed, or have been deemed not suitable candidates for gemcitabine or liposomal doxorubicin&lt;/li&gt;&lt;li&gt;Recurrent symptomatic malignant ascites requiring therapeutic paracentesis&lt;/li&gt;&lt;li&gt;At least 1 therapeutic paracentesis within 4 weeks prior to baseline paracentesis&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&lt;/li&gt;&lt;li&gt;Life expectancy &gt;/= 16 weeks&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.5 x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&amp;lt;/= 2.5 x ULN, and total bilirubin &amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;li&gt;Absolute neutrophil count (ANC) &gt;/= 1500/mm3 and platelet count &gt;/= 75,000/mm3&lt;/li&gt;&lt;li&gt;Negative serum pregnancy test result at screening in women of childbearing potential (applies to patients without documented menopause or sterility)&lt;/li&gt;&lt;li&gt;Willingness of patients of childbearing potential to use an effective contraceptive method (ie, oral contraceptive, cervical cap, diaphragm with spermicide, condom with spermicide, or intrauterine device) during the study and for at least 6 months after the last infusion&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Acute or chronic systemic infection&lt;/li&gt;&lt;li&gt;Exposure to investigational drugs, chemotherapy or radiotherapy 21 days prior to the first dose of&lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Major surgery 2 weeks prior to first dose&lt;/li&gt;&lt;li&gt;Previous treatment with mouse or rat antibodies&lt;/li&gt;&lt;li&gt;Known or suspected hypersensitivity to&lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt; or other monoclonal antibodies-Body mass index (BMI) &amp;lt; 19 (body weight after paracentesis to be used for calculation of BMI)&lt;/li&gt;&lt;li&gt;Serum albumin level&amp;lt; 2.0 g/dl&lt;/li&gt;&lt;li&gt;Reduced nutritional status requiring predominantly parenteral nutrition (&amp;gt; 50% of energy intake). Permanent naso-gastric (NG) feeding tube&lt;/li&gt;&lt;li&gt;Ileus in a location that precludes paracentesis&lt;/li&gt;&lt;li&gt;Extensive liver metastases (&amp;gt; 70% organ volume comprises malignancy)&lt;/li&gt;&lt;li&gt;Documented brain metastases&lt;/li&gt;&lt;li&gt;History of myocardial infarction, congestive heart failure or relevant cardiac arrhythmia 3 months prior to the first dose of&lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Portal vein obstruction or portal vein thrombosis diagnosed by computed tomography (CT) scan at screening&lt;/li&gt;&lt;li&gt;Persistent massive pleural effusion or inadequate respiratory function of any other etiology (except if related to ascite symptoms) in the opinion of the investigator&lt;/li&gt;&lt;li&gt;Any other condition which, according to the investigator, results in an undue risk to the patient by participating in the study&lt;/li&gt;&lt;li&gt;Prior exposure to&lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The Proportion of Patients Who Achieved at Least a 4-fold Increase of Puncture/Paracentesis-free Interval Following Catumaxomab Relative to Their Pre-treatment Interval: The parameter to be estimated is the proportion of patients who achieve at least a 4-fold increase in their puncture/paracentesis-free interval. The pretreatment interval is defined as the length of time between the patient's most recent paracentesis (baseline) and the subsequent paracentesis necessitated by her increasing ascites-related symptoms. The post-treatment interval is defined as the time between the last dose of catumaxomab plus 1 day to the time of recurrence of ascites requiring therapeutic paracentesis or death, whichever occurred sooner</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Increase of Paracentesis/Puncture-free Interval (ratio): the parameter to be tested is the ratio of the post-treatment puncture/paracentesis-free interval divided by the pre-treatment puncture/paracentesis-free interval. The pre-treatment interval is defined as the length of time between the patient's most recent paracentesis (baseline) and the subsequent paracentesis necessitated by her increasing ascites-related symptoms. The post-treatment interval is defined as the time between the last dose of catumaxomab plus 1 day to the time of recurrence of ascites requiring therapeutic paracentesis or death, whichever occurred sooner</Description><Timeframe>180 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Puncture/Paracentesis-free Survival (PuFS): Puncture/Paracentesis-free Survival (PuFS), Defined as the Number of Days Between the Date of Last Dose and the Date of Documented End of Study (EoS) Paracentesis or Death, Whichever Occurred First</Description><Timeframe>Survival &gt;/= 6 months</Timeframe></Measure><Measure><Description>Overall survival (OS): overall survival is defined as the interval from the date of first dose to the date of death</Description><Timeframe>Survival &gt;/= 6 months</Timeframe></Measure><Measure><Description>Ascites signs and symptoms: patient-reported ascites symptoms were to be assessed using the patient questionnaire, Functional Assessment of Chronic Illness Therapy - Ascites Index (FACIT-AI). At 6 months following catumaxomab administration, the patient was requested to assess the severity of the following parameters during the past week using a 5-point scale with scores from '0 = not at all' to '4 = very much': anorexia, insomnia, decreased mobility, dyspnea, nausea, vomiting, abdominal pain, abdominal distention, fatigue, early satiety, urinary frequency, constipation, and emotional distress. For the parameters anorexia, insomnia, and decreased mobility, high scores mean good response, for the other parameters low scores mean good response</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Ascites volume: ascites volume measurement were to be performed at screening (= prior to baseline), at baseline (= before start of therapy with catumaxomab) and during the 6-month follow-up period when the patient had recurrence of symptomatic ascites requiring therapeutic paracentesis. At each paracentesis, drainage to dryness was to be achieved and the exact volume was to be measured and documented</Description><Timeframe>6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2011, results were presented. Pyrexia (59.4%), nausea (62.5%), vomiting (65.6%), fatigue (50%), chills (40.6%) , abdominal pain (37.5%),  decreased appetite (29%),  constipation (28%) and diarrhea (25%) were the most common adverse events (AEs) of all grades. Elevations in liver enzymes and declines in blood lymphocytes, all of which were transient, were frequently observed but, for the most part, were not clinically important [&lt;ulink linkType="Reference" linkID="1196050"&gt;1196050&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether the investigational drug &lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt; is a safe and effective treatment for recurrent symptomatic malignant ascites.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2011, results were presented. The primary endpoint, a four-fold increase in the puncture-free survival interval relative to the pretreatment interval, was achieved by 22.6% of patients; however, this was below the predefined threshold of 60%. The median puncture-free survival interval was augmented 2-fold (from median of 1.7 to 3.9 weeks) in the full-analysis set and 2.9-fold (from median of 2.6 to 7.1 weeks) in the per-protocol set. During post-&lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt; treatment, paracentesis was required by 59.4% of patients, and the remaining patients died or were lost to follow up. The median overall survival of patients was 3.6 months and the median puncture-free survival (PuFS) was 4.2 weeks. &lt;ulink linkType="Drug" linkID="50340"&gt;Catumaxomab&lt;/ulink&gt; was associated with improvements or stability in patients' disease symptoms, and, at repuncture, most symptoms were ameliorated compared with baseline. A total of 7 out of 13 functional assessment of cancer therapy-ascites index (FACIT-AI) symptom categories were  improved  during post-&lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt; treatment, while three were unchnaged and four were  worsened [&lt;ulink linkType="Reference" linkID="1196050"&gt;1196050&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A multicenter, phase II study of &lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt; in ovarian cancer patients with recurrent symptomatic malignant ascites requiring therapeutic paracentesis. Each eligible patient would receive four ascending doses of &lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt;, administered intraperitoneally via an indwelling catheter. &lt;ulink linkType="Drug" linkID="50340"&gt;Catumaxomab&lt;/ulink&gt; would be administered as a 3-h constant rate infusion with a dosing interval of 3 to 4 days. Each patient would participate in this study for up to 7 months (includes the baseline therapeutic paracentesis and screening period, 11 to 21 days treatment period, and up to 180 days/6 months follow-up), with monthly post-study follow-up for the lifetime of the patient.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 32) received four 3-h ip infusions of &lt;ulink linkType="Drug" linkID="50340"&gt;catumaxomab&lt;/ulink&gt; (10, 20, 50 and 150 microg) on days 0, 3, 7 and 10, respectively [&lt;ulink linkType="Reference" linkID="1196050"&gt;1196050&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>catumaxomab</Name><Drug id="50340">catumaxomab</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>25.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsAffectedPercentage>65.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1833">Fever</Indication><CountPatientsAffectedPercentage>59.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>62.5</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>29.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3050">Chill</Indication><CountPatientsAffectedPercentage>40.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3472">Abdominal pain</Indication><CountPatientsAffectedPercentage>37.5</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="404">Constipation</Indication><CountPatientsAffectedPercentage>28.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>50.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="27643">catumaxomab</Intervention><Treatments><Treatment><Dose>10 microgram</Dose><Route>Intraperitoneal</Route></Treatment><Treatment><Dose>20 microgram</Dose><Route>Intraperitoneal</Route></Treatment><Treatment><Dose>50 microgram</Dose><Route>Intraperitoneal</Route></Treatment><Treatment><Dose>150 microgram</Dose><Route>Intraperitoneal</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of San Diego</Name><Address1>La Jolla</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of Miami</Name><Address1>Miami</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Columbia University Cancer center</Name><Address1>New York</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>The Methodist Hospital</Name><Address1>Houston</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>University of Arizona Cancer Center</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Stanford University Hospital and Clinics</Name><Address1>Stanford</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Massachusetts General Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Dana Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Dartmouth-Hitchock Medical Center</Name><Address1>Lebanon</Address1><Address2>New Hampshire</Address2><CountrySubDivision code="NH">New Hampshire</CountrySubDivision><Contacts/></Site><Site><Name>University of Oklahoma Health Science Center</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts/></Site><Site><Name>Wake-Forest University</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Magee Women's Hospital, University of Pittsburgh</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Huntsman Cancer Institute</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Name>Florida Hospital Cancer Center</Name><Address1>Orlando</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Northern Indiana Cancer Research Consortium</Name><Address1>South Bend</Address1><Address2>Indiana</Address2><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>University of Louisville Cancer Center</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Johns Hopkins Medical Institute</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Wayne State University</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ovary tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7879">Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7894">Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7904">Early Stage Ovarian Cancer Subjects</PatientSegment><SubSegments><SubSegment id="7905">Stage I ovarian cancer subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7909">Advanced Ovarian Cancer Subjects</PatientSegment><SubSegments><SubSegment id="7910">Stage II ovarian cancer subjects</SubSegment><SubSegment id="7914">Stage III ovarian cancer subjects</SubSegment><SubSegment id="7918">Stage IV or metastatic ovarian cancer subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00326885</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ovary tumor" id="10938"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10961">Assessment of Other Efficacy Parameters</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Ovary tumor" id="10838"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10840">Assessment of Clinical Benefit Rate (CBR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ovary tumor" id="10900"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ovary tumor" id="8204"><Criterion>Subjects with Ovarian Epithelial Tumor</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8219"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8229"><Criterion>Stage I ovarian cancer</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8233"><Criterion>Stage II ovarian cancer</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8237"><Criterion>Stage III ovarian cancer</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8241"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8254"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8255"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8259">Subjects with life expectancy of four months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8262"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8263">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Ovary tumor" id="8264">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Ovary tumor" id="8265">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8273"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8274">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="8279">Subjects with history of surgery/procedure for Ovarian Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8281"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8282">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Ovary tumor" id="8283">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8288"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8290">Subjects with other gynecological cancers</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34009"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8284">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ovary tumor" id="9801"><Criterion>Stage IV or Metastatic Ovarian Cancer</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="9810"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="9829"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9831">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion><SubCriterion disease="Ovary tumor" id="9832">Subjects with hypersensitivity/contraindication to biological therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="9837"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9838">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9839">Subjects with history of targeted therapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9842">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9843">Patient with history of surgical interventions/procedure</SubCriterion><SubCriterion disease="Ovary tumor" id="9844">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="26341"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9822">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="26841"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9840">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>44.06 Months</EnrollmentPeriod><EnrollmentRate>0.73 Patients/Month</EnrollmentRate><DateFirstReceived>2006-05-15T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-07-08T13:49:30Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="192403"><TitleDisplay>Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors</TitleDisplay><TitleOfficial>Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors: Evaluation of Acute and Late Side Effects</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01049230</Identifier><Identifier type="Organisational Study">09-263</Identifier></Identifiers><Indications><Indication id="759">Central nervous system tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Proton beam radiation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="15615" type="Company"><TargetEntity id="5000369732" type="organizationId">Dana-Farber Cancer Institute Inc</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="759" type="ciIndication"><TargetEntity id="10007958" type="MEDDRA"/><TargetEntity id="D016543" type="MeSH"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="15615">Dana-Farber Cancer Institute Inc</Company><Company id="20518">National Institutes of Health</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>45</PatientCountEnrollment><DateStart>2010-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2020-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-11-10T00:15:42Z</DateChangeLast><DateAdded>2014-06-02T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Massachusetts General Hospital</Affiliation><Name>Shannon MacDonald, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically confirmed germ cell tumor or elevated AFP or B-HCG in the setting of radiographic disease consistent with a germ cell tumor. Disease must be confined to the central nervous system&lt;/li&gt;&lt;li&gt;Patient do not need to have measurable disease. Most patients will not have measurable disease at the time of treatment&lt;/li&gt;&lt;li&gt;Age &gt;/= 3 years and,&amp;lt;/= 25 years at the time of diagnosis because this study evaluates this disease entity in the pediatric population which may differ from the adult population&lt;/li&gt;&lt;li&gt;Life expectancy of &gt; 12 months&lt;/li&gt;&lt;li&gt;ECOG performance status of 0, 1 or 2&lt;/li&gt;&lt;li&gt;Baseline MRI of the brain and spinal axis with gadolinium and prior to any chemotherapy is required. If surgical resection is performed a post-operative MRI is required. If the patient receives chemotherapy prior to radiation, a post-chemotherapy MRI of the brain is required. If spinal involvement was seen on initial MRI and prior to chemotherapy, a MRI of the spine is required after chemotherapy and prior to radiation&lt;/li&gt;&lt;li&gt;Serum and lumbar CSF must be obtained to evaluate for alpha fetoprotein (AFP) and beta human chorionic gonadotropin (HCG). This is needed to stratify patients into pure GCT and NGGCT&lt;/li&gt;&lt;li&gt;Female patients of child bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients will be ineligible if any prior therapeutic radiation therapy &gt; 200 c Gy has been delivered to the central nervous system&lt;/li&gt;&lt;li&gt;Patients will be ineligible if chemotherapy was completed &gt; 1 year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone&lt;/li&gt;&lt;li&gt;Patients with a history of a different malignancy are ineligible except for the following circumstances: disease free for at least five years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Patients diagnosed and treated within the past five years for cervical cancer in situ and basal cell or squamous cell carcinoma of the skin&lt;/li&gt;&lt;li&gt;Pregnant female patients&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To describe late complications of craniospinal, whole ventricle, and involved field radiation therapy delivered with proton radiotherapy in place of photon radiation for this patient population</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>To evaluate acute and subacute toxicities of craniospinal, whole ventricle, and involved field radiation therapy delivered with proton radiotherapy in place of photon radiation in this patient population</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To determine three years progression free survival rate of patients with pure germ cell tumors and non-germinomatous germ cell tumors treated with proton radiation</Description><Timeframe>Three years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this research study is to determine if radiation using proton beam therapy      will kill the germ cell tumor in the patients central nervous system.    This study       will  examine the effects of proton beam radiation therapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Before patients begin radiation therapy they will have scans done to prepare them for radiation treatment.  Doctors will use the information gathered from these scans to           plan the best way to deliver radiation to the tumor. Patients will receive treatment as an outpatient at the Francis H. Burr Proton Center located at the &lt;ulink linkType="Company" linkID="21569"&gt;Massachusetts General Hospital&lt;/ulink&gt;. Everyone who participates in this study will not receive the same amount of proton           radiation therapy.  The length of time and amount of radiation that the patient           will receive will depend on the type of germ cell tumor they have and the stage of the           their disease. Radiation treatment will be given once a day, 5 days a week (monday to friday), for 4 to 8           weeks depending on the condition of the  disease. During each week of proton radiation therapy, patients will have a physical exam           and be asked questions about their general health and any problems they will  be           experiencing.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Dana-Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Massachusetts General Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Dana Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3> 2115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9685">Subjects with CNS germ cell tumor</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01049230</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Central nervous system tumor" id="13551"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13576"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13578">Assessment of Other Treatment Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Central nervous system tumor" id="13477"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Central nervous system tumor" id="13033"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13038"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13044">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13045"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13046">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13047">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13048">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13072"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13075">Subjects with CNS germ cell tumor</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Central nervous system tumor" id="10640"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10668"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10669">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10673">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>82.06 Months</EnrollmentPeriod><EnrollmentRate>0.55 Patients/Month</EnrollmentRate><DateFirstReceived>2010-01-13T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-07-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="208283"><TitleDisplay>Prospective, open-label, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Losartan H, tablets, film-coated, 12.5 + 100 mg Ltd. "Ozone", Russian and Cozaar-Plus tablets, film-coated, 12.5 + 100 mg "Merck Sharp &amp; Dohme BV," United Kingdom, in healthy volunteers</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">GL-1/24012014</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication><Indication id="65">Stroke</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Losartan H</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>losartan potassium + hydrochlorothiazide (hypertension), Merck &amp; Co</Name><Drug id="70334">losartan potassium + hydrochlorothiazide (hypertension), Merck &amp; Co</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1090922" type="Company"><TargetEntity id="5040790846" type="organizationId">Atoll OOO</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"/><TargetEntity id="-1815339002" type="omicsDisease"/><TargetEntity id="93" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1090922">Atoll LLC</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="175">Drug combination</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>34</PatientCountEnrollment><DateStart>2014-08-11T00:00:00Z</DateStart><DateEnd type="estimated">2016-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-10-26T22:00:59Z</DateChangeLast><DateAdded>2014-08-15T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy volunteers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Pharmacokinetics</Description></Measure><Measure><Description>Bioequivalence</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A comparative study of the bioequivalence of drugs Losartan H (hydrochlorothiazide + losartan)  film-coated tablets 12.5 + 100 mg  (Ozone Ltd.) and &lt;ulink linkType="Drug" linkID="70334"&gt;Cozaar-Plus&lt;/ulink&gt; tablets, film-coated 12.5 + 100 mg (Merck Sharp &amp;amp; Dohme BV, UK).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Russian Federation"><Sites><Site><Name>Regional Budget Institution of Health "Cardio Clinic"</Name><Address1>Ivanovo</Address1><Address3>153012</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="388"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="391">Assessment of Bioequivalence</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24287"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="212367"><TitleDisplay>Autologous stem cell transplantation following maintenance therapy in multiple myeloma</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="1828">Multiple myeloma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Autologous stem cell transplantation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bortezomib</Name><Drug id="15954">bortezomib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>interferon</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lenalidomide</Name><Drug id="27572">lenalidomide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>thalidomide, Celgene</Name><Drug id="8050">thalidomide, Celgene</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>bortezomib</Name><Drug id="15954">bortezomib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15954">bortezomib</Drug><IndicationsPioneer/><Companies><Company><Company id="1047580">St. Petersburg State Pavlov Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15954">bortezomib</Drug><IndicationsPioneer/><Companies><Company><Company id="1047580">St. Petersburg State Pavlov Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="27572">lenalidomide</Drug><IndicationsPioneer/><Companies><Company><Company id="1047580">St. Petersburg State Pavlov Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8050">thalidomide, Celgene</Drug><IndicationsPioneer/><Companies><Company><Company id="1047580">St. Petersburg State Pavlov Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15954" type="Drug"><TargetEntity id="260757" type="siDrug">Bortezomib</TargetEntity><TargetEntity id="260757" type="siDrug">Bortezomib</TargetEntity></SourceEntity><SourceEntity id="27572" type="Drug"><TargetEntity id="277395" type="siDrug">Lenalidomide</TargetEntity></SourceEntity><SourceEntity id="8050" type="Drug"><TargetEntity id="91361" type="siDrug">Thalidomide</TargetEntity></SourceEntity><SourceEntity id="1047580" type="Company"><TargetEntity id="5035546352" type="organizationId">St Petersburg State Pavlov Medical University</TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"/><TargetEntity id="10028228" type="MEDDRA"/><TargetEntity id="D009101" type="MeSH"/><TargetEntity id="29073" type="ORPHANET"/><TargetEntity id="-18870694" type="omicsDisease"/><TargetEntity id="710" type="siCondition"/></SourceEntity><SourceEntity id="4917" type="Action"><TargetEntity id="1125" type="Mechanism">Proteasome Inhibitors</TargetEntity><TargetEntity id="3073" type="Mechanism">Immunoproteasome Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1047580">St. Petersburg State Pavlov Medical University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4917">Proteasome inhibitor</Action><Action id="76469">26S proteasome complex inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="1594">Antibacterial</Class><Class id="1596">Immunomodulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="382">TNF alpha synthesis inhibitor</Class><Class id="61">Angiogenesis inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>91</PatientCountEnrollment><PatientCountEvaluable>91</PatientCountEvaluable><DateChangeLast>2017-05-11T16:00:15Z</DateChangeLast><DateAdded>2014-10-08T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with multiple myeloma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Overall survival (OS)</Description></Measure><Measure><Description>Progression free survival (PFS)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to determine the effect of autologous stem cell transplantation following maintenance therapy in multiple myeloma [&lt;ulink linkType="Reference" linkID="1599744"&gt;1599744&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In 2014, results were published. Complete or near complete response was seen in 51 patients and partial response was seen in 37 patients and stabilization was seen in three patients. After steroid maintenance therapy, overall survival (OS) was 43% at 90 months and median OS was 81 months. In patients treated with &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; , OS was 41% at 80 months and medium OS was 85 months. In patients treated with &lt;ulink linkType="Drug" linkID="8050"&gt;thalidomide&lt;/ulink&gt;, OS at 60 months was 62% and medium OS was not achieved. In patients who received interferon, OS was 20% at 120 months and medium OS was 58 months. Statistical difference was found between groups  (p = 0.01). Medium PFS in patients who received maintenance therapy was 40  months and In patients who were on no-maintenance therapy it was 23 months. At eight years, PFS was 31 and 21% in patients who received maintenance therapy and no-maintenance therapy, respectively (p = 0.03). In patients treated with &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; , PFS was 71% at five years and medium PFS was not achieved. PFS in patients who were treated with &lt;ulink linkType="Drug" linkID="8050"&gt;thalidomide&lt;/ulink&gt; and  at high risk was 61% at 40 months and medium PFS was not achieved. PFS was 32 and 8% at five years in patients who received steroids and interferon respectively with a 	statistical difference (p = -0.04)  [&lt;ulink linkType="Reference" linkID="1599744"&gt;1599744&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received single or tandem transplantation. A total of 58 out of 91 patients received maintenance therapy. Patients (n = 16) received &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; with or without dexamethasone. A total of 15 patients received interferon and 20 patients received steroids and seven patients received immunomodulatory drugs like &lt;ulink linkType="Drug" linkID="8050"&gt;thalidomide&lt;/ulink&gt; (n = 5),&lt;ulink linkType="Drug" linkID="27572"&gt; lenalidomide&lt;/ulink&gt; (n = 2) [&lt;ulink linkType="Reference" linkID="1599744"&gt;1599744&lt;/ulink&gt;] .&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-10-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="216090"><TitleDisplay>Efficacy and safety of adjuvant intra-articular corticosteroids in bacterial arthritis</TitleDisplay><TitleOfficial>Efficacy and safety of adjuvant intra-articular corticosteroids in bacterial arthritis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">NTR855</Identifier><Identifier type="Trial Acronym">BACI trial</Identifier></Identifiers><Indications><Indication id="747">Infectious arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Disease marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="579" role="Disease marker" type="Genomic;Proteomic">Cartilage oligomeric matrix protein</BiomarkerName><BiomarkerName id="781" role="Disease marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>corticosteroids</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="26011" type="Company"><TargetEntity id="5035524344" type="organizationId">Academic Medical Center</TargetEntity></SourceEntity><SourceEntity id="747" type="ciIndication"><TargetEntity id="10060968" type="MEDDRA"/><TargetEntity id="D001170" type="MeSH"/><TargetEntity id="-1191643844" type="omicsDisease"/><TargetEntity id="726" type="siCondition"/><TargetEntity id="722" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="26011">Academic Medical Center, University of Amsterdam</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2006-03-09T00:00:00Z</DateStart><DateChangeLast>2019-06-12T03:12:34Z</DateChangeLast><DateAdded>2014-11-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>j.t.van_dissel@lumc.nl</Email><Name>Prof. dr. J.T. Dissel, van</Name><Phone>+31715262613</Phone></Contact><Contact type="Scientific contact"><Email>j.t.van_dissel@lumc.nl</Email><Name>Prof. dr. J.T. Dissel, van</Name><Phone>+31715262613</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provision of a written informed consent&lt;/li&gt;&lt;li&gt;Age range 18 to 85 years&lt;/li&gt;&lt;li&gt;Bacterial arthritis of at least on of the following native joints: wrist, elbow, shoulder, knee or ankle&lt;/li&gt;&lt;li&gt;Positive culture of synovial fluid&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Adequate antibiotic therapy&amp;gt; 72 h at time of inclusion&lt;/li&gt;&lt;li&gt;Overt signs of osteomyelitis on conventional X rays&lt;/li&gt;&lt;li&gt;Bacterial arthritis of a prosthetic joint&lt;/li&gt;&lt;li&gt;Surgical drainage of the infected joint before inclusion&lt;/li&gt;&lt;li&gt;Need for surgical drainage at time of inclusion&lt;/li&gt;&lt;li&gt;Bacterial arthritis due to Borrelia burgdorferi or mycobacteria&lt;/li&gt;&lt;li&gt;Allergy for corticosteroids&lt;/li&gt;&lt;li&gt;Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude&lt;/li&gt;&lt;li&gt;Clinical judgment by the investigator that the subject should not participate in the study, such as severe co-morbidity&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The difference of the range of Blantyre Septic Joint Score (BSJS) measurements between placebo and active treatment group</Description><Timeframe>At multiple corresponding time points</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>ESR and CRP</Description></Measure><Measure><Description>Cartilage Oligomeric Matrix Protein (COMP)</Description></Measure><Measure><Description>Radiological joint damage</Description></Measure><Measure><Description>Measurement of Health Status with SF-36</Description></Measure><Measure><Description>Visual Analog Scale (VAS) measurements</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial is to study whether adjuvant intra-articular corticosteroids reduce the clinical signs and symptoms of bacterial arthritis and improve outcome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive either intra-articular corticosteroid injection or placebo, after 72 h of adequate antibiotic regimen for bacterial artritis.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1015">Netherlands Trial Registry (NTR)</Name><Identifiers><Identifier type="Secondary Organisational">NTR855</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-11-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="218289"><TitleDisplay>A Multicenter, Baseline-controlled, Exploratory Study of Gait Improvement Effects Through a Gait Program Using a Dedicated Hoist in Patients with HTLV-1-associated Myelopathy (HAM)</TitleDisplay><TitleOfficial>A Multicenter, Baseline-controlled, Exploratory Study of Gait Improvement Effects Through a Gait Program Using a Dedicated Hoist in Patients with HTLV-1-associated Myelopathy (HAM)(Study HHH-1001)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">HHH-1001</Identifier><Identifier type="Other">JMA-IIA00203</Identifier></Identifiers><Indications><Indication id="2920">Spinal cord disease</Indication></Indications><BiomarkerNames><BiomarkerName id="48189" role="Therapeutic effect marker" type="Physiological">Gait</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Gait training program</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>HAL-HN01</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1041701" type="Company"><TargetEntity id="5000044890" type="organizationId">Japan, Ministry Of Health Labour And Welfare(Government)</TargetEntity></SourceEntity><SourceEntity id="1103974" type="Company"><TargetEntity id="5044175842" type="organizationId">National Hospital Organization Niigata Hospital</TargetEntity></SourceEntity><SourceEntity id="2920" type="ciIndication"><TargetEntity id="10061367" type="MEDDRA"/><TargetEntity id="D013118" type="MeSH"/><TargetEntity id="-1096918096" type="omicsDisease"/><TargetEntity id="176" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1103974">National Hospital Organization Niigata Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1041701">Japanese Ministry of Health, Labor and Welfare</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2014-02-17T00:00:00Z</DateStart><DateEnd type="actual">2016-08-31T00:00:00Z</DateEnd><DateChangeLast>2017-05-18T16:00:17Z</DateChangeLast><DateAdded>2014-12-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Niigata National Hospital, National Hospital Organization</Affiliation><Email>kenkyuuhan@niigata-nh.go.jp</Email><Name>Takashi Nakajima</Name><Phone>+81-257-22-2130</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Capable of providing written consent. If the patient has sufficient ability to give consent but has difficulty writing due to disease progression, written consent is to be obtained from the patient's legally acceptable representative after confirming that the subject himself/herself consents to participate in the study&lt;/li&gt;&lt;li&gt;Aged &gt;/= 18 years at the time of providing consent. In the case of minors aged&amp;lt; 20 years, a person with parental authority or the guardian is required to affix their name and seal or sign the consent form in addition to the name and seal or the signature of the patient&lt;/li&gt;&lt;li&gt;Onset of HAM at least two years ago&lt;/li&gt;&lt;li&gt;No abrupt changes in gait symptoms or changes in the grade of Osame's motor disability scale during the previous 3 months based on evaluation by the investigator or subinvestigator&lt;/li&gt;&lt;li&gt;Incapable of walking 10 m independently and safely without a cane, walker, or handrail due to ambulation disorder associated with HAM but capable of walking 10 m or more with minor assistance, eg, holding a handrail, walker, or movable hoist (an assistive device may be placed on the lower limb when necessary)&lt;/li&gt;&lt;li&gt;Capable of performing the visits on an outpatient or inpatient basis according to the study schedule during the study period&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients for whom gait training is considered difficult due to dyspnea on exertipn, heart failure, arrhythmia, myocardial infarction, or other conditions&lt;/li&gt;&lt;li&gt;Patients complicated with spinal cord compression lesions due to spinal stenosis, such as spondylosis deformans, ossification of posterior longitudinal ligament, and calcification of ligamentum flavum, for whom gait training is considered difficult&lt;/li&gt;&lt;li&gt;Patients for whom gait training is considered difficult due to severe skeletal deformation, such as osteoarthritis of the hip or knee, poorly controlled rheumatoid arthritis, and scoliosis&lt;/li&gt;&lt;li&gt;Gait disturbance due to diseases of the brain, spinal cord, peripheral nerves, and muscles other than HAM&lt;/li&gt;&lt;li&gt;Complications that cause problems in gait exercise, such as tendency to bleed and osteoporosis&lt;/li&gt;&lt;li&gt;Serious hepatic disorder, renal disorder, or cardiovascular disease ('serious diseases' will be assessed using grade 3 as specified in the Seriousness Grading Criteria for Adverse Reactions to Pharmaceuticals [PAB/SD Notification No 80 issued by Director, Safety Division, Pharmaceutical Affairs Bureau, MHW] as a reference)&lt;/li&gt;&lt;li&gt;Malignant tumor that has not been completely cured&lt;/li&gt;&lt;li&gt;Administered the following drugs within 6 months of the pre-observation (visit 1):&lt;ul&gt;&lt;li&gt;Interferon-alpha&lt;/li&gt;&lt;li&gt;Botox injection&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Received steroid pulse therapy within 3 months of the pre-observation (visit 1)&lt;/li&gt;&lt;li&gt;The daily dosage of the following drugs was changed within 2 months of the pre-observation (visit 1):&lt;ul&gt;&lt;li&gt;Steroids (other than topical application, such as skin application and inhalation)&lt;/li&gt;&lt;li&gt;Salazosulfapyridine and other immunosuppressants&lt;/li&gt;&lt;li&gt;Erythromycin&lt;/li&gt;&lt;li&gt;Antispastics (tizanidine hydrochloride, eperisone hydrochloride, baclofen, etc)&lt;/li&gt;&lt;li&gt;Drugs for neuropathic pain (pregabalin, duloxetine hydrochloride, amitriptyline hydrochloride, clonazepam, etc)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The daily dosage of the following drugs was changed within 2 weeks of the pre-observation (visit 1):&lt;ul&gt;&lt;li&gt;Vitamin C&lt;/li&gt;&lt;li&gt;Casei Shirota strain&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;A rehabilitation program for gait improvement was newly started, discontinued, or significantly changed in frequency within 2 months of the pre-observation (visit 1)&lt;/li&gt;&lt;li&gt;Bone fracture, bruise, trauma, or other complications necessitating hospitalization for treatment within 3 months of the pre-observation (visit 1)&lt;/li&gt;&lt;li&gt;Pregnant patients and patients who may be pregnant; Patients willing to become pregnant during the study&lt;/li&gt;&lt;li&gt;Participated in other clinical studies or clinical trials within 12 weeks of the pre-observation (visit 1)&lt;/li&gt;&lt;li&gt;Underwent gait training using HALR for well-being, etc, or wearing a dedicated hoist within one year&lt;/li&gt;&lt;li&gt;Ineligibility for participating in this study according to the investigator or subinvestigator&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Walking distance: 2-min walk test</Description><Timeframe>Visits 1, 2, 5, 8, and, 11</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The 10-m walk test</Description><Timeframe>Visits 2, 5, 8, and, 11</Timeframe></Measure><Measure><Description>Osame's Motor Disability Score (OMDS)</Description></Measure><Measure><Description>Evaluation of spasticity (Modified Ashworth scale [MAS])</Description></Measure><Measure><Description>Duration of lower extremity clonus (SCATS Clonus scale)</Description></Measure><Measure><Description>Manual Muscle Test (MMT)</Description></Measure><Measure><Description>ADL assessment (Barthel index)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objectives of this multicenter, exploratory study were:&lt;br/&gt;To collect and analyze data on gait improvement effects through a gait program using a dedicated hoist as preparation for a clinical trial.&lt;br/&gt;To verify a hypothesis that the hybrid assistive limb model for intractable rare neuromuscular diseases in lower limbs (HAL-HN01), a wearable robot developed for intractable rare neuromuscular diseases, significantly improves gait disturbance in patients with HTLV-1-associated myelopathy (HAM).&lt;br/&gt;To examine the design of the clinical trial of HAL-HN01 scheduled for the future.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The treatment period would be started from the day after visit 1 and by 2 weeks after visit 1. Following the evaluation at the start of the treatment period, the once-daily, 40-min gait program would  be implemented using the dedicated hoist for nine sessions. Evaluation would occur 1 to 7 days (preferably within 3 days) after the last session of the gait program. The nine sessions of the gait program should be completed within 13 weeks. The program may be implemented up to four times a week, but implementation for 3 or more consecutive days would not be acceptable. The investigators would determine the frequency of implementation of gait program in consideration of subject conditions, such as muscle fatigue and pain.&lt;/para&gt;&lt;para&gt;This gait program would consist of walk training lasting for a total of 40 min, consisting of warming up, walking exercise, and cooling down. The walking exercise using HAL-HN01 with hoist would be started after warming up for about 5 min. After the walking exercise, stretching of extremities and trunk would be performed for the cooling down period. During the walking exercise, the subject may rest depending on his/her condition; however, the total resting time should not exceed 20 min.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Address1>Kanagawa</Address1><Contacts/></Site><Site><Address1>Niigata</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1005">Japan Medical Association - Center for Clinical Trials (JMACCT CTR)</Name><Identifiers><Identifier>JMA-IIA00203</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-12-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-09-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="219822"><TitleDisplay>A single-center, phase I trial to determine MEC (minimum Effective Concentration) and MEAC (Minimum Effective Analgesic Concentration) of Intravenous Oxycodone in Major Intra-abdominal Open Surgeries</TitleDisplay><TitleOfficial>A single-center, phase I trial to determine MEC (minimum Effective Concentration) and MEAC (Minimum Effective Analgesic Concentration) of Intravenous Oxycodone in Major Intra-abdominal Open Surgeries</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Other">KCT0001340</Identifier><Identifier type="Other">OXI13-KR-102</Identifier><Identifier type="Other">2014- 0601</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication><Indication id="4010">Abdominal surgery</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>oxycodone hydrochloride, Mundipharma Korea Ltd</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1093508" type="Company"><TargetEntity id="5041750217" type="organizationId">Mundipharma Korea Ltd</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1093508">Mundipharma Korea Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Single Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><PatientCountEvaluable>50</PatientCountEvaluable><DateStart>2014-08-27T00:00:00Z</DateStart><DateEnd type="actual">2015-03-17T00:00:00Z</DateEnd><DateChangeLast>2017-10-27T22:01:20Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Asan Medical Center</Affiliation><Name>Noh Gyujeong</Name></Contact><Contact type="Public contact"><Affiliation>Asan Medical Center</Affiliation><Name>Jeongsim Yang</Name></Contact><Contact type="Public contact"><Affiliation>Mundipharma Korea</Affiliation><Name>Seunghee Lee</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female patient at the age of 20 or above&lt;/li&gt;&lt;li&gt;American society of anesthesiologist physical status 1 or 2&lt;/li&gt;&lt;li&gt;Patient planned to have stomach, colorectal, and hepatobiliary surgery&lt;/li&gt;&lt;li&gt;Patient who signed the informed consent form (ICF)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnant or lactating woman; pregnancy is defined as the time period from after conception to the end of gestation and is to be confirmed by urine test&lt;/li&gt;&lt;li&gt;Known hypersensitivity reactions to oxycodone or its excipients or any other opioids&lt;/li&gt;&lt;li&gt;Serious respiratory dysfunction or respiratory depression&lt;/li&gt;&lt;li&gt;Current or past treatment with monoamine oxidase inhibitors (MAOIs) within 2 weeks&lt;/li&gt;&lt;li&gt;Convulsive disorder, head injury, decreased level of consciousness of unknown cause, intracranial lesion, increased intracranial pressure, or serious liver injury&lt;/li&gt;&lt;li&gt;Treatment with other central nerve system depressants that may induce respiratory depression, hypotension, deep sedation, or coma&lt;/li&gt;&lt;li&gt;Applicable to contraindications for oxycodone as listed in the Investigators brochure or package insert&lt;/li&gt;&lt;li&gt;Clinically significant cardiovascular, respiratory, hepatobiliary, or renal impairment&lt;/li&gt;&lt;li&gt;Patient considered by the investigator to be not appropriate for study participation due to other reasons not mentioned in the inclusion/exclusion criteria&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Minimum effective analgesic concentration (MEAC) of intravenous oxycodone in major intra-abdominal open surgeries: blood sample was obtained after titration with 2 mg of oxycodone to yield wound pain &lt; 3 at rest and &lt; 5 during wound compression, and MEAC was determined</Description><Timeframe>In Post-anesthesia care unit (PACU) for 4 h</Timeframe></Measure><Measure><Description>Minimum effective concentration (MEC) of intravenous oxycodone in major intra-abdominal open surgeries: the wound pain at rest and during compression was rated as &gt;/= 3 or &gt;/= 5, respectively, the first blood sample was obtained to determine the MEC</Description><Timeframe>In Post-anesthesia care unit (PACU) for 4 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to assess the MEC and MEAC of intravenous oxycodone in major intra-abdominal open surgeries such as gastrointestinal, colonic, and hepatobiliary surgeries.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2017, results were published. In patients (n = 50), the median MEC and MEAC were 31.5 and 74.1 ng/ml, respectively, in first measurement and 63.4 and 76.1 ng/ml, respectively, in second measurement [&lt;ulink linkType="Reference" linkID="1910674"&gt;1910674&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive oxycodone 0.1 mg/kg iv PCA immediately after the end of skin suture, followed by oxycodone 2 mg if body weight is &amp;lt; 80 kg or oxycodone 3 mg if body weight is &gt;/= 80 kg.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patient received oxycodone(0.1 mg/kg) iv, 30 min before the end of the surgery and were placed in the postoperative anaesthesia care unit (PACU). Patients were asked to rate their pain every 10min using a visual analogue scale (0 = no pain, 10 = most severe pain) [&lt;ulink linkType="Reference" linkID="1910674"&gt;1910674&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="502032">oxycodone hydrochloride, Mundipharma Korea Ltd</Intervention><Treatments><Treatment><Dose>2 milligram</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>3 milligram</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>0.1 milligram/kg</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Asan Medical Center</Name><Address1>Seoul</Address1><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8425">Subjects in need of Procedural Analgesia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1010">Korea Clinical Research Information Service (CRiS)</Name><Identifiers><Identifier>KCT0001340</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20179"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-03-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-03-24T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="220401"><TitleDisplay>Effect of resistance physical training periodization on women with Hyperandrogenic Anovulation</TitleDisplay><TitleOfficial>Effect of resistance physical training periodization on women with Hyperandrogenic Anovulation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">RBR-7p23c3</Identifier><Identifier type="Other">13475 /2009</Identifier><Identifier type="Other">U111111570262</Identifier></Identifiers><Indications><Indication id="112">Endocrine disease</Indication></Indications><BiomarkerNames><BiomarkerName id="2643" role="Therapeutic effect marker" type="Genomic">Telomere length</BiomarkerName><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>physical training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1046329" type="Company"><TargetEntity id="5035546157" type="organizationId">Fundacao De Apoio Ao Ensino  Pesquisa E Assistencia Do Hospital Das Clinicas Da Fmrpusp</TargetEntity></SourceEntity><SourceEntity id="1053098" type="Company"><TargetEntity id="5035549474" type="organizationId">Fundacao Hemocentro de Ribeirao Preto</TargetEntity></SourceEntity><SourceEntity id="1072874" type="Company"><TargetEntity id="5037843891" type="organizationId">Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira</TargetEntity></SourceEntity><SourceEntity id="CM28215" type="Company"><TargetEntity id="5035561052" type="organizationId">National Council for Scientific and Technological Development</TargetEntity></SourceEntity><SourceEntity id="112" type="ciIndication"><TargetEntity id="10014698" type="MEDDRA"/><TargetEntity id="D004700" type="MeSH"/><TargetEntity id="-202336293" type="omicsDisease"/><TargetEntity id="501" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1053098">Fundacao Hemocentro de Ribeirao Preto</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1046329">Fundacao De Apoio Ao Ensino, Pesquisa E Assistencia Do Hospital Das Clinicas Da FMRPUSP</Company><Company id="1072874">Instituto do Cancer do Estado de So Paulo</Company><Company id="CM28215">Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2010-08-31T00:00:00Z</DateStart><DateChangeLast>2018-06-23T09:48:30Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Faculdade de Medicina de Ribeiro Preto</Affiliation><Email>romareis@fmrp.usp.br</Email><Name>Rosana Maria dos Reis</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age between 18 to 37 years&lt;/li&gt;&lt;li&gt;Body Mass Index between 18 and 39.9 kg/m2 (normal overweight and obesity grades I and II)&lt;/li&gt;&lt;li&gt;Do not practice regular physical activity&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Presence of systemic disease that indicate against the practice of physical activity&lt;/li&gt;&lt;li&gt;Presence of disabling musculoskeletal disorders; use of drugs that interfere with the hypothalamic-pituitary ovarian axis and hormonal contraceptives&lt;/li&gt;&lt;li&gt;Smoking; pregnant&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Increased muscle strength in all subjects, verified by comparative analysis before and after a period of four months of intervention with the protocol of physical resistance training</Description></Measure><Measure><Description>Women with polycystic ovary syndrome, because they are hyperandrogenic, have more muscle strength than women with regular menstrual cycles</Description></Measure><Measure><Description>The periodized physical exercise improved body composition and increased telomere length in leukocytes</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To measure the outcome, the one repetition maximum (1-RM) test was employed as a noninvasive measure of muscle strength These test was conducted after two weeks of familiarisation, in which four exercises were performed per day, being separated by two days or 48 hours, for muscle recovery and avoiding influences from other exercises on testing. Body composition was assessed by bone densitometry (X-ray Dual-energy absorptiometry, DXA) and telomere length was measured by Real Time Polymerase Chain Reaction</Description></Measure><Measure><Description>To investigate outcomes, considering a 10% difference in muscle strength between in groups, with 80% power and alpha = 0.05, 120 participants would be needed, considering previously published studies to muscle strength in young women: bench press = 29.54 +/- 5,37 kg (mean +/- standard deviation); leg extension = 41.09 +/- 18,78 kg; barbell and 16.00 +/- 3.13</Description></Measure><Measure><Description>Body Composition Measurement</Description></Measure><Measure><Description>Body Composition was evaluated by Dual-energy X-ray absorptiometry (DEXA), bioimpedance and skinfold thickness measurement</Description></Measure><Measure><Description>The periodized physical resistance exercise improved body composition regardless of whether or not the polycystic ovary syndrome (PCOS), and PCOS patients had a reduction of central fat (distribution of gynoide fat)</Description></Measure><Measure><Description>Telemere Lenght Measurement</Description></Measure><Measure><Description>Telomere length was measured by Quantitative Real Time Polymerase Chain Reaction (qPCR)</Description></Measure><Measure><Description>Telomere length was reduced after Physical Resistance Training considering all women in the present study, regardless of whether or not the polycystic ovary syndrome (PCOS)</Description></Measure><Measure><Description>Quality of life</Description></Measure><Measure><Description>Quality of life was verified by Short Form Health Survey (SF36), Index of Female Sexual Function (IFSF) and Hospital Anxiety and Depression Scale (HADS)</Description></Measure><Measure><Description>After physical resistance training there was an improvement in quality of life, although this benefit has not persisted after discontinuation of training</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to assess the effect of resistance physical training periodization on women with Hyperandrogenic Anovulation&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Atotal of  120 women participated in a linear periodization of physical training for a period of 4 months, three times per week, during 1 h, preceded by adaptation of 2 weeks or 6 sessions and test dynamic muscle strength of 1 repetition maximum (1-RM).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1020">Brazilian Clinical Trials Registry (ReBec)</Name><Identifiers><Identifier>RBR-7p23c3</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><DateEnrollmentEnd type="actual">2013-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>40.03 Months</EnrollmentPeriod><EnrollmentRate>3.00 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type><Type>Government</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="224992"><TitleDisplay>Rheolytic Thrombectomy For Adult Intraventricular Hemorrhage</TitleDisplay><TitleOfficial>Rheolytic Thrombectomy For Adult Intraventricular Hemorrhage</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02394678</Identifier><Identifier type="Organisational Study">A093205</Identifier><Identifier type="Trial Acronym">rtIVH</Identifier></Identifiers><Indications><Indication id="552">Bleeding</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>AngioJet Thrombectomy System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Rheolytic thrombectomy (RT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1041090" type="Company"><TargetEntity id="5035543661" type="organizationId">Cambridge University Hospitals Nhs Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="552" type="ciIndication"><TargetEntity id="10055798" type="MEDDRA"/><TargetEntity id="D006470" type="MeSH"/><TargetEntity id="-1283225934" type="omicsDisease"/><TargetEntity id="327" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1041090">Cambridge University Hospitals NHS Foundation Trust</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2015-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-05-31T00:00:00Z</DateEnd><DateChangeLast>2015-04-07T02:06:30Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>pjk21@medschl.cam.ac.uk</Email><Name>Peter J Kirkpatrick, FRCS(SN)</Name></Contact><Contact type="Public contact"><Email>karol.budohoski@gmail.com</Email><Name>Karol P Budohoski, MD, PhD</Name></Contact></Contacts><MeasuresOutcome><MeasuresPrimary><Measure><Description>Clearance of intraventricular blood measured on CT</Description><Timeframe>96 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>14-day survival</Description><Timeframe>14 days</Timeframe></Measure><Measure><Description>Culture-proven CNS infection</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Duration of external ventricular drainage</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Intra- or post-operative rebleeding</Description><Timeframe>96 h</Timeframe></Measure><Measure><Description>Modified Rankin Score</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Permanent CSF diversion</Description><Timeframe>Two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust</Name><Address1>Cambridge</Address1><Address3>CB2 0QQ</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02394678</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10360"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Thrombosis" id="10256"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thrombosis" id="10344"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10368">Assessment of infections</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thrombosis" id="10350"><Endpoint>Assessment of Survival</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thrombosis" id="28010"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="28024">Assessment by Modified Rankin Scale (MRS) Score</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Thrombosis" id="10344"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10345">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thrombosis" id="6000"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="6013">Subjects scheduled for other major surgeries</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="6027"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7578"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Thrombosis" id="26665"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7823">Subjects with thrombotic thrombocytopenic purpura</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-05-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="23850"><TitleDisplay>Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin</TitleDisplay><TitleOfficial>Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">06-077</Identifier><Identifier type="NCT">NCT00423852</Identifier><Identifier type="Secondary Organisational">MSKCC-06077</Identifier></Identifiers><Indications><Indication id="3737">Germ cell and embryonic cancer</Indication><Indication id="759">Central nervous system tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="67" role="Disease marker" type="Genomic;Proteomic">Alpha-fetoprotein</BiomarkerName><BiomarkerName id="17251" role="Disease marker" type="Biochemical">Human chorionic gonadotropin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>autologous PBSCs</Name></Intervention><Intervention type="InterventionPrimary"><Name>carboplatin</Name><Drug id="44383">carboplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>filgrastim</Name><Drug id="3130">filgrastim</Drug></Intervention><Intervention type="InterventionPrimary"><Name>ifosfamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel + ifosfamide + carboplatin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3130">filgrastim</Drug><IndicationsPioneer/><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44383">carboplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="44383" type="Drug"><TargetEntity id="125568" type="siDrug">Carboplatin</TargetEntity></SourceEntity><SourceEntity id="3130" type="Drug"><TargetEntity id="178994" type="siDrug">Filgrastim</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="22122" type="Company"><TargetEntity id="4296508772" type="organizationId">Memorial Sloan-Kettering Cancer Center</TargetEntity></SourceEntity><SourceEntity id="3737" type="ciIndication"><TargetEntity id="D009373" type="MeSH"/><TargetEntity id="-720598874" type="omicsDisease"/><TargetEntity id="603" type="siCondition"/></SourceEntity><SourceEntity id="759" type="ciIndication"><TargetEntity id="10007958" type="MEDDRA"/><TargetEntity id="D016543" type="MeSH"/></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3151">GCSF receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="50">Anticancer alkylating agent</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="127">Cell culture</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>26</PatientCountEnrollment><PatientCountEvaluable>26</PatientCountEvaluable><DateStart>2006-08-31T00:00:00Z</DateStart><DateEnd type="actual">2013-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-06-09T04:13:54Z</DateChangeLast><DateAdded>2008-09-11T12:56:58Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Memorial Sloan-Kettering Cancer Center</Affiliation><Name>Robert Motzer</Name></Contact><Contact type="Scientific contact"><Affiliation>Memorial Sloan Kettering Cancer Center</Affiliation><Name>Darren Feldman, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically confirmed germ cell tumor (GCT):&lt;ul&gt;&lt;li&gt;Primary CNS GCT allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Unidimensionally measurable disease OR elevated serum tumor markers (alpha-fetoprotein and/or human chorionic gonadotropin)&lt;/li&gt;&lt;li&gt;Advanced disease:&lt;ul&gt;&lt;li&gt;Disease resistant to a cisplatin-based chemotherapy regimen (ie, failed to achieve a durable complete response to cisplatin)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Known residual disease after post-chemotherapy surgery allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Platelet count &gt;/= 100,000/mm3&lt;/li&gt;&lt;li&gt;WBC &gt;/= 3000/mm3&lt;/li&gt;&lt;li&gt;Creatinine clearance &gt; 50 ml/min (unless due to tumor obstructing the ureters)&lt;/li&gt;&lt;li&gt;AST and ALT&amp;lt; 2 x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Bilirubin&amp;lt; 1.5 x ULN&lt;/li&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;li&gt;No active infection&lt;/li&gt;&lt;li&gt;Negative serology for HIV type I and II, human T-lymphotropic virus type I and II, hepatitis B or C virus, syphilis, and cytomegalovirus:&lt;ul&gt;&lt;li&gt;Hepatitis C negative serology by RIBA or PCR&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate medical condition for general anesthesia&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;Recovered from recent surgery&lt;/li&gt;&lt;li&gt;At least 3 weeks since prior chemotherapy&lt;/li&gt;&lt;li&gt;No prior high-dose therapy with autologous bone marrow transplantation&lt;/li&gt;&lt;li&gt;No other concurrent chemotherapy&lt;/li&gt;&lt;li&gt;No other concurrent treatment (eg, surgery or radiotherapy)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum Tolerated Dose of Ifosfamide</Description><Timeframe>Four years</Timeframe></Measure><Measure><Description>Response (complete  and partial): Response assessed at the completion of therapy (after four to five cycles of chemotherapy and after surgery if necessary). Complete Response (CR): A complete response is defined as one of the following: Complete disappearance of all clinical and radiographic and biochemical (normal AFP and HCG) evidence of disease for a minimum of 4 weeks (CR to chemotherapy), Complete disappearance of all biochemical evidence of disease with resection of residual radiographic masses that prove to be negative for residual GCT; this includes both mature teratoma and necrotic debris (CR to chemotherapy) for a minimum of 4 weeks, Complete disappearance of all biochemical evidence of disease with complete surgical excision of all residual radiographic masses that, if pathologically positive for residual malignant GCT, show margins to microscopically free of disease (CR to chemotherapy + surgery). Patients must be free of disease for a minimum of 4 weeks</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Efficacy</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Safety</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Phase II: complete response (CR) rate at the MTD: estimated using Simon two-stage design</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2015, results were published. No dose-limiting toxicities were observed. A total of three  phase II patients developed delayed chronic kidney disease, which resulted  in premature trial closure [&lt;ulink linkType="Reference" linkID="1726503"&gt;1726503&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase I/II trial was to study the side effects and best dose of ifosfamide when given together with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; followed by an autologous stem cell transplant and to see how well they work in treating patients with germ cell tumors that did not respond to cisplatin. &lt;/para&gt;&lt;para&gt;The objectives of this study were to:&lt;br/&gt;Determine the safety of paclitaxel and ifosfamide followed by dose-escalated, dose-intensive paclitaxel, carboplatin, and ifosfamide with autologous peripheral blood stem cell support in patients with cisplatin-resistant germ cell tumor (Phase I).&lt;br/&gt;Determine the maximum tolerated dose of paclitaxel, carboplatin, and ifosfamide when given with a high-dose treatment program in these patients (Phase I).&lt;br/&gt;Determine the efficacy of this regimen when given as salvage therapy in the second-line or third-line setting, in terms of complete response, in these patients (Phase II).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2015, results were published. The maximum tolerated dose (MTD) was not reached and the highest prespecified dose level was considered the MTD. The highest prespecified dose levels were paclitaxel 250 mg/m2, ifosfamide 9990 mg/m2, and carboplatin area under the curve 24. Treatment efficacy was demonstrated in 7 out of 11 phase II patients who achieved a CR [&lt;ulink linkType="Reference" linkID="1726503"&gt;1726503&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This would be a phase I, dose-escalation study of paclitaxel, carboplatin, and ifosfamide followed by a phase II, open-label study:&lt;br/&gt;Phase I: carboplatin, ifosfamide, and paclitaxel would be dose escalated to determine the maximum tolerated dose (MTD).&lt;br/&gt;Paclitaxel, ifosfamide, and autologous peripheral blood stem cell (PBSC) collection: patients would receive paclitaxel iv over 3 h on day 1 and ifosfamide iv over 2 h on days 1 to 3. Patients would undergo leukapheresis on days 11 to 13. Patients would also receive &lt;ulink linkType="Drug" linkID="3130"&gt;filgrastim&lt;/ulink&gt; (G-CSF) sc twice-daily beginning on day 3 and continuing until leukapheresis is completed. Beginning on day 14 or 21, patients might receive a second course of paclitaxel, ifosfamide, and filgrastim. Patients might also undergo additional leukapheresis.&lt;br/&gt;Paclitaxel, carboplatin, ifosfamide, and autologous PBSC transplantation: patients would receive paclitaxel iv over 3 h, high-dose carboplatin iv over 30 min, and ifosfamide iv over 4 h on days 1 to 3. Patients would also receive filgrastim sc beginning on day 3 and continuing until blood counts recover. Patients would undergo reinfusion of autologous PBSCs on day 5. Treatment would repeat every 21 to 28 days for three courses in the absence of disease progression or unacceptable toxicity. &lt;br/&gt;Cohorts of three to six patients would receive escalating doses of paclitaxel, carboplatin, and ifosfamide until the MTD was determined. &lt;/para&gt;&lt;para&gt;Phase II: patients would receive treatment as in phase I with paclitaxel, carboplatin, and ifosfamide at the MTD determined in phase I.&lt;/para&gt;&lt;para&gt;After completion of study treatment, patients would be followed periodically for one year and then annually thereafter. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received  one to two cycles of paclitaxel with ifosfamide and granulocyte colony-stimulating factor for stem cell mobilization followed by three cycles of high-dose paclitaxel, ifosfamide,   carboplatin (TIC) with autologous stem cell transplant (ASCT) every 21 to 28 days. A standard 3 + 3 dose-escalation design was used for  phase I [&lt;ulink linkType="Reference" linkID="1726503"&gt;1726503&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>paclitaxel + ifosfamide + carboplatin</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="3251">End stage renal disease</Indication><CountPatientsTotal>26</CountPatientsTotal><CountPatientsAffected>3</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="38415">ifosfamide</Intervention><Treatments><Treatment><Dose>9990 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="38416">paclitaxel</Intervention><Treatments><Treatment><Dose>250 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Memorial Sloan-Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stem cell transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="10712">Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10714">Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11488">Subjects with H/O Solid Tumours Indicated for SCT</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Ovary tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7890">Subjects with Less Common Ovarian Histopathologies (LCOH)</PatientSegment><SubSegments><SubSegment id="7891">Subjects with ovarian germ cell tumors</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7895">Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7909">Advanced Ovarian Cancer Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Testis tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9295">Subjects with Testicular Germ Cell Tumor (TGCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9307">Subjects with Metastatic Testicular Cancer</PatientSegment><SubSegments><SubSegment id="9308">Subjects with non-pulmonary metastatic testicular cancer</SubSegment><SubSegment id="9310">Subjects with CNS metastasis</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9317">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9673">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9685">Subjects with CNS germ cell tumor</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00423852</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ovary tumor" id="10838"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10842">Assessment of Partial Response (PR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Ovary tumor" id="10900"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Ovary tumor" id="10938"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10961">Assessment of Other Efficacy Parameters</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Ovary tumor" id="10939"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13242"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Testis tumor" id="13245">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Testis tumor" id="13246">Assessment of Complete Response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13286"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13304"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13307"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Testis tumor" id="13308">Assessment of Other Treatment Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13551"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13573"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13576"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13578">Assessment of Other Treatment Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17422"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="19853">Assessment of efficacy/effectiveness of intervention</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17441"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17460"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Testis tumor" id="13286"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Testis tumor" id="13291">Assessment of treatment induced toxicity</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ovary tumor" id="8215"><Criterion>Subjects with Less Common Ovarian Histopathologies (LCOH)</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8216">Ovarian germ cell tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8243"><Criterion>Advanced Ovarian Cancer</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8273"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8274">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="8279">Subjects with history of surgery/procedure for Ovarian Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8281"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8282">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Ovary tumor" id="8283">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="8886"><Criterion>Subjects with Testicular Germ Cell Tumor (TGCT)</Criterion></Inclusion><Inclusion disease="Testis tumor" id="8899"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8900">Subjects with non-pulmonary metastatic testicular cancer</SubCriterion><SubCriterion disease="Testis tumor" id="8902">Subjects with CNS/brain metastases</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="8929"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8930">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Testis tumor" id="8932">Subjects with history of surgery/procedure for Testicular Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="8935"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13037"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13056"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13061">Subjects with history of surgery/procedure for CNS Tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13064"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13065"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13066">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13067">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13072"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13075">Subjects with CNS germ cell tumor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17840"><Criterion>Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</Criterion></Inclusion><Inclusion disease="Stem cell transplantation" id="17850"><Criterion>Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</Criterion></Inclusion><Inclusion disease="Stem cell transplantation" id="17865"><Criterion>Subjects with Solid Tumors Indicated for SCT</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17871">Subjects with tumors originating from germ cells</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17938"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17946">Subjects with Protocol Specified Tumor Characteristics</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="33605"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8220">Platinum-Resistant/Refractory Ovarian Cancer Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34009"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8284">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="34035"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13068">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ovary tumor" id="9810"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="9837"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9838">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9842">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9843">Patient with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Testis tumor" id="10484"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="10485">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Testis tumor" id="10486">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Testis tumor" id="10487">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10641"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10668"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10669">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10673">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stem cell transplantation" id="15718"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15723">Subjects with history of infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stem cell transplantation" id="15780"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15777">Subjects with history of/scheduled to receive radiotherapy</SubCriterion><SubCriterion disease="Stem cell transplantation" id="15802">Subjects with history of/scheduled to receive antineoplastic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="26807"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10671">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stem cell transplantation" id="26893"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15776">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-02-28T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>55.03 Months</EnrollmentPeriod><EnrollmentRate>0.47 Patients/Month</EnrollmentRate><DateFirstReceived>2007-01-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-09-11T12:56:58Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-01-18T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="242144"><TitleDisplay>Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders</TitleDisplay><TitleOfficial>Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02568007</Identifier><Identifier type="Organisational Study">798217</Identifier></Identifiers><Indications><Indication id="106">Eating disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17664" role="Therapeutic effect marker" type="Anthropomorphic">Arm circumference</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cyproheptadine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="21040" type="Company"><TargetEntity id="5000346917" type="organizationId">Medical College of Wisconsin Inc</TargetEntity></SourceEntity><SourceEntity id="106" type="ciIndication"><TargetEntity id="F50" type="ICD10"/><TargetEntity id="307.5" type="ICD9"/><TargetEntity id="10014062" type="MEDDRA"/><TargetEntity id="D001068" type="MeSH"/><TargetEntity id="-2028070801" type="omicsDisease"/><TargetEntity id="41" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="21040">Medical College of Wisconsin</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>75</PatientCountEnrollment><DateStart>2015-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2020-10-31T00:00:00Z</DateEnd><DateChangeLast>2016-04-29T16:00:19Z</DateChangeLast><DateAdded>2015-10-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>cgorges@mcw.edu</Email><Name>Christina Beesley, BS</Name><Phone>414-266-6131</Phone></Contact><Contact type="Scientific contact"><Affiliation>Medical College of Wisconsin Department of Pediatric Gastroenterology</Affiliation><Name>Praveen Goday, MD</Name></Contact><Contact type="Public contact"><Email>pgoday@mcw.edu</Email><Name>Praveen Goday, MD</Name><Phone>414-266-3690</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All children aged 1 to 10 years&lt;/li&gt;&lt;li&gt;Presenting to initial intake appointment with the Pediatric Gastroenterology Feeding Team Clinic at the Children's Hospital of Wisconsin (CHW)&lt;/li&gt;&lt;li&gt;With BMI Z score of&amp;lt;&amp;lt;/= to 0 (normal WHO BMI defined as Z score of -1 to 1)&lt;/li&gt;&lt;li&gt;Who have a parent willing to participate, will qualify for inclusion in the study&lt;/li&gt;&lt;li&gt;Children with vomiting due to presumed volume intolerance may be included in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Untreated organic disease&lt;/li&gt;&lt;li&gt;Anatomical barrier to swallowing or known swallowing disorder&lt;/li&gt;&lt;li&gt;Diagnosis of severe developmental delay or mental retardation&lt;/li&gt;&lt;li&gt;Significant brain pathology or seizure disorder that may affect oropharyngeal motor skills&lt;/li&gt;&lt;li&gt;On medication with known effects on appetite or interactions with cyproheptadine&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Feeding behavior questionnaire: patients guardians will complete the mealtime behavior questionnaire (MBQ). This is a validated, 31-item, parent-report questionnaire assessing the mealtime behavior structure in young children above two years. The questionnaire measures variables including: food refusals/avoidance; food manipulation; mealtime aggression and choking/gagging/vomiting related to meals. Each behavior is assigned a frequency scale with 1 corresponding to 'never' and 5 corresponding to 'always'. The MBQ then consist of a total score and four subcategory scores (listed above)</Description><Timeframe>2 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A 24 h diet recall: change in calorie intake will be recorded</Description><Timeframe>2 months</Timeframe></Measure><Measure><Description>Anthropometrics: BMI: change in BMI as measured by kg/m2 and z-score percentiles</Description><Timeframe>2 months</Timeframe></Measure><Measure><Description>Anthropometrics: mid-arm circumference: change in mid-arm circumference as measure by cm and z-score percentiles</Description><Timeframe>2 months</Timeframe></Measure><Measure><Description>Anthropometrics: skin fold thickness: change in skin fold thickness as measured by cm and z-score percentiles</Description><Timeframe>2 months</Timeframe></Measure><Measure><Description>Anthropometrics: height: change in height as measured in cm and z-score percentiles</Description><Timeframe>2 months</Timeframe></Measure><Measure><Description>Anthropometrics: weight: change in weight as measured in km and z-score percentiles</Description><Timeframe>2 months</Timeframe></Measure><Measure><Description>Percentage of patients experiencing side effects from cyproheptadine: patients will answer affirmative or negative to a descriptive list of side effects commonly experienced when taking cyproheptadine. Examples of these descriptive variables include nausea, emesis, etc. Percentage of patients experiencing each side effect will be calculated and compared across the course of study</Description><Timeframe>2 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to examine the effect of standard dosing of cyproheptadine for      both cycled and continuous administration, as compared to no medication, on appetite      stimulation and growth in the pediatric gastroenterology feeding team patient population.      The secondary aim is to evaluate the effect, if any, of the suspected tachyphylaxis that is      commonly associated with cyproheptadine use. &lt;br/&gt;The third aim will be to examine the type and      duration of side effects of cyproheptadine in this population. &lt;br/&gt;The ultimate goal will be to      create a standardized protocol for cyproheptadine therapy in children with feeding disorders      and suboptimal growth. &lt;br/&gt;The key significance of this study is the analysis of the effect that cyproheptadine has on stimulating weight gain and improving behaviors associated with feeding.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total number of 75 patients (25 in each group) will be randomized into three arms: &lt;br/&gt;Arm A (no cyproheptadine treatment): patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.&lt;br/&gt;Arm B (continuous cyproheptadine):  patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of 2 months. Standard dose of cyproheptadine 0.25 mg/kg bid.&lt;br/&gt;Arm C (cycled cyproheptadine): patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for 2 weeks cycled with no cyproheptadine given for 2 weeks for a total of 2 months. Patients on cycled dosing will be given cyproheptadine for 2 weeks, then no medication for 2  weeks; repeating this cycle for the 2-month duration of study.&lt;/para&gt;&lt;para&gt;Data collection: the following categories of data will be collected: medical record number (MRN), demographics, feeding behavior, side effects experience      from use cyproheptadine, 24 h diet recalls, medical history, and anthropometrics.&lt;br/&gt;A 24 h diet recall: guardians of patients will be questioned weekly regarding oral      intake (type of food consumed and amount) over the past 24 h. Caloric intake will be      calculated based on these recalls and compared across duration of study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02568007</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Anticipated">2020-10-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-10-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="246627"><TitleDisplay>A longitudinal, observational study to evaluate the skeletal effects of selective serotonin reuptake inhibitors and risperidone in healthy boys</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="14">Alzheimers disease</Indication><Indication id="1935">Post traumatic stress disorder</Indication><Indication id="1957">Mania</Indication><Indication id="24">Anorexia nervosa</Indication><Indication id="299">Schizophrenia</Indication><Indication id="34">Attention deficit hyperactivity disorder</Indication><Indication id="423">Autism</Indication><Indication id="4898">Major depressive disorder</Indication><Indication id="653">Bipolar disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="17640" role="Therapeutic effect marker" type="Structural (imaging)">Trabecular bone</BiomarkerName><BiomarkerName id="48953" role="Therapeutic effect marker" type="Physiological">Lumbar spine bone mineral density</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>risperidone</Name><Drug id="4236">risperidone</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>selective serotonin reuptake inhibitors therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4236">risperidone</Drug><IndicationsPioneer/><Companies><Company><Company id="1043014">National Alliance for Research on Schizophrenia and Depression</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20518">National Institutes of Health</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4236" type="Drug"><TargetEntity id="127142" type="siDrug">Risperidone</TargetEntity></SourceEntity><SourceEntity id="1043014" type="Company"><TargetEntity id="5035544137" type="organizationId">Narsad Research Institute Inc</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="1935" type="ciIndication"><TargetEntity id="F43.1" type="ICD10"/><TargetEntity id="10036316" type="MEDDRA"/><TargetEntity id="D013313" type="MeSH"/><TargetEntity id="-1731993138" type="omicsDisease"/><TargetEntity id="38" type="siCondition"/></SourceEntity><SourceEntity id="1957" type="ciIndication"><TargetEntity id="F30" type="ICD10"/><TargetEntity id="10026749" type="MEDDRA"/><TargetEntity id="52" type="siCondition"/></SourceEntity><SourceEntity id="24" type="ciIndication"><TargetEntity id="F50.0" type="ICD10"/><TargetEntity id="307.1" type="ICD9"/><TargetEntity id="10002649" type="MEDDRA"/><TargetEntity id="D000856" type="MeSH"/><TargetEntity id="-558410060" type="omicsDisease"/><TargetEntity id="42" type="siCondition"/></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="34" type="ciIndication"><TargetEntity id="F90" type="ICD10"/><TargetEntity id="10003736" type="MEDDRA"/><TargetEntity id="D001289" type="MeSH"/><TargetEntity id="-197354408" type="omicsDisease"/><TargetEntity id="87" type="siCondition"/></SourceEntity><SourceEntity id="423" type="ciIndication"><TargetEntity id="F84.0" type="ICD10"/><TargetEntity id="10003805" type="MEDDRA"/><TargetEntity id="D001321" type="MeSH"/><TargetEntity id="-1744075483" type="omicsDisease"/><TargetEntity id="39" type="siCondition"/></SourceEntity><SourceEntity id="4898" type="ciIndication"><TargetEntity id="F33" type="ICD10"/><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="-1357758656" type="omicsDisease"/><TargetEntity id="54" type="siCondition"/></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"/><TargetEntity id="296" type="ICD9"/><TargetEntity id="10057667" type="MEDDRA"/><TargetEntity id="D001714" type="MeSH"/><TargetEntity id="-1667300745" type="omicsDisease"/><TargetEntity id="47" type="siCondition"/></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1043014">National Alliance for Research on Schizophrenia and Depression</Company><Company id="20518">National Institutes of Health</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="13">5-HT 2 receptor antagonist</Action><Action id="150">Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2943">Antipsychotic</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Longitudinal</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>94</PatientCountEnrollment><PatientCountEvaluable>94</PatientCountEvaluable><DateChangeLast>2017-04-25T16:00:22Z</DateChangeLast><DateAdded>2015-12-01T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male healthy  volunteers&lt;/li&gt;&lt;li&gt;Age 7 to 17 years&lt;/li&gt;&lt;li&gt;Previously treated with risperidone for 6 months or more&lt;/li&gt;&lt;li&gt;Enrolled through child psychiatry outpatient clinics&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Age-sex-height-race-specific areal bone mineral density (BMD) z score at the lumbar spine</Description></Measure><Measure><Description>Radius trabecular volumetric BMD</Description></Measure><Measure><Description>To evaluate skeletal effects of SSRIs and risperidone at follow-up study</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In May 2015, results were published. Participants (26%, n = 24) discontinued resperidone by follow-up  [&lt;ulink linkType="Reference" linkID="1715669"&gt;1715669&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study aimed to evaluate longitudinally the skeletal effects of selective serotonin reuptake inhibitors (SSRI) and &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; at follow-up in boys [&lt;ulink linkType="Reference" linkID="1715669"&gt;1715669&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2015, results were published.  In this study, after accounting for significant covariates, declineinparticipants'lumbar spine age-sex-height-race-specific areal bone mineral density (BMD) z score (p &amp;lt; 0.04) and failure to increase radius trabecular volumetric BMD (p &amp;lt; .03) was associated with  continuation of risperidone treatment. Decreased lumbar spine areal BMD z score and radius trabecular volumetric BMD were found at both study entry (p &amp;lt; 0.02 and p &amp;lt; 0.03, respectively) and follow-up (p &amp;lt; 0.06 and p &amp;lt; 0.03, respectively)  associated with receiving an SSRI and  no further declination was seen between two visits  [&lt;ulink linkType="Reference" linkID="1715669"&gt;1715669&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Participants treated with risperidone for 6 months or more, with  or without SSRIs were included and evaluated [&lt;ulink linkType="Reference" linkID="1715669"&gt;1715669&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Government</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-12-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="277629"><TitleDisplay>A single-institution, case series to study efficacy of alectinib against CNS metastases in ALK-positive non-small cell lung cancer patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="759">Central nervous system tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="5700" role="Disease marker" type="Genomic;Proteomic">ALK receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>alectinib</Name><Drug id="69066">alectinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="69066">alectinib</Drug><IndicationsPioneer/><Companies><Company><Company id="1062632">Associazione Italiana per la Ricerca sul Cancro</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="69066" type="Drug"><TargetEntity id="714991" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1062632" type="Company"><TargetEntity id="5036351859" type="organizationId">Italian Association for Cancer Research</TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"/><TargetEntity id="613" type="siCondition"/></SourceEntity><SourceEntity id="759" type="ciIndication"><TargetEntity id="10007958" type="MEDDRA"/><TargetEntity id="D016543" type="MeSH"/></SourceEntity><SourceEntity id="3736" type="Action"><TargetEntity id="2470" type="Mechanism">ALK Tyrosine Kinase Receptor Inhibitors</TargetEntity><TargetEntity id="5613" type="Mechanism">ALK Tyrosine Kinase Receptor (L1196M Mutant) Inhibitors</TargetEntity><TargetEntity id="6977" type="Mechanism">Anti-ALK (Anaplastic lymphoma kinase)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1062632">Associazione Italiana per la Ricerca sul Cancro</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3736">Anaplastic lymphoma kinase receptor inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3851">ALK tyrosine kinase receptor family inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>11</PatientCountEnrollment><PatientCountEvaluable>11</PatientCountEvaluable><DateChangeLast>2016-11-02T16:00:20Z</DateChangeLast><DateAdded>2016-11-03T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;NSCLCs with ALK-positive disease as assessed by fluorescence in situ hybridization&lt;/li&gt;&lt;li&gt;CNS metastases&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Progression-free survival</Description></Measure><Measure><Description>Activity in the CNS</Description></Measure><Measure><Description>Overall survival</Description></Measure><Measure><Description>Alectinib's concentrations in serum and cerebro-spinal fluid (CSF)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study aimed to assess the efficacy of &lt;ulink linkType="Drug" linkID="69066"&gt;alectinib&lt;/ulink&gt; in patients with ALK-postive, advanced non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases [&lt;ulink linkType="Reference" linkID="1868882"&gt;1868882&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2016, results were published. Majority of the patients were pretreated with crizotinib (n=10, 90.9%), and cranial radiotherapy (n=8, 72.7%). A total of six  out of seven patients with measurable CNS disease experienced a CNS response, including three patients who were nave for cranial radiation. Median duration of response was reported as 8months. Median CNS-progression-free survival (-PFS), systemic-PFS, overall-PFS, overall survival, and one-year survival were 8, 11, 8, 13months, and 31.1%, respectively for the whole population. Alectinib's concentrations in serum and cerebro-spinal fluid (CSF) was assessed in two patients experiencing a CNS response  and CSF-to-serum ratio was observed to range from 0.001 to 0.003ng/ml. Irrespective of prior treatment(s) with ALK-TKI(s) and/or cranial radiotherapy, alectinib was observed to be highly active against CNS metastases    [&lt;ulink linkType="Reference" linkID="1868882"&gt;1868882&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  received alectinib 600mg bid  [&lt;ulink linkType="Reference" linkID="1868882"&gt;1868882&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="647015">alectinib</Intervention><Treatments><Treatment><Dose>600 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="284067"><TitleDisplay>Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)</TitleDisplay><TitleOfficial>Phase I Clinical Trial - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03007576</Identifier><Identifier type="Organisational Study">EMOCT01</Identifier></Identifiers><Indications><Indication id="245">Osteoarthritis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>mesenchymal stromal cells (knee osteoarthritis), EMO Biomedicine</Name><Drug id="106564">mesenchymal stromal cells (knee osteoarthritis), EMO Biomedicine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="106564">mesenchymal stromal cells (knee osteoarthritis), EMO Biomedicine</Drug><IndicationsPioneer><Indication id="245">Osteoarthritis</Indication></IndicationsPioneer><Companies><Company><Company id="1040731">Far Eastern Memorial Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1106426">EMO Biomedicine Corp</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1040731" type="Company"><TargetEntity id="5035543144" type="organizationId">Far Eastern Memorial Hospital</TargetEntity></SourceEntity><SourceEntity id="1106426" type="Company"><TargetEntity id="5045504321" type="organizationId">EMO Biomedicine Corp</TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"/><TargetEntity id="D010003" type="MeSH"/><TargetEntity id="-478836143" type="omicsDisease"/><TargetEntity id="747" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1106426">EMO Biomedicine Corp</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1040731">Far Eastern Memorial Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="856">Autologous stem cell therapy</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="864">Mesenchymal stem cell therapy</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>14</PatientCountEnrollment><DateStart>2017-08-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-08-31T00:00:00Z</DateEnd><DateChangeLast>2019-02-13T02:03:09Z</DateChangeLast><DateAdded>2017-01-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>memphis@emobio.com</Email><Name>Hung-Hsuan Chen</Name><Phone>+886228096390</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects who understand and sign the informed consent form for this study&lt;/li&gt;&lt;li&gt;Grade 2 to 3 osteoarthritis according to the Kellgren-Lawrence grading scale with 1-month X-ray&lt;/li&gt;&lt;li&gt;Age is 50 to 75 years&lt;/li&gt;&lt;li&gt;Postmenopausal women&lt;/li&gt;&lt;li&gt;VAS scores in 50 to 90 mm&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Abnormal of liver and kidney: GOT and GPT&amp;gt; 100 IU/l, BUN &amp;gt; 22 mg/dl and creatinine &amp;gt; 1.2 mg/dl&lt;/li&gt;&lt;li&gt;Positive serology for HIV, HTLV-1/2 and syphilis&lt;/li&gt;&lt;li&gt;Women who are pregnant or breast feeding&lt;/li&gt;&lt;li&gt;Serious pre-existing medical conditions: coagulation disorders, cardiovascular diseases (arrhythmias, myocardial infarction and surgery), renal diseases (chronic renal failure), liver diseases (cirrhosis), diabetes mellitus type I, cancer history&lt;/li&gt;&lt;li&gt;Other joint diseases: knee deformity (knee varus greater than 10 degree or valgus &gt; 20degree), rheumatic arthritis, gouty arthritis, septic arthritis, serious meniscal tear, other autoimmune arthritis&lt;/li&gt;&lt;li&gt;Skin inflammatory of knee&lt;/li&gt;&lt;li&gt;Knee pain caused by referred pain from spine disease or hip joint disease. Knee pain combined with pain from spine disease or hip disease&lt;/li&gt;&lt;li&gt;Immunosuppressive state&lt;/li&gt;&lt;li&gt;Subjects who were injected with hyaluronic acid and PRP in the past 6 months&lt;/li&gt;&lt;li&gt;Body mass index (BMI) &gt; 30&lt;/li&gt;&lt;li&gt;Have a history of allergic reaction of any medication&lt;/li&gt;&lt;li&gt;Participation in another clinical trial or treatment within 3 months&lt;/li&gt;&lt;li&gt;Other pathological conditions or circumstances that difficult participation in this study according to PI's evaluations&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Clinical assessment of International Knee Documentation Committee (IKDC) score: assess symptoms of knee, sport activity and function of knee</Description><Timeframe>48 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Clinical assessment of knee MRI</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Clinical assessment of knee X-ray</Description><Timeframe>48 weeks</Timeframe></Measure><Measure><Description>Clinical assessment of visual analog scale (VAS)</Description><Timeframe>48 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to isolate and expand MSCs (&lt;ulink linkType="Drug" linkID="106564"&gt;RegStem&lt;/ulink&gt;) from infrapatellar fat pad of subject.      When the number of MSCs expands to 1 x 10(8), cells would be cryopreserved in the liquid nitrogen      tank until all release tests passed. On the distribution day, cells were  thawed and      injected into joint cavity of patient (5 x 10[7]). &lt;/para&gt;&lt;para&gt;By June 2017,  the trial has been initiated in Taiwan [&lt;ulink linkType="Reference" linkID="1938541"&gt;1938541&lt;/ulink&gt;]&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive one injection og 5 x 10(7) MSCs. Subjects would be monitored after MSC product      infusion of 7 days, 1, 6 months and one year. The monitoring items would include the      changes of knee (by appearance, X-ray and MRI of knee) and pain improvement (by      questionnaire).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Taiwan"><Sites><Site><Name>Far Eastern Memorial Hospital</Name><Address1>Taipei</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Chih-Hung Chang, MD PhD</Name></Contact><Contact type="Facility investigator"><Name>Chih-Hung Chang, MD PhD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Osteoarthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="8848">Subjects with Osteoarthritis of Knee</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8849">Subjects with Specific Grade of Severity in Kellgren and Lawrence scale</PatientSegment><SubSegments><SubSegment id="8851">Subjects with Kellgren and Lawrence grade 2 osteoarthritis</SubSegment><SubSegment id="8852">Subjects with Kellgren and Lawrence grade 3 osteoarthritis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03007576</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoarthritis" id="13889"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="28614">International Knee Documentation Committee (IKDC) scores</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="13927"><Endpoint>Assessment of Joint Structure/Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13932">Assessment of knee structure and function</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="13957"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="13973"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="13974"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="44768"><Endpoint>Assessment of Physical Examination</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="44898"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="45569"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Osteoarthritis" id="13886"><Endpoint>Assessment of Joint Stiffness</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="25799">Assessment of joint stiffness by VAS score</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13996">Assessment of Pain by Visual Analog Scale (VAS)</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="14008">Assessment of Pain by Knee injury and Osteoarthritis Outcome Score (KOOS)</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="25788">Assessment by Knee Injury and Osteoarthritis Outcome Score (KOOS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13963"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13964">Assessment by x-ray</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="13966">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="45569"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoarthritis" id="14166"><Criterion>Subjects with Osteoarthritis of Knee</Criterion></Inclusion><Inclusion disease="Osteoarthritis" id="14176"><Criterion>Subjects with Specific Grade of Severity Based on Kellgren and Lawrence scale</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14178">Subjects with Kellgren and Lawrence grade 2 osteoarthritis</SubCriterion><SubCriterion disease="Osteoarthritis" id="14179">Subjects with Kellgren and Lawrence grade 3 osteoarthritis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="14185"><Criterion>Subjects Diagnosed by Specific Methods</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14186">Subjects with osteoarthritis confirmed by radiograph</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="14227"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Osteoarthritis" id="33726"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14236">Postmenopausal women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34165"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14237">Non Pregnant/Non lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34331"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14231">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Osteoarthritis" id="11592"><Criterion>Subjects co-morbid with musculoskeletal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11595">Subjects with disorders of knee joint</SubCriterion><SubCriterion disease="Osteoarthritis" id="11596">Subjects co-morbid with rheumatoid arthritis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11602"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11603">Subjects with neurological/CNS disorder</SubCriterion><SubCriterion disease="Osteoarthritis" id="11606">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Osteoarthritis" id="11609">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Osteoarthritis" id="11617">Subjects with autoimmune diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11604"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11607"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11611"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11613"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11614"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11620"><Criterion>Subjects with History of Use of Medications for Osteoarthritis</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11624">Subjects with history of use of hyaluronate injections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11645"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11646">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11649"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11654">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Osteoarthritis" id="11657">Subjects unsuitable for study participation as per investigator's assessment</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="25601"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11652">Subjects with history of/current participation in other clinical trials</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="25889"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11615">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="27015"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11656">Subjects excluded based on prespecified body weight/BMI</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="27739"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11658">Subjects Excluded Based on Abnormal Laboratory Values</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-12-21T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="285745"><TitleDisplay>The Genetic Education for Men Trial: Web-Based Education versus Standard Care</TitleDisplay><TitleOfficial>The Genetic Education for Men (GEM) Trial: Web-Based Genetic Education versus Standard Care in Men From Hereditary Cancer Families</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02957981</Identifier><Identifier type="Organisational Study">2016-1162</Identifier><Identifier type="Trial Acronym">GEM</Identifier></Identifiers><Indications><Indication id="249">Pancreas tumor</Indication><Indication id="276">Prostate tumor</Indication><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="22" role="Therapeutic effect marker" type="Genomic;Proteomic">Breast cancer type 1 susceptibility protein</BiomarkerName><BiomarkerName id="41" role="Therapeutic effect marker" type="Genomic">Breast cancer type 2 susceptibility protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>web-based counseling</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="22821" type="Company"><TargetEntity id="4297088770" type="organizationId">Georgetown University</TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"/><TargetEntity id="10060862" type="MEDDRA"/><TargetEntity id="D011471" type="MeSH"/><TargetEntity id="-405461207" type="omicsDisease"/><TargetEntity id="637" type="siCondition"/><TargetEntity id="5083" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22821">Georgetown University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2016-10-31T00:00:00Z</DateStart><DateEnd type="estimated">2020-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T02:07:23Z</DateChangeLast><DateAdded>2017-01-24T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>eorgetown University Medical Center/Lombardi Comprehensive Cancer Center</Affiliation><Email>schwartm@georgetown.edu</Email><Name>Marc D Schwartz, PhD</Name><Phone>202-687-0185</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male&lt;/li&gt;&lt;li&gt;Age 30 to 70&lt;/li&gt;&lt;li&gt;At least one first-, second- or third-degree relative who has been found to carry a BRCA1 or BRCA2 mutation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Personal diagnosis of any cancer, other than non-melanoma skin cancer&lt;/li&gt;&lt;li&gt;Prior genetic counseling or testing for hereditary breast/ovarian cancer&lt;/li&gt;&lt;li&gt;Family history suggestive of a hereditary cancer syndrome not attributable to the BRCA1 or BRCA2 mutation in their family, based on pedigree review by the study team&lt;/li&gt;&lt;li&gt;An uncertain risk of carrying the familial BRCA1 or BRCA2 mutation (ie, because it is not clear on what side of the family the mutation is segregating), based on pedigree review by the study team&lt;/li&gt;&lt;li&gt;Have one one or more children who are BRCA1 or BRCA2 positive&lt;/li&gt;&lt;li&gt;Cannot participate in or understand English&lt;/li&gt;&lt;li&gt;Cannot provide meaningful informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Completion of BRCA1/BRCA2 gene testing: the number of participants in each arm who choose to be tested for the BRCA1 or BRCA2 mutation that has previously been identified in their family</Description><Timeframe>6-months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Completion of genetic counseling: the number of men in each arm who choose to obtain genetic counseling</Description><Timeframe>6-months</Timeframe></Measure><Measure><Description>Decision conflict: scores on the decision conflict scale at 6-months post-randomization</Description><Timeframe>6-months</Timeframe></Measure><Measure><Description>Decision satisfaction: scores on the satisfaction with decision scale at 6-months post-randomization</Description><Timeframe>6-months</Timeframe></Measure><Measure><Description>Cancer distress: impact of events scale</Description><Timeframe>6-months</Timeframe></Measure><Measure><Description>Genetic testing distress: multidimensional Impact of Cancer Risk Assessment Scale</Description><Timeframe>6-months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary goal of this research is to develop and test a web-based genetic      education/counseling intervention. &lt;br/&gt;Aim 1: develop a web-based intervention to increase genetic counseling/testing uptake in men at high risk for carrying a BRCA mutation.&lt;br/&gt;Aim 2: evaluate the impact of the web-based intervention (WI) versus usual care (UC).&lt;br/&gt;Aim 3: examine the behavioral and psychosocial impact of BRCA testing in men from BRCA families.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This intervention is designed to educate men from      hereditary cancer families about the personal relevance of genetic testing in order to help      them make decisions about whether to pursue genetic testing. The investigators will test      this intervention against standard care for men from hereditary cancer families. The      web-based educational intervention includes all of the information typically covered during      genetic counseling. As a result, after completing the education intervention participants      can proceed directly to genetic testing if they choose. The investigators will conduct a      survey prior to randomization and then follow-up surveys at 1- and 6-months      post-randomization. The primary outcome will be uptake of genetic testing. Secondary      outcomes will be completion of genetic counseling and decision satisfaction.&lt;/para&gt;&lt;para&gt;Participants will be recruited via the &lt;ulink linkType="Company" linkID="1044963"&gt;Lombardi Comprehensive Cancer Center&lt;/ulink&gt;'s Familial Cancer Registry and the Non-therapeutic Subject Registry Shared Resource.  In addition, the investigators will recontact participants from prior trials who have consented to be recontacted for future research and will accept self-referred index cases who contact the study about participation. Female index cases will be identified based on vital status, recency of contact, and availability of test reports documenting their positive BRCA1/2 status. Where available, pedigrees will also be reviewed.&lt;/para&gt;&lt;para&gt;To protect the privacy of study participants, participants will be recruited through their female BRCA mutation carrier relatives (index patients) who will provide their contact information. The investigators will identify adult female mutation carriers who are enrolled in the Non-therapeutic Subject Registry Shared Resource, Familial Cancer Registry or who received a positive test result as a participant in IRB 2004-133 and provided consent to be contacted about future research studies or who contactthe studydirectly about enrollment. The study staff will mail a study invitation to potentially eligible index cases. This mailing will include: an introductory letter; an informed consent document; a HIPAA Authorization form; study brochures for distribution to male relatives if desired; and a family contact form requesting contact information and current ages for potentially eligible male relatives. The investigators will request that index patients return the Family Contact Form in a self-addressed stamped envelope or complete an electronic version of the form. Consistent with prior research and Institutional Review Board guidance, the letter and Family Contact Form will reiterate that index patients should request permission from their potentially eligible male relative(s) prior to providing contact information to investigators, and the index participants signature on the Family Contact Form will attest to this. The packet will also contain information on how women may decline participation (an opt-out post card). If, after 2 to 3 weeks, participants do not decline participation, a research assistant will call to determine interest in the study and request completion of the Family Contact Form.&lt;/para&gt;&lt;para&gt;Upon receiving returned Family Contact Forms, the research team  will contact potentially eligible male relatives by mail. The study packet that is sent will include: an introductory letter; informed consent document; study brochure, and opt-out postcard. On the opt-out contacts, men can also indicate if they are ineligible for the study due to a cancer diagnosis or prior genetic counseling/testing.&lt;/para&gt;&lt;para&gt;The baseline survey can be completed via telephone or electronically. A 2 weeks following the mailing, the researchers will contact eligible men who have not opted out by email or telephone. For email contact, the investigators will send an email link to an electronic study consent and baseline survey. If no email address is provided, a research assistant will contact the participant by telephone. If the participant has already returned the print informed consent document, the research assistant will answer any questions about the study and proceed with the baseline survey. If the participant has not returned an informed consent document, the research assistant will complete a verbal consent process and administer the baseline survey. Following completion of the baseline survey, a research assistant will randomize participants to either the Web Intervention or Usual Care. Randomization will be achieved via computer generated random numbers (blocks of 8). Family members will be assigned to the same intervention to avoid contamination. Men who complete the baseline survey online will be notified of their randomization assignment via email. Men who complete the baseline survey by telephone will be notified of their randomization status at the end of the baseline survey.&lt;/para&gt;&lt;para&gt;Men who are randomized to the Usual Care arm will receive an email and letter informing them of their group assignment. These contacts will include a list of resources for men from hereditary cancer families and for those who have not previously completed the print or electronic consent form, another copy of the print consent and a link to the electronic consent will also be provided. At this time, Usual Care participants will be informed that if they are interested in genetic counseling and testing, they can contact the study team (via a toll-free number provided to them in the letter) to schedule a telephone genetic counseling session (free of charge) or the study team can provide a local referral for in-person genetic counseling. All participants will be required to complete the print or electronic study consent form prior to study-provided genetic counseling.&lt;/para&gt;&lt;para&gt;Men randomized to the Web Intervention will receive an email and letter (sent through US Mail) with the web address, and an individualized code. When participants access the website, they will be asked to enter their email address and their code, and then choose a password for future log-ins. Participants who forget their passwords can request a new log-in code at any time. The investigators will provide participants with a toll-free support number to call if they have any questions. Participants who have not completed the print or electronic informed consent document will be required to complete the electronic consent prior to viewing the Web Intervention.&lt;/para&gt;&lt;para&gt;At the conclusion of the Web Intervention, participants will be provided with the following options for pursuing genetic testing for their familial BRCA1 or BRCA2 mutation: they can indicate that they are not interested in pursuing genetic testing; they can indicate that they have questions about genetic testing, in which case an RA will follow-up, answer any process-related questions, and determine if a genetic counselor consultation is required; they can schedule an individual genetic counseling session (with a LCCC genetic counselor or with a genetic counselor of their choice); they can proceed directly to genetic testing.&lt;/para&gt;&lt;para&gt;All participants have multiple options for pre-test genetic counseling. Since the Web Intervention provides participants with content that is comparable to that of standard pre-test genetic counseling, Web Intervention participants have the option to proceed directly to genetic testing after viewing the intervention. However, since investigators expect that some participants may prefer traditional genetic counseling, participants will have the option of free pre-test telephone genetic counseling provided through the study by a board-certified genetic counselor at the Lombardi Comprehensive Cancer Center. In contrast, because Usual Care participants will not receive electronic genetic education/counseling, they will not have the option to proceed directly to genetic testing. Usual Care participants who are interested in pursuing genetic counseling will have the option to receive free pre-test telephone genetic counseling through the study by a board certified genetic counselor at Lombardi Comprehensive Cancer Center. After completing genetic counseling, participants will be provided with the opportunity to proceed to genetic testing. This arm is designed to replicate standard care in which individual genetic counseling often proceeds genetic testing.&lt;/para&gt;&lt;para&gt;Men in either group who prefer in-person genetic counseling, will be provided with a referral to a local counselor and informed that those costs are not covered by the study. Men whose insurance company requires them to be seen by a genetic counselor within a specified organization before testing is ordered will be informed of that requirement if they proceed to testing.&lt;/para&gt;&lt;para&gt;Genetic testing is not required as part of this study. Any participants interested in proceeding with genetic testing will receive standard clinical genetic testing from a certified commercial laboratory. All testing will be provided under standard clinical protocols and laboratory consents. The standard of care for relatives of BRCA1 or BRCA2 carriers is to test only for the specific familial mutation. The familial mutation will be known to study staff because documentation of test reports must be available for female cases, from whom eligible participants for the study are recruited. Men who have Ashkenazi Jewish background will be offered testing for the three BRCA mutations common in this ethnic group, as is also standard clinical practice. Men will have the option to go through their insurance company or pay out of pocket for genetic testing. In either case, the fees associated with testing will be paid directly to the clinical laboratory that performs the test.&lt;/para&gt;&lt;para&gt;All participants who indicate that they are interested in genetic testing will be contacted by a research assistant to obtain information needed for insurance billing, pre-verification and the completion of laboratory test requisition forms. The research assistant will provide a laboratory consent form and laboratory requisition form to participants who are interested in completing genetic testing. After these completed and signed forms are returned to us, the research assistant will send the participant a kit to collect saliva (DNA). The participant is then responsible for mailing the postage paid DNA kit and required forms directly to the testing laboratory. Billing and payment arrangements for testing will be handled between the testing lab and the participant. Georgetown University will not bill patients for genetic testing services.&lt;/para&gt;&lt;para&gt;All participants who receive genetic testing through the study will receive individual post-test genetic counseling by telephone from a board-certified genetic counselor. In general, DNA testing results are available within 2 weeks. Results will be sent directly to a study genetic counselor. The genetic counselor will call the participant to review the test results, including cancer risks, management options/guidelines, implications to family members, and emotional response to testing. Questions and concerns will be addressed, and referrals for follow-up will be provided as needed, including (if appropriate), genetic counseling referrals for relatives. If participants did not undergo pre-test genetic counseling, a brief medical and family history will be taken at this time, so that risk and management information can be individualized. This session is expected to take between 10 to 30 min. After the post-test session, the genetic counselor will mail a copy of the laboratory's genetic testing report and a brief genetic counseling summary letter that the participant can share with his health care providers and family members if desired.&lt;/para&gt;&lt;para&gt;Participants will be contacted for follow-up surveys at 1- and 6-months post-randomization. These surveys will be similar to (but shorter than) the baseline survey. As for the baseline survey, these follow-up surveys will be conducted electronically or via telephone. Participants who have provided verbal consent at the time of the baseline but who have not completed written or electronic consent (and therefore have not proceeded to genetic counseling) will remain eligible to complete the follow-up surveys.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Georgetown University Medical Center/Lombardi Comprehensive Cancer Center</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20007</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>schwartm@georgetown.edu</Email><Name>Marc D Schwartz, PhD</Name><Phone>202-687-0185</Phone></Contact><Contact type="Facility investigator"><Name>Marc D Schwartz, PhD</Name></Contact><Contact type="Facility investigator"><Name>Beth N Peshkin, MS</Name></Contact><Contact type="Facility investigator"><Name>Kathryn L Taylor, PhD</Name></Contact><Contact type="Facility investigator"><Name>Claudine Isaacs, MD</Name></Contact><Contact type="Facility investigator"><Name>Kristi Graves, PhD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="12849">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1085079355" id="15429">BRCA1_HUMAN_Mutation</SubSegment><SubSegment genevariantId="-613688363" id="15430">BRCA2_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02957981</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15256"><Endpoint>Assessment of Tumor Suppressor Genes/Proteins</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15258">Assessment of Breast Cancer Gene (BRCA)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15227"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15315"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Solid tumor" id="15227"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13137"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="14852">Subjects with BRCA Mutation Status</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="12316"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Solid tumor" id="25667"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10744">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-11-04T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="290889"><TitleDisplay>A study to evaluate the clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="598">Enterobacteriaceae infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ceftazidime-avibactam</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1009750" type="Company"><TargetEntity id="5001110852" type="organizationId">Kamrai Tawee Fund's Capital Unit</TargetEntity></SourceEntity><SourceEntity id="598" type="ciIndication"><TargetEntity id="D004756" type="MeSH"/><TargetEntity id="-1005348715" type="omicsDisease"/><TargetEntity id="1580" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1009750">University of Pittsburgh Medical Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>37</PatientCountEnrollment><PatientCountEvaluable>37</PatientCountEvaluable><DateChangeLast>2018-03-14T22:04:29Z</DateChangeLast><DateAdded>2017-03-18T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with carbapenem-resistant Enterobacteriaceae infections&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Clinical success, survival rates and microbiologic failure rate</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was  to evaluate the clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections [&lt;ulink linkType="Reference" linkID="1908997"&gt;1908997&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2016, results were published. At 30 days, clinical success and survival rates were 59 and 76%, respectively.Within 90 days carbapenem-resistant Enterobacteriaceae infections were recurredin 23% of clinical successes. Microbiologic failure rate was found to be 27%. Ceftazidime-avibactam resistance was detected in 30% of microbiologic failures [&lt;ulink linkType="Reference" linkID="1908997"&gt;1908997&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received ceftazidime-avibactam were included and observed [&lt;ulink linkType="Reference" linkID="1908997"&gt;1908997&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="299568"><TitleDisplay>Phase Ib Study of Chiauranib in Patients With Ovarian Cancer</TitleDisplay><TitleOfficial>Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multisite, Exploratory Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03166891</Identifier><Identifier type="Organisational Study">CAR102</Identifier><Identifier type="Other">CTR20170767</Identifier></Identifiers><Indications><Indication id="2243">Fallopian tube cancer</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="799">Ovary tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="4571" role="Therapeutic effect marker" type="Genomic">L-myc-1 proto-oncogene protein</BiomarkerName><BiomarkerName id="5481" role="Therapeutic effect marker" type="Genomic;Proteomic">Macrophage colony stimulating factor 1 receptor</BiomarkerName><BiomarkerName id="46244" role="Therapeutic effect marker" type="Genomic">Circulating tumor DNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>chiauranib</Name><Drug id="65700">chiauranib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="65700">chiauranib</Drug><IndicationsPioneer><Indication id="2243">Fallopian tube cancer</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1008516">Shenzhen Chipscreen Biosciences Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="65700" type="Drug"><TargetEntity id="791750" type="siDrug">Chiauranib</TargetEntity></SourceEntity><SourceEntity id="1008516" type="Company"><TargetEntity id="4297057362" type="organizationId">Shenzhen Chipscreen Biosciences Co Ltd</TargetEntity></SourceEntity><SourceEntity id="2243" type="ciIndication"><TargetEntity id="C57.0" type="ICD10"/><TargetEntity id="10016180" type="MEDDRA"/><TargetEntity id="D005185" type="MeSH"/><TargetEntity id="-33569282" type="omicsDisease"/><TargetEntity id="600" type="siCondition"/></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"/><TargetEntity id="10061344" type="MEDDRA"/><TargetEntity id="D010534" type="MeSH"/><TargetEntity id="-745704479" type="omicsDisease"/><TargetEntity id="633" type="siCondition"/></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"/><TargetEntity id="10033128" type="MEDDRA"/><TargetEntity id="D010051" type="MeSH"/><TargetEntity id="-1370909262" type="omicsDisease"/><TargetEntity id="626" type="siCondition"/></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="4418" type="Action"><TargetEntity id="1386" type="Mechanism">Aurora-B (ARK2) Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1b Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>10</NumberOfSites><CompaniesSponsor><Company id="1008516">Shenzhen Chipscreen Biosciences Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="4418">Aurora protein kinase 1 inhibitor</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-12-04T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-02-04T09:36:38Z</DateChangeLast><DateAdded>2017-05-31T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Fudan University Cancer Hospital</Affiliation><Email>docwuxh@hotmail.com</Email><Name>Wu Xiaohua, MD</Name><Phone>13601772486</Phone></Contact><Contact type="Scientific contact"><Affiliation>Fudan University Cancer Hospita</Affiliation><Name>Cao Junning</Name></Contact><Contact type="Scientific contact"><Affiliation>West China Second Hospital of Sichuan University</Affiliation><Name>Yin Ru iro</Name></Contact><Contact type="Scientific contact"><Affiliation>Shandong University Qilu Hospital</Affiliation><Name>Hole North China</Name></Contact><Contact type="Scientific contact"><Affiliation>Peking University Cancer Hospital</Affiliation><Name>High rain farming</Name></Contact><Contact type="Scientific contact"><Affiliation>Peking University People's Hospital</Affiliation><Name>Cui Heng</Name></Contact><Contact type="Scientific contact"><Affiliation>Jiangsu Provincial People's Hospita</Affiliation><Name>Cheng Wenjun</Name></Contact><Contact type="Scientific contact"><Affiliation>Hunan Cancer Hospital</Affiliation><Name>Wang Jing</Name></Contact><Contact type="Scientific contact"><Affiliation>Xi'an Jiaotong University School of Medicine, First Affiliated Hospital</Affiliation><Name>An Ruifang</Name></Contact><Contact type="Scientific contact"><Affiliation>Sun Yat-sen Cancer Hospital</Affiliation><Name>Liu Jihon</Name></Contact><Contact type="Public contact"><Affiliation>Shenzhen Micro-core biotechnology limited liability company</Affiliation><Email>zhangqian@chipscreen.com</Email><Name>Qian Zhang</Name><Phone>8610-57394060</Phone></Contact></Contacts><MeasuresOutcome><MeasuresPrimary><Measure><Description>Overall response rate (ORR): ORR will be calculated from the data obtained from the end visit</Description><Timeframe>Assessed up to two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A 16 week-disease control rate (16W-DCR): rate of the patients with disease control &gt; 6 weeks</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Duration of response (DOR): from the first date of response until the date of first documented progression</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Number of participants with treatment-related adverse events: measured by adverse events (AE), serious adverse events (SAE), abnormal vital signselectrocardiograph(ECG) and abnormal laboratory results according to CTCAE V4.03</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Overall survival (OS): time from treatment to death from any cause</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Progression-free survival (PFS): from date of treatment until the date of first documented progression or date of death from any cause, whichever came first</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Time to progression (TTP): duration from date of treatment until the date of first documented progression</Description><Timeframe>Through treatment completion, up to two years</Timeframe></Measure><Measure><Description>Any single mutation of oncogene and copy number variation in ctDNA (single gene analysis)</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Mutation of polygene and copy number variation in signal pathway (multi-gene analysis)</Description><Timeframe>Assessed up to two years</Timeframe></Measure><Measure><Description>Immunohistochemical (IHC) staining results of Aurora BCSF-1R and Myc protein: the IHC staining results were assigned a mean follows: 0, negative; 1, weak; 2, moderate; and 3, strong. The frequency of positive cells was defined as follows: 0, &lt; 5%; 1, 5% to 25%; 2, 26% to 50%; 3, 51% to 75%; and 4, &gt; 75%</Description><Timeframe>Assessed up to two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to assess the efficacy and safety include adverse events, vital      signs, laboratory tests, etc,      of chiauranib (&lt;ulink linkType="Drug" linkID="65700"&gt;CS-2164&lt;/ulink&gt;) (50 mg, po, qd; Westoni)  in treating patients with relapsed or refractory ovarian      cancer, due to the outcomes      of the phase I study, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well      as the relevancy of which and clinical benefit.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The patients in this study will recieve chiauranib (CS-2164) capsules 50 mg, po qd, for 28 days as a cycle.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Fudan University Cancer Hospital</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site><Site><Name>West China Second Hospital of Sichuan University</Name><Address1>Chengdu</Address1><Address2>Sichuan</Address2><CountrySubDivision>Sichuan</CountrySubDivision><Contacts/></Site><Site><Name>Shandong University Qilu Hospital</Name><Address1>Jinan</Address1><Address2>Shandong</Address2><CountrySubDivision>Shandong</CountrySubDivision><Contacts/></Site><Site><Name>Peking University Cancer Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Peking University People's Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Jiangsu Provincial People's Hospital</Name><Address1>Nanjing</Address1><Address2>Jiangsu</Address2><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts/></Site><Site><Name>Hunan Cancer Hospital</Name><Address1>Changsha</Address1><Address2>Hunan</Address2><CountrySubDivision>Hunan</CountrySubDivision><Contacts/></Site><Site><Name>Xi'an Jiaotong University School of Medicine, First Affiliated Hospital</Name><Address1>Xi'an</Address1><Address2>Shaanxi</Address2><CountrySubDivision>Shaanxi</CountrySubDivision><Contacts/></Site><Site><Name>Sun Yat-sen Cancer Hospital</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>Fudan University Shanghai Cancer Center</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><Address3>200032</Address3><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ovary tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7895">Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03166891</Identifier></Identifiers></Registry><Registry><Name id="1039">Center for Drug Evaluation</Name><Identifiers><Identifier>CTR20170767</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ovary tumor" id="10838"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10839">Assessment of overall/objective response rate(ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Ovary tumor" id="10900"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10901">Assessment of frequency and severity of adverse events (AE) &amp; serious adverse events (SAEs) </SubEndpoint><SubEndpoint disease="Ovary tumor" id="10902">Assessment of adverse events as graded by CTCAE/CTC</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ovary tumor" id="8248"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8250">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8255"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8258">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8262"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8263">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Ovary tumor" id="8264">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8281"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8282">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Ovary tumor" id="8283">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8312"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="33605"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8220">Platinum-Resistant/Refractory Ovarian Cancer Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34009"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8284">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34426"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8295">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ovary tumor" id="9809"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="9810"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.90 Months</EnrollmentPeriod><EnrollmentRate>2.16 Patients/Month</EnrollmentRate><DateFirstReceived>2017-05-22T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-12-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-06T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="303149"><TitleDisplay>Women's Lifestyle Balance Study</TitleDisplay><TitleOfficial>Women's Lifestyle and Sleep Intervention for Prediabetes and Metabolic Syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03184337</Identifier><Identifier type="Organisational Study">LB STUDY</Identifier><Identifier type="Trial Acronym">LB</Identifier></Identifiers><Indications><Indication id="57">Cardiovascular disease</Indication><Indication id="97">Diabetes mellitus</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="303" role="Therapeutic effect marker" type="Genomic;Proteomic">Leptin</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="3044" role="Therapeutic effect marker" type="Physiological">Homeostasis model assessment insulin resistance</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>CDC's Prevent T2 program with added sleep content</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>CDC's PreventT2 Program</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="24773" type="Company"><TargetEntity id="4298366404" type="organizationId">University of California San Francisco</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"/><TargetEntity id="D003920" type="MeSH"/><TargetEntity id="-203480060" type="omicsDisease"/><TargetEntity id="506" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="24773">University of California San Francisco</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>26</PatientCountEnrollment><DateStart>2017-04-24T00:00:00Z</DateStart><DateEnd type="actual">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-27T09:24:24Z</DateChangeLast><DateAdded>2017-07-07T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Catherine Chesla, RN, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Female (or self-identify as female)&lt;/li&gt;&lt;li&gt;Age 30 to 70 years&lt;/li&gt;&lt;li&gt;BMI 25 to 38 (or 23 to 38 if Asian or other Pacific Islander)&lt;/li&gt;&lt;li&gt;Time in bed&amp;lt;/= 7 h on a typical weeknight&lt;/li&gt;&lt;li&gt;Meets diagnostic criteria for prediabetes and/or metabolic syndrome&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;No regular access to telephone or email (for maintaining contact)&lt;/li&gt;&lt;li&gt;No access to smartphone, tablet, or laptop computer (for using Fitbit)&lt;/li&gt;&lt;li&gt;Having a condition that limits physical activity, such as brisk walking&lt;/li&gt;&lt;li&gt;Having a diagnosis of type 1 or type 2 diabetes or been previously treated with diabetes medications&lt;/li&gt;&lt;li&gt;Having a cardiac event or cardiac surgery in the past year&lt;/li&gt;&lt;li&gt;Having a metabolic condition that prevents weight loss&lt;/li&gt;&lt;li&gt;Working night shift (Midnight - 4 AM)&lt;/li&gt;&lt;li&gt;Inability to complete the baseline assessment (REDCap survey and Fitbit tracking of activity, diet, and sleep for 7 days)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in body mass index: body mass index is calculated as the participant's body weight divided by the square of their height</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in Fasting Plasma Glucose (FPG): FPG will be used to measure current blood glucose levels</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in HbA1c: HbA1c blood tests will be used to measure average blood glucose levels</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR): HOMA-IR is calculated from fasting plasma glucose and insulin levels and will be used to measure insulin resistance</Description><Timeframe>Baseline and 6 weeks after start of intervention</Timeframe></Measure><Measure><Description>Change in blood pressure: blood pressure will be used as a measure of cardiovascular risk</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in caloric intake: daily calories consumed over 7 days and recorded using a Fitbit monitor</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in leptin levels: leptin levels will be used to measure the hormone that regulates satiety</Description><Timeframe>Baseline and 6 weeks after start of intervention</Timeframe></Measure><Measure><Description>Change in lipid profile (total cholesterol, LDL, HDL, triglycerides): a standard lipid panel will be used to measure cardiovascular risk factors</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in physical activity (objective): daily step counts over 7 days using a Fitbit monitor</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in physical activity (self-report): international Physical Activity Questionnaire (IPAQ)</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in self-assessed general health: the Promis General Health measure will be used to assess the participant's perception of their general health</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in self-reported dietary intake: 'Starting the Conversation' will be used to assess self-reported dietary intake</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in sleep duration (objective): nighttime sleep duration will be objectively assessed over 7 days using a Fitbit monitor</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in sleep quality (self-report): Pittsburgh Sleep Quality Index (PSQI)</Description><Timeframe>Baseline and 6 weeks, 3 and 6 months after start of intervention</Timeframe></Measure><Measure><Description>Change in waist circumference: waist circumference will be used to measure central adiposity, an indicator of cardiovascular risk</Description><Timeframe>Baseline and 6 months after start of intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This pilot study aims to determine whether adding a sleep extension and sleep hygiene      intervention to an existing lifestyle improvement program improves its efficacy for weight      loss in those at risk for diabetes and cardiovascular disease.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Half of the participants will      receive the Centers for Disease Control's standard Prevent T2 program and half of the      participants will receive the same program with an additional sleep intervention. A sample of 24 to 30 women will be assigned to either the Centers for Disease      Control's (CDC's) standard Prevent T2 program (control) or the same program with an additional      integrated sleep intervention (experimental). Program with added Sleep Content designed to extend and improve sleep. Both programs will involve eight group sessions administered over      3 months, and all women will be followed for a total of 6 months. CDC's PreventT2 Program will be  a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.The primary outcome will be       weight loss, and secondary outcomes include sleep quality and duration, physical activity,      caloric intake, and physiological indicators of cardiovascular and diabetes risk (HbA1c,      HOMA-IR, lipids, blood pressure). The combined program has the potential to significantly      improve weight loss in those at risk for diabetes and cardiovascular disease (CVD).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of California, San Francisco</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94143-0606</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="19587">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="7593">Subjects with Prediabetes/Impaired Glucose Tolerance</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="19588">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="94">Subjects with Prediabetes/Impaired Glucose Tolerance</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03184337</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1502">Assessment of BMI</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1503">Assessment of body weight</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="44714"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18219">Assessment of weight</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="18222">Assessment of BMI</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1359">Change in HbA1c</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1412"><Endpoint>Assessment of Insulin Sensitivity</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1416">Homeostasis model assessment (HOMA)- insulin sensitivity index (HOMA-I, HOMA-IR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1451"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1452">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1453">Triglyceride levels (TG)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1454">HDL-C (High-density lipoprotein cholesterol)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1455">LDL-C (Low-density lipoprotein cholesterol)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1501"><Endpoint>Obesity, Body Weight &amp; Fat Tissue Assessment</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1345">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1580"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1504">Assessment of abdominal circumference</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="6729"><Endpoint>Assessment of Cardiovascular Risk Factors</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18118"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18158"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18174"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18175">Assessment of cholesterol</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="18178">Assessment of HDL-C</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="18179">Assessment of LDL-C</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="18186">Assessment of Triglycerides</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18210"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18238">Physical activity level</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="32006"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="32059">Assessment by International Physical Activity Questionnaire (IPAQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="33857"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33903">Assessment by International Physical Activity Questionnaire (IPAQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43088"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="43878"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1510">Serum leptin</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="44035"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="44211"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18123">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="44298"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33904">Assessment by Pittsburgh Sleep Quality Index (PSQI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="44714"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="45639"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18221">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="46468"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="6692"><Criterion>Subjects with Prediabetes/Impaired Glucose Tolerance</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16298"><Criterion>Subjects with Prediabetes/Impaired Glucose Tolerance</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16333"><Criterion>Subjects with Protocol Specified BMI</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16356"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="32809"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="32945"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33696"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34922"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1042">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="849"><Criterion>Subjects  with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="851">Subjects with type 1 diabetes mellitus</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="852">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="896"><Criterion>Subjects with history of cardiac surgery/intervention</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="995"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1081">Working in rotating shifts/night shifts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13654"><Criterion>Subjects  with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13656">Subjects with type 1 diabetes mellitus</SubCriterion><SubCriterion disease="Insulin dependent diabetes" id="13657">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13773"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13791"><Criterion>Subjects with history of cardiac surgery/intervention</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13871"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="25146"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="24456">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="25811"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="24353">Subjects with history of/scheduled for cardiac surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="27976"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13904">Subjects unable/unwilling to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="27977"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1055">Subjects unable/unwilling to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-06-20T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>1.90 Months</EnrollmentPeriod><EnrollmentRate>13.68 Patients/Month</EnrollmentRate><DateFirstReceived>2017-05-30T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-07-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-10-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="311109"><TitleDisplay>A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastasis</TitleDisplay><TitleOfficial>A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastasis (OGSG 1701)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000028749</Identifier><Identifier type="Other">OGSG 1701</Identifier></Identifiers><Indications><Indication id="3666">Metastatic stomach cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="3" role="Disease marker" type="Genomic;Proteomic">HER2</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1075383">Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20961">Yakult Honsha Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1075383">Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20961">Yakult Honsha Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="1075383" type="Company"><TargetEntity id="5037952967" type="organizationId">Osaka Gastrointestinal cancer chemotherapy Study Group</TargetEntity></SourceEntity><SourceEntity id="20961" type="Company"><TargetEntity id="4295878046" type="organizationId">Yakult Honsha Co Ltd</TargetEntity></SourceEntity><SourceEntity id="3666" type="ciIndication"><TargetEntity id="10063916" type="MEDDRA"/><TargetEntity id="647" type="siCondition"/></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1075383">Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20961">Yakult Honsha Co Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Historical Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2018-02-02T00:00:00Z</DateStart><DateEnd type="estimated">2026-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-08-23T03:05:26Z</DateChangeLast><DateAdded>2017-09-01T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Osaka International Cancer Institute ; Department of medical oncology</Affiliation><Email>sugimoto-na2@mc.pref.osaka.jp</Email><Name>Naotoshi Sugimoto</Name><Phone>06-6945-1181</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kindai University School of Medicine ; Department of Surgery</Affiliation><Email>you-kimura@surg.med.kindai.ac.jp</Email><Name>Yutaka Kimura</Name><Phone>072-366-0221</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically proven gastric carcinoma by endoscopic detection&lt;/li&gt;&lt;li&gt;HER2 negative or unknown&lt;/li&gt;&lt;li&gt;With any lesion written below by upper abdominal enhanced CT:&lt;ul&gt;&lt;li&gt;Paraaortic node metastases (16a2/16b1) &gt;  10mm&lt;/li&gt;&lt;li&gt;Bulky lymph node metastases located at celiac axis, common hepatic artery, splenic artery and/or upper mesenteric vein which make a huge bulk &gt; 3.0 cm and/or multiple large bulks larger than 1.5 cm&lt;/li&gt;&lt;li&gt;Paraaortic and bulky metastatic nodes&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Without any lesions written below by thoratic, upper abdominal and pelvic enhanced CT:&lt;ul&gt;&lt;li&gt;Mediastinal node metastases&lt;/li&gt;&lt;li&gt;Lung metastases&lt;/li&gt;&lt;li&gt;Peritoneal metastases&lt;/li&gt;&lt;li&gt;Liver metastases&lt;/li&gt;&lt;li&gt;Pleural fluid and/or ascites&lt;/li&gt;&lt;li&gt;Paraaortic nodes metastases (# 16a1 and/or #16b2)&lt;/li&gt;&lt;li&gt;Other distant nodes metastases and/or CY1&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Not a large type 3 or type 4 gastric cancer Large: the size of cancer is &gt;  8 cm&lt;/li&gt;&lt;li&gt;Without esophageal invasion &gt;  3 cm&lt;/li&gt;&lt;li&gt;Not a remnant gastric cancer&lt;/li&gt;&lt;li&gt;Without cervical nodes metastases and/or distant metastases&lt;/li&gt;&lt;li&gt;Age between 20 and 75 years old&lt;/li&gt;&lt;li&gt;An Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1&lt;/li&gt;&lt;li&gt;Without any prior chemotherapy, radiation therapy and/or hormone therapy for the gastric cancer and/or any other cancers&lt;/li&gt;&lt;li&gt;Without prior surgical therapy except EMR/ESD and/or bypass&lt;/li&gt;&lt;li&gt;Patients can take food orally with /without bypass&lt;/li&gt;&lt;li&gt;With good functions of important organs by a data taken within 2 weeks of registration&lt;ul&gt;&lt;li&gt;Neutrophil: &gt;/= 1,500/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin: &gt;/= 8.0 g/dl without blood transfusion&lt;/li&gt;&lt;li&gt;Platelet: &gt;/= 100,000/mm3&lt;/li&gt;&lt;li&gt;AST, ALT:&amp;lt;/=100 IU/l&lt;/li&gt;&lt;li&gt;T.bil.:&amp;lt;/= 2.0 mg/dl&lt;/li&gt;&lt;li&gt;Creatinine clearance: &gt;/= 60 ml/min/body CC by Cockcroft-Gault method is available: &gt;/= 60 ml/min&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;With written Informed Consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;With active double cancers excluding carcinoma in situ and/or prior cancer cured with longer than five year interval period&lt;/li&gt;&lt;li&gt;Pregnant or nursing female&lt;/li&gt;&lt;li&gt;Male expecting pregnancy of partner&lt;/li&gt;&lt;li&gt;Impossible to register to the study due to a psychological disorder by physician in charge's decision&lt;/li&gt;&lt;li&gt;Under continuous steroids medication&lt;/li&gt;&lt;li&gt;Patients who receives systemic continuous administration of phenytoin or warfarin potassium&lt;/li&gt;&lt;li&gt;With neuropathy on peripheral motor and/or sensory nerves: &gt;  glade 2 of CTCAE version 4.0&lt;/li&gt;&lt;li&gt;With interstitial pneumonitis, pulmonary fibrosis and/or severe pulmonary emphysema&lt;/li&gt;&lt;li&gt;With active bacterial/fungal infectious disease (with a fever &gt; 38degC)&lt;/li&gt;&lt;li&gt;With a history of cardiac infarction and/or anxiety angina pectoris within 6 months&lt;/li&gt;&lt;li&gt;With uncontrollable blood hypertension&lt;/li&gt;&lt;li&gt;With uncontrollable DM&lt;/li&gt;&lt;li&gt;With uncontrollable Diarrhea&lt;/li&gt;&lt;li&gt;Positive HBs antigen&lt;/li&gt;&lt;li&gt;Severe complications&lt;/li&gt;&lt;li&gt;Any other patients whom the physician in charge of the study judges to be unsuitable&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Response Rate(RR)(RECISTversion1.0)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Complete rate of operation</Description></Measure><Measure><Description>Complete rate of postoperative chemotherapy</Description></Measure><Measure><Description>Complete rate of preoperative chemotherapy</Description></Measure><Measure><Description>Complete rate of protocol</Description></Measure><Measure><Description>Incidence of a intraoperative and postoperative complication</Description></Measure><Measure><Description>Incidence of adverse events on perioperative chemotherapy</Description></Measure><Measure><Description>Overall survival(OS)</Description></Measure><Measure><Description>Progression free survival</Description></Measure><Measure><Description>Rate of curative resection</Description></Measure><Measure><Description>Relative Dose Intensity (RDI)</Description></Measure><Measure><Description>Response Rate (RR)(RECISTversion1.1)</Description></Measure><Measure><Description>Response Rate of Histologically</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to confirm the efficacy and safety of perioperative &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; combined chemotherapy (CapeOx) for advanced gastric cancer with multiple lymph node metastasis which cannot be resected curatively, or very poor prognosis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive preoperative capeOx therapy: capecitabine: 1,000 mg/m2 bid, day1 to 14, q3w, and oxaliplatin : 130 mg/m2, day 1, q3w for three 3 cycles and  postoperative CapeOx therapy: capecitabine: 1,000 mg/m2 bid, day1 to 14, q3w and oxaliplatin : 130 mg/m2, day 1, q3w for five cycles.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stomach tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8010">Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000028749</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stomach tumor" id="12155"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12168"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stomach tumor" id="12148"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12151"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12155"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12168"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12209"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12223">Assessment of Efficacy</SubEndpoint><SubEndpoint disease="Stomach tumor" id="12227">Assessment of Resection Rate</SubEndpoint><SubEndpoint disease="Stomach tumor" id="12229">Assessment of Procedure Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="44929"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stomach tumor" id="7913"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7934"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7935">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Stomach tumor" id="7936">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7943"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="12900">Subjects with history of endoscopic intervention (EMR/ESD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7953"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7954">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Stomach tumor" id="7955">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7960"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7972">Subjects with ability to administer the medications as required</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34019"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7956">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34411"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7964">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stomach tumor" id="9483"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9484"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9485"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9487">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9494"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9498">Subjects with abnormal pulmonary functions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9511"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9512">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Stomach tumor" id="9515">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Stomach tumor" id="9516">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Stomach tumor" id="9517">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="9523"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9536">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="20297"><Criterion>Subjects with Adenocarcinoma of the Gastroesophageal Junction</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="25503"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9530">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="26358"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9497">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-09-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-10-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="311948"><TitleDisplay>New prognostic markers for breast cancer patients based on immunoresponse monitoring</TitleDisplay><TitleOfficial>Development of the new prognostic markers for breast cancer patients based on immunoresponse monitoring</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000029036</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="4806" role="Therapeutic effect marker" type="Cellular">Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>flow cytometry</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1081125" type="Company"><TargetEntity id="5044169924" type="organizationId">Grants-in-Aid for Scientific Research</TargetEntity></SourceEntity><SourceEntity id="DOL1000061" type="Company"><TargetEntity id="4298184040" type="organizationId">Juntendo University</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000061">Juntendo University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1081125">Grants-in-Aid for Scientific Research</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><PatientCountEnrollment>300</PatientCountEnrollment><DateStart>2015-12-21T00:00:00Z</DateStart><DateChangeLast>2017-09-14T10:30:45Z</DateChangeLast><DateAdded>2017-09-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Juntendo University School of Medicine ; Department of Breast Oncology</Affiliation><Email>yoshiyahorimoto@hotmail.com</Email><Name>Yoshiya Horimoto</Name><Phone>03-3813-3111</Phone></Contact><Contact type="Scientific contact"><Affiliation>Juntendo University School of Medicine ; Department of Breast Oncology</Affiliation><Email>yoshiyahorimoto@hotmail.com</Email><Name>Yoshiya Horimoto</Name><Phone>03-3813-3111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Breast cancer patients who are going to undergo surgery at our department&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who didn't agree to participate in this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Subset of lymphocytes is investigated using flow cytometry and the relationship with patient outcome will be analyzed</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to evaluate the clinicopathological features of immune cells in peripheral blood   before the treatment to search for prognostic biomarker for breast cancer patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Breast cancer patients who will be  undergoing  surgery will be enrolled and observed. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3955">Subjects with Resectable/Operable Breast Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000029036</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8950"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8955">Assessment of lymphocytes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="37159"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Breast tumor" id="8902"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint><OtherEndpoint disease="Breast tumor" id="44979"><Endpoint>Assessment of Immune Response</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4870"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4924"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22398"><Criterion>Subjects with Resectable Tumor</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="26752"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6418">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-09-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="315073"><TitleDisplay>Efficacy of green tea extract on ocular redness</TitleDisplay><TitleOfficial>Efficacy of EyeCalmin eye drop on inflammation of ocular surface</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT138903234166N1</Identifier><Identifier type="Secondary Organisational">2922/4/5</Identifier></Identifiers><Indications><Indication id="686">Ocular inflammation</Indication></Indications><BiomarkerNames><BiomarkerName id="37109" role="Therapeutic effect marker" type="Structural (imaging)">Tear film</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>EyeCalmin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1084572" type="Company"><TargetEntity id="5040036332" type="organizationId">Drug Applied Research Center</TargetEntity></SourceEntity><SourceEntity id="686" type="ciIndication"><TargetEntity id="10015943" type="MEDDRA"/><TargetEntity id="4686" type="siCondition"/><TargetEntity id="783" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1084572">Drug Applied Research Center Tabriz</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2009-04-04T00:00:00Z</DateStart><DateChangeLast>2017-10-11T10:06:32Z</DateChangeLast><DateAdded>2017-10-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tabriz universit of medacal sciences</Affiliation><Email>sorkhabi_r@yahoo.com , rana@tbzmed.ac.ir</Email><Name>Rana Daei Sorkhabi</Name><Phone>00984116551332</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tabriz university of medical sciences</Affiliation><Email>rana@tbzmed.ac.ir</Email><Name>Rana Daei Sorkhabi</Name><Phone>00984116551332</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Ocular redness&lt;/li&gt;&lt;li&gt;Foriegn body sensation&lt;/li&gt;&lt;li&gt;Eyestrain&lt;/li&gt;&lt;li&gt;Ocular allergy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any intraocular inflammation&lt;/li&gt;&lt;li&gt;Any corneal disease&lt;/li&gt;&lt;li&gt;Viral or bacterial infections&lt;/li&gt;&lt;li&gt;Any drug induced side effects&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Foreign body sensation, redness, irritation, eye strain: clinical exam</Description><Timeframe>2 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Tear film stability: clinical exam</Description><Timeframe>2 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim is to   evaluate efficacy of green tea extract as EyeCalmin eye drop (Dinee company) on signs and symptoms of ocular surface irritation such as redness, pruritus, foreign body sensation and eyestrain. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this clinical trial 30 patients with ocular surface irritation will be enrolled and  randomly divided to receive either  Eyecalmin eyedrop or placebo four times a day 2 two weeks. Patients will be examined before the enrollment, then they take drugs four times a day for 2 weeks and the second examination will be performed. After passing the time required for drug washout, the same patients will receive the alternate drug and examination with the same schedule will be performed. The results of the two drugs will be compared in the same patients.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Tabriz university clinics</Name><Address1>East Azarbayjan</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT138903234166N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other ocular disease" id="43437"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other ocular disease" id="43555"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other ocular disease" id="43437"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other ocular disease" id="43555"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other ocular disease" id="32980"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other ocular disease" id="24053"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="24648">Subjects with infectious diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other ocular disease" id="24306"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="24993"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2009-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>5.90 Months</EnrollmentPeriod><EnrollmentRate>5.08 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-10-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="355126"><TitleDisplay>A study to evaluate the safety and efficacy of sodium glucose cotransporter 2 inhibitors (SGLT2-Is) in diabetic patients with drug-refractory heart failure (HF)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="55">Cardiac failure</Indication><Indication id="97">Diabetes mellitus</Indication></Indications><BiomarkerNames><BiomarkerName id="105" role="Therapeutic effect marker" type="Genomic;Proteomic">Natriuretic peptides B</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sodium glucose cotransporter 2 inhibitors</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="14929" type="Company"><TargetEntity id="4298193774" type="organizationId">University of Tsukuba</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"/><TargetEntity id="D003920" type="MeSH"/><TargetEntity id="-203480060" type="omicsDisease"/><TargetEntity id="506" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="14929">University of Tsukuba</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>12</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateChangeLast>2018-10-08T22:01:00Z</DateChangeLast><DateAdded>2018-10-09T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with diabetes and advanced heart failure&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2018, results were published. No cardiac events or side effects were observed during follow-up [&lt;ulink linkType="Reference" linkID="2078741"&gt;2078741&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to evaluate the safety and efficacy of sodium glucose cotransporter 2 inhibitors (SGLT2-Is) in diabetic patients with drug-refractory heart failure (HF) [&lt;ulink linkType="Reference" linkID="2078741"&gt;2078741&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2018, results were published. There were improvements in New York Heart Association class and reduction in B-type natriuretic peptide levels at 6 months after administration, in particular in patients with high atrial pressure [&lt;ulink linkType="Reference" linkID="2078741"&gt;2078741&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who were treated with sodium glucose cotransporter 2 inhibitors (SGLT2-Is) were included and evaluated [&lt;ulink linkType="Reference" linkID="2078741"&gt;2078741&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-10-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="360634"><TitleDisplay>International Pediatric Peritoneal Biopsy Study</TitleDisplay><TitleOfficial>International Pediatric Peritoneal Biopsy Study in Children on PD and Healthy Controls</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01893710</Identifier><Identifier type="Organisational Study">PEDIATRIC PD BIOPSY STUDY</Identifier><Identifier type="Secondary Organisational">UNIVERSITY OF HEIDELBERG</Identifier></Identifiers><Indications><Indication id="2037">Kidney dialysis</Indication><Indication id="69">Renal failure</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Disease marker" type="Cellular">Leukocyte count</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>biopsy sampling</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="28348" type="Company"><TargetEntity id="5035524090" type="organizationId">Heidelberg University</TargetEntity></SourceEntity><SourceEntity id="2037" type="ciIndication"><TargetEntity id="10018875" type="MEDDRA"/><TargetEntity id="D006435" type="MeSH"/><TargetEntity id="-1007190129" type="omicsDisease"/><TargetEntity id="1020" type="siCondition"/></SourceEntity><SourceEntity id="69" type="ciIndication"><TargetEntity id="10038435" type="MEDDRA"/><TargetEntity id="346" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>26</NumberOfSites><CompaniesSponsor><Company id="28348">University of Heidelberg</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>400</PatientCountEnrollment><DateStart>2011-02-28T00:00:00Z</DateStart><DateEnd type="estimated">2020-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-11-22T07:20:08Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>claus.peter.schmitt@med.uni-heidelberg.de</Email><Extension>39313</Extension><Name>Claus P Schmitt, MD</Name><Phone>+49 6221 56</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Heidelberg, Center for Pediatric and Adolescent Medicine</Affiliation><Name>Claus P Schmitt, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Children's Mercy Hospital</Affiliation><Name>Bradley A. Warady, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Department of Pediatrics, Medical University Vienna</Affiliation><Name>Klaus Arbeiter, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>UZ Ghent</Affiliation><Name>Johan Van de Walle, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Service de Nphrologie Pdiatrique, Hpital Femme Mere Enfant</Affiliation><Name>Bruno Ranchin, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Children`s Hospital</Affiliation><Name>Michel Fischbach, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Children`s Hospital</Affiliation><Name>Uwe Querfeld, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Children`s Hospital</Affiliation><Name>Peter Sallay, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Children`Hospital</Affiliation><Name>Enrico Verrina, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Children`s Hospital</Affiliation><Name>Sara Testa, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University children`s Hospital</Affiliation><Name>Rimante Cerkauskiene, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Hospital Universitario Materno-Infantil Vall d' Hebron</Affiliation><Name>Gema Ariceta, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Karolinska University Hospital</Affiliation><Name>Rafael T Krmar, MD, PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Children`s Hospital</Affiliation><Name>Aysun K Bayazit, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Cerrahpasa School of Medicine</Affiliation><Name>Salim Caliskan, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 0 to 21 years. A 0 to 70 years in patients with normal renal function&lt;/li&gt;&lt;li&gt;CKD 5d, peritoneal dialysis and&lt;/li&gt;&lt;li&gt;Patients with normal renal function and elective abdominal surgery due to limited pathology not affecting the Peritoneum, 0 to 70 years&lt;/li&gt;&lt;li&gt;Oral and written consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Contraindications to peritoneal dialysis, such as severe abdominal adhesions, malformations and inflammations&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Preterm babies (below 37 weeks of gestational age)&lt;/li&gt;&lt;li&gt;If serum hemoglobin&amp;lt; 8 g/dl in children and &amp;lt; 10 g/dl in newborns&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Semiquantitiave score of peritoneal vasculopathy (grade 0 to 5): children requiring peritoneal dialysis will undergo repeated biopsy sampling, i.e. at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation, according to a standardized biopsy protocol. All samples will be transferred to the pediatric nephrology laboratory Heidelberg for central analyses</Description><Timeframe>Two years (Mean PD treatment time)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of vessels per peritoneal membrane area (per mm2): quantitative histomorphometry will assess neoangiogenesis, ie, the number of vessels per peritoneal membrane area, the major factor of peritoneal transport property and ultrafiltration capacity</Description><Timeframe>At time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation</Timeframe></Measure><Measure><Description>Leukocyte number (/mm2): leukocyte infiltration is a parameter of PD induced membrane inflammation</Description><Timeframe>Two years (mean PD duration)</Timeframe></Measure><Measure><Description>Submesothelial thickness (microm): further parameter of interst is submesothelial thickness as a marker of peritoneal fibrosis</Description><Timeframe>Two years (average PD duration)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;An international, prospective peritoneal membrane biopsy study in children on peritoneal dialysis (PD) will       be performed. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Biopsies will be obtained at time of PD catheter insertion, on      occasion of intercurrent abdominal surgery (eg, hernia repair, catheter exchange) and at      time of renal transplantation. Quantitative histomorphometry and tissue protein expression      analysis will be correlated with time integrated PD treatment modalities and functional      characteristics as well as inflammatory and cardiovascular comorbidity surrogate parameter.      Blood will be obtained during clinical routine sampling. Biopsies will be obtained during      clinically indicated operations, without substantially increasing operation time and      associated surgical risks. The detailed histomorphometry of the PD membrane will give      additional information, potentially impacting on the individual PD regime. Peritoneal biopsies from children without kidney disease, ie, diseases not related to the kidney and not affecting the peritoneum, will be compared with biopsies from patients with chronic kidney disease, at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation. Two parietal peritoneal samples, each 1 cm2 x 0.3 cm in depth and three omental tissue samples, each 1 cm2 in size will be obtained.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>Department of Pediatrics, Medical University Vienna</Name><Address1>Vienna</Address1><Address3>1090</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>klaus.arbeiter@meduniwien.ac.at</Email><Name>Klaus Arbeiter, MD</Name><Phone>+43 1404003257</Phone></Contact><Contact type="Facility investigator"><Name>Klaus Arbeiter, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><Name>UZ Ghent</Name><Address1>Ghent</Address1><Address3>9890</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Johan.VandeWalle@uzgent.be</Email><Name>Johan Van de Walle, MD</Name><Phone>+32 93322483</Phone></Contact><Contact type="Facility investigator"><Name>Johan Van de Walle, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Switzerland"><Sites><Site><Name>Children's Hospital, Inselspital, Bern University Hospital and University of Bern</Name><Address1>Bern</Address1><Address3>3010</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>UKE, University Childrens Hospital</Name><Address1>Hamburg</Address1><Address3>20246</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>University Children`s Hospital</Name><Address1>Berlin</Address1><Address3>10117</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>uwe.querfeld@charite.de</Email><Name>Uwe Querfeld, MD</Name><Phone>+49 30450516031</Phone></Contact><Contact type="Facility investigator"><Name>Uwe Querfeld, MD</Name></Contact></Contacts></Site><Site><Name>University Children`s Hospital</Name><Address1>Cologne</Address1><Address3>50931</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>christina.taylan@uk-koeln.de</Email><Name>Christina Taylan, MD</Name><Phone>+49 2214784391</Phone></Contact><Contact type="Facility investigator"><Name>Christina Taylan, MD</Name></Contact></Contacts></Site><Site><Name>University Children`s Hospital</Name><Address1>Essen</Address1><Address3>45122</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>Hospital Universitario Materno-Infantil Vall d' Hebron</Name><Address1>Barcelona</Address1><Address3>08035</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>gariceta@vhebron.net</Email><Name>Gema Ariceta, MD</Name><Phone>+34 934893082</Phone></Contact><Contact type="Facility investigator"><Name>Gema Ariceta, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Hpital des Enfants</Name><Address1>Bordeaux</Address1><Address3>33076</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Service de Nphrologie Pdiatrique, Hpital Femme Mere Enfant</Name><Address1>Lyon</Address1><Address3>69677</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>bruno.ranchin@chu-lyon.fr</Email><Name>Bruno Ranchin, MD</Name><Phone>+33 427856129</Phone></Contact><Contact type="Facility investigator"><Name>Bruno Ranchin, MD</Name></Contact></Contacts></Site><Site><Name>Service de pdiatrie 2, Hpital saint Jacques</Name><Address1>Besancon</Address1><Address3>25030</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>University Children`s Hospital</Name><Address1>Strasbourg</Address1><Address3>67098</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Michel.Fischbach@chru-strasbourg.fr</Email><Name>Michel Fischbach, MD</Name><Phone>+33 3127743</Phone></Contact><Contact type="Facility investigator"><Name>Michel Fischbach, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><Name>University Children`s Hospital</Name><Address1>Budapest</Address1><Address3>1083</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>sallay.peter@med.semmelweis-univ.hu</Email><Name>Peter Sallay, MD</Name><Phone>+36 13343186</Phone></Contact><Contact type="Facility investigator"><Name>Peter Sallay, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Name>Pediatric Nephrology, Dialysis and Transplant Unit</Name><Address1>Padova</Address1><Address3>35128</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>University Children`Hospital</Name><Address1>Genova</Address1><Address3>16147</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>enricoverrina@ospedale-gaslini.ge.it</Email><Name>Enrico Verrina, MD</Name><Phone>+39 3475704081</Phone></Contact><Contact type="Facility investigator"><Name>Enrico Verrina, MD</Name></Contact></Contacts></Site><Site><Name>University Children`s Hospital</Name><Address1>Milano</Address1><Address3>20122</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>saratesta@tiscali.it</Email><Name>Sara Testa, MD</Name><Phone>+39 0257992471</Phone></Contact><Contact type="Facility investigator"><Name>Sara Testa, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Lebanon"><Sites><Site><Name>Rafik Hariri University Hospital</Name><Address1>Beirut</Address1><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Lithuania"><Sites><Site><Name>University children`s Hospital</Name><Address1>Vilnius</Address1><Address3>08406</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>rimantec@yahoo.com</Email><Name>Rimante Cerkauskiene, MD</Name><Phone>+37 052720427</Phone></Contact><Contact type="Facility investigator"><Name>Rimante Cerkauskiene, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Malaysia"><Sites><Site><Name>Paediatric CAPD unit, Kuala Lumpur Hospital</Name><Address1>Kuala Lumpur</Address1><Address3>50586</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Name>Krakow, Jagiellonian University Medical College</Name><Address1>Krakow</Address1><Address3>30663</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>dadrozdz@cm-uj.krakow.pl</Email><Name>Dorota Drozdz, MD</Name><Phone>+48 12 658 11 59</Phone></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><Name>Karolinska University Hospital</Name><Address1>Stockholm</Address1><Address3>17176</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Rafael.Krmar@ki.se</Email><Name>Rafael T Krmar, MD, PhD</Name><Phone>+46 858581480</Phone></Contact><Contact type="Facility investigator"><Name>Rafael T Krmar, MD, PhD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Turkey"><Sites><Site><Name>Cerrahpasa School of Medicine</Name><Address1>Istanbul</Address1><Address3>34303</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>salimc@istanbul.edu.tr</Email><Name>Salim Caliskan, MD</Name><Phone>+90 5322121302</Phone></Contact><Contact type="Facility investigator"><Name>Salim Caliskan, MD</Name></Contact></Contacts></Site><Site><Name>University Children`s Hospital</Name><Address1>Adana</Address1><Address3>01330</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ayskar@cu.edu.tr</Email><Name>Aysun K Bayazit, MD</Name><Phone>+90 3223386935</Phone></Contact><Contact type="Facility investigator"><Name>Aysun K Bayazit, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Children's Mercy Hospital</Name><Address1>Kansas City</Address1><Address2>Missouri</Address2><Address3>64108</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>bwarady@cmh.edu</Email><Name>Bradley A. Warady, MD</Name><Phone>816-234-3010</Phone></Contact><Contact type="Facility investigator"><Name>Bradley A. Warady, MD</Name></Contact></Contacts></Site><Site><Name>The Childrens Hospital of Philadelphia</Name><Address1>Narberth</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>University of Alabama at Birmingham</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35233</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry><Sites><Site><Name>University Children`s Hospital</Name><Address1>Prague</Address1><Address2>Czechia</Address2><Address3>15006</Address3><CountrySubDivision>Czechia</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7704">Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7726">Others</PatientSegment><SubSegments><SubSegment id="7727">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="20180">Subjects by disease severity</PatientSegment><SubSegments><SubSegment id="7702">Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="20202">Subjects Received/Scheduled for Other Therapies</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01893710</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22539"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22542">Assessment of vascular structure/function</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22578"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="45206"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="45223"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22569"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="45206"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="End stage renal disease" id="22598"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="End stage renal disease" id="43820"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></OtherEndpoint><OtherEndpoint disease="End stage renal disease" id="45206"><Endpoint>Clinical Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="End stage renal disease" id="45223"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17652">Subjects with stage 5 CKD/end stage renal disease(ESRD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17700"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="33660"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="34674"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17701">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="35543"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="35544">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17521"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17555"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="27701"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="27790"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="28269"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-06-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="366487"><TitleDisplay>Clinical observation for single intravenous pre-injection of small dose of remifentanil to inhibit cough caused by sufentanil during induction of general anesthesia</TitleDisplay><TitleOfficial>Clinical observation for single intravenous pre-injection of small dose of remifentanil to inhibit cough caused by sufentanil during induction of general anesthesia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1900020587</Identifier></Identifiers><Indications><Indication id="82">Cough</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>remifentanil</Name><Drug id="4208">remifentanil</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4208">remifentanil</Drug><IndicationsPioneer/><Companies><Company><Company id="1056719">The First Affiliated Hospital of Wenzhou Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4208" type="Drug"><TargetEntity id="185000" type="siDrug">Remifentanil hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1056719" type="Company"><TargetEntity id="5035560535" type="organizationId">First Affiliated Hospital of Wenzhou Medical University</TargetEntity></SourceEntity><SourceEntity id="82" type="ciIndication"><TargetEntity id="R05" type="ICD10"/><TargetEntity id="10011224" type="MEDDRA"/><TargetEntity id="D003371" type="MeSH"/><TargetEntity id="-62743552" type="omicsDisease"/><TargetEntity id="283" type="siCondition"/></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1056719">The First Affiliated Hospital of Wenzhou Medical University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1668">General anesthetic</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2019-01-05T00:00:00Z</DateStart><DateEnd type="estimated">2019-01-20T00:00:00Z</DateEnd><DateChangeLast>2019-01-21T10:52:35Z</DateChangeLast><Contacts><Contact type="Public contact"><Affiliation>The First Affiliated Hospital of Wenzhou Medical University</Affiliation><Email>linwendong2000@163.com</Email><Name>Wendong Lin</Name><Phone>+86 13819705490</Phone></Contact><Contact type="Scientific contact"><Affiliation>The First Affiliated Hospital of Wenzhou Medical University</Affiliation><Email>linwendong2000@163.com</Email><Name>Jiehao Sun</Name><Phone>+86 13819705490</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 18 to 65 years old&lt;/li&gt;&lt;li&gt;BMI: 18 to 28 kg/m2&lt;/li&gt;&lt;li&gt;ASA I to II grade&lt;/li&gt;&lt;li&gt;Patients undergoing elective general anesthesia surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnancy or lactation women&lt;/li&gt;&lt;li&gt;With a history of drug allergy&lt;/li&gt;&lt;li&gt;Cognitive or mental illness&lt;/li&gt;&lt;li&gt;Severe cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic diseases -Long-term use of analgesics or hormones, drug abuse History&lt;/li&gt;&lt;li&gt;Those who participated in other clinical trials or researchers considered inappropriate to participate in this experiment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Coughing times</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean arterial pressure</Description></Measure><Measure><Description>Heart rate</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Objectives of study: to observe the inhibitory effect of pre-injection of low-dose &lt;ulink linkType="Drug" linkID="4208"&gt;remifentanil&lt;/ulink&gt; on cough caused by sufentanil during general anesthesia induction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized into one of the two arms and will receive remifentanil iv injection,0.3 microg/kg before induction or no intervention.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>The First Affiliated Hospital of Wenzhou Medical University</Name><Address2>Zhejiang</Address2><CountrySubDivision>Zhejiang</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other respiratory disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18269">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1900020587</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other respiratory disease" id="43450"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other respiratory disease" id="43449"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other respiratory disease" id="32992"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other respiratory disease" id="32995"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Other respiratory disease" id="35082"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other respiratory disease" id="24054"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24309"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24430"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24670"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24674"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24677"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24966"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other respiratory disease" id="24661">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other respiratory disease" id="25986"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="27440"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="27923"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="28520"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="29142"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType></Trial><Trial id="376832"><TitleDisplay>Colchicine for the Treatment of Osteoarthritis of the Knee</TitleDisplay><TitleOfficial>A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Colchicine on Pain and Inflammation in Subjects With Knee Osteoarthritis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03913442</Identifier><Identifier type="Organisational Study">16-01796</Identifier><Identifier type="Trial Acronym">CLOAK</Identifier></Identifiers><Indications><Indication id="188">Inflammatory disease</Indication><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="50336" role="Therapeutic effect marker" type="Physiological">Knee stiffness</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>colchicine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1187202" type="Company"><TargetEntity id="5064589797" type="organizationId">NYU Langone Health System</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1187202">NYU Langone Health</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2019-05-15T00:00:00Z</DateStart><DateEnd type="estimated">2021-05-15T00:00:00Z</DateEnd><DateChangeLast>2019-05-27T11:14:08Z</DateChangeLast><DateAdded>2019-04-16T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>Rebecca.Cohen@nyulangone.org</Email><Name>Rebecca Cohen</Name><Phone>1 212 598 6119</Phone></Contact><Contact type="Scientific contact"><Affiliation>New York Langone Medical Center</Affiliation><Name>Michael H Pillinger, MD, FACP</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Are 40 years old or older&lt;/li&gt;&lt;li&gt;Continue to experience frequent knee symptoms as defined above&lt;/li&gt;&lt;li&gt;Have KL grade 2 or 3 on their last knee radiograph done for the parent study&lt;/li&gt;&lt;li&gt;Have an estimated glomerular filtration rate (eGFR)&amp;gt; 30 ml/min (MDRD equation) and liver transaminases &amp;lt; 2 x the upper limit of normal&lt;/li&gt;&lt;li&gt;Have a BMI&amp;lt;/= 32 at the time of enrollment&lt;/li&gt;&lt;li&gt;Agree to be randomized to take colchicine or placebo daily for 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have received hyaluronic acid or corticosteroid steroid injection within the past 3 months&lt;/li&gt;&lt;li&gt;Have a diagnosis of gout/pseudogout or other inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy etc)&lt;/li&gt;&lt;li&gt;Have a diagnosis of diabetes mellitus, chronic infectious disease, congestive heart failure, non-cutaneous cancer within the past five years&lt;/li&gt;&lt;li&gt;Plan on undergoing total knee replacement within the next 3 months&lt;/li&gt;&lt;li&gt;Be using any medication that is a strong CYP3A4 inhibitor whose metabolism may interact with colchicine (eg, certain protease inhibitors, certain azole antifungal agents, clarithromycin)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Difference in mean changes of VAS pain scores between treatment groups: the VAS scale asks patients to rate the pain that they've had in each knee during the past 30 days on a scale of 0 to 10, where '0' means 'no pain' and '10' means 'pain as bad as you can imagine'</Description><Timeframe>3 Months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean changes and absolute differences in the Knee injury and Osteoarthritis Outcome Score (KOOS) for pain</Description><Timeframe>3 Months</Timeframe></Measure><Measure><Description>Mean absolute doses and changes in dosage of acetaminophen or other medications used for pain between and within the groups</Description><Timeframe>3 Months</Timeframe></Measure><Measure><Description>Mean changes between total KOOS scores between and within the groups</Description><Timeframe>3 Months</Timeframe></Measure><Measure><Description>Mean changes of KOOS physical function</Description><Timeframe>3 Months</Timeframe></Measure><Measure><Description>Mean changes of KOOS stiffness</Description><Timeframe>3 Months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to evaluate the effects of colchicine on pain and inflammation in subjects with knee osteoarthritis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this prospective, double-blinded, placebo-controlled, randomized, phase IV trial, 120       patients  with knee osteoarthritis will be enrolled at the NYU center for musculoskeletal care.&lt;br/&gt;Patients meeting entry criteria will be      randomized in 1 : 1 ratio into two arms:&lt;br/&gt;Arm 1 (placebo comparator: placebo): patients will receive placebo oral capsule in capsule identical to study drug, 0.8 mg po qd for 3 months.&lt;br/&gt;Arm 2 (experimental: colchicine): patients will receive colchicine 0.8 mg po qd for 3 months.&lt;/para&gt;&lt;para&gt;Patients will have      detailed evaluation of standardized clinical pain outcomes, candidate peripheral blood      biomarkers, baseline knee radiographs as well as MSK-US, and a subset will undergo evaluation      of their synovial fluid.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>NYU Langone Health</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Rebecca.Cohen@nyulangone.org</Email><Name>Rebecca Cohen</Name><Phone>212-598-6119</Phone></Contact><Contact type="Facility investigator"><Name>Michael Pillinger, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Osteoarthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="8848">Subjects with Osteoarthritis of Knee</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8849">Subjects with Specific Grade of Severity in Kellgren and Lawrence scale</PatientSegment><SubSegments><SubSegment id="8851">Subjects with Kellgren and Lawrence grade 2 osteoarthritis</SubSegment><SubSegment id="8852">Subjects with Kellgren and Lawrence grade 3 osteoarthritis</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8861">Subjects with Symptomatic Disease</PatientSegment><SubSegments><SubSegment id="8862">Subjects with pain&amp; stiffness</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03913442</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13996">Assessment of Pain by Visual Analog Scale (VAS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Osteoarthritis" id="13995"><Endpoint>Assessment of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13999">Assessment of Pain Intensity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Osteoarthritis" id="13886"><Endpoint>Assessment of Joint Stiffness</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13902"><Endpoint>Assessment of use of Rescue Medication</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="14008">Assessment of Pain by Knee injury and Osteoarthritis Outcome Score (KOOS)</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="25788">Assessment by Knee Injury and Osteoarthritis Outcome Score (KOOS)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Osteoarthritis" id="13927"><Endpoint>Assessment of Joint Structure/Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13934">Assessment of synovial fluid</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Osteoarthritis" id="13957"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Osteoarthritis" id="13963"><Endpoint>Imaging/Radiological Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoarthritis" id="14166"><Criterion>Subjects with Osteoarthritis of Knee</Criterion></Inclusion><Inclusion disease="Osteoarthritis" id="14176"><Criterion>Subjects with Specific Grade of Severity Based on Kellgren and Lawrence scale</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14178">Subjects with Kellgren and Lawrence grade 2 osteoarthritis</SubCriterion><SubCriterion disease="Osteoarthritis" id="14179">Subjects with Kellgren and Lawrence grade 3 osteoarthritis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="14185"><Criterion>Subjects Diagnosed by Specific Methods</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14186">Subjects with osteoarthritis confirmed by radiograph</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="14189"><Criterion>Subjects with Osteoarthritis Presenting with Pain</Criterion></Inclusion><Inclusion disease="Osteoarthritis" id="14227"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Osteoarthritis" id="34563"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14234">Subjects with protocol specified weight/BMI values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34871"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14230">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Osteoarthritis" id="11592"><Criterion>Subjects co-morbid with musculoskeletal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11596">Subjects co-morbid with rheumatoid arthritis</SubCriterion><SubCriterion disease="Osteoarthritis" id="11598">Subjects with other inflammatory joint disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11602"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11604"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11614"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11627"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11628">Subjects treated with anticoagulant</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11631"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="25889"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11615">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="26814"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11625">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="27114"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-05-15T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-04-02T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="380976"><TitleDisplay>A phase II/III clinical trial of voclosporin ophthalmic solution for the treatment of patients with dry eye syndrome (DES)</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="3016">Xerophthalmia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>voclosporin (eye drop, ocular inflammation), Aurinia Pharmaceuticals</Name><Drug id="59376">voclosporin (eye drop, ocular inflammation), Aurinia Pharmaceuticals</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59376">voclosporin (eye drop, ocular inflammation), Aurinia Pharmaceuticals</Drug><IndicationsPioneer/><Companies><Company><Company id="1078510">Aurinia Pharmaceuticals Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59376" type="Drug"><TargetEntity id="469796" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="3016" type="ciIndication"><TargetEntity id="H04.12" type="ICD10"/><TargetEntity id="10048221" type="MEDDRA"/><TargetEntity id="D014985" type="MeSH"/><TargetEntity id="-455555105" type="omicsDisease"/><TargetEntity id="773" type="siCondition"/></SourceEntity><SourceEntity id="4010" type="Action"><TargetEntity id="1500" type="Mechanism">Calcineurin (PP-2B) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="15">Planned</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1078510">Aurinia Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4010">Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15128">Ophthalmological agent</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1668">Nanoparticle formulation</Technology><Technology id="620">Ophthalmic formulation</Technology><Technology id="659">Ophthalmic liquid formulation</Technology><Technology id="80">Peptide</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2019-05-17T22:01:25Z</DateChangeLast><DateAdded>2019-05-17T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with dry eye syndrome&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a phase II/III clinical trial of &lt;ulink linkType="Drug" linkID="59376"&gt;voclosporin&lt;/ulink&gt; ophthalmic solution for the treatment of patients with dry eye syndrome (DES) [&lt;ulink linkType="Reference" linkID="2151754"&gt;2151754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2019, &lt;ulink linkType="Company" linkID="1078510"&gt;Aurinia&lt;/ulink&gt; planned to initiate the trial in late 2019 [&lt;ulink linkType="Reference" linkID="2151754"&gt;2151754&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><ChangeHistory><Change type="added"><Date>2019-05-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="381145"><TitleDisplay>To study whether a drug (Saroglitazaar) used to treat diabetes and deranged lipid profile can lead to improvement in fatty liver also</TitleDisplay><TitleOfficial>To Study The Effect Of Saroglitazar On Non-Alcoholic Fatty Liver Disease In Patients With Diabetic Dyslipidemia: An Open, Longitudinal, Observational Cohort Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2019/05/019199</Identifier></Identifiers><Indications><Indication id="3288">Non alcoholic fatty liver disease</Indication><Indication id="584">Lipid metabolism disorder</Indication><Indication id="99">Diabetic complication</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>saroglitazar magnesium</Name><Drug id="53350">saroglitazar magnesium</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="53350">saroglitazar magnesium</Drug><IndicationsPioneer><Indication id="99">Diabetic complication</Indication></IndicationsPioneer><Companies><Company><Company id="1071090">Dayanand Medical College and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="53350" type="Drug"><TargetEntity id="353426" type="siDrug">ZYH-1</TargetEntity></SourceEntity><SourceEntity id="1071090" type="Company"><TargetEntity id="5000931119" type="organizationId">Dayanand Medical College &amp; Hospital</TargetEntity></SourceEntity><SourceEntity id="3288" type="ciIndication"><TargetEntity id="K76.0" type="ICD10"/><TargetEntity id="-468189475" type="omicsDisease"/><TargetEntity id="2263" type="siCondition"/></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"/><TargetEntity id="D052439" type="MeSH"/><TargetEntity id="-386237446" type="omicsDisease"/><TargetEntity id="2898" type="siCondition"/></SourceEntity><SourceEntity id="99" type="ciIndication"><TargetEntity id="10061104" type="MEDDRA"/><TargetEntity id="D048909" type="MeSH"/><TargetEntity id="-1536080297" type="omicsDisease"/><TargetEntity id="513" type="siCondition"/></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="2479" type="Action"><TargetEntity id="1681" type="Mechanism">PPARgamma Modulators</TargetEntity><TargetEntity id="2117" type="Mechanism">PPARgamma Ligands</TargetEntity></SourceEntity><SourceEntity id="2480" type="Action"><TargetEntity id="895" type="Mechanism">PPARgamma Agonists</TargetEntity></SourceEntity><SourceEntity id="3033" type="Action"><TargetEntity id="893" type="Mechanism">PPARalpha Agonists</TargetEntity><TargetEntity id="2789" type="Mechanism">PPARalpha Partial Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1071090">Dayanand Medical College and Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1919">Insulin sensitizer</Action><Action id="2479">PPAR gamma modulator</Action><Action id="2480">PPAR gamma agonist</Action><Action id="3033">PPAR alpha agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1389">Lipid metabolism modulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="399">Hypoglycemic agent</Class><Class id="7018">Antihypertriglyceridemic agent</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Longitudinal</Term><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2019-05-27T00:00:00Z</DateStart><DateChangeLast>2019-05-22T09:35:52Z</DateChangeLast><DateAdded>2019-05-21T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Dayanand Medical College and Hospital</Affiliation><Email>goyalomesh@yahoo.co.in</Email><Name>Dr Omesh Goyal</Name><Phone>9914821155</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age between 18  to 70 years&lt;/li&gt;&lt;li&gt;Diabetes and dyslipidemia requiring medical treatment&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Chronic viral hepatitis&lt;/li&gt;&lt;li&gt;Significnt alcohol intake&lt;/li&gt;&lt;li&gt;Uncontrolled thyroid disease&lt;/li&gt;&lt;li&gt;Active cardio-pulmonary disease&lt;/li&gt;&lt;li&gt;Current or past history of malignancy&lt;/li&gt;&lt;li&gt;Chronic liver disease or chronic kidney disease (CKD)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Effect of saroglitazar on liver enzymes in patients with diabetic dyslipidemia</Description><Timeframe>For 24 weeks</Timeframe></Measure><Measure><Description>Effect of saroglitazaar on transient elastography</Description><Timeframe>For 24 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;An open, longitudinal, observational cohort study to find whether &lt;ulink linkType="Drug" linkID="53350"&gt;saroglitazar&lt;/ulink&gt;  used to treat diabetes and deranged lipid profile, can lead to improvement in fatty liver.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who received saroglitazar will be observed. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Dayanand Medical College and Hospital</Name><Address1>Ludhiana</Address1><Address2>Punjab</Address2><Address3>141001</Address3><CountrySubDivision>Punjab</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7617">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7620">Subjects with dyslipidemia</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="104">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="105">Subjects with dyslipidemia</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18219">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="18805">Subjects with Non alcoholic fatty liver disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2019/05/019199</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gastrointestinal disease" id="43414"><Endpoint>Assessment of Liver Functions</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other gastrointestinal disease" id="43528"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="613"><Criterion>Subjects with Dyslipidemia</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="639"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16322"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16325">Subjects co-morbid with dyslipidemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16350"><Criterion>Subjects Requiring/Scheduled for Other Anti-diabetic Therapy</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="32959"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35070"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="839">Subjects with chronic kidney disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="925"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5072"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5074"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13757"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13758">Subjects with chronic kidney disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13773"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13811"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13812"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13815"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13835"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="25150"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="25151"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="28259"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="28262"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="29272"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13892">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="29284"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1003">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="45138"><TitleDisplay>Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer</TitleDisplay><TitleOfficial>A Phase I/II Study of R-115777 (Tipifarnib, Zarnestra) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB to IIIC Breast Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Other">NCI-2009-00239</Identifier><Identifier type="Other">06-12-487</Identifier><Identifier type="Other">N01CM62202</Identifier><Identifier type="Other">N01CM62204</Identifier><Identifier type="Other">7868</Identifier><Identifier type="Other">P30CA013330</Identifier><Identifier type="Organisational Study">CDR0000543434</Identifier><Identifier type="NCT">NCT00470301</Identifier><Identifier type="Secondary Organisational">NYCC-06-12-487</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin (liposomal, STEALTH), Alza</Name><Drug id="7934">doxorubicin (liposomal, STEALTH), Alza</Drug></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin + cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>pegfilgrastim</Name><Drug id="21374">pegfilgrastim</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tipifarnib</Name><Drug id="17113">tipifarnib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17113">tipifarnib</Drug><IndicationsPioneer/><Companies><Company><Company id="1042562">New York Cancer Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="21374">pegfilgrastim</Drug><IndicationsPioneer/><Companies><Company><Company id="1042562">New York Cancer Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="1042562">New York Cancer Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7934">doxorubicin (liposomal, STEALTH), Alza</Drug><IndicationsPioneer/><Companies><Company><Company id="1042562">New York Cancer Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="7934" type="Drug"><TargetEntity id="191261" type="siDrug">Liposomal doxorubicin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="17113" type="Drug"><TargetEntity id="253457" type="siDrug">Tipifarnib</TargetEntity></SourceEntity><SourceEntity id="21374" type="Drug"><TargetEntity id="279036" type="siDrug">Pegfilgrastim</TargetEntity></SourceEntity><SourceEntity id="1042562" type="Company"><TargetEntity id="5035544400" type="organizationId">New York Cancer Consortium</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="10451" type="Action"><TargetEntity id="4342" type="Mechanism">RAS GTPases Inhibitors</TargetEntity></SourceEntity><SourceEntity id="138" type="Action"><TargetEntity id="416" type="Mechanism">DNA-Directed DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="1065" type="Mechanism">DNA Polymerase Inhibitors</TargetEntity><TargetEntity id="3618" type="Mechanism">Nucleic Acid Polymerase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1875" type="Action"><TargetEntity id="426" type="Mechanism">Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors</TargetEntity><TargetEntity id="429" type="Mechanism">Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors</TargetEntity><TargetEntity id="2361" type="Mechanism">Geranylgeranyl Transferase Type II (GGTase-II) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>7</NumberOfSites><CompaniesSponsor><Company id="1042562">New York Cancer Consortium</Company><Company id="20519">National Cancer Institute</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10451">Ras GTPase inhibitor</Action><Action id="138">DNA polymerase inhibitor</Action><Action id="142">Topoisomerase II inhibitor</Action><Action id="1875">Protein farnesyltransferase inhibitor</Action><Action id="3151">GCSF receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="2953">Anti-inflammatory</Class><Class id="610">Hematopoietic stimulator</Class><Class id="750">DNA intercalator</Class><Class id="767">Cell cycle inhibitor</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="127">Cell culture</Technology><Technology id="112">DNA technology</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="598">Liposome formulation injectable</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="348">PEGylated formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><PatientCountEvaluable>60</PatientCountEvaluable><DateStart>2007-04-30T00:00:00Z</DateStart><DateEnd type="actual">2013-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-13T05:56:32Z</DateChangeLast><DateAdded>2009-02-12T10:34:35Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Montefiore Medical Center</Affiliation><Name>Dawn Hershman</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically or cytologically confirmed adenocarcinoma of the breast, clinical stage IIB, IIIA, IIIB, or IIIC disease&lt;/li&gt;&lt;li&gt;At least 1 week since prior tamoxifen or other selective estrogen receptor modulator for prevention or for other indications (eg, osteoporosis or prior ductal carcinoma in situ)&lt;/li&gt;&lt;li&gt;HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization (FISH)&lt;/li&gt;&lt;li&gt;Hormone receptor status:&lt;ul&gt;&lt;li&gt;Estrogen and/or progesterone receptor-positive (note: patients enrolled on the phase I portion of the trial may have estrogen and progesterone receptor-negative disease)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Normal organ function including:&lt;/li&gt;&lt;li&gt;WBC &gt;/= 3,000/mm3&lt;/li&gt;&lt;li&gt;Absolute neutrophil count &gt;/= 1,500/mm3&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/mm3&lt;/li&gt;&lt;li&gt;Bilirubin normal&lt;/li&gt;&lt;li&gt;AST and ALT&amp;lt;/= 2.5 x upper limit of normal&lt;/li&gt;&lt;li&gt;LVEF normal by echocardiogram or nuclear scan&lt;/li&gt;&lt;li&gt;Creatinine normal or creatinine clearance &gt;/= 60 ml/min&lt;/li&gt;&lt;li&gt;FEV1 &gt;/= 1 l and DLCO &gt;/= 50% (note: only if baseline CT scan of chest shows parenchymal lung disease or there is a history of chronic obstructive or other pulmonary disease)&lt;/li&gt;&lt;li&gt;No prior chemotherapy, radiotherapy, or definitive therapeutic surgery (eg, mastectomy, lumpectomy, or axillary dissection) for this cancer but prior sentinel lymph node biopsy for this malignancy allowed&lt;/li&gt;&lt;li&gt;No prior adjuvant chemotherapy for a previous breast malignancy&lt;/li&gt;&lt;li&gt;No concurrent combination antiretroviral therapy for HIV-positive patients&lt;/li&gt;&lt;li&gt;No other concurrent investigational agents&lt;/li&gt;&lt;li&gt;No other concurrent anticancer agents or therapies&lt;/li&gt;&lt;li&gt;ECOG performance status 0 to 1&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;No other invasive malignancy within the past five years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix&lt;/li&gt;&lt;li&gt;No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs (eg, imidazoles or quinolones)&lt;/li&gt;&lt;li&gt;No other uncontrolled illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would preclude study compliance&lt;/li&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Recommended phase II dose of tipifarnib when combined with weekly sequential paclitaxel (phase I)</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>Pathological Complete Response Rate (pCR) Evaluated Using RECIST (Phase II): an increase in the breast pCR from 15% (anticipated for chemotherapy alone) to 35% would be considered promising</Description><Timeframe>Up to five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  purpose of this phase I/II trial was to study the side effects and best dose of &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; when given together with combination chemotherapy and to see how well they work in treating patients with stage II or stage III breast cancer.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2013, published results reported no dose limiting toxicities among the first six patients treated with &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; (100or 200 mg bid; n =3 in each dose) plus &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;. In 18 and 4% of inflammatory carcinoma patients breast pathological complete response (pCR) was observed. In patients with locally advanced HER-2/neu-negative inflammatory or non-inflammatory estrogen and/or progesterone receptor-positive   breast carcinoma, combination of &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; with weekly &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="7934"&gt;doxorubicin&lt;/ulink&gt;-cyclophosphamide did not show  breast pCR rate of &gt;/= 35% [&lt;ulink linkType="Reference" linkID="1509506"&gt;1509506&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The objectives of the study were to:&lt;br/&gt;Determine the recommended phase II dose of &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; when given together with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; in patients with stage IIB to IIIC breast cancer (phase I).&lt;br/&gt;Determine the pathological complete remission rate (including breast and breast plus axillary nodes) in patients treated with sequential &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; followed by dose-dense &lt;ulink linkType="Drug" linkID="7934"&gt;doxorubicin hydrochloride&lt;/ulink&gt;, cyclophosphamide, and &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; (phase II).&lt;br/&gt;Determine the feasibility and safety of this regimen in these patients (phase I and II).&lt;/para&gt;&lt;para&gt;This was a multicenter, phase I, dose-escalation study of &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; followed by a phase II study.&lt;br/&gt;Phase I:&lt;br/&gt;&lt;ulink linkType="Drug" linkID="3803"&gt;Paclitaxel&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt;: patients would  receive &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; iv over 1 h on day 1 and oral &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; twice daily on days 1 to 3. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.&lt;br/&gt;Patients with no evidence of disease progression after 12 courses proceed to AC chemotherapy plus &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt;.&lt;br/&gt;Cohorts of three to six patients would receive escalating doses of &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; until the recommended phase II dose (RTPD) is determined. The RTPD is defined as the dose preceding that at which  two of  three or  two of  six patients experience dose-limiting toxicity.&lt;br/&gt;AC chemotherapy plus &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt;: patients would receive &lt;ulink linkType="Drug" linkID="7934"&gt;doxorubicin hydrochloride&lt;/ulink&gt; iv over 5 to 10 min and cyclophosphamide iv over 30 to 60 min on day 1, oral &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; twice-daily on days 2 to 7, and &lt;ulink linkType="Drug" linkID="21374"&gt;pegfilgrastim&lt;/ulink&gt; subcutaneously on day 2. Treatment repeats every 2 weeks for four courses in the absence of disease progression or unacceptable toxicity.&lt;br/&gt;Phase II: patients would receive &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; at the RTPD and AC chemotherapy plus &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; as in phase I.&lt;br/&gt;After completion of AC plus &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; (in both phases), patients would be  re-evaluated for surgery (ie, modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection).&lt;/para&gt;&lt;para&gt;After completion of study treatment, patients would be  followed every 6 months for  five years and then annually for  five years. A total of 86 patients would be accrued for this study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received 80mg/m2 of &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; in 12 weekly doses, followed by &lt;ulink linkType="Drug" linkID="7934"&gt;doxorubicin&lt;/ulink&gt;-cyclophosphamide (60/600mg/m2 q2w and &lt;ulink linkType="Drug" linkID="21374"&gt;filgrastim&lt;/ulink&gt;), plus &lt;ulink linkType="Drug" linkID="17113"&gt;tipifarnib&lt;/ulink&gt; (100 or 200mg po on days 1 to 3 of each &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; dose, and 200mg po on days 2 to 7 of each &lt;ulink linkType="Drug" linkID="7934"&gt;doxorubicin&lt;/ulink&gt;-cyclophosphamide cycle) [&lt;ulink linkType="Reference" linkID="1509506"&gt;1509506&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="374516">cyclophosphamide</Intervention><Treatments><Treatment><Dose>600 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="99795">doxorubicin (liposomal, STEALTH), Alza</Intervention><Treatments><Treatment><Dose>60 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="99796">paclitaxel</Intervention><Treatments><Treatment><Dose>80 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="99798">tipifarnib</Intervention><Treatments><Treatment><Dose>100 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>200 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Albert Einstein College of Medicine</Name><Address1>Bronx</Address1><Address2>New York</Address2><Address3>10461</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Columbia University Medical Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10032</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>H. Lee Moffitt Cancer Center and Research Institute</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>M D Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Montefiore Medical Center</Name><Address1>Bronx</Address1><Address2>New York</Address2><Address3>10467-2490</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Mount Sinai Medical Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10029</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Weill Medical College of Cornell University</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3929">Subjects at Risk of Developing Invasive Breast Cancer</PatientSegment><SubSegments><SubSegment id="3941">Lobular carcinoma in situ (LCIS)</SubSegment><SubSegment id="3942">Ductal carcinoma in situ/Intraductal carcinoma (DCIS)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3930">Subjects with Hormone Receptor Positive Breast Cancer</PatientSegment><SubSegments><SubSegment id="3931">Estrogen receptor positive (ER+) breast cancer</SubSegment><SubSegment id="3932">Progesterone receptor positive (PR+) breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3933">Subjects with Hormone Receptor Negative Breast Cancer</PatientSegment><SubSegments><SubSegment id="3934">Estrogen receptor negative (ER-) breast cancer</SubSegment><SubSegment id="3935">Progesterone receptor negative (PR-) breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3937">Subjects with HER-2 Negative Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3938">Subjects with Triple Negative Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3944">Subjects with Stage II Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3945">Subjects with Stage III Breast Cancer</PatientSegment><SubSegments><SubSegment id="3946">TNM stage IIIA Breast cancer</SubSegment><SubSegment id="3947">TNM stage IIIB Breast cancer</SubSegment><SubSegment id="3948">TNM stage IIIC Breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3950">Subjects with Early Stage Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3952">Subjects with Locally Advanced Breast Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00470301</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8730">Assessment of histo-pathologic response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="9122"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8720">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Breast tumor" id="8721">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Breast tumor" id="8730">Assessment of histo-pathologic response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8996"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="44935"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9325">Assessment of Feasibility</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Breast tumor" id="8902"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8926">Assessment of Farnesyl transferase (FTase) activity levels</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Breast tumor" id="8996"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9008">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4803"><Criterion>Subjects at Risk of Developing Invasive Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4821">Ductal carcinoma in situ/Intraductal carcinoma (DCIS)</SubCriterion><SubCriterion disease="Breast tumor" id="4822">Lobular carcinoma in situ (LCIS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4807"><Criterion>Subjects with Hormone Receptor Positive Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4808">Estrogen receptor positive (ER+) breast cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4809">Progesterone receptor positive (PR+) breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4810"><Criterion>Subjects with Hormone Receptor Negative Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4811">Estrogen receptor negative (ER-) breast cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4812">Progesterone receptor negative (PR-) breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4814"><Criterion>Subjects with HER-2 Negative Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4815"><Criterion>Subjects with Triple Negative Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4824"><Criterion>TNM Stage II Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4826">TNM stage IIB Breast Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4827"><Criterion>TNM Stage III Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4828">TNM stage IIIA Breast Cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4829">TNM stage IIIB Breast Cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4830">TNM stage IIIC Breast Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4879">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Breast tumor" id="4880">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4893"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4895">Subjects with history of anti-cancer hormonal therapy</SubCriterion><SubCriterion disease="Breast tumor" id="22394">Subjects with history of anti-cancer biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="5381"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Alzheimers disease" id="6675"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Alzheimers disease" id="6676"><Criterion>Subjects scheduled to receive disease specific therapy</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22417"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22418"><Criterion>Subjects with Early Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22517"><Criterion>Subjects with History of/Scheduled for Diagnostic Procedures</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="22521">Subjects scheduled for biopsy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6253">Subjects with central nervous system diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6272"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20288">Subjects contraindicated to targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6328"><Criterion>Subjects with History of/Scheduled for Anti-neoplastic Therapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6331">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26891"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20290">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>42.06 Months</EnrollmentPeriod><EnrollmentRate>1.43 Patients/Month</EnrollmentRate><DateFirstReceived>2007-05-03T00:00:00Z</DateFirstReceived><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-12T10:34:35Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-12-20T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2015-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="54399"><TitleDisplay>A phase I/II, safety and efficacy of exisulind in combination with paclitaxel and carboplatin in chemotherapy naive patients with advanced non-small-cell lung cancer</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="1262">Non-small-cell lung cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>carboplatin</Name><Drug id="44383">carboplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>exisulind</Name><Drug id="12153">exisulind</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12153">exisulind</Drug><IndicationsPioneer/><Companies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23024">Cell Pathways Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="23024">Cell Pathways Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44383">carboplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23024">Cell Pathways Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="44383" type="Drug"><TargetEntity id="125568" type="siDrug">Carboplatin</TargetEntity></SourceEntity><SourceEntity id="12153" type="Drug"><TargetEntity id="218849" type="siDrug">Exisulind</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="23024" type="Company"><TargetEntity id="4295909360" type="organizationId">Cell Pathways Inc</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="429" type="Action"><TargetEntity id="2360" type="Mechanism">cGMP Phosphodiesterase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23024">Cell Pathways Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="429">Cyclic GMP phosphodiesterase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1588">Apoptosis modulator</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="50">Anticancer alkylating agent</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><DateStart>2001-10-05T00:00:00Z</DateStart><DateChangeLast>2009-05-08T10:03:48Z</DateChangeLast><DateAdded>2009-05-08T10:03:48Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Rush-Presbyterian-St. Luke's Medical Center</Affiliation><Name>Dr Philip Bonomi. Bonomi</Name></Contact><Contact type="Scientific contact"><Affiliation>Rush Medical College</Affiliation><Name>Alice Wirtz</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Chemotherapy naive patients with advanced non-small-cell lung cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Tumor response rate</Description></Measure><Measure><Description>Median survival</Description></Measure><Measure><Description>One year survival</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a phase I/II, safety and efficacy of &lt;ulink linkType="Drug" linkID="12153"&gt;exisulind&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; in chemotherapy naive patients with advanced non-small-cell lung cancer [&lt;ulink linkType="Reference" linkID="408114"&gt;408114&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="424565"&gt;424565&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive a 28-day treatment regimen of 250 mg bid po &lt;ulink linkType="Drug" linkID="12153"&gt;exisulind&lt;/ulink&gt; along with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; on day 1, 8 and 15 and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; on day 1. Patients would receive a total of six treatment cycles. The study endpoints would be tumor response rate, median survival and one year survival. Patients who respond to treatment could continue to receive &lt;ulink linkType="Drug" linkID="12153"&gt;exisulind&lt;/ulink&gt; alone  [&lt;ulink linkType="Reference" linkID="424565"&gt;424565&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Rush-Presbyterian-St. Luke's Medical Center</Name><Address1>Chicago</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-05-08T10:03:48Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="57250"><TitleDisplay>Effect of Full Length Parathyroid Hormone, PTH(1-84)or Strontium Ranelate on Bone Markers in Post-Menopausal Women With Primary Osteoporosis</TitleDisplay><TitleOfficial>A 24-Week, International, Multicenter, Randomized, Open-Label, Parallel-Group, Phase IV Clinical Trial Investigating Changes in Bone Formation Markers in Post-Menopausal Women With Primary Osteoporosis Treated With Either PTH(1-84) or Strontium Ranelate</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">FP-006-IM</Identifier><Identifier type="NCT">NCT00479037</Identifier><Identifier type="Secondary Organisational">2006-006065-16</Identifier></Identifiers><Indications><Indication id="246">Osteoporosis</Indication></Indications><BiomarkerNames><BiomarkerName id="483" role="Therapeutic effect marker" type="Proteomic">Collagen type I trimeric cross-linked peptide</BiomarkerName><BiomarkerName id="2072" role="Therapeutic effect marker" type="Proteomic">Procollagen Type I N-terminal peptide</BiomarkerName><BiomarkerName id="3712" role="Therapeutic effect marker" type="Genomic;Proteomic">Paired box protein Pax-5</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire</Name><Drug id="6791">recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>strontium ranelate</Name><Drug id="4319">strontium ranelate</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6791">recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire</Drug><IndicationsPioneer/><Companies><Company><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="19863">Servier</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6791" type="Drug"><TargetEntity id="202813" type="siDrug">Parathyroid hormone (human recombinant)</TargetEntity></SourceEntity><SourceEntity id="1002503" type="Company"><TargetEntity id="4297904097" type="organizationId">Takeda Pharmaceuticals International AG</TargetEntity></SourceEntity><SourceEntity id="19863" type="Company"><TargetEntity id="4296695285" type="organizationId">Les Laboratoires Servier SAS</TargetEntity></SourceEntity><SourceEntity id="246" type="ciIndication"><TargetEntity id="10031282" type="MEDDRA"/><TargetEntity id="D010024" type="MeSH"/><TargetEntity id="-1487907849" type="omicsDisease"/><TargetEntity id="965" type="siCondition"/></SourceEntity><SourceEntity id="13409" type="Action"><TargetEntity id="922" type="Mechanism">Parathyroid Hormone Secretion Stimulants</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company></CompaniesSponsor><CompaniesCollaborator><Company id="19863">Servier</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="13409">Parathyroid hormone ligand</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1599">Bone metabolism modulator</Class><Class id="445">Bone synthesis stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="585">Oral formulation</Technology><Technology id="84">Protein fusion</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>82</PatientCountEnrollment><PatientCountEvaluable>81</PatientCountEvaluable><DateStart>2007-04-30T00:00:00Z</DateStart><DateEnd type="actual">2009-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-05T07:30:49Z</DateChangeLast><DateAdded>2009-06-03T08:40:23Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Headquarters</Affiliation><Name>Nycomed Clinical Trial Operations</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Postmenopausal women at or above the age of 50 years, diagnosed with primary osteoporosis may be        enrolled in the trial if the following inclusion/exclusion criteria apply&lt;/li&gt;&lt;li&gt;All inclusion criteria must be answered 'yes' for a subject to be enrolled in the trial&lt;ul&gt;&lt;li&gt;Has the subject given informed consent according to local requirements before any             trial related activities? (A trial related activity is any procedure that would not             have been performed during the routine management of the subject)&lt;/li&gt;&lt;li&gt;Is the subject female and at or above the age of 50 years?&lt;/li&gt;&lt;li&gt;Has the subject been postmenopausal for more than five years - in the judgement of the             investigator?&lt;/li&gt;&lt;li&gt;Does the subject have primary osteoporosis and a T-score&amp;lt;/= -3 SD;             T-scores must be assessed by DXA at the lumbar spine L1 to L4, with a minimum of two             assessable vertebrae, or at the total hip (right hip, if there is a right hip             prosthesis, left hip can be used. If both hips are replaced the subject can be             included with a lumbar scan only)&lt;/li&gt;&lt;li&gt;Is the subject currently taking calcium and vitamin D3 or is she willing to start such             supplemental treatment and continue throughout the trial period, unless she develops             hypercalcaemia?&lt;/li&gt;&lt;li&gt;Has the subject been taking supplemental calcium (1000 mg) and vitamin D3 (800 IU)             daily for at least 14 days (after screening) before blood sampling for eligibility             evaluation?1&lt;/li&gt;&lt;li&gt;Is the subject able to self-inject&lt;ulink linkType="Drug" linkID="6791"&gt;PTH(1-84)&lt;/ulink&gt;, or get the injections by a helper? 1             Note that inclusion criteria no. 6 can not be evaluated at the time for screening,             must be evaluated at randomisation, visit 2. See also exclusion criteria and note 2&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;All exclusion criteria must be answered 'no' for a subject to be enrolled in the trial&lt;ul&gt;&lt;li&gt;Has the subject:&lt;ul&gt;&lt;li&gt;Been treated with SERMS (selective oestrogen receptor modulators) or calcitonin within             the last 1 month?&lt;/li&gt;&lt;li&gt;Ever been treated with any bisphosphonate in intravenous form (iv)?&lt;/li&gt;&lt;li&gt;Been treated with any bisphosphonates (alendronate, risedronate, or other             bisphosphonates) for more than three years in total, or within the last 6 months?&lt;/li&gt;&lt;li&gt;Been treated with fluoride for more than 3 months within the last ten years?&lt;/li&gt;&lt;li&gt;Ever been treated with&lt;ulink linkType="Drug" linkID="4319"&gt;strontium ranelate&lt;/ulink&gt;?&lt;/li&gt;&lt;li&gt;Ever been treated with teriparatide or&lt;ulink linkType="Drug" linkID="6791"&gt;PTH(1-84)&lt;/ulink&gt;?&lt;/li&gt;&lt;li&gt;Received or is the subject currently receiving chronic glucocorticosteroid treatment?&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Defined as more or equal to:&lt;ul&gt;&lt;li&gt;0mg prednisolon or equivalent daily for 3 months during the last year or 2.5mg             prednisolon or equivalent daily for 6 months during the last year. Local and             inhalation steroids are permitted&lt;/li&gt;&lt;li&gt;Been treated for cancer (other than basocellular skin cancer) within the last five             years?&lt;/li&gt;&lt;li&gt;Ever received radiation therapy to the skeleton?&lt;/li&gt;&lt;li&gt;Ever had malignant disease affecting the skeleton? or does the subject:&lt;/li&gt;&lt;li&gt;Currently receive antiepileptic medication?&lt;/li&gt;&lt;li&gt;Take any other medication (other than calcium and vitamin D3) that is known to affect             bone metabolism? according to the investigator's opinion&lt;/li&gt;&lt;li&gt;Have any known clinically significant diseases affecting calcium metabolism?&lt;/li&gt;&lt;li&gt;Have any known history of metabolic bone diseases other than primary osteoporosis             including hyperparathyroidism, Paget's disease, osteogenesis imperfecta, or             osteomalacia)?&lt;/li&gt;&lt;li&gt;Have any known history of hypersensitivity to parathyroid hormone or strontium or any             of the excipients in the products?&lt;/li&gt;&lt;li&gt;Have a serum vitamin D3, (serum 25(OH)D) level&amp;lt; 20 ng/ml after at least 14 days of             calcium and vitamin D3 supplementation?2&lt;/li&gt;&lt;li&gt;Have a serum PTH of&amp;gt; 65 pg/ml and also a total serum calcium value &amp;gt;2.49 mmol/l?&lt;/li&gt;&lt;li&gt;Have hypercalcaemia (total serum calcium value&amp;gt;2.55 mmol/l), measured after at least             14 days of calcium and vitamin D3 supplementation?2&lt;/li&gt;&lt;li&gt;Have elevated serum alkaline phosphatase? Defined as&amp;gt; 3X ULN2&lt;/li&gt;&lt;li&gt;Have impaired kidney function with creatinine clearance&amp;lt; 30 ml/min (indirect             measurement by serum creatinine)?2&lt;/li&gt;&lt;li&gt;Have severe impaired liver function (total score of&amp;gt; 9 on the Child-Pugh scale)? 2&lt;/li&gt;&lt;li&gt;Have phenylketonuria? or is the subject:&lt;/li&gt;&lt;li&gt;At risk of having venous thromboembolism including pulmonary embolism? - according to             the investigator's opinion&lt;/li&gt;&lt;li&gt;Scheduled for vertebroplasty?&lt;/li&gt;&lt;li&gt;Currently participating in a clinical trial with an investigational medical product,             or has done so within the last 90 days, or plan to do so within the next 32 weeks?             Previous and current participation in non-interventional trials is allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in N-terminal Propeptides of P1NP from baseline to end of treatment: P1NP is a bone formation marker that is derived from the amino-terminal propeptides of type I collagen and is considered a quantitative measure of newly formed type I collagen. Bone marker measurements were done by blood analysis</Description><Timeframe>Baseline and 24 weeks of treatment</Timeframe></Measure><Measure><Description>Change in BSAP from baseline to end of treatment: BSAP is a marker of bone formation that reflects the cellular activity of osteoblasts. Bone marker measurements were done by blood analysis.</Description><Timeframe>Baseline and 24 weeks of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in C-telopeptide cross-links (CTX) from baseline to end of treatment: CTX is a marker of bone resorption, which is a degradation product of bone collagen.Bone marker measurements were done by blood analysis</Description><Timeframe>Baseline and 24 weeks of treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this trial was to show that &lt;ulink linkType="Drug" linkID="6791"&gt;PTH(1-84)&lt;/ulink&gt; is superior to &lt;ulink linkType="Drug" linkID="4319"&gt;strontium      ranelate&lt;/ulink&gt; in bone formation measured as changes in bone formation markers over a treatment      period of 24 weeks in postmenopausal women with primary osteoporosis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2011, results were published. At week 24  procollagen type 1 amino-terminal propeptide (P1NP) and bone specific alkaline phosphatase (BSAP) showed significant percentage increase from baseline in   &lt;ulink linkType="Drug" linkID="6791"&gt;PTH(1-84)&lt;/ulink&gt; treated group when compared to   &lt;ulink linkType="Drug" linkID="4319"&gt;strontium      ranelate&lt;/ulink&gt;   group. The   &lt;ulink linkType="Drug" linkID="6791"&gt;PTH(1-84)&lt;/ulink&gt; treatment also had a positive impact on quality of life (QoL). The safety data coincided with that of the previous analyses [&lt;ulink linkType="Reference" linkID="1218553"&gt;1218553&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were randomized to receive either  &lt;ulink linkType="Drug" linkID="6791"&gt;PTH(1-84)&lt;/ulink&gt; (100 microg, n = 41), sc or  &lt;ulink linkType="Drug" linkID="4319"&gt;strontium      ranelate&lt;/ulink&gt;  (2 g, po, n = 40) for 24 weeks along with daily supplements such as 800 IU vitamin D3 and 1000 mg calcium [&lt;ulink linkType="Reference" linkID="1218553"&gt;1218553&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="135256">recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire</Intervention><Treatments><Treatment><Dose>100 microgram</Dose><Route>Subcutaneous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="135331">strontium ranelate</Intervention><Treatments><Treatment><Dose>2 gram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Denmark"><Sites><Site><Name>Nycomed</Name><Address1>Roskilde</Address1><Address3>4000</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Osteoporosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7654">Subjects with Primary Osteoporosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7657">Subjects with Postmenopausal Osteoporosis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Menopause</Disease><PatientSegments><PatientSegment><PatientSegment id="11622">Subjects with Bone Disorders</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19017">Subjects with Protocol Specified Menstrual Status</PatientSegment><SubSegments><SubSegment id="11612">Postmenopausal Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00479037</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2006-006065-16</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoporosis" id="13782"><Endpoint>Assessment of Markers of Bone/Cartilage/Collagen Turnover</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13785">Assessment of bone specific alkaline phosphatase</SubEndpoint><SubEndpoint disease="Osteoporosis" id="13787">Serum procollagen type I N-terminal propeptide (P1NP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Menopause" id="23555"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Menopause" id="23556">Assessment of bone markers</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Osteoporosis" id="13789"><Endpoint>Assessment of Bone Resorption Markers</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13795">Serum and urinary collagen type I cross-linked C-terminal telopeptide(CTX)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Menopause" id="23555"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Menopause" id="23556">Assessment of bone markers</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoporosis" id="8682"><Criterion>Subjects with Primary Osteoporosis</Criterion></Inclusion><Inclusion disease="Osteoporosis" id="8685"><Criterion>Subjects with Postmenopausal Osteoporosis</Criterion></Inclusion><Inclusion disease="Menopause" id="20768"><Criterion>Subjects with Bone Disorders</Criterion></Inclusion><Inclusion disease="Menopause" id="33715"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Menopause" id="20758">Postmenopausal subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Menopause" id="18295"><Criterion>Subjects with Bone Disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18296"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Menopause" id="18301"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18304"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Menopause" id="18305"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Menopause" id="18306"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18307"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18309"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Menopause" id="18310"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Menopause" id="18311">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Menopause" id="18312">Subjects with history/scheduled for dietary supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Menopause" id="18317"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-02-28T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>27.06 Months</EnrollmentPeriod><EnrollmentRate>3.03 Patients/Month</EnrollmentRate><DateFirstReceived>2007-05-23T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-06-03T08:40:23Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="61866"><TitleDisplay>Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma</TitleDisplay><TitleOfficial>A Randomized, Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Versus High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01011920</Identifier><Identifier type="Other">UKCRN ID: 10139</Identifier><Identifier type="Other">ISRCTN49014661</Identifier><Identifier type="Other">MREC N: 11/LO/0420</Identifier><Identifier type="Other">DRKS00003763</Identifier><Identifier type="Other">10139</Identifier><Identifier type="Other">RHMCAN0743</Identifier><Identifier type="Other">11/LO/0420</Identifier><Identifier type="Other">IELSG 32</Identifier><Identifier type="Other">2009-012432-32</Identifier><Identifier type="Other">4036295</Identifier><Identifier type="Other">121/10</Identifier><Identifier type="Trial Acronym">IELSG 32</Identifier></Identifiers><Indications><Indication id="203">Lymphoma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>BCNU</Name></Intervention><Intervention type="InterventionPrimary"><Name>ara-C</Name></Intervention><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention><Intervention type="InterventionPrimary"><Name>rituximab</Name><Drug id="6736">rituximab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>thiotepa</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6736">rituximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1044132">International Extranodal Lymphoma Study Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074047">University Hospital Southampton NHS Foundation Trust</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1095284">Stuttgart Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="29469">Cancer Research UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6736" type="Drug"><TargetEntity id="204337" type="siDrug">Rituximab</TargetEntity></SourceEntity><SourceEntity id="1044132" type="Company"><TargetEntity id="5037049397" type="organizationId">ASSOCIATION INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG</TargetEntity></SourceEntity><SourceEntity id="1074047" type="Company"><TargetEntity id="5037928819" type="organizationId">University Hospital Southampton NHS Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="1095284" type="Company"><TargetEntity id="4298168815" type="organizationId">Klinikum Stuttgart</TargetEntity></SourceEntity><SourceEntity id="29469" type="Company"><TargetEntity id="4295951236" type="organizationId">Cancer Research UK</TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>27</NumberOfSites><CompaniesSponsor><Company id="1044132">International Extranodal Lymphoma Study Group</Company><Company id="1074047">University Hospital Southampton NHS Foundation Trust</Company><Company id="1095284">Stuttgart Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="29469">Cancer Research UK</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>126</PatientCountEnrollment><PatientCountEvaluable>43</PatientCountEvaluable><DateStart>2009-11-30T00:00:00Z</DateStart><DateEnd type="actual">2017-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-11T11:20:34Z</DateChangeLast><DateAdded>2009-11-13T10:52:50Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Clinical Trials Unit</Affiliation><Name>Ms Debbie Hamid</Name></Contact><Contact type="Scientific contact"><Affiliation>San Raffaele H Scientific Institute, Milan, Italy</Affiliation><Name>Andrs JM Ferreri, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Medical Center, Freiburg, Germany</Affiliation><Name>Gerald Illerhaus, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>IOSI, Bellinzona, Switzerland</Affiliation><Name>Emanuele Zucca, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histological or cytological assessed diagnosis of non-Hodgkin's lymphoma&lt;/li&gt;&lt;li&gt;Diagnostic sample obtained by stereotactic or surgical biopsy, Cerebrospinal Fluid             (CSF) cytology examination or vitrectomy&lt;/li&gt;&lt;li&gt;Disease exclusively localized into the central nervous system, CSF, cranial nerves or             eyes&lt;/li&gt;&lt;li&gt;At least one measurable lesion&lt;/li&gt;&lt;li&gt;Previously untreated patients (previous or ongoing steroid therapy admitted)&lt;/li&gt;&lt;li&gt;Age 18 to 65 years (with ECOG performance status 0 to 3) or 66 to 70 (with ECOG performance             status 0 to 2)&lt;/li&gt;&lt;li&gt;Adequate bone marrow, renal, cardiac, and hepatic function&lt;/li&gt;&lt;li&gt;Sexually active patients of childbearing potential agreeing in implementing adequate             contraceptive measures during study participation&lt;/li&gt;&lt;li&gt;Absence of any familial, sociological or geographical condition potentially hampering             compliance with the study protocol and follow-up schedule&lt;/li&gt;&lt;li&gt;Patient-signed informed consent obtained before registration&lt;/li&gt;&lt;li&gt;Male or female participants&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with lymphomatous lesions outside the CNS&lt;/li&gt;&lt;li&gt;Patients with a previous non-Hodgkin lymphoma at any time&lt;/li&gt;&lt;li&gt;Previous or concurrent malignancies with the exception of surgically cured carcinoma             in-situ of the cervix, carcinoma of the skin or other cancers without evidence of             disease at least from five years&lt;/li&gt;&lt;li&gt;HBsAg and HCV positivity&lt;/li&gt;&lt;li&gt;HIV infection, previous organ transplantation or other clinically evident form of             immunodeficiency&lt;/li&gt;&lt;li&gt;Concurrent treatment with other experimental drugs&lt;/li&gt;&lt;li&gt;Concurrent pregnancy or lactation&lt;/li&gt;&lt;li&gt;Patients not agreeing to take adequate contraceptive measures during the study&lt;/li&gt;&lt;li&gt;Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication             or myocardial infarction within the last 6 months (New York Heart Association Class             III or IV heart disease)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Complete remission following primary chemotherapy</Description></Measure><Measure><Description>Response rate after primary chemotherapy and two years failure free survival at second randomization</Description><Timeframe>3 months, two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Failure-free survival</Description><Timeframe>At two years</Timeframe></Measure><Measure><Description>Safety, as acute and long-term toxicity</Description></Measure><Measure><Description>Overall survival</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2012, results were published.  High-dose chemotherapy followed by autologous stem-cell transplantation (HCTASCT) associated related mortality was not observed [&lt;ulink linkType="Reference" linkID="1344102"&gt;1344102&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a multicenter, open-label, randomized, phase II trial. Objectives:&lt;br/&gt;To establish in a prospective, randomized phase II trial, the activity of three different chemotherapy combinations in patients with newly diagnosed primary central nervous system lymphoma (PCNSL):&lt;br/&gt;High-dose methotrexate (HD-MTX) + high-dose cytarabine (HD-araC).&lt;br/&gt;HD-MTX + HD-araC + &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt;.&lt;br/&gt;HD-MTX + HD-araC + rituximab + thiotepa.&lt;br/&gt;To establish the efficacy of two consolidation strategies: conventional whole-brain radiotherapy (WBRT) versus highdose chemotherapy supported by autologous stem cell transplantation (HDC + ASCT) in patients with newly diagnosed PCNSL.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2012, results were published.  Complete remission was achieved in 34 patients of which 12 had relapse including the six patients who had relapse five years after diagnosis. A  median follow-up of 120 months showed a median overall survival (OS) after  104 months. After two and five years, OS was 81 and 70%, respectively and event-free survival (EFS) was 81 and 67%, respectively. The five-year OS and EFS was 82% and 79%, respectively according to a per-protocol analysis (n=34) [&lt;ulink linkType="Reference" linkID="1344102"&gt;1344102&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to one of the five arms to receive:&lt;br/&gt;Arm A: methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-h infusion) on day 1 along with cytarabine 2 g/m2 1 h infusion, bid on days 2 to 3.&lt;br/&gt;Arm B: rituximab 375 mg/m2 conventional infusion on days -5 and 0 with methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-h infusion) on day 1 along with cytarabine 2 g/m2 1 h infusion, bid on days 2 to 3.&lt;br/&gt;Arm C: rituximab 375 mg/m2 conventional infusion on days -5 and 0 with methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-h infusion) on day 1, cytarabine 2 g/m2 1 h infusion, bid on days 2 to 3 and thiotepa 30 mg/m2 30 min infusion on day 4.&lt;br/&gt;ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1 to 2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4 to 10 Mev, 180 cGy per day, five weekly fractions&lt;br/&gt;Arm E: BCNU 400 mg/m2 in 500 ml saline  as 1h infusion on day -6 along with thiotepa 5 mg/kg in 250 ml saline as 2-h infusion q12w on  days -5 and -4 and reinfusion of PBSC &gt;/= 5 x 10(6) CD34+ cells/kg on day 0.&lt;br/&gt;Patients who would not achieve a CR after WBRT would be managed according to           physician's preferences. Patients who would not achieve a CR after APBSCT would be           referred to WBRT.              Follow-up ength would be 120 month(s).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 43) received  two different high-dose methotrexate-based protocols followed by high-dose carmustine/thiotepa (BCNU/TT) plus ASCT (with or without whole brain irradiation) [&lt;ulink linkType="Reference" linkID="1344102"&gt;1344102&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="244202">BCNU</Intervention><Treatments><Treatment><Dose>400 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="147520">ara-C</Intervention><Treatments><Treatment><Dose>2 gram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="147519">methotrexate</Intervention><Treatments><Treatment><Dose>3.5 gram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="147521">rituximab</Intervention><Treatments><Treatment><Dose>375 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="147522">thiotepa</Intervention><Treatments><Treatment><Dose>30 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>5 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Switzerland"><Sites><Site><Contacts/></Site><Site><Name>IOSI - Oncology Institute of Southern Switzerland</Name><Address1>Bellinzona</Address1><Address3>6500</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Contacts/></Site><Site><Name>"Klinik fr Hmatologie Universittsklinikum Essen"</Name><Address1>Essen</Address1><Contacts/></Site><Site><Name>Friedrich Schiller Universitaet Jena</Name><Address1>Jena</Address1><Contacts/></Site><Site><Name>Johannes Gutenberg Universitt Mainz</Name><Address1>Mainz</Address1><Contacts/></Site><Site><Name>Technische Universitt in Mnchen</Name><Address1>Mnchen</Address1><Contacts/></Site><Site><Name>Uniklinik Freiburg</Name><Address1>Freiburg</Address1><Contacts/></Site><Site><Name>University Hospital</Name><Address1>Aachen</Address1><Contacts/></Site><Site><Name>Universittsklinikum Erlangen</Name><Address1>Erlangen</Address1><Contacts/></Site><Site><Name>Universittsklinikum Ulm</Name><Address1>Ulm</Address1><Contacts/></Site><Site><Name>Universittskrankenhaus Hamburg-Eppendorf</Name><Address1>Hamburg</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Denmark"><Sites><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Contacts/></Site><Site><Name>Clinical Trials Unit</Name><Address1>Southampton</Address1><Address3>SO16 6YD</Address3><Contacts/></Site><Site><Name>Nottingham City Hospital</Name><Address1>Nottingham</Address1><Contacts/></Site><Site><Name>Queen's Hospital</Name><Address1>Romford</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Contacts/></Site><Site><Name>A.O. SS. Antonio e Biagio e Cesare Arrigo</Name><Address1>Alessandria</Address1><Contacts/></Site><Site><Name>Arcispedale Santa Maria Nuova</Name><Address1>Reggio Emilia</Address1><Contacts/></Site><Site><Name>Humanitas</Name><Address1>Rozzano</Address1><Contacts/></Site><Site><Name>Istituto Nazionale dei Tumori Regina Elena</Name><Address1>Roma</Address1><Contacts/></Site><Site><Name>Ospedale Civile S.Spirito</Name><Address1>Pescara</Address1><Contacts/></Site><Site><Name>Ospedale Maggiore S. Giovanni Battista</Name><Address1>Torino</Address1><Contacts/></Site><Site><Name>Ospedale Umberto I</Name><Address1>Nocera Inferiore</Address1><Contacts/></Site><Site><Name>Policlinico G.B. Rossi</Name><Address1>Verona</Address1><Contacts/></Site><Site><Name>San Raffaele H Scientific Institute</Name><Address1>Milan</Address1><Contacts/></Site><Site><Name>Spedali Civili</Name><Address1>Brescia</Address1><Contacts/></Site><Site><Name>Universit degli Studi La Sapienza</Name><Address1>Roma</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stem cell transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="10712">Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10714">Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11487">Subjects with H/O Hematological Malignancies Indicated for SCT</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3489">Subjects with B Cell Non Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3482">Subjects with central nervous system (CNS) lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3490">Subjects with T Cell Non Hodgkin's Lymphoma</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9630">Subjects with CNS Lymphoma</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01011920</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2009-012432-32</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier>ISRCTN49014661</Identifier></Identifiers></Registry><Registry><Name id="1019">German Clinical Trials Register (DRKS)</Name><Identifiers><Identifier>DRKS00003763</Identifier></Identifiers></Registry><Registry><Name id="1023">UK Clinical Research Network (UKCRN)</Name><Identifiers><Identifier>UKCRN ID: 10139</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7554"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7558">Assessment of event free survival (EFS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7611">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13480"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17422"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7538"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13472"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13551"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17405"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17460"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3464"><Criterion>Subjects with B Cell Non Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3457">Subjects with central nervous system B Cell Non Hodgkin's lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3465"><Criterion>Subjects with T Cell Non Hodgkin's Lymphoma</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3537">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lymphoma" id="3538">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Lymphoma" id="3539">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion><SubCriterion disease="Lymphoma" id="3540">Subjects with ECOG/WHO/Zubrod score performance status of 3</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3548"><Criterion>Subjects Diagnosed Based on Histo-Pathological Examination</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3633">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Lymphoma" id="3642">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="12987"><Criterion>Subjects with CNS Lymphoma</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13033"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13045"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13046">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13062"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13065"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13066">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17840"><Criterion>Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</Criterion></Inclusion><Inclusion disease="Stem cell transplantation" id="17850"><Criterion>Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</Criterion></Inclusion><Inclusion disease="Stem cell transplantation" id="17859"><Criterion>Subjects with Hematological Malignancy Indicated for SCT</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17862">Subjects with lymphoma indicated for SCT</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17877"><Criterion>Subjects with Systemic Disorders Indicated for SCT</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17887">Subjects with history of spinal cord injury indicated for SCT</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3628">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4783">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="6766"><Criterion>Lymphoma Subjects with Advanced Disease</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10640"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10641"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="15718"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15720">Subjects with history of CNS/neurological disorder</SubCriterion><SubCriterion disease="Stem cell transplantation" id="15723">Subjects with history of infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stem cell transplantation" id="15719"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="15722"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="26915"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="15710">Subjects with lymphoma</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>46.06 Months</EnrollmentPeriod><EnrollmentRate>2.74 Patients/Month</EnrollmentRate><DateFirstReceived>2009-11-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-11-13T10:52:50Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-12-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-04-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-04-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-08-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-11T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-11T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="63777"><TitleDisplay>Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome</TitleDisplay><TitleOfficial>An Open-Label, Pilot Study Evaluating Synera in the Treatment of Patients With Shoulder Impingement Syndrome</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">SC-202</Identifier><Identifier type="NCT">NCT01055444</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lidocaine + tetracaine (CHADD patch, local anesthesia), ZARS</Name><Drug id="54738">lidocaine + tetracaine (CHADD patch, local anesthesia), ZARS</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54738">lidocaine + tetracaine (CHADD patch, local anesthesia), ZARS</Drug><IndicationsPioneer/><Companies><Company><Company id="1005570">ZARS Pharma Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="15713">Nuvo Pharmaceuticals Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="54738" type="Drug"><TargetEntity id="386247" type="siDrug">Lidocaine/Tetracaine</TargetEntity></SourceEntity><SourceEntity id="1005570" type="Company"><TargetEntity id="4298093860" type="organizationId">Zars Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="15713" type="Company"><TargetEntity id="4295862549" type="organizationId">Nuvo Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1005570">ZARS Pharma Inc</Company><Company id="15713">Nuvo Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1669">Local anesthetic</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="175">Drug combination</Technology><Technology id="600">Patch formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2010-03-31T00:00:00Z</DateStart><DateEnd type="actual">2010-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-19T06:49:26Z</DateChangeLast><DateAdded>2010-02-05T09:24:25Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Richard Radnovich, DO</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Pain associated with shoulder impingement syndrome in a single shoulder&lt;/li&gt;&lt;li&gt;Have tenderness at the attachment site of the rotator cuff tendons in the affected             shoulder&lt;/li&gt;&lt;li&gt;Have positive Hawkins and Neers signs&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have used any topically applied pain medication on the target treatment area within 3             days preceding the screening/baseline visit&lt;/li&gt;&lt;li&gt;Have used any injected pain medication within 14 days preceding the             screening/baseline visit&lt;/li&gt;&lt;li&gt;Are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine etc)&lt;/li&gt;&lt;li&gt;Have a history of and/or past diagnosis of severe hepatic disease&lt;/li&gt;&lt;li&gt;Other protocol-defined inclusion/exclusion criteria may apply&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain intensity</Description><Timeframe>2 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Pain interference with activities (general, normal work, and sleep)</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In April 2013, pooled data from this and &lt;ulink linkType="Protocol" linkID="85395"&gt;NS001&lt;/ulink&gt; studies were published (n = 49).There were no serious adverse events. The most frequently observed   adverse event  was application site erythema in 32 patients (65%). All cases of erythema were mild or moderate in severity and no patients withdrew from the studies due to erythema.Other application site reactions observed were  skin irritation (n = 2), pruritus (n = 2), dermatitis (n = 1), induration, (n = 1), rash (n = 1), swelling (n = 1), urticaria (n = 1), and bullous reaction (n = 1). All were mild in severity, except the episode of dermatitis which was considered moderate in severity [&lt;ulink linkType="Reference" linkID="1406747"&gt;1406747&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to explore the potential usefulness of &lt;ulink linkType="Drug" linkID="54738"&gt;Synera&lt;/ulink&gt; (lidocaine 70      mg/tetracaine 70 mg) topical patch for the treatment of pain associated with shoulder      impingement syndrome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2013, pooled data from this and &lt;ulink linkType="Protocol" linkID="85395"&gt;NS001&lt;/ulink&gt; studies were published (n = 49).Treatment with &lt;ulink linkType="Drug" linkID="54738"&gt;Synera&lt;/ulink&gt; resulted in clinically significant meaningful reduction (&gt;/= 30% reduction) in average pain scores of 70% of patients. Also, reductions in pain interference with sleep, work, and general activity, as well as, improvements in range of motion in the affected shoulder were observed. Approximately 76% of patients reported being 'satisfied' or 'very satisfied' with the treatment [&lt;ulink linkType="Reference" linkID="1406747"&gt;1406747&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The purpose of this single center, 2-week, open-label, pilot study was to explore the potential      usefulness of &lt;ulink linkType="Drug" linkID="11376"&gt;Synera&lt;/ulink&gt; for the treatment of pain associated with shoulder impingement      syndrome.  A number of efficacy variables would be employed to evaluate their utility for      assessing painful responses in this population. Patients would be instructed to apply one &lt;ulink linkType="Drug" linkID="54738"&gt;Synera&lt;/ulink&gt; topical patch to the affected shoulder every 12 h starting on the evening of day 1 through the morning of day 14 (morning and evening applications) and to remove the patch after 2 to 4 h.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received a single &lt;ulink linkType="Drug" linkID="54738"&gt;Synera&lt;/ulink&gt; patch to the painful shoulder for 2 to 4 h twice daily at approximately 12-h intervals [&lt;ulink linkType="Reference" linkID="1406747"&gt;1406747&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Injury Care Medical Center</Name><Address1>Boise</Address1><Address2>Idaho</Address2><Address3>83713</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01055444</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25983"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22125"><Criterion>Subjects with Somatic Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22178">Subjects with pre-specified functional assessments</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22207">Subjects with musculoskeletal disorder/injury associated pain</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20140">Subjects with history/scheduled to receive anti-arrhythmics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-01-21T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-02-05T09:24:25Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="69830"><TitleDisplay>Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients with Moderate to Severe Plaque Psoriasis</TitleDisplay><TitleOfficial>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CC-10004-PSOR-008</Identifier><Identifier type="NCT">NCT01194219</Identifier><Identifier type="Other">2010-019991-55</Identifier><Identifier type="Other">UKCRN 9835</Identifier><Identifier type="Other">CCRN 398</Identifier><Identifier type="Other">63499</Identifier><Identifier type="Trial Acronym">ESTEEM 1</Identifier></Identifiers><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Toxic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="133" role="Toxic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="213" role="Toxic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="288" role="Therapeutic effect marker" type="Biochemical">Uric acid</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1211" role="Therapeutic effect marker;Toxic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="1236" role="Toxic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1925" role="Toxic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="2054" role="Toxic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="2387" role="Toxic effect marker" type="Biochemical">Bilirubin</BiomarkerName><BiomarkerName id="2417" role="Therapeutic effect marker" type="Biochemical">Calcium</BiomarkerName><BiomarkerName id="2527" role="Therapeutic effect marker;Toxic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName><BiomarkerName id="3083" role="Therapeutic effect marker" type="Biochemical">Phosphate</BiomarkerName><BiomarkerName id="4806" role="Toxic effect marker" type="Cellular">Lymphocytes</BiomarkerName><BiomarkerName id="5234" role="Therapeutic effect marker" type="Anthropomorphic">Body surface area</BiomarkerName><BiomarkerName id="12058" role="Toxic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Ultraviolet B</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>apremilast</Name><Drug id="44897">apremilast</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44897">apremilast</Drug><IndicationsPioneer/><Companies><Company><Company id="15331">Celgene Corp</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44897" type="Drug"><TargetEntity id="392619" type="siDrug">Apremilast</TargetEntity></SourceEntity><SourceEntity id="15331" type="Company"><TargetEntity id="4295905897" type="organizationId">Celgene Corp</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="304" type="Action"><TargetEntity id="470" type="Mechanism">Phosphodiesterase PDE4 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="15331">Celgene Corp</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="304">PDE 4 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15180">Topical antipruritic product</Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>844</PatientCountEnrollment><PatientCountEvaluable>844</PatientCountEvaluable><DateStart>2010-09-09T00:00:00Z</DateStart><DateEnd type="actual">2016-11-22T00:00:00Z</DateEnd><DateChangeLast>2019-04-12T08:48:49Z</DateChangeLast><DateAdded>2010-09-07T10:13:57Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Celgene</Affiliation><Name>Irina Khanskaya, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males or females, &gt;/= 18 years of age at the time of signing the informed consent             document&lt;/li&gt;&lt;li&gt;Diagnosis of chronic plaque psoriasis for at least 12 months prior to screening. Have moderate to severe plaque psoriasis at screening and baseline (Psoriasis Area and Severity Index [PASI] &gt;/= 12, body surface area [BSA] &gt;/= 10%, static Physician's Global Assessment [sPGA] &gt;/= 3)&lt;/li&gt;&lt;li&gt;Females of childbearing potential (FCBP) must have a negative pregnancy test at             screening and baseline.  FCBP who engage in activity in which conception is possible             must use two forms of contraception as described by the study  doctor while on study             medication and for at least 28 days after taking the last dose of study medicationwith either: &lt;ul&gt;&lt;li&gt;One highly effective form (non-oral hormonal, intrauterine device [IUD], tubal ligation, vasectomized partner)&lt;/li&gt;&lt;li&gt;An oral hormonal contraceptive plus one additional form of barrier contraception (male or female latex condom or nonlatex condom not made out of natural [animal] membrane [for example, polyurethane], diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge with spermicide)&lt;/li&gt;&lt;li&gt;A total of two forms of barrier contraception (male or female latex condom or nonlatex condom not made out of natural [animal] membrane [for example, polyurethane]) plus one of the following (diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge with spermicide) &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Note: the protocol language regarding contraception has been revised. As this study is fully enrolled, the updated language regarding contraception is included in Section 6.2 (contraception education) of this amendment&lt;/li&gt;&lt;li&gt;The female patient's chosen form of contraception must be effective by the time the female patient is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization)&lt;/li&gt;&lt;li&gt;Male patients (including those who have had a vasectomy) who engage in activity in             which conception is possible must use barrier contraception (latex condom or any             nonlatex condom not made out of natural [animal] membrane [eg, polyurethane]) while             on study medication and for a least 28 days after the last dose of study medication&lt;/li&gt;&lt;li&gt;Have moderate to severe plaque psoriasis at screening and baseline as defined by:&lt;ul&gt;&lt;li&gt;PASI score &gt;/= 12&lt;/li&gt;&lt;li&gt;BSA &gt;/= 10%&lt;/li&gt;&lt;li&gt;sPGA &gt;/= 3 (moderate)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted  -Must be a candidate for phototherapy and/or systemic therapy&lt;/li&gt;&lt;li&gt;Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, 12-lead ECG, clinical laboratories, and urinalysis&lt;/li&gt;&lt;li&gt;Must meet the following laboratory criteria:&lt;ul&gt;&lt;li&gt;White blood cell count &gt;/= 3000/mm3 (&gt;/= 3.0 x 10[9]/l) and&amp;lt; 14,000/mm3 (&amp;lt; 14 x 10[9]/l)&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/microl (&gt;/= 100 x 10[9]/l)&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.5 mg/dl (&amp;lt;/= 132.6 micromol/l)&lt;/li&gt;&lt;li&gt;AST (SGOT) and ALT (SGPT)&amp;lt;/= 2 x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;lt;/= 2 mg/dl (34 micromol/l)&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 9 g/dl (&gt;/= 5.6 mmol/l)&lt;/li&gt;&lt;li&gt;Hemoglobin A1c&amp;lt;/= 9.0%&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Able to adhere to the study visit schedule and other protocol requirements&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Other than psoriasis, history of any clinically significant (as determined by the             investigator) or other major uncontrolled disease (cardiac, endocrinological, pulmonary, neurological, psychiatric, hepatic, renal, hematological, immunological disease, or other major uncontrolled disease)&lt;/li&gt;&lt;li&gt;Any condition, including the presence of laboratory abnormalities, which would place the patient at unacceptable risk if he/she were to participate in the study&lt;/li&gt;&lt;li&gt;Any condition that confounds the ability to interpret data from the study&lt;/li&gt;&lt;li&gt;AST (SGOT) and/or ALT (SGPT) &gt; 1.5 x ULN and total bilirubin &gt; ULN and/or albumin&amp;lt; LLN -Pregnant or breast-feeding&lt;/li&gt;&lt;li&gt;History of allergy to any component of the study drug&lt;/li&gt;&lt;li&gt;Hepatitis B surface antigen positive at screening&lt;/li&gt;&lt;li&gt;Anti-hepatitis C antibody positive at screening&lt;/li&gt;&lt;li&gt;Active tuberculosis (TB) or a history of incompletely treated TB&lt;/li&gt;&lt;li&gt;Clinically significant abnormality on 12-lead ECG at screening&lt;/li&gt;&lt;li&gt;Clinically significant abnormal chest X-ray/radiography with at least PA view (radiograph must be taken within 12 weeks prior to screening or during the screening visit). An additional lateral view is strongly recommended but not required&lt;/li&gt;&lt;li&gt;History of  positive human immunodeficiency virus (HIV), or have congenital or             acquired immunodeficiency&lt;/li&gt;&lt;li&gt;Active substance abuse or a history of substance abuse within 6 months prior to             screening&lt;/li&gt;&lt;li&gt;Bacterial infections requiring treatment with oral or injectable antibiotics, or             significant viral or fungal infections, within 4 weeks of screening&lt;/li&gt;&lt;li&gt;Malignancy or history of malignancy (except for treated  basal cell or             squamous cell in situ skin carcinomas and treated  cervical             intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence             of recurrence within the previous five years)&lt;/li&gt;&lt;li&gt;Psoriasis flare or rebound within 4 weeks prior to screening&lt;/li&gt;&lt;li&gt;Evidence of skin conditions that would interfere with clinical assessments&lt;/li&gt;&lt;li&gt;Topical therapy within 2 weeks of randomization (including but not limited to topical corticosteroids, topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol). Exceptions: low-potency corticosteroids (class 6 or 7; please refer to the investigators' manual) will be allowed as background therapy for treatment of the face, axillae, and groin in accordance with the manufacturers' suggested usage during the course of the study. Patients with scalp psoriasis will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on scalp lesions. An unmedicated skin moisturizer (eg, Eucerin) will be also permitted for body lesions only. Patients should not use these topical treatments within 24 h prior to the clinic visit&lt;/li&gt;&lt;li&gt;Systemic therapy for psoriasis within 4 weeks prior to randomization (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, fumaric acid esters)&lt;/li&gt;&lt;li&gt;Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)&lt;/li&gt;&lt;li&gt;Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to             randomization&lt;/li&gt;&lt;li&gt;Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization&lt;/li&gt;&lt;li&gt;Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer)&lt;/li&gt;&lt;li&gt;Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light             sources&lt;/li&gt;&lt;li&gt;Prior treatment with&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportion of subjects treated with either apremilast 30 mg BID or placebo who achieve at least a 75% reduction in PASI (PASI-75) at Week 16 from baseline</Description><Timeframe>From baseline (pre-dose) to week 16</Timeframe></Measure><Measure><Description>Percentage of patients who achieved a 75% improvement (response) in the Psoriasis Area Severity Index (PASI-75): the improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on four anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the four anatomic regions is scored on a scale of 0 (no involvement) to 6 (90 to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing</Description><Timeframe>Baseline to week 16</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of participants with TEAEs during the apremilast-exposure period through week 260: the apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants originally randomized to apremilast or week 16 for participants originally randomized to placebo) to the last dose of apremilast. Adverse events that started after 28 days of initiating placebo and before resuming apremilast treatment in the randomized treatment withdrawal phase (weeks 32 to 52) were excluded in the apremilast-exposure period. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above</Description><Timeframe>Weeks 0 to 260; mean exposure to apremilast 30 mg bid during the apremilast-exposure period up to week 260 was 97.83 weeks</Timeframe></Measure><Measure><Description>Number of Participants With a Psoriasis Flare or Rebound During the During the Apremilast-exposure Period Through Week 260: psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. Note categories below. [1] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase. [2] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase</Description><Timeframe>Weeks 0 to 260</Timeframe></Measure><Measure><Description>Proportion of subjects treated with either apremilast 30 mg BID or placebo with a sPGA score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16</Description><Timeframe>From baseline (pre-dose) to week 16</Timeframe></Measure><Measure><Description>Psoriasis flare or rebound</Description><Timeframe>From the time of Informed Consent, through dosing, and for 28 days after the last dose of study medication</Timeframe></Measure><Measure><Description>Frequency of clinically significant changes in physical examination, vital signs, electrocardiogram, and/or laboratory findings</Description><Timeframe>From the time of Informed Consent, through dosing, and for 28 days after the last dose of study medication</Timeframe></Measure><Measure><Description>Number of subjects who prematurely discontinue IP due to an adverse event</Description><Timeframe>From the time of Informed Consent, through dosing, and for 28 days after the last dose of study medication</Timeframe></Measure><Measure><Description>Type, frequency, severity, seriousness, and relationship of adverse events to apremilast</Description><Timeframe>From the time of Informed Consent, through dosing, and for 28 days after the last dose of study medication</Timeframe></Measure><Measure><Description>Percent change from baseline in percent of affected Body Surface Area (BSA): BSA was a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or 'handprint' including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline (visit 2 week 0) was determined at each visit of the study, which is calculated as 100 x (visit BSA - baseline BSA)/baseline BSA (%)</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Percent change from baseline in PASI score: PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on four anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the four anatomic regions is scored on a scale of 0 (no involvement) to 6 (90 to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. The PASI score was set to missing if any severity score or degree of involvement is missing. PASI score percent change from baseline was calculated as 100 x (visit score - baseline score)/baseline score (%)</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Percentage of patients who achieved a 50% improvement (response) in the PASI score (PASI-50): a patient was classified as having at least a 50% improvement in PASI score from baseline, which was equivalent to a percent change from baseline ranging from 100 to 50%. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Change from baseline in Pruritus Visual Analog Scale (VAS) score: the Pruritus Visual Analog Scores (VAS) were used to measure the amount of itching and discomfort a participant experiences. Participant's Assessment of Pruritus (Itch) asked: on average, how much itch have you had because of your condition in the past week? All VAS values range from 0 to 100. Higher scores correspond to more severe symptom or disease. Change from baseline was calculated for the VAS scale, where change = visit value  baseline value</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Change from baseline in the Dermatology Life Quality Index (DLQI) total score: DLQI is used in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of item number 7, the participant responds on a four-point scale, ranging from 'very much' (score 3) to 'not at all' or 'not relevant' (score 0). Item number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (yes or no, scores 3 or 0 respectively), and if 'no', then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 'a lot', 'a little', or 'not at all' (scores 2, 1, or 0 respectively). DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 to the best</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Percentage of patients who achieved a Static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least two points reduction: the sPGA was a five-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the investigator factored in areas that have already been cleared (ie, have scores of 0) and did not just evaluate remaining lesions for severity, ie, the severity of each sign was averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Health-Related Quality of Life (HRQOL) included Dermatology Quality of Life Index (DLQI) and Patient Health Questionnaire (PHQ-8): reductions in scores indicate improvement</Description></Measure><Measure><Description>Change from baseline in Mental Component Summary (MSC) score of the medical outcome study Short Form 36-item (SF-36) Health Survey version 2.0: the SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained  a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from US general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health for normal based scores, change from baseline were calculated for the 8 scales and two summary scales, where change = visit value - baseline value</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Prespecified exploratory analyzes evaluated the effects of APR on patients with nail psoriasis, using the Nail Psoriasis Severity Index (NAPSI; 0 to 8 scale; target nail representing the most severe nail psoriasis), and at least moderate scalp psoriasis (baseline [BL] score &gt;/= 3) using the Physician Global Assessment for scalp lesions (ScPGA; 0 to 5 scale)</Description></Measure><Measure><Description>Number of patients with a psoriasis flare or rebound during the placebo-controlled phase: psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued: (1) psoriasis adverse events (ie, preferred term as Guttate psoriasis, psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase; (2) psoriasis adverse events (ie, preferred term as Guttate psoriasis, psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase; (3) PASI &gt;/= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in (1) and/or (2)</Description><Timeframe>Weeks 0 to 16</Timeframe></Measure><Measure><Description>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase: AE: noxious, unintended, or untoward medical occurrence, may appear or worsen. May be new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above An AE is a treatment emergent AE if the AE start date is on or after date of first dose of study drug</Description><Timeframe>Weeks 0 to 16; mean duration of exposure was 14.8  and 15.0 weeks for subjects randomized to placebo and apremilast, respectively</Timeframe></Measure><Measure><Description>Kaplan Meier Estimate of Time to loss of PASI-75 response (loss of effect) at week 32 during the re-randomized treatment withdrawal phase: time to loss was the time between the re-randomization date and the date of the first assessment where loss of PASI-75 was observed (event); or the time between the re-randomization date and the date of the last PASI assessment in the weeks 32 to 52 interval prior to addition of protocol-prohibited medication/therapy, or resumption of APR 30 twice daily, or discontinuation, or week 52 if no loss</Description><Timeframe>Weeks 32 to 52</Timeframe></Measure><Measure><Description>Percentage of patients who achieved both a 75% improvement (response) in the PASI and sPGA score of clear (0) or almost clear (1) with at least two points reduction: PASI-75 response was the percentage of patients who achieved at least a 75% reduction (improvement) from baseline in PASI score at week 16. The improvement in PASI score was used as a measure of efficacy. See outcome measure 1 for further description. sPGA is a five-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation</Description><Timeframe>Baseline to week 16</Timeframe></Measure><Measure><Description>Clinical meaningfulness of PRO (patient-reported outcomes) improvements: assessed using percentage of patients who met the minimum clinically important differences (MCID) of each instrument, which were defined as an improvement from baseline of &gt;/= 2.5 for the SF-36v2 MCS, &gt;/= 5 for DLQI among patients whose baseline DLQI &gt; 5, and &gt;/=10 mm for the Pruritus VAS among patients whose baseline VAS&gt;1 0 mm</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2013, results were presented. Results  showed that &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; was consistently safe and well tolerable. Most common adverse events (AEs) reported (&gt;/= 5%), ie diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache, were mild to moderate in severity. During the first week of dosing nausea, vomiting, and diarrhea were observed which subsequently decreased. Discontinuation rate due to  AEs was low. Further results showed that there were no new safety or laboratory findings seen [&lt;ulink linkType="Reference" linkID="1483670"&gt;1483670&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1484923"&gt;1484923&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1485346"&gt;1485346&lt;/ulink&gt;]. Similar results were presented in March 2014, further  data were presented  that diarrhea (18.7%), URTI (17.8%), nausea (15.3%), nasopharyngitis (13.4%), tension headache (9.6%), and headache (6.5%) were the mild or moderate adverse events reported. A total of 6% of patients had severe AEs. Infrequent serious AEs were reported in &amp;lt; 3% of patients in any phase of the study and in 4.2% in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; exposure period. In the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo groups, the major adverse cardiac events (MACE) were 0.5 and 0.9/100 patient years, respectively, and the potential MACE events were 0.8 and 0.9/100 patient years, respectively. In &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo groups, there were no imbalance in rates of major adverse cardiac events, serious infections including systemic opportunistic infection systemic opportunistic infection. There were no cases of TB (new infection/reactivation)  [&lt;ulink linkType="Reference" linkID="1537036"&gt;1537036&lt;/ulink&gt;].  In March 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;]. In April 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1717540"&gt;1717540&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2014, further  data were presented at the 72nd AAD Annual Meeting in Denver, CO. &lt;ulink linkType="Drug" linkID="44897"&gt;Apremilast&lt;/ulink&gt; was generally well tolerated for up to 52 weeks, with no increase in AE incidence over time. Severe AEs and study discontinuations were reported by 6 and 4.2% of patients, respectively. Diarrhea (18.7%), URTI (17.8%), nausea (15.3%), nasopharyngitis (13.4%), tension headache (9.6%), and headache (6.5%) were the adverse events reported by &gt;/= 5% of patients. Laboratory value changes and  serious AEs (including serious infections, malignancies, and cardiovascular events) were consistent with prior &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; studies [&lt;ulink linkType="Reference" linkID="1537027"&gt;1537027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, pooled results from ESTEEM 1, &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; and another clinical trial  (n = 1426) were published. Diarrhea, nausea, upper respiratory tract infection, tension headache, and headache were the side effects [&lt;ulink linkType="Reference" linkID="1596597"&gt;1596597&lt;/ulink&gt;]. Similar results were n November 2014  [&lt;ulink linkType="Reference" linkID="1613536"&gt;1613536&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014 results of pooled results from ESTEEM 1 and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; studies were presented. Low incidence of weight loss as adverse events was reported. No patient reported a serious AE of weight decrease or discontinued treatment due to decreased weight during thr placebo-controlled period and long-term exposure period. There was no association between weight loss and gastrointestinal AEs [&lt;ulink linkType="Reference" linkID="1601111"&gt;1601111&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014 results of pooled results from &lt;ulink linkType="Protocol" linkID="69830"&gt;ESTEEM 1&lt;/ulink&gt; and ESTEEM 2 randomized, controlled phase III trials, underlined the favorable safety of apremilast as a treatment for psoriasis were presented. During the placebo-controlled period, the exposure-adjusted incidence rates of adverse events were 536.4 events/100 patient years with apremilast and 350.3 events/100 patient years with placebo, and the incidence rates of serious and severe adverse events were 7.2 and 13.7 events/100 patient years in the active treatment and 9.5 and 13.0 events/100 patient years in the control arm, respectively. Only 0.4 and 0.9 events/100 patient years in the apremilast and placebo group led to death of the patient. Considering the whole period of treatment with apremilast through week 52, the incidence rate of adverse events was 287.4 events/100 patient years, including 6.2 and 8.9 serious and severe events/100 patient years, and only 0.2 events/100 patient years resulting in death. The most commonly reported adverse events were diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache and headache. Diarrhea and nausea caused discontinuation of apremilast in 0.9 and 1.4% of the patients, were predominantly mild and exhibited highest incidence during the first 2 weeks of treatment. Major adverse cardiovascular events, malignancies and serious infections did not appear in excess in patients treated with apremilast compared with the control group.No evidence of increased suicidality or depression with longer exposure to apremilast were observed, and no clinically relevant laboratory abnormalities were recorded [&lt;ulink linkType="Reference" linkID="1601754"&gt;1601754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, results were presented. The incidence of &gt;/=1 adverse events (AE) were reported in 55.7, 69.3, 79.4 and 57.9% of patients receiving placebo and apremilast at 0 to 16, 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively; however, the respective &gt;/=1 severe AE reported were 3.2, 3.6, 6.2 and 3.2% and &gt;/=1 serious AE reported were 2.8, 2.1 and 4.5 and 5.4%. AE leading to drug withdrawal were 3.2, 5.2, 7.8 and 2.9% in placebo-treated patients during 0 to 16 weeks, apremilast-treated patients during 0 to 16 weeks, 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively. There were two deaths occurred due to apremilast exposure (n=1, 0 to &amp;lt;/= 52 weeks; n=1, &gt;52 to &amp;lt;/= 104 weeks). Diarrhea (7.1, 18.8, 18.7 and 1.8%), URTI (7.4, 10.2, 18.2 and 9.7%), nausea (6.7, 15.7, 15.2 and 0.7%), nasopharyngitis (8.2, 7.3, 13.7 and 6.8%), tension headache (4.3, 7.3, 9.6 and 1.6%) and headache (4.6, 5.5, 6.5 and 0.7%) were the AE &gt;/= 5% reported placebo-treated patients during 0 to 16 weeks, apremilast-treated patients during 0 to 16 weeks, 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively [&lt;ulink linkType="Reference" linkID="1662857"&gt;1662857&lt;/ulink&gt;]. Similar results were published in July 2015. Mild/moderate adverse events were observed. New significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period were not observed [&lt;ulink linkType="Reference" linkID="1689865"&gt;1689865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Depression (0.0, 2.0 and 0.5%) was reported in placebo-treated patients during 0 to 16 weeks, apremilast-treated patients during 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively. Serious adverse events reported were urinary tract infection (0, 0, 0.2 and 0%), coronary artery disease (0, 0, 0.4 and 0%), acute myocardial infarction (0, 0.2, 0.2 and 0.2%), COPD (0, 0.2, 0.2 and 0%), osteoarthritis (0, 0, 0.1 and 0.5%), nephrolithiasis (0, 0, 0.4 and 0.2%) and depression (0, 0, 0.1 and 0.2%) in placebo-treated patients during 0 to 16 weeks, apremilast-treated patients during 0 to 16 weeks, 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively. Till week 104, no suicidal ideation, suicide attempt or completed suicide was reported. Nausea (0.4, 1.8, 1.7 and 0%), diarrhea (0.4, 1.3, 1.2 and 0%), psoriasis (0.4, 0.4, 0.9 and 0.9%), vomiting (0.0, 0.2, 0.5 and 0.0%), headache (0, 0.5, 0.4 and 0.2%), tension headache (0, 0.4, 0.4 and 0.0%), dyspepsia (0, 0.5, 0.4 and 0%), psoriatic arthropathy (0, 0.2, 0.2 and 0.7%) were the AE leading to discontinuation in placebo-treated patients during 0 to 16 weeks, apremilast-treated patients during 0 to 16 weeks, 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively [&lt;ulink linkType="Reference" linkID="1662857"&gt;1662857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Long-term exposure to apremilast did not show increase in major cardiac events, potential major cardiac events, solid malignancies, hematologic tumors and serious infections. Laboratory anomalies reported were ALT, AST, total bilirubin, hemoglobin, total cholesterol, lymphocytes and neutrophils. The mean decrease in body weight from baseline were 1.50, 2.07 and 1.94 in apremilast-treated patients during 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively. Patients with &amp;gt; 5% weight loss were 13.4, 18.5 and 25.1% in apremilast-treated patients during 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, respectively [&lt;ulink linkType="Reference" linkID="1662857"&gt;1662857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, results were presented from phase IIb (PSOR-005) and phase III studies (ESTEEM 1 and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;) which evaluated the efficacy, safety and tolerability of the PDE4 inhibitor &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; in a subset of patients with moderate to severe plaque psoriasis. During the placebo-controlled period (to week 16), the common adverse events reported in &gt;/= 5% of patients were diarrhea (6.3 versus 17.4% for placebo and apremilast, respectively), nausea (6.9 versus 16.8%), upper respiratory tract infection (6.1 versus 9.1%), nasopharyngitis (7.1 versus 7.2%), headache (3.8 versus 6%) and tension headache (4.2 versus 8.2%), with exposure-adjusted incidence rates/100 patient-years for placebo versus apremilast of 24.1 versus 72.4, 26.4 versus 69.8, 22.8 versus 33.7, 26.8 versus 26.3, 14 versus 22.1, and 15.5 versuss 30.9, respectively. Treatment with apremilast was generally well tolerated [&lt;ulink linkType="Reference" linkID="1644279"&gt;1644279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, week-16 results were presented from a phase III study comprising two randomized, placebo-controlled studies (ESTEEM 1 and 2) which evaluated the safety, efficacy and tolerability of apremilast in patients with moderate to severe plaque psoriasis. The most frequently reported adverse events (AEs; &amp;gt; 5%) were nausea, diarrhea, nasopharyngitis, upper respiratory tract infection, tension headache and headache. Majority of adverse events were mild or moderate in severity and did not lead to discontinuation. Discontinuation rates due to AEs (3.8 and 5.4%, respectively) were low and the incidence of serious AEs was low (2.6 and 2.0%, respectively) and comparable across placebo and apremilast groups, respectively. Laboratory parameter changes were transient and not clinical meaningful over time and there was no trend  observed. In ESTEEM 1 study, deaths due to completed suicide (placebo) and cardiac failure (apremilast) were reported [&lt;ulink linkType="Reference" linkID="1644273"&gt;1644273&lt;/ulink&gt;].   In March 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In August 2015, pooled results from ESTEEM 1 and ESTEEM 2 studies that assessed the overall safety and tolerability of apremilast in moderate to severe plaque psoriasis were presented. In placebo or apremilast patients, adverse events reported (5%, weeks 0 to 16) were diarrhea (6.7, 17.8%), nausea (6.7, 16.6%), headache (including tension headache; 6.7, 13.1%), upper respiratory tract infection (6.5, 8.4%), and nasopharyngitis (6.9, 7.3%), respectively. For all treatment periods, these were the most frequently reported AEs. In severity, most AEs were reported to be mild or moderate. For placebo and apremilast, the incidence of serious AEs was reported to be similar (2.6 and 2%), respectively and due to AEs, discontinuation rates were low (weeks 0 to 16: placebo, 3.8%; apremilast, 5.4%). Based on exposure-adjusted incidence rates/100 patient-years, long-term (uncontrolled) data did not indicate an increase in AEs or discontinuations. With the highest incidence in the first 2 weeks of treatment, and reduced incidence after the first month of dosing, diarrhea and nausea with apremilast were reported to be predominantly mild. Patients treated with apremilast reported weight loss and depression in clinical trials when compared with placebo. For placebo and apremilast, adjudicated events of major adverse cardiac events, malignancies, and serious and opportunistic infections were found to be comparable. In laboratory tests, no clinically meaningful changes were reported [&lt;ulink linkType="Reference" linkID="1685838"&gt;1685838&lt;/ulink&gt;].  In April 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1716457"&gt;1716457&lt;/ulink&gt;]. Similar results were presented in March 2016 [&lt;ulink linkType="Reference" linkID="1740778"&gt;1740778&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, pooled results from two phase III, multicenter, multinational, randomized, double-blind, placebo-controlled studies (ESTEEM 1 and ESTEEM 2) were performed to evaluate the safety and efficacy of apremilast, for the treatment of plaque psoriasis. Major cardiac events, potential major cardiac events, hematological, skin, solid malignancies, non-opportunistic, non-serious infections, non-opportunistic serious infections, and systemic, opportunistic infections were observed in 0.9, 0.9, 0.0, 0.9, 0.9, 0.0, 1.7, 0.0, and 0.0% of patients in period A and 0.5, 0.8, 0.0, 1.1, 0.4, 0.0, 1.0, 0.0, and 0.0% of patients in apremilast-exposure period (0 to &gt;/= 52 weeks), respectively. Infrequent and transient laboratory abnormalities were observed among patients treated with apremilast. Weight loss was associated with apremilast treatment, without overt clinical complications. Based on exposure adjusted incidence rates (EAIR)/100 patient-years, evidence of increasing incidence of depression or suicidality with longer apremilast treatment were not reported. Adverse events occurning in &gt;/= 5% of patients in nay treatment group were reported. A &gt;/= 1 AE, &gt;/= 1 serious AE, &gt;/= 1 severe AE, AE leading to drug withdrawal, diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache (AEs &gt;/= 5% in any treatment groups) were reported in 57.2, 2.6, 3.6, 3.8, 6.7, 6.7, 6.5, 6.9, 3.3, and 3.3%, 68.9, 2.0, 3.8, 5.4, 17.8, 16.6, 8.4, 7.3, 7.3, and 5.8%, and 80.5, 5.7, 8.2, 8.4, 17.6, 15.9, 16.9, 15.0, 9.2, and 6.4% of patients, respectively, in placebo, apremilast, 30 mg (period A: 0 to 16 weeks) and apremilast 30 mg exposure period 0 to &gt;/= 52 weeks. Most of the AEs were mild to moderate in severity and did not lead to discontinuation [&lt;ulink linkType="Reference" linkID="1709807"&gt;1709807&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, results of the post-hoc analysis that assessed the efficacy and safety of apremilast 30 mg bid (APR), with and without topical therapies and/or UVB therapy in the subgroup of patients with &amp;lt; PASI-75 response at week 32 were presented. Any adverse events (AEs) during 32 to 52 weeks in placebo/apremilast with and without T/P were observed in 63.1 and 39.2%, respectively, whereas in apremilast/apremilast group 58.7 and 45.3% of patients, respectively. In placebo/apremilast group, AEs including upper respiratory tract infection (URTI) in 10.7 and 7.8%; nasopharyngitis in 6 and 2%; back pain in 6 and 3.9%; diarrhea in 3.6 and 3.9%; and nausea in 2.4 and 2% were reported with or without T/P, respectively. Whereas in apremilast/apremilast URTI in 8.7 and 9.4%; nasopharyngitis in 8.7 and 6%; back pain in 3.2 and 0.9%; diarrhea in 3.2 and 1.7%; and nausea in 2.4 and 2.6% were reported with or without T/P, respectively [&lt;ulink linkType="Reference" linkID="1742604"&gt;1742604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, pooled results from two studies (ESTEEEM 1 and ESTEEM 2) were presented, which evaluated the long-term (&amp;lt;/= 182 weeks) safety of apremilast 30 mg bid. Patients with apremilast-exposure period of 0 to &amp;lt;/= 52 weeks (group 1; n = 1184) and 0 to &amp;lt;/= 182 weeks (group 2; n = 1184) were studied. Overall, 44.8 and 79% of patients, respectively, in group 1and 2 exposure periods, discontinued due to adverse event (7.6 and 11.2%), lack of efficacy (20.6 and 34.7%), non-compliance with study drug (2.1 and 3.1%), withdrawal by patient (8.5 and 18.8%), death (0.1 and 0.3%), lost to follow-up (3.6 and 6.9%), protocol violation (1.2 and 1.4%) and other (0.9 and 2.4%). Percentage of patients with &gt;/= 1 AE, &gt;/= 1 severe AE, &gt;/= 1 serious AE, AE leading to drug withdrawal and AE leading to death were 79.3 versus 83.2%, 7.3 versus 10.6%, 4.9 versus 9%, 7.9 versus 11% and 0.1 versus 0.3% in exposure groups 1 versus 2, respectively. Diarrhea (17.3 versus 18.7%), nausea (15.7 versus 16.5%), upper respiratory tract infection (15.5 versus 19.2%), nasopharyngitis (14.1 versus 16.6%), tension headache (9 versus 9.7%) and headache (6.3 versus 7.3%) were the adverse events (AEs) reported in &gt;/= 5% of patients in apremilast-exposure groups 1 versus 2, respectively. Diarrhea and nausea were mostly mild to moderate in severity, occurred during the first week of dosing, and generally resolved within 1 month. Urinary tract infection (0.2 and 0.2%), breast cancer (0.2 and 0.3%), coronary artery disease (0.3 and 0.5%), acute myocardial infarction (0.2 and 0.3%), COPD (0.2 and 0.2%), osteoarthritis (0.1 and 0.3%), nephrolithiasis (0.3 and 0.3%), intervertebral disc protrusion (0.2 and 0.2%), psoriasis (0.2 and 0.2%), abdominal pain (0.2 and 0.2%) and transient ischemic attack (0.2 and 0.3%) were the serious AEs (SAEs) reported in &gt;/=2% of patients in apremilast-exposure groups 1 and 2, respectively. These AEs and SAEs did not increase with long-term exposure to apremilast [&lt;ulink linkType="Reference" linkID="1740778"&gt;1740778&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Nausea (1.4 and 1.4%), diarrhea (0.9 and 0.1%), psoriasis (0.8 and 1.5%), vomiting (0.4 and 0.5%), headache (0.4 and 0.6%), tension headache (0.3 and 0.3%), dyspepsia (0.3 and 0.3%), abdominal discomfort (0.3 and 0.3%), hematochezia (0.3 and 0.3%) and psoriatic arthropathy (0.3 and 0.6%) were the AEs leading to discontinuation in &amp;gt; 2 patients in apremilast-exposure groups 1 and 2, respectively. Across apremilast exposure periods (group 1 and 2, respectively), the rates of major cardiac events (0.3 and 0.8%), malignancies (1.3 and 1.9%), depression as an AE (2 and 2.8%), depression as a serious AE (0.1 and 0.2) and suicide attempt (0.1 and 0.1%) were comparable. Also rates of serious infections were comparable across groups. Urinary tract infection (0.2%), appendicitis, pneumonia and diverticulitis (each 0.1%) were the serious infections seen in exposure group 1 and appendicitis (0.3%), urinary tract infection (0.2%), pneumonia (0.2%), diverticulitis, bacterial infection, brain abscess, infectious mononucleosis, nasopharyngitis, sepsis, viral meningitis, pneumonia staphylococcal, influenza, lung abscess and pyelonephritis (each 0.1%) were the serious infections seen in exposure group 2. No serious opportunistic infections were seen in both groups. Percent median change in body weight from baseline was -1.28 and -1.20 and percentage of patients with &amp;gt; 5% weight loss were 18.8 and 21.9% in exposure group 1 and 2, respectively. Percentage of patients with ALT &amp;gt; 3 x ULN (U/l), AST &amp;gt; 3 x ULN (U/l), total bilirubin &amp;gt; 1.8 x ULN (micromol/l), hemoglobin A1C &amp;gt; 9%, total cholesterol &amp;gt; 7.8 mmol/l, lymphocytes &amp;lt; 0.8 x 10(9)/l and neutrophils &amp;lt; 1 x 10(9)/l was 0.5 versus 0.1%, 1.1 versus 1.5%, 0.5 versus 0.6%, 0.5 versus 1%, 1.9 versus 2.4%, 2.7 versus 3.7% and 0.1 versus 0.3% in exposure group 1 versus 2, respectively [&lt;ulink linkType="Reference" linkID="1740778"&gt;1740778&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A female patient aged 30 year with a history of depression and obesity reported fatal cardiac failure on day 111 (during exposure period 1). In addition, a male patient aged 69-year with a history of diabetes, hypertension, and hyperlipidemia reported fatal cerebrovascular accident on day 666 and a female patient aged 57-year with a history of congestive heart failure, hypertension, and coronary artery disease died due to severe mitral stenosis with congestive heart failure on day 979 of apremilast-exposure [&lt;ulink linkType="Reference" linkID="1740778"&gt;1740778&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, pooled results from five studies: ESTEEM 1, &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="68729"&gt;PALACE-1&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="70875"&gt;PALACE2&lt;/ulink&gt;  and &lt;ulink linkType="Protocol" linkID="70872"&gt;PALACE 3&lt;/ulink&gt;  were presented. The overall rate of infections, both non-serious and serious, during the placebo-controlled period was comparable between patients receiving placebo and apremilast (20.6 versus 24.8%). During 0 to &amp;lt;/= 52 weeks, the overall rate of infections was 42%, with majority of reported infections (upper respiratory tract infections, nasopharyngitis, sinusitis) categorized as non-serious. During the second (30.4%) and third (30.7%) years of apremilast exposure, no increase in overall infections was observed compared with the first year. During the 0 to 16 week period, the rate of discontinuation of treatment due to infections was low (&amp;lt; 1.0%) and comparable between patients receiving placebo and apremilast (0.3 and 0.4%, respectively), and the EAIR/100 patient-years of discontinuations did not increase with increasing exposure to apremilast (0 to &amp;lt;/= 52 weeks = 0.5 and 0 to &gt;/= 156 week = 0.4). Rates of serious infections with apremilast during the placebo-controlled period were low and comparable to placebo. During 0 to &amp;lt;/= 52 weeks and 0 to &gt;/= 156 week, serious infection rates were low (EAIR/100 patient-years = 0.7 and 1.0). In the general US population, with prolonged apremilast exposure the rate of serious infections occurring in one patient was consistent, as expected for these infections. Serious infections were reported by four (0.4%; EAIR/100 patient-years = 1.5) and two patients (0.2%; EAIR/100 patient-years = 0.5) receiving placebo and apremilast, respectively; however, no case of serious opportunistic infections were reported with long-term apremilast exposure. In each treatment group, pneumonia was reported for one patient. One patients receiving apremilast reported lobar pneumonia; for the placebo group, the serious infections reported were cellulitis, Clostridium difficile colitis, and bacterial wound infection. Despite study sites located in areas with endemic tuberculosis (TB), in the long-term apremilast-exposure (0 to &gt;/= 156 weeks), no cases of clinical reactivation of TB were reported. During 0 to &amp;lt;/= 52 weeks apremilast-exposure period and the cumulative apremilast-exposure period (0 to &gt;/= 156 weeks) serious infections like pneumonia, urinary tract infection, appendicitis, diverticulitis, bronchitis and sepsis were reported by 11, 2, 2, 1, 1, 0 and 0, patients and 35, 5, 2, 3, 2, 3, and 2 patients, respectively. Between the placebo and apremilast groups, overall, marked abnormalities in hematology laboratory parameters, including leukocyte, neutrophil, and lymphocyte counts during the placebo-controlled period (0 to 16 weeks) were infrequent, transient, and comparable. The EAIR/100 patient-years of marked hematologic abnormalities were comparable during 0 to &amp;lt;/= 52 weeks apremilast-exposure period and the cumulative long-term apremilast-exposure period (0 to &gt;/= 156 weeks) and the marked abnormalities occurred infrequently. Due to changes in lymphocyte or neutrophil counts none of the patients discontinued the study. During 0 to &amp;lt;/= 52 weeks apremilast-exposure period and the cumulative apremilast-exposure period (0 to &gt;/= 156 weeks), leukocytes &amp;lt; 1.5 x 10(9)/l, lymphocytes &amp;lt; 0.8 x 10(9)/l and neutrophils &amp;lt; 1 x 10(9)/l was reported by 0.0, 3.1 and 0.2% of patients, and 0.0, 4.8 and 0.6% of patients, respectively [&lt;ulink linkType="Reference" linkID="1906602"&gt;1906602&lt;/ulink&gt;]. Similar pooled results were presented in June 2017 [&lt;ulink linkType="Reference" linkID="1935731"&gt;1935731&lt;/ulink&gt;]. Similar pooled results were presented in November 2017 [&lt;ulink linkType="Reference" linkID="1978443"&gt;1978443&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  March 2017, pooled data were presented from ESTEEM 1, ESTEEM 2,  &lt;ulink linkType="Protocol" linkID="68729"&gt;PALACE 1&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="70875"&gt;PALACE2&lt;/ulink&gt;, and    &lt;ulink linkType="Protocol" linkID="70872"&gt;PALACE 3&lt;/ulink&gt;  phase III trials,  performed to evaluate the long-term safety and tolerability of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; (30 mg) in patients with psoriasis and psoriatic arthritis for overall 156 weeks (n = 2242). Adverse events (AEs; &gt;/=1) were reported by 49.0 and 61.6% of patients receiving placebo and apremilast, respectively, during the placebo-controlled period. The rates of severe and serious AEs with apremilast (4.2 and 2.1%) were comparable to placebo (3.6 and 3.1%) during 0 to 16 weeks. During the apremilast-exposure period, the exposure-adjusted incidence rates (EAIR)/100 patient-years for AEs, serious AEs, and discontinuations due to AEs, did not increase with increasing cumulative exposure which is confirmed by year by year exposure basis. The incidence rates of &gt;/= 1AE, &gt;/= 1 severe AE, &gt;/= 1 SAE, AE leading to drug withdrawal, and any AE leading to death were 76.8, 7.4, 5.5, 7.8, and 0.1% at weeks 0 to &amp;lt;/= 52; 59.2, 4.9, 6, 2.8, and 0.2% at weeks &amp;gt; 52 to &amp;lt;/= 104; 60, 4.6, 6.5, 2.4, and 0.1% at at weeks &amp;gt; 104 to &amp;lt;/= 156; 83.9, 11.3, 11.7, 11.1, and 0.3% (cumulative events). AE &gt;/= 1, &gt;/= 1 severe AE, &gt;/= 1 serious AE, AE leading to drug withdrawal and any AE leading to death was reported by 83.2, 10.6, 9.0, 11.1 and 0.3% of patients, respectively, in ESTEEM 1 and 2 trials; by 85.0, 12.3, 16.1, 11.0 and 0.3% of patients, respectively, in PALACE 1 to 3 trials; and by 83.9, 11.3, 11.7, 11.1 and 0.3% of patients, respectively, from pooled ESTEEM and PALACE. Most common AEs were diarrhea, nausea, upper respiratory tract infections, nasopharyngitis and headache reported by 15.3, 13.2, 6.8, 5.4, 6.5% or patients, respectively, during 0 to 16 weeks; by 16.6, 15.4, 12.8, 10.9 and 7.9% of patients, respectively, during 0 to &amp;lt;/= 52 weeks; by 3.0, 1.4, 7.2, 6.3 and 2.0% of patients, respectively, during &amp;gt; 52 to &amp;lt;/= 104 weeks; and by 2.1, 1.9, 5.9, 5.1 and 2.3% of patients, respectively, during &gt;104 to &amp;lt;/= 156 weeks. Most cases of diarrhea and nausea were mild to moderate in severity, occurred during the first 2 weeks of apremilast exposure which resolved within one month. Apremilast discontinuation due to diarrhea and nausea occurred in 1.3 and 1.7% of patients, respectively, during 0 to &amp;lt;/= 52 weeks; 0.1 and 0% during &amp;gt; 52 and &amp;lt;/= 104 weeks of apremilast-exposure period. No apremilast discontinuation were observed during &amp;gt; 104 to &amp;lt;/= 156 weeks [&lt;ulink linkType="Reference" linkID="1906591"&gt;1906591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Major and potentially major adverse cardiac events (MACE) (0.1 and 0.1%), malignancies (0.5 and 0.5%), opportunistic infections (1.1 and 0.5%), and serious opportunistic infections (0.0 and 0.0%) were the AEs of interest, which occurred at low and comparable rates between placebo and apremilast, during the placebo-controlled period (0 to 16 weeks). The EAIR/100 patient-years for MACE, malignancies, and serious infections during the 0 to &amp;lt;/= 52 week period and the cumulative apremilast-exposure period (0 to &gt;/= 156 weeks), remained low and within the range of that reported in the placebo-controlled period. Throughout 0 to &gt;/= 156 weeks, none of the patients reported new clinical tuberculosis cases in ESTEEM and PALACE 1 to 3 populations. The EAIR/100 patient-years for depression were 2.1, 0.9, and 1.3 at 0 to &amp;lt;/= 52, &amp;gt; 52 to &amp;lt;/= 104, and &amp;gt; 104 to &amp;lt;/= 156 weeks during apremilast-exposure periods, respectively. With increasing cumulative long-term apremilast exposure, there was no increase in EAIR/100 patient-years for depression (0 to &gt;/= 156 weeks: 1.4) in relation to 0 to &amp;lt;/=52 week apremilast-exposure period. During apremilast-exposure period, one patient each at 0 to &amp;lt;/= 52 and &amp;gt; 52 to &amp;lt;/= 104 weeks, reported suicide attempt. Between the placebo and apremilast groups, overall changes in laboratory parameters were infrequent, transient, and comparable during the placebo-controlled period. ALT &amp;gt; 3 x upper limit of normal (ULN), AST &amp;gt; 3 x ULN, creatinine &amp;gt; 1.7 x ULN, total bilirubin &amp;gt; 1.8 x ULN, hemoglobin A1C &amp;gt; 9%, total cholesterol &amp;gt; 7.8 mmol/l, neutrophils &amp;lt; 1.0 x 10(9)/l, lymphocytes &amp;lt; 0.8 x 10(9)/l, leucocytes &amp;lt; 1.5 x 10(9)/l and platelets &amp;lt; 75 x 10(9)/l was reported by 0.8, 0.9, 0.2, 0.4, 0.6, 2.6, 0.2, 3.1, 0.0 and 0.0% of patients, respectively, during 0 to &amp;lt;/= 52 weeks; by 0.5, 0.5, 0.3, 0.2, 0.5, 1.8, 0.4, 2.0, 0.0 and 0.0% of patients, respectively, during &gt;52 to &amp;lt;/= 104 weeks; and by 0.6, 0.6, 0.2, 0.2, 0.6, 1.9, 0.4, 2.5, 0.0 and 0.1% of patients, respectively, during &amp;gt; 104 to &amp;lt;/= 156 weeks, during apremilast exposure period. Corresponding cumulative events rates were 1.1, 1.5, 0.9, 0.6, 1, 2.4, 0.3, 3.7, 0, and 0% in ESTEEM 1 and 2; 1.8, 1.4, 0.3, 0.3, 1, 5.2, 1.1, 6.6, 0, and 0.1% in PALACE 1 to 3; 1.4, 1.5, 0.6, 0.5, 1, 3.5, 0.6, 4.8, 0, and 0.1% in pooled ESTEEM and PALACE. Mean change from baseline in weight were -1.42, -1.64, -1.63, and -1.34 during 0 to &amp;lt;/= 52, &amp;gt; 52 to &amp;lt;/= 104, and &amp;gt; 104 to &amp;lt;/= 156, and 0 to &gt;/= 156 (cumulative) weeks, respectively. No increase in mean percent change in weight from baseline was observed with prolonged apremilast exposure. Most patients taking apremilast for &gt;/= 156 weeks maintained body weight within 5% of baseline; 16.9, 24.5, 25.5, and 21.1% experienced &amp;gt; 5% weight loss and 5.3, 9.4, 11.2, and 10.0% experienced &amp;gt; 5% weight gain from baseline during the 0 to &amp;lt;/= 52 week, &amp;gt; 52 to &amp;lt;/= 104 week, &amp;gt; 104 to &amp;lt;/= 156 week, and 0 to &gt;/= 156 week apremilast-exposure periods, respectively. During each of the apremilast-exposure periods, the proportion of patients with &amp;gt; 20% weight loss was&amp;lt;/= 1.0%, and none of these patients discontinued treatment due to weight loss. During the 0 to &amp;lt;/= 52 week apremilast-exposure period, due to weight loss, three patients discontinued treatment, and the reported weight loss was &amp;lt; 12%. During &amp;gt; 52 to &amp;lt;/= 104 and &gt;104 to &amp;lt;/= 156 weeks of apremilast-exposure period, no patients discontinued treatment due to weight loss during apremilast-exposure period, the rate of treatment discontinuation due to weight loss remained low as 0.2%. Over 0 to &gt;/= 156 week of apremilast-exposure period, weight loss in patients receiving apremilast did not lead to any overt medical squealae [&lt;ulink linkType="Reference" linkID="1906591"&gt;1906591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, results of pooled analysis of five phase III trials (ESTEEM 1, &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="68729"&gt;PALACE-1&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="70875"&gt;PALACE2&lt;/ulink&gt;  and &lt;ulink linkType="Protocol" linkID="70872"&gt;PALACE 3&lt;/ulink&gt;), which reported the incidence of major adverse cardiac events (MACE), malignancies, and serious infections in patients with psoriasis and psoriatic arthritis treated with apremilast for &gt;/= 156 weeks. Among 2242 patients included in the safety analysis for 0 to 16 weeks (placebo, n = 913; apremilast 30 mg bid, n = 1329), 1905 patients received apremilast 30 mg bid during the apremilast-exposure period (0 to &amp;lt;/= 52 weeks and 0 to &gt;/= 156 weeks). During 0 to 16 weeks (placebo), the incidence of MACE with apremilast 30 mg bid was low and comparable to placebo. Overall incidence of MACE (exposure-adjusted incidence rates [EAIR]/100 patient-years) during 0 to &amp;lt;/= 52 week and 0 to &gt;/= 156 weeks apremilast-exposure period was 0.3 and 0.5, respectively, other major adverse cardiac events included acute myocardial infarction (0.1 and 0.1), myocardial infarction (0.1 and 0.1), subarachnoid hemorrhage (0.1 and 0.1), cardiac arrest (0.0 and 0.1) and cerebral infarction (0.0 and 0.1), respectively. Incidence rates (EAIR/100 patient-years) of hematological malignancies, non-melanoma skin cancers, and solid tumors were similar with placebo (0.0, 1.2 and 0.4) and apremilast 30 mg bid (0.0, 1.3 and 0.3) during 0 to 16 weeks (placebo-controlled period). Incidence rates for malignant neoplasms overall remained low during 0 to &amp;lt;/= 52 weeks and did not increase with increasing cumulative apremilast-exposure through &gt;/= 156 weeks. Overall malignancy (EAIR/100 patient-years) during 0 to &amp;lt;/= 52 week and 0 to &gt;/= 156 weeks of apremilast-exposure period was 1.2 and 0.9, respectively, other malignancies included B-cell lymphoma (0.0 and 0.03), diffuse large B-cell lymphoma (0.0 and 0.03), basal cell carcinoma (0.7 and 0.4), squamous cell carcinoma of skin (0.3 and 0.2), breast cancer (0.2 and 0.1), thyroid neoplasm (0.1 and 0.1), renal cell carcinoma (0.1 and 0.1), lung neoplasm (0.0 and 0.1), uterine cancer (0.1 and 0.03), prostate cancer (0.0 and 0.03), lip and/or oral cavity cancer (0.0 and 0.03), lung adenocarcinoma (0.1 and 0.03), malignant melanoma (0.0 and 0.03), rectal cancer (0.0 and 0.03) and thyroid cancer (0.0 and 0.03). There was no clustering of any particular event noted with respect to SIs; most events occurred in only one patient. There was no clinical reactivation of tuberculosis reported with long-term apremilast 30 mg bid exposure (0 to &gt;/= 156 weeks). Further, no cases of serious opportunistic infection were reported with long-term apremilast exposure. The incidence of marked hematologic abnormalities remained low with long-term apremilast exposure [&lt;ulink linkType="Reference" linkID="1935731"&gt;1935731&lt;/ulink&gt;]. Similar pooled results were presented in November 2017 [&lt;ulink linkType="Reference" linkID="1978443"&gt;1978443&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2017, results of pooled analysis of two  phase III trials (ESTEEM 1 and  &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;) were published, which assessedlong-termsafety(&gt;/= 156 weeks) of oralapremilastinpsoriasispatients. During 0 to &amp;lt;/= 52weeks, the adverse events (AEs) reported in &gt;/= 5% ofpatientswere diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. During 0to &gt;/= 156weeks, new AEs (affecting &gt;/= 5% of the population) were not reported. AEs, serious AEs and study drug discontinuations due to  AEs were  not associated with an increase inlong-termexposure. During the 0 to &gt;/= 156-week period, the rates of major cardiac events (exposure-adjusted incidence rate[EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) were not increased when compared to  the rates found during the 0 to &amp;lt;/= 52-week period. Serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were not reported [&lt;ulink linkType="Reference" linkID="2002784"&gt;2002784&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2017, further pooled results from five studies (ESTEEM 1, ESTEEM 2, PALACE-1, PALACE-2 and PALACE-3) were presented. Gastrointestinal AEs that occurred in apremilast exposure period of 0 to &amp;lt;/= 52 and 0 to &gt;/= 156 weeks, respectively, were diarrhea (16.6 and 18.5%), nausea (15.4 and 16.7%) and vomiting (4.7 and 5.1%); and GI AEs that lead to study discontinuation were diarrhea (1.3 and 1.4%), nausea (1.7% and 1.7%), vomiting (0.6 and 0.6%), upper abdominal pain (0.3 and 0.3%), abdominal discomfort (0.2 and 0.2%), dyspepsia (0.2 and 0.2%) and hematochezia (0.2 and 0.2%). Diarrhea and nausea were predominantly mild or moderate in severity across the 156-week apremilast-exposure period. Mean change from baseline in weight was -1.42 and -1.34 kg; mean percentage change from baseline in weight was -1.48 and -1.32 and patients with &amp;gt; 5% weight loss were 16.9 and 21.1% in apremilast-exposure period of 0 to &amp;lt;/= 52 weeks and 0 to &gt;/= 156 weeks, respectively [&lt;ulink linkType="Reference" linkID="1978443"&gt;1978443&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, pooled results of two phase III trials (NCT01194219, ESTEEM 1; NCT01232283, ESTEEM 2) which described time to first onset and duration of Psoriasis Area and Severity Index (PASI) response was presented. In ESTEEM 1 and ESTEEM 2 study, few patients prematurely discontinued at week 32 to 52 phase due to adverse event (n = 1), lack of efficacy (n = 1), lost to follow up (n = 2) and adverse event (n = 1), withdrawal (n = 3), other (n = 1), respectively [&lt;ulink linkType="Reference" linkID="2121948"&gt;2121948&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase III, randomized, placebo-controlledstudy was to test      &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and compare its effects to placebo.  This study objectives were to test efficacy, safety and tolerability of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; in patients with moderate to severe      psoriasis [&lt;ulink linkType="Reference" linkID="1613536"&gt;1613536&lt;/ulink&gt;]. Also to evaluate effect of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; on quality of life [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1702023"&gt;1702023&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1716457"&gt;1716457&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1740856"&gt;1740856&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1802414"&gt;1802414&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Main objective was to evaluate the clinical efficacy of apremilast 30 mg bid, compared with placebo, in patients with moderate to severe plaque psoriasis. &lt;br/&gt;Secondary objective of the trial were to evaluate the safety and tolerability of apremilast 30 mg bid, compared with placebo, in patients with moderate to severe plaque psoriasis and to evaluate the effect of apremilast 30 mg bid compared with placebo on quality of life in patients with moderate to severe plaque psoriasis.&lt;/para&gt;&lt;para&gt;By January 2013, the trial was ongoing [&lt;ulink linkType="Reference" linkID="1355103"&gt;1355103&lt;/ulink&gt;].  &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2013, results showed that the study met  primary and major secondary endpoint  [&lt;ulink linkType="Reference" linkID="1355104"&gt;1355104&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2013,  results showed that  PASI-75 was achieved at week 16 by 33.1% of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; recipients compared with 5.3% for placebo (p&amp;lt; 0.0001). The figures in systemic-naive patients were 38.7 versus 7.6%, and in biological-naive patients were 35.8 versus 5.9%. The mean percent change from baseline in PASI score with &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; was a 54.9% reduction at week 16 and a 61.9% reduction at week 32 [&lt;ulink linkType="Reference" linkID="1388007"&gt;1388007&lt;/ulink&gt;]. In April 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1717540"&gt;1717540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, results  were presented. Data showed that at 16 weeks, patients in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; 30 mg, bid group showed significantly greater improvement than the placebo group in both NAPSI score (22.5% versus a worsening of 6.5%; p  &amp;lt;  0.0001) and ScPGA score (46.5% versus 17.5%;p &amp;lt; 0.0001). Improvement was maintained for patients on &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; through week 32. Treatment with &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; significantly improved the quality-of-life. Patients in the placebo group when switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; group also showed improvement. Further results showed that at week 16, significant improvements were observed with &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; in HRQOL from baseline on the DLQI, SF-36 MCS, EQ-5D index, and PHQ-8 (p &amp;lt; 0.01). At wee k 16, patients with a baseline Dermatology Life Quality Index (DLQI) total score &amp;gt; 5, a significantly greater proportion achieved a &gt;/= 5 point improvement in DLQI with &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; (70.2%) versus placebo (33.5%) (-6.6 versus -2.1, P &amp;lt; 0.0001). At week 16, the mean change from baseline of Patient Health Questionnaire-8 (PHQ-8) (-0.6 in &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; versus 0.3 in placebo, p &amp;lt; 0.01), SF-36 MCS (2.28 versus -0.81, p &amp;lt;0.0001), SF-36 PCS (1.15 versus 0.17) and EQ-5D index (0.0362 versus -0.0108, p &amp;lt; 0.0001) were observed. At week 32, patients with a baseline DLQI total score &amp;gt; 5, a significantly greater proportion achieved a &gt;/= 5 point improvement in DLQI with &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; (57.5%) versus placebo/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; (58.3%) (-6.6 versus -5.8). At week 32, the mean change from baseline of PHQ-8 (-0.9 in &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; versus -0.7 in placebo/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;), SF-36 MCS (3.01 versus 2.12), SF-36 PCS (0.76 versus 0.76) and EQ-5D index (0.0212 versus -0.0404) were observed. At week 32, maintenance of improvements in HRQOL were observed in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; group. At week 32, in the placebo/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; group, there were improvements in HRQOL parameters observed, with improvements in DLQI and PHQ-8 similar to those achieved in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; group. In the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo groups, 33.3 and 14.9% of patients achieved NAPSI50 at week 16, respectively. Mean reductions were -43.6% with  &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and -24.6% with placebo/&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; at week 32. At week 32, 45.2% of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;-treated patients had achieved NAPSI50 when compared with 34.9% of placebo recipients who switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;, and 37.4% of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;-treated patients and 43.6% of placebo recipients who switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; had achieved ScPGA. Mean change in NAPSI was found to be -60.2% (n = 41) at week  52 during the randomized withdrawal phase, in patients receiving &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; over 52 weeks (&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/30/30).  About 81.3% of patients were randomized to continue &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; (&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/30/30; n = 48) for the  withdrawal phase and 82.6% of patients randomized to placebo (&lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/30/placebo; n = 46) had achieved ScPGA 0 to 1 at week 32. ScPGA 0 to 1 was achieved by 72.9% of &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;/30/30 patients at  week  52 [&lt;ulink linkType="Reference" linkID="1483670"&gt;1483670&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1484923"&gt;1484923&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1485346"&gt;1485346&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, further  data were presented at the 72nd AAD Annual Meeting in Denver, CO. In the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; group, 33.1 and 58.7% of patients achieved PASI-75 and PASI-50 at week 16, respectively, when compared with 5.3 and 17% of patients in the placebo group, respectively (p &amp;lt; 0.0001). At week 16, the respective mean/median percent change from baseline (BL)   in PASI and dermatology life quality index (DQLI) scores from baseline was -52.1 and -59.0% for &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and -16.8 and -14.0% for placebo  (p &amp;lt; 0.0001) and PASI responses were maintained through week 32. DQLI responses were seen in 70.2% of patients receiving &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; when compared to 33.5% of placebo recipients. Nail psoriasis severity index (NAPSI)50 responses were achieved by 33.3 and 14.9% of patients in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo groups, respectively. The change in NAPSI was -22.5 and +6.5% for &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo, respectively (p &amp;lt; 0.0001). In the randomized treatment withdrawal phase, 61.0% of 77 patients randomized to receive &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;  at week 32 were PASI-75 responders at week 52, and 75.3% had &gt;/= 70% improvement in PASI from BL and the mean percent change from BL in PASI score ranged from -81 to -88% between weeks 32 and 52. By week 32, approximately 30% of placebo recipients switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;  achieved  PASI75 while  physician's global assessment score 0/1 was seen in approximately 20% of placebo recipients switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;. Among patients re-randomized to placebo at week 32 (n = 77), 11.7% had PASI-75 at week 52 and the median time to PASI-75 loss in patients re-randomized to placebo was 5.1 weeks. Of patients rerandomized to placebo who lost response and restarted &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;, PASI-75 response after reinitiation of treatment was regained in 70.3% patients. At week 52, stable responses were seen in patients receiving &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and in placebo recipients who switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1537027"&gt;1537027&lt;/ulink&gt;]. Similar results were published in July 2015 [&lt;ulink linkType="Reference" linkID="1689865"&gt;1689865&lt;/ulink&gt;]. Similar results were published in January 2016 [&lt;ulink linkType="Reference" linkID="1728923"&gt;1728923&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In September 2014, pooled results from ESTEEM 1 and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; studies were published. At week 16, there were significant and clinically meaningful improvements in plaque psoriasis as measured by PASI scores. Also, clinical improvement were demonstrated as measured by sPGA scores of clear to almost clear [&lt;ulink linkType="Reference" linkID="1596597"&gt;1596597&lt;/ulink&gt;]. Similar results were published in November 2014 [&lt;ulink linkType="Reference" linkID="1613536"&gt;1613536&lt;/ulink&gt;]. Similar results were published in January 2015. Further,  significant improvements in difficult to treat areas, such as nail and scalp, and itch were observed in patients treated with &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;, which were known to have a marked impact on patients' quality of life and perception of disease severity [&lt;ulink linkType="Reference" linkID="1626980"&gt;1626980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, results were presented. Results showed that, SF-36 (MCS) score was acheived by 44.3 and 30.1 in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo group, respectively and was 52.2% in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; + psoriasis area and severity index (PASI)-75 responder group (p &amp;lt; 0.0001). DLQI was achieved by 70.2 and 33.5% of patients in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo group, respectively and was 92.6% in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; + PASI-75 responder group (p &amp;lt; 0.0001). In the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo groups, pruritus visual activity score was seen in 70.6 and 33.79% of patients, respectively and was 90.3% demonstrated in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; + PASI-75 responder group (p &amp;lt; 0.0001). Significantly higher percentage of patients who achieved MCID at week 16 was observed with  &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;. On DLQI or pruritis VAS, &amp;gt; 90% of the patients achieved MCID improvements at week 16, among &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; PAS175 responders [&lt;ulink linkType="Reference" linkID="1601112"&gt;1601112&lt;/ulink&gt;]. Similar results were presented in March 2015 [&lt;ulink linkType="Reference" linkID="1644287"&gt;1644287&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further in October 2014 results of pooled results from ESTEEM 1 and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; studies were presented. At week 16, change from baseline for APR30 in weight was -1.51 kg and long-term change was -1.99 kg for APR30 at week 52. Between weeks 52 and 65, mean and median weight loss showed plateau effect. Weight loss of &amp;gt; 5% was reported in 13.7 and 5.5% of patients in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo group, respectively during weeks 0 to 16. During weeks 0 to 52, 19.2% of patients experienced weight loss of &amp;gt; 5%. Weight gain of &amp;gt; 5% was reported in 2.8 and 6% of patients in the &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; and placebo group, respectively during weeks 0 to 16. During weeks 0 to 52, 5.5% of patients experienced weight gain of &amp;gt; 5%[&lt;ulink linkType="Reference" linkID="1601111"&gt;1601111&lt;/ulink&gt;].  In October 2014 similar results of pooled results from &lt;ulink linkType="Protocol" linkID="69830"&gt;ESTEEM 1&lt;/ulink&gt; and ESTEEM 2 randomized, controlled phase III trials, underlined the favorable safety of apremilast as a treatment for psoriasis were presented [&lt;ulink linkType="Reference" linkID="1601754"&gt;1601754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014 further results of pooled results from &lt;ulink linkType="Protocol" linkID="69830"&gt;ESTEEM 1&lt;/ulink&gt; and ESTEEM 2 randomized, controlled phase III trials, underlined the favorable safety of apremilast as a treatment for psoriasis were presented. Weight loss was not associated with sequelae and was not associated with diarrhea, nausea or vomiting [&lt;ulink linkType="Reference" linkID="1601754"&gt;1601754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, pooled results from &lt;ulink linkType="Protocol" linkID="36656"&gt;PSOR-005&lt;/ulink&gt;, ESTEEM 1and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; were published. There was an improvement in palmoplantar psoriasis who received apremilast in a subset of patients with moderate to severe chronic plaque psoriasis who had palmoplantar involvement. At week 16, in all three trials a higher percentage of patients treated with apremilast 30 mg bid had PPPGA reduced to clear or almost clear compared with placebo those who had any palmoplantar psoriasis at baseline (PPPGA score of one or greater, n = 427 across the three studies - 49 in &lt;ulink linkType="Protocol" linkID="36656"&gt;PSOR-005&lt;/ulink&gt;, 254 in ESTEEM 1 and 124 in &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;) (&lt;ulink linkType="Protocol" linkID="36656"&gt;PSOR-005&lt;/ulink&gt;: 70% (19/27) versus 32% (7/22), respectively, p = 0.0072;  ESTEEM 1: 63% (107/169) versus 45% (38/85), respectively, p = 0.0047; &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;: 71% (55/78) versus 37% (17/46), respectively, p = 0.0003). Among patients who had moderate to severe palmoplantar psoriasis at baseline (PPPGA score of three or greater) (across the three studies  : PSOR-005, &lt;ulink linkType="Protocol" linkID="69830"&gt;ESTEEM 1&lt;/ulink&gt; and  &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;), a higher percentage of patients treated with apremilast 30 mg bid had PPPGA reduced to clear or almost clear compared with placebo at week 16 in PSOR-005 [67% (6/9) versus 20% (2/10), respectively, p = 0.0397] and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; [65% (17/26) versus 31% (5/16), respectively, p = 0.0315]. No significant difference was observed between the apremilast and placebo groups at week 16 in &lt;ulink linkType="Protocol" linkID="69830"&gt;ESTEEM 1&lt;/ulink&gt; (39% [22/57] versus 31% [8/26], respectively, p = 0.4912). When compared to placebo-controlled period,    the exposure adjusted incidence rate (EAIR) for serious AEs did not increase with longer apremilast exposure. No clinically meaningful changes were observed in laboratory measurements  over the apremilast 104-week exposure period. Incidence rates of major cardiac events, solid tumors, hematological malignancies and serious infections were comparable between the placebo and apremilast arms during the placebo-controlled period. There was no increase in incidence rates  with longer-term exposure to apremilast between weeks 52 to 104 [&lt;ulink linkType="Reference" linkID="1643824"&gt;1643824&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, results were presented from phase IIb (PSOR-005) and phase III studies (ESTEEM 1 and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;) which evaluated the efficacy, safety and tolerability of the PDE4 inhibitor &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; in a subset of patients with moderate to severe plaque psoriasis.  In the placebo and apremilast groups, the respective proportion of patients who achieved a palmoplantar psoriasis physician global assessment (PPPGA) score of 0 or 1, a PPPGA score of 0 or 1 with &gt;/= 1-point improvement , or PASI-75 plus PPPGA score of 0 or 1 were  63.3% and 12.5 and 50%  [&lt;ulink linkType="Reference" linkID="1644279"&gt;1644279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, pooled results from ESTEEM 1 and ESTEEM 2 studies which evaluated the effect of apremilast on work limitations questionnaire and work productivity were presented. At baseline, work limitations questionnaire and work productivity of the two groups were similar. At 16 weeks, greater mean improvement in the work limitations questionnaire (WLQ) index (-0.004 versus 0.003, respectively; p = 0.031), and mean percent improvement in productivity loss (-0.403 versus 0.238, respectively; p = 0.035) was observed for apremilast (30 mg bid) when compared with placebo. In PASI75 responders, prominent improvement in the WLQ index (-0.009 and 0.003, respectively; p = 0.005), productivity loss (-0.816 and 0.238, respectively; p = 0.006), scores of time management scale (TMS), mental demands scale (MDS) and output demands scale (ODS) were observed for apremilast (30 mg bid) when compared with placebo. In the respective placebo, apremilast (30 mg bid) and PASI75 responders, the mean change from baseline at week 16 in time management scale (TMS) was 2.77, -2.07 (p = 0.002) and -5.56 (p = 0.001), in physical demands scale (PDS) was -1.63, -1.06 and -1.94, in mental demands scale (MDS) was 0.86, -1.78 and -3.68 (p = 0.013) and in output demands scale (ODS) was 1.05, -1.51 (p = 0.046) and -2.57 (p = 0.02) [&lt;ulink linkType="Reference" linkID="1644285"&gt;1644285&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, week-16 results were presented from a phase III study comprising two randomized, placebo-controlled studies (ESTEEM 1 and 2) which evaluated the safety, efficacy and tolerability of apremilast in patients with moderate to severe plaque psoriasis. In ESTEEM 1 study at week 16, significantly greater decrease in pruritus VAS score (-31.5 and -7.3 mm respectively; p &amp;lt; 0.0001) and DLQI score (-6.6 and -2.1, respectively) representing a nearly 50% decrease in pruritus severity with APR30 was observed in apremilast group when compared with placebo group. The respective MCID in pruritus VAS and DLQI MCID were achieved by 70.6 and 70.2% of patients in apremilast group and 33.7 and 33.5% of patients in placebo group, respectively [&lt;ulink linkType="Reference" linkID="1644273"&gt;1644273&lt;/ulink&gt;].  In April 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1717540"&gt;1717540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, combined results showed improvement in pruritus was observed as early as week 2 and maintained through week 32in apremilast group when compared with placebo group (30.3). A decrease of approximately 50% in pruritus VAS score from baseline in the severity of pruritus was observed. MCID for both pruritus and DLQI were achieved by 46.4% of patients receiving apremilast. In ESTEEM 1 and 2, improvement in pruritus was correlated with an improvement in DLQI at week 16 (correlation coefficient, &gt;/= 0.43 in either group, p &amp;lt; 0.001) [&lt;ulink linkType="Reference" linkID="1644273"&gt;1644273&lt;/ulink&gt;]. In April 2015, similar results were presented [&lt;ulink linkType="Reference" linkID="1717540"&gt;1717540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, results were presented. Significantly greater improvements in each PASI scores by individual body regions (head, trunk and upper and lower limb) and PASI components (erythema, thickness and scaling) as well as overall PASI score was observed in apremilast group when compared with placebo group. For all PASI body regions and components, significant improvement were observed as early as week 2 [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, further combined results were presented from ESTEEM 1 and ESTEEM 2 studies. Between treatment groups, demographic/disease characteristics were generally well balanced. Mean changes (improvements) in skin discomfort/pain VAS (mm) scores were significantly greater with apremilast at week 16 (28.3)  versus palcebo (5.0) (p&amp;lt; 0.0001)  [&lt;ulink linkType="Reference" linkID="1717540"&gt;1717540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015,  results were presented from a  post-hoc analysis which assessed the relationship between PGA x BSA-75 and PASi-75 responses in patients receiving  apremilast therapy. The corresponding PGA x BSA-75 response was not attained by nearly 28.6% of patients attaining PASI-75 response.  Spearman correlations of  PASI-75 and PGA x BSA were moderate to highly positive at baseline, weeks 16 and 32. The effect sizes were larger with PASI when compared to PGA x BSA. At baseline, mean change in PASI and  PGA x BSA was 18.7 and  81.8 with a Spearman correlation of 0.757 (p &amp;lt; 0.05), standardized PASI versus PGA x BSA of 0.886. At weeks 16 and 32, mean change in PASI was -10.2 and  -11.3 and  PGA x BSA was -46.5 and -53.3 with a Spearman correlation of 0.807 and 0.742 (p &amp;lt; 0.05 for both), standardized PASI versus PGA x BSA of 0.834 and 0.805, effect size with PASI  was -1.41 and -1.57 and effect size with PGA x BSA  was -0.85 and -0.97, respectively  [&lt;ulink linkType="Reference" linkID="1705505"&gt;1705505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the pooled results from ESTEEM 1 and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; were presented. Median weight loss at week 16 and 52 for apremilast-treated patients were -1.05 (-1.41%) and -1.40 kg (-1.68%), respectively, compared to placebo (0.0%) group. Weight loss (&gt; 5%), and median % weight loss in patients with baseline A1c &gt;/= 7% (placebo 21 and apremilast 52), observed during 0 to 16 week period, in apremilast and placebo treated groups were 13.7 and 5.5% and -2.9 and 0.4%, respectively; with long-term exposure of apremilast 19.2% was observed. There were no meaningful changes observed in electrolytes, calcium or phosphate, and renal parameters through week 52. The mean change from baseline to week 16 in ALT (U/l) was -0.7 and  -2.3, AST (U/l) was -0.1 and -1.9, urate (micromol/l) was 3 and -9.2, and A1c% was -0.5 and -0.5, respectively in placebo and apremilast 30 mg groups. Decrease in AST/ALT levels were continued through week 52.  Decrease in serum urate levels and ALT/AST levels were less, during 52-week period. Median decrease in baseline A1c (&gt;/= 7%) observed in apermilast and placebo-treated patients were -0.5 and -0.2% respectively [&lt;ulink linkType="Reference" linkID="1705496"&gt;1705496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, results were presented. The aim of this post-hoc analysis was to evaluate the relationship between psoriasis area and severity index score at baseline at week 16 and 52 assessed by using Pearson correlation coefficient and proportion of patients with weight loss &amp;gt; 5% who achieved PASI-75 response at week 16 and 52 were also examined. There was no correlation between percent change from baseline weight and percent change from baseline PASI score in the apremilast, 30 mg group at week 16 (r = 0.11) and at week 52 no correlations were observed in all patients exposed to apremilast, 30 mg (r = 0.02). At week 16, PASI-75 was achieved in 30/71, 151/425 and not achieved in 41/71, 273/425 patients, respectively, in the apremilast, 30 mg group with weight loss &amp;gt; 5% and &amp;lt;/= 5% from baseline. None of the patient in placebo group with weight loss &amp;gt; 5% from baseline achieved PASI-75 at week 16. At week 52, patients in apremilast 30/ apremilast 30 mg group who experienced weight loss &amp;gt; 5% from baseline, PASI-75 was achieved in 33/80 and was not achieved in 47/80 patients, respectively [&lt;ulink linkType="Reference" linkID="1705506"&gt;1705506&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, pooled results from two phase III, multicenter, multinational, randomized, double-blind, placebo-controlled studies (ESTEEM 1 and ESTEEM 2) were performed to evaluate the safety and efficacy of apremilast, for the treatment of plaque psoriasis. At week 16, significantly greater number of patients treated with apremilast 30 mg showed Nail Psoriasis Severity Index (NAPSI) improvements when compared with placebo in both ESTEEM-1 (p &amp;lt; 0.001) and ESTEEM-2 (p = 0.0052) studies. NAPSI-50 response achievement continued to increase in the apremilast group at week 32. Improvements were also observed in the placebo/apremilast group. In both the studies, the sPGA score of 0 or 1 was generally maintained at week 32 in the apremilast group (37.4 and 32.4% in ESTEEM-1 and 2 studies, respectively). Improvements in mean percent changes in PASI score were maintained over 52 weeks among patients who were randomized to apremilast 30 mg at baseline, had a PASI-75 or PASI-50 (ESTEEM 1 or 2, respectively) response at week 32 and continued taking apremilast 30 mg. Mean percent change in PASI score was maintained during Period C (weeks 32 to 52) among patients who were randomized ti placebo at baseline and switch to apremilast at week 16, had a PASI-75 or PASi-50 response at week 32 and continued to take the apremilast, 30 mg. The mean percent improvement from baseline in PASI score at week 52 (period C) was -80.0% and -71.8% (ESTEEM 1 and 2, respectively) [&lt;ulink linkType="Reference" linkID="1709807"&gt;1709807&lt;/ulink&gt;]. Similar pooled results were published in January 2016. Further,  treatment with apremilast versus placebo reported greater NAPSI-50 and ScPGA response at week 16 (both studies p&amp;lt;0.0001) [&lt;ulink linkType="Reference" linkID="1728923"&gt;1728923&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, further results were presented at the same conference. Significantly more patients who received apremilast 30 mg (p &amp;lt; 0.0001) achieved PASI-75 (33.1 versus 5.3%), 50 (58.7 versus 17.0%) and a static physician global assessment (sPGA) score (21.7 versus 3.9%) 0 or 1 versus placebo, at week 16 in ESTEEM 1. At week 16, NAPSI-50 was achieved in 14.9 versus 33.3% of patients treated with placebo and apremilast 30 mg (p &amp;lt; 0.0001). PASI improvements (ie, decreased) were observed as early as week 2 with apremilast 30 mg, with a mean percent improvement from baseline of -22.3 versus -6.5% in patients treated with apremilast 30 mg versus placebo, respectively. At week 16, mean percent improvement in PASI was -52.1 versus -16.7% in patients treated with apremilast 30 mg versus placebo, respectively. Mean percent change in NAPSI score at week 16 and 32 were 6.5 versus -22.5 and -47.6 versus -60.0, respectively in placebo versus apremilast group [&lt;ulink linkType="Reference" linkID="1709807"&gt;1709807&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, results of the post-hoc analysis that assessed the efficacy and safety of apremilast 30 mg bid (APR), with and without topical therapies and/or UVB therapy in the subgroup of patients with &amp;lt; PASI-75 response at week 32 were presented. Patients achieving PASI 75 response with and without T/P during weeks 32 to 52 were 15.6 and 4.4%, respectively in placebo/apremilast group and 12.2 and 6.9%, respectively in apremilast/apremilast group. Mean percentage reduction at week 52 in PASI score in non-responders was -61.3 and -52.6% (placebo/apremilast) and -58.2 and -57.3% (apremilast/apremilast) with T/P during 32 to 52 week and without T/P, respectively  [&lt;ulink linkType="Reference" linkID="1742604"&gt;1742604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, pooled results were published from a post-hoc analysis of data from one phase IIb (PSOR-005; &lt;ulink linkType="Protocol" linkID="36656"&gt;NCT00773734&lt;/ulink&gt;) study and two phase III (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1], and &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt;) clinical studies which aimed to determine the effect of apremilast 30mg bid versus placebo at week 16 in a subset of patients with moderate to severe plaque psoriasis with active palmoplantar psoriasis (baseline Palmoplantar Psoriasis Physician Global Assessment [PPPGA] score &gt;/= 1). Compared with placebo at week 16 (48 versus 27%; p=0.021), PPPGA score 0 (clear) or 1 (almost clear)was achieved by significantly more patients taking apremilast with moderate to severe palmoplantar psoriasis (baseline PPPGA score &gt;/= 3). A total of 46 and 59% of the apremilast group with baseline PPPGA score 1 or higher achieved a PPPGA score of 0 versus 25% of the placebo group (p&amp;lt;0.001) and PPPGA score of 0 or 1 with one-point or more improvement versus 39% receiving placebo (p&amp;lt;0.001), respectively, at week 16 [&lt;ulink linkType="Reference" linkID="1795080"&gt;1795080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, pooled results from ESTEEM 1, ESTEEM 2 and &lt;ulink linkType="Protocol" linkID="30063"&gt;CHAMPION&lt;/ulink&gt; which compared apremilast's relative efficacy with that of methotrexate for moderate to severe psoriasis were published. Statistically significant difference was not observed between apremilast and methotrexate in PASI 75 (risk difference 13.1%; p=0.09). Number needed to treat with apremilast versus methotrexate to gain 1 additional PASI 75 responder was 7.6 [&lt;ulink linkType="Reference" linkID="1887523"&gt;1887523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, pooled results from ESTEEM 1and ESTEEM 2 were published that evaluated the impact of apremilast on health-related quality of life (HRQOL), general functioning mental health using assessments of patient-reported outcome (PRO) among patients with moderate to severe plaque psoriasis. Except 36-Item Short-Form Health Survey version 2 physical component summary scores (SF-36v2 PCS), all HRQOL PROs at week 16 were improved with apremilast versus placebo, and these improvements sustained through week 32. Improvements in mean dermatology life quality index and SF-36v2 mental component summary scores exceeded minimal clinically important differences. Week 16 changes in patient health questionnaire-8 (PHQ-8) and and psoriasis area and severity index (PASI) showed weak correlations, with only 35.8% of apremilast treated patients achieving  &gt;/= 75% reduction from baseline in PASI score (PASI-75) and also PHQ-8 scores of 0 to 4 [&lt;ulink linkType="Reference" linkID="1938386"&gt;1938386&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, results of a post-hoc analysis of data from the ESTEEM 1 and 2 trials were published, which assessed clinical response and defined minimal disease activity in patients with plaque psoriasis with the Physician Global Assessment and body surface area (PGA x BSA) composite tool. A significant correlation was observed between mean percent change in PGA x BSA and percent change in PASI (range, 0.915 to 0.943; all p &amp;lt; 0.001) and mean change in DLQI (range, 0.303 to 0.407; all p &amp;lt; 0.008), irrespective of baseline PASI score category (12 to 19 or &gt;/= 20). The median (IQR) PGA x BSA scores decreased in a distinct stepwise fashion with increasing levels of clinical improvement as defined by PASI or PASI/DLQI response. PGA x BSA response rates were found to be similar to those observed with the corresponding PASI or PASI/ DLQI anchors, particularly for the most widely achieved PASI response categories (PASI 50 to &amp;lt;75 and PASI 75 to &amp;lt;90). However, discrepant response rates were observed for the proposed PGA x BSA MDA criterion of 3 or lower versus the corresponding anchor of PASI 90 + DLQI 0 or 1 for ESTEEM 1 (20.2 versus 6.4%) and ESTEEM 2 ( 21.1 versus 8.0%). Additional analyses showed that when a PGA x BSA MDA of 1 or lower or 1.5 or lower was used, the response rates was found to better aligned with those for PASI 90 and PASI 90 + DLQI 0 or 1 [&lt;ulink linkType="Reference" linkID="2014053"&gt;2014053&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, results were presented from placebo-controlled, multicenter, phase III ESTEEM 1 (NCT01194219) and 2 (NCT01232283) studies which evaluated the impact of apremilast withdrawal on symptom recurrence in patients with moderate to severe psoriasis. During maintenance phase (weeks 16 to 32), 494 ESTEEM 1 and 234 ESTEEM 2 patients received apremilast. During randomized treatment withdrawal phase (weeks 32 to 52) in ESTEEM 1 and 2, patients with no response at week-32 continued apremilast (n = 245 and 58, respectively), while patients with response at week-32 (n = 154 and 123, respectively) were re-randomized to apremilast (n = 77 and 61, respectively) or placebo (n = 77 and 62, respectively). In ESTEEM 1 and 2, the loss of response/relapse occurred in 65 and 50 apremilast/apremilast/placebo-treated patients after the last dose of apremilast, respectively. In ESTEEM 1 and 2, the proportion of apremilast/apremilast/placebo-treated patients who experienced loss of response/relapse after the last dose of apremilast was greater among patients had disease duration of &gt;/= 10 years (70.8 and 78.0%, respectively) versus patients with duration of &amp;lt; 10 years (29.2 and 22.0%, respectively). By week 40 (8 weeks after the last apremilast dose), most patients experienced loss of response/relapse (ESTEEM 1: 78.5%; ESTEEM 2: 92.0%). In most patients, loss of response/relapse occurred by Week 40 (8 weeks after the last apremilast dose) (ESTEEM 1: 78.5%; ESTEEM 2: 92.0%). Following re-initiation of apremilast treatment, most patients regained Psoriasis Area and Severity Index -75/90 response [&lt;ulink linkType="Reference" linkID="2006499"&gt;2006499&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, results from a post-hoc sub-analysis which evaluated the clinical and quality-of-life outcomes for patients with moderate to severe plaque psoriasis who did not achieve PASI 75 (a 75 percent reduction in PASI) at either week 32 or 52, but continued apremilast treatment in this time period (n = 203/844). For patients who did not achieve a PASI 75 at week 32 or 52, more than half achieved a 50 percent reduction in PASI score (PASI 50) at weeks 32 and 52 following treatment with apremilast. This improvement, when taken together in disease-specific quality-of-life measures, may more reliably indicate clinically meaningful benefit. For example, itching, as measured by Visual Analog Scale (VAS), was decreased from baseline by approximately 30% during weeks 4 to 52 in those patients (n = 134) who received apremilast from baseline and weeks 20 to 52 in patients (n = 69) who were switched from placebo to apremilast at week 16. During the same time period, the quality of life, as measured by the Dermatology Life Quality Index (DLQI), was improved by at least 5 points in the two groups [&lt;ulink linkType="Reference" linkID="2071771"&gt;2071771&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, pooled post-hoc analysis results from the ESTEEM 1, &lt;ulink linkType="Protocol" linkID="71865"&gt;ESTEEM 2&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="227808"&gt;UNVEIL&lt;/ulink&gt; studies were presented. The purpose of this analysis was to examine the changes in scalp and nail psoriasis, along with quality of life, following treatment with apremilast. The sub-analysis included patients who had nail psoriasis (n = 768 in ESTEEM 1 and 2 and n = 73 in UNVEIL) or moderate to very severe scalp psoriasis (n = 1049 in ESTEEM 1 and 2 and n = 129 in UNVEIL) at baseline. At week 32 in ESTEEM and UNVEIL, clearance of nail psoriasis (Nail Psoriasis Severity Index [NAPSI] = 0) among patients receiving apremilast from baseline was achieved by 31.3% (n = 146/466) and 36.2% (n = 17/47) of patients, respectively. Among patients who were switched from placebo to apremilast at week 16, NAPSI clearance at week 32 was attained by 15.5% (n = 37/239) and 26.1% (n = 6/23) of patients, respectively. Among patients with moderate to severe scalp psoriasis at baseline, clear or minimal involvement of scalp psoriasis (Scalp Physician's Global Assessment [ScPGA] response of 0 or 1) was achieved by greater proportions of patients receiving apremilast versus placebo at week 16 in both trials: 45.2% (n = 351/694) versus 22.5% (n = 80/355), respectively, in ESTEEM and 44.1% (n = 30/68) versus 33.3% (n = 23.3) in UNVEIL. Of patients who had nail psoriasis or moderate to very severe scalp psoriasis at baseline, a DLQI of 0 or 1 was attained by greater proportions of patients receiving apremilast versus placebo at week 16 (28.7% [n = 206/719] versus 8.1% [n = 29/358], respectively, in ESTEEM and 23.7% [n = 23/97] versus 10.6% [n = 5/47] in UNVEIL) [&lt;ulink linkType="Reference" linkID="2071771"&gt;2071771&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2121994"&gt;2121994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, results were presented. By week 4 in ESTEEM 1 study, Psoriasis Area and Severity Index (PASI) response was PASI-75 for apremilast, 30/562 (5.3%) and for placebo, 2/282 (0.7%). Apremilast-treated patients with PASI-75 (n = 262) were included in the onset and maintenance of response analysis. Median time to first PASI response was 85 days and median duration of PASI-75 was 140 days. In patients who remained on continuous apremilast treatment and had a week 52 evaluation, 66.2% of patients demonstrated PASI-75 response [&lt;ulink linkType="Reference" linkID="2121948"&gt;2121948&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, results which characterized clinical and quality of life outcomes observed among patients who did not achieve a &gt;/= 75% reduction from baseline in PASI score at weeks 32 and 52 (PASI-75 nonresponders) but continued apremilast treatment were presented. In arm A and B groups, at baseline, mean PASI, pruritus VAS (mm), and DLQI scores were 17.8, 65.7 and 12.0 and 19.4, 64.7, and 12.4, respectively. Among PASI-75 nonresponders, about 50% improvement in PASI from baseline was maintained from weeks 12 to 52 in arm A (48.2 to 55.1%) and weeks 24 to 52 in arm B (49.3 to 55.7%) and pruritus VAS scores from baseline were reduced by approximately 30% from week 4 to 52 ( 29.8 to 38.3%) in arm A and weeks 20 to 52 (27.7% to 36.9%) in arm B. In arm A from weeks 8 to 52 (6.4 to 7.7) and arm B from weeks 24 to 52 (5.8 to 6.8), mean improvements from baseline in DLQI score of at least 5.8 points was maintained. Among PASI-75 nonresponders, proportion of arm A and B patients attaining PASI-50 at week 16, 32 and 52 was 60.2 and 11.9, 56.0 and 60.9 and 62.1 and 55.1%, respectively [&lt;ulink linkType="Reference" linkID="2121911"&gt;2121911&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, results of an analysis which characterized clinical and impact quality of life (QOL) outcomes observed among patients in ESTEEM 1, ESTEEM 2  and UNVEIL trials who had scalp or nail involvement at baseline were presented. Among patients with scalp or nail involvement, the mean psoriasis-involved body surface area was 24.8% in the apremilast groups and 26.5% in the placebo groups, respectively (ESTEEM) and 7.1 and 7.2%, respectively (UNVEIL). At week-16 in placebo and apremilast groups, the proportion of patients who achieved Scalp Physician's Global Assessment (ScPGA) of 0 or 1 was 22.5 and 50.6, respectively (ESTEEM); 33.3 and 46.0%, respectively (UNVEIL). At week-32 in placebo/apremilast and apremilast groups, the proportion of patients who achieved DLQI of 0 or 1 was 23.5 and 28.9, respectively (ESTEEM), and 37.5 and 22.4% (UNVEIL), respectively; and ScPGA of 0 or 1 was 55.1 and 51.9, respectively (ESTEEM); and 67.6 and 63.1%, respectively (UNVEIL) [&lt;ulink linkType="Reference" linkID="2121994"&gt;2121994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, post-hoc pooled data were presented from three trials including multicenter, randomized, double-blind phase IIb PSOR-011 study (&lt;ulink linkType="Protocol" linkID="161729"&gt;NCT01988103&lt;/ulink&gt;), multicenter, randomized, double-blind, placebo-controlled phase III ESTEEM 1 (&lt;ulink linkType="Protocol" linkID="69830"&gt;NCT01194219&lt;/ulink&gt;) and ESTEEM 2 study (&lt;ulink linkType="Protocol" linkID="71865"&gt;NCT01232283&lt;/ulink&gt;), and multicenter, randomized, double-blind phase IV UNVEIL study (&lt;ulink linkType="Protocol" linkID="227808"&gt;NCT02425826&lt;/ulink&gt;) which evaluated the quality of life finding in white and non-white patients, as well as Hispanic and non-Hispanic patients with psoriasis who were treated with apremilast (APR). In both white and non-white patients, at week 16 the proportion of patients who achieved a DLQI score of 0 or 1 was greater with APR compared to placebo (PBO), but at week 52 the proportion of patients who achieved a DLQI score of 0 or 1 increased in patients who switched to APR (PBO/APR) and was generally maintained in patients who remained on APR (APR/APR) in both white and non-white patients. In both Hispanic and non-Hispanic patients at week 16, a greater proportion of patients treated with APR achieved a DLQI score of 0 or 1 compared to PBO. The proportion of patients who achieved the DLQI minimal clinically important difference (MCID) was greater in white and non-white patients receiving APR compared to PBO, whereas at wee 52 the DLQI MCID was maintained with APR/APR and increased in patients who switched from PBO to APR in both white and non-white patients. In Hispanic and non-Hispanic patients, the proportion of patients who achieved the DLQI MCID was greater in patients receiving APR compared to PBO [&lt;ulink linkType="Reference" linkID="2126258"&gt;2126258&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, further results of post-hoc pooled ESTEEM studies (ESTEEM 1 [NCT01194219] and ESTEEM 2 study [&lt;ulink linkType="Protocol" linkID="71865"&gt;NCT01232283&lt;/ulink&gt;]) were presented to evaluate the quality of life finding in white and non-white patients, as well as Hispanic and non-Hispanic patients with psoriasis who were treated with apremilast. The proportion of white patients with placebo versus apremilast who achieved DLQI 0 or 1 were 10.8 versus 31.3%; proportion of non-white patients was 2.9 versus 24.6%, respectively at week 16. Similarly at week 52 the proportion of white patients who achieved DLQI 0 or 1 with placebo/apremilast versus apremilast/apremilast was 36.0 versus 32.7%; and the proportion of non-white patients was 5.6 versus 20.5%, respectively. At week 16, proportion of non-Hispanic patients who achieved DLQI 0 or 1 with placebo versus apremilast was 9.6 versus 30.7%; and the proportion of Hispanic patients was 15.4 versus 30.9%, respectively. The proportion of white patients with PBO versus APR who achieved DLQI minimal clinically important difference (MCID) at week 16 were 40.1 versus 68.8% and the proportion of of non-white patients was 47.1 versus 68.1%, respectively. The proportion of white patients who achieved DLQI MCID at week 52 with PBO/APR versus APR/APR was 66.2 versus 72.9%; and the proportion of non-white patients was 83.3 versus 75%, respectively. The proportion of Hispanic patients who achieved DLQI MCID at week 16 with PBO versus APR was 46.2 versus 72.7%; and the proportion of non-Hispanic patients was 40.5 versus 68.3%, respectively [&lt;ulink linkType="Reference" linkID="2126258"&gt;2126258&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In March 2019, pooled results were presented from five phase III studies (ESTEEM-1; NCT01194219 and ESTEEM-2; &lt;ulink linkType="Protocol" linkID="71865"&gt;NCT01232283&lt;/ulink&gt; and PALACE-1; &lt;ulink linkType="Protocol" linkID="68729"&gt;NCT01172938&lt;/ulink&gt;, PALACE-2; &lt;ulink linkType="Protocol" linkID="70875"&gt;NCT01212757&lt;/ulink&gt;, and PALACE-3; &lt;ulink linkType="Protocol" linkID="70872"&gt;NCT01212770&lt;/ulink&gt;) and one phase IIIb study (LIBERATE; &lt;ulink linkType="Protocol" linkID="92048"&gt;NCT01690299&lt;/ulink&gt;) which evaluated the long-term hemoglobin A1c changes with apremilast in patients (n = 2409) with moderate to severe psoriasis.  At week-16, the mean change from baseline in HbA1c in patients taking anti-diabetic medications was 0.13 and 0 (A1C &amp;lt; 5.7%); - 0.04 and 0.20 (A1c 5.7 to 6.4%); - 0.06 and  0.35 (A1c &gt;/ = 6.5%), - 0.03 and  0.17 (overall) in placebo and apremilast arms, respectively, whereas that observed in patients not taking anti-diabetic medications were 0.02 and 0.04 (A1C &amp;lt; 5.7%); - 0.07 and  0.15 (A1c 5.7 to 6.4%); - 0.13 and  0.26 (A1c &gt;/ = 6.5%), - 0.02 and  0.03 (overall) in placebo and apremilast arms, respectively. At week-52, the mean change from baseline in HbA1c was  0.07, 0.16, - 0.37 and  0.19% (in patients taking anti-diabetic medicines); - 0.06, - 0.24,  0.32 and  0.13% (in patients not taking anti-diabetic medicines) in apremilast treated group, respectively [&lt;ulink linkType="Reference" linkID="2126274"&gt;2126274&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  would be  randomized to either  placebo or &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;. Patients  initially randomized to placebo, would be  assigned to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; 30 mg bid beginning at week 16 for the duration of the patient's  participation in the study (maintenance phase). Patients  initially randomized to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; 30 mg, po, bid, and who demonstrate a Psoriasis Area Severity Index (PASI) score 75 response at week 32 would be randomized (1 : 1) to either continue to receive &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; 30 mg  bid or to receive oral placebo (until effect would be lost). At relapse/loss of response to therapy prior to week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at week 52, patients would be re-treated with apremilast 30 mg bid for the duration of their participation in the study. Non-responders or partial responders (PASI response &amp;lt; 75) in both arms might receive additional topical or phototherapy beginning at week 32 [&lt;ulink linkType="Reference" linkID="1355103"&gt;1355103&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 844) were randomized in 2 : 1 ratio to receive either &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; 30 mg bid (n = 562) or placebo (n = 282) for the first 16 weeks, followed by a maintenance phase from weeks 16 to 32 in which placebo patients were switched to &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; 30 mg, bid through week 32, and a randomized withdrawal phase for responders from week 32 to 52 based on their initial &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; randomization and PASI response in which  all &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt;-treated patients who achieved PASI-75 were randomized (1 : 1, blinded) to continue &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; or receive placebo, and upon PASI-75 loss, patients re-randomized to placebo resumed &lt;ulink linkType="Drug" linkID="44897"&gt;apremilast&lt;/ulink&gt; treatment [&lt;ulink linkType="Reference" linkID="1388007"&gt;1388007&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1484923"&gt;1484923&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1485346"&gt;1485346&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1537036"&gt;1537036&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1537027"&gt;1537027&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1596597"&gt;1596597&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1601112"&gt;1601112&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1601111"&gt;1601111&lt;/ulink&gt;],   [&lt;ulink linkType="Reference" linkID="1601754"&gt;1601754&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1643824"&gt;1643824&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1662857"&gt;1662857&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1644273"&gt;1644273&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1689865"&gt;1689865&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1702023"&gt;1702023&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1716457"&gt;1716457&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1717540"&gt;1717540&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1705505"&gt;1705505&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1705506"&gt;1705506&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1740856"&gt;1740856&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1728923"&gt;1728923&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1906602"&gt;1906602&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1935731"&gt;1935731&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2006499"&gt;2006499&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2014053"&gt;2014053&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2071771"&gt;2071771&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2121911"&gt;2121911&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="2121994"&gt;2121994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 844) were randomized (2 : 1) to receive apremilast (30 mg, bid) or placebo through week 16 ; all patients were then treated with apremilast through week 32  and all apremilast-treated patients who achieved psoriasis area and severity index (PASI)75 response at week 32 were randomized (1:1) to either continue to receive apremilast or placebo (until effect was lost) and those who achieved &amp;lt; PASI75 response in both arms received additional topical or ultraviolet B through week 52 [&lt;ulink linkType="Reference" linkID="1644278"&gt;1644278&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1644279"&gt;1644279&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1742604"&gt;1742604&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2121948"&gt;2121948&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>apremilast</Name><Drug id="44897">apremilast</Drug><Dose unit="milligram dose">30.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>17.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication><CountPatientsAffectedPercentage>13.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>16.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>7.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="516">Upper respiratory tract infection</Indication><CountPatientsAffectedPercentage>8.4</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>apremilast</Name><Drug id="44897">apremilast</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="3062">Death</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="169667">apremilast</Intervention><Treatments><Treatment><Dose>30 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trials Disclosure</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>ClinicalTrialsDisclosure</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Name>Royal Free Hospital</Name><Address1>London</Address1><Address3>NW3 2QG</Address3><Contacts/></Site><Site><Name>Salford Royal NHS Trust</Name><Address1>Salford</Address1><Address2>Manchester</Address2><Address3>M6 8HD</Address3><CountrySubDivision>Manchester</CountrySubDivision><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Disclosure</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3434">Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3451">Subjects with Moderate Psoriasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3452">Subjects with Severe Psoriasis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pruritus</Disease><PatientSegments><PatientSegment><PatientSegment id="9246">Subjects with Pruritus Associated with Dermatological Disorders</PatientSegment><SubSegments><SubSegment id="9249">Subjects with psoriasis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01194219</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2010-019991-55</Identifier></Identifiers></Registry><Registry><Name id="1023">UK Clinical Research Network (UKCRN)</Name><Identifiers><Identifier>UKCRN 9835</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6486"><Endpoint>Disease Severity Assessment by PASI Scores/Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6489">PASI-75 response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Psoriasis" id="6486"><Endpoint>Disease Severity Assessment by PASI Scores/Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6488">PASI-50 response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6540"><Endpoint>Changes in Characteristics of Skin/Lesion</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6594">Body surface area (BSA%) involvement</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6559"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6561">Assessment by SF-36/SF-12</SubEndpoint><SubEndpoint disease="Psoriasis" id="6563">Assessment by Dermatology Life Quality Index (DLQI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6599"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6626"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6638"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6652">Therapy/Intervention Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6640"><Endpoint>Assessment of Psoriasis Recurrence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21124"><Endpoint>Pruritus Assessed by Visual Analog Scale</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21135"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21136"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21138"><Endpoint>Assessment of Organ Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21140"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21142"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pruritus" id="21144"><Endpoint>Assessment of compliance/adherence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="44873"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6547">Assessment of pruritus</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="46095"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6504">Assessment by Investigator/Physician Global Assessment (PGA) Scale</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="3285"><Criterion>Subjects with Plaque Psoriasis/Psoriasis Vulgaris</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3296"><Criterion>Subjects with Moderate Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3297"><Criterion>Subjects with Severe Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3396"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Pruritus" id="18917"><Criterion>Subjects with Pruritus Associated with Dermatological Disorders</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="18920">Subjects with psoriasis associated pruritius</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pruritus" id="18948"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Psoriasis" id="4524"><Criterion>Subjects with Psoriasis Flare/Exacerbation</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4525"><Criterion>Subjects co-morbid with dermatological disease/disorder</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4532"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4543">Subjects with HIV infections/immunodeficiency syndrome</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4556"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4557">Subjects with history of / current bacterial infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4564"><Criterion>Subjects with History of/Scheduled for Psoriasis Treatment</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4565">Subjects with history of/scheduled for systemic therapy</SubCriterion><SubCriterion disease="Psoriasis" id="4569">Subjects with history of/scheduled for humanized monoclonal antibodies</SubCriterion><SubCriterion disease="Psoriasis" id="4572">Subjects with history of/scheduled for phototherapy/photochemotherapy</SubCriterion><SubCriterion disease="Psoriasis" id="4573">Subjects with history of/scheduled for topical therapy</SubCriterion><SubCriterion disease="Psoriasis" id="5041">Subjects with history of/scheduled for biologics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4586"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4592">Abnormal radiographic findings</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4590"><Criterion>Subjects with abnormal ECG</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4619"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4620">Subjects with contraindications to study drug and its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pruritus" id="16897"><Criterion>Subjects co-morbid with dermatological disease/disorder</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="16899">Subjects co-morbid with psoriasis</SubCriterion><SubCriterion disease="Pruritus" id="16900">Subjects with skin malignancies</SubCriterion><SubCriterion disease="Pruritus" id="16902">Subjects with photosensitivity disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pruritus" id="16903"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Pruritus" id="16904"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pruritus" id="16906"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pruritus" id="16912"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Pruritus" id="16913"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="16914">Subjects with history of/scheduled to receive an investigational drug</SubCriterion><SubCriterion disease="Pruritus" id="16917">Subjects with history of/current use of a prohibited immunomodulator</SubCriterion><SubCriterion disease="Pruritus" id="16919">Subjects with history of/scheduled for protocol prohibited phototherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pruritus" id="16922"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="16923">Subjects hypersensitive to drugs or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pruritus" id="16926"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Pruritus" id="16930">Subjects with abnormal cardiac function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="25895"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4554">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="26080"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4542">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="26258"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="5040">Subjects with history/ scheduled to receive study drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="26889"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4571">Subjects with history of/scheduled for alternative therapies</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-02-23T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>16.74 Months</EnrollmentPeriod><EnrollmentRate>50.42 Patients/Month</EnrollmentRate><DateFirstReceived>2010-09-02T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-09-07T10:13:57Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-04-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-27T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="updated"><Date>2019-03-29T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-29T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-29T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-29T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="72156"><TitleDisplay>Treatment of Childhood Acute Lymphoblastic Leukemia</TitleDisplay><TitleOfficial>Treatment of Childhood Acute Lymphoblastic Leukemia</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">95-001</Identifier><Identifier type="NCT">NCT00165087</Identifier><Identifier type="Other">NCT00004034</Identifier><Identifier type="Other">CDR0000066202</Identifier><Identifier type="Other">NCI-G99-1651</Identifier><Identifier type="Other">DFCI-FDR001197</Identifier><Identifier type="Other">DFCI-95001</Identifier></Identifiers><Indications><Indication id="1728">Acute lymphoblastic leukemia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>dexrazoxane</Name><Drug id="7126">dexrazoxane</Drug></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7126">dexrazoxane</Drug><IndicationsPioneer><Indication id="1728">Acute lymphoblastic leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="15615">Dana-Farber Cancer Institute Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7126" type="Drug"><TargetEntity id="186244" type="siDrug">Dexrazoxane hydrochloride</TargetEntity></SourceEntity><SourceEntity id="15615" type="Company"><TargetEntity id="5000369732" type="organizationId">Dana-Farber Cancer Institute Inc</TargetEntity></SourceEntity><SourceEntity id="1728" type="ciIndication"><TargetEntity id="C91.0" type="ICD10"/><TargetEntity id="204" type="ICD9"/><TargetEntity id="513" type="ORPHANET"/><TargetEntity id="685" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><NumberOfSites>10</NumberOfSites><CompaniesSponsor><Company id="15615">Dana-Farber Cancer Institute Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1276">Chemoprotectant</Class><Class id="170">Free radical scavenger</Class><Class id="2659">Cardioprotectant</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>491</PatientCountEnrollment><PatientCountEvaluable>134</PatientCountEvaluable><DateStart>1996-01-31T00:00:00Z</DateStart><DateEnd type="actual">2006-09-01T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:14:53Z</DateChangeLast><DateAdded>2010-11-12T07:43:37Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Dana-Farber Cancer Institute</Affiliation><Name>Stephen E. Sallan, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Acute lymphoblastic leukemia, excluding known mature B-cell ALL&lt;/li&gt;&lt;li&gt;Less than 18 years of age&lt;/li&gt;&lt;li&gt;Patients who are leukopheresed or exchanged are eligible for study only after             completion of the pheresis or exchange transfusion&lt;/li&gt;&lt;li&gt;Absence of a t(8,14) (q24; q32), t (8,22), t(2,8)&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;lt; 1.4mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known HIV positive&lt;/li&gt;&lt;li&gt;Prior steroid therapy within 30 days of diagnosis&lt;/li&gt;&lt;li&gt;Septic shock&lt;/li&gt;&lt;li&gt;Ongoing intracranial hemorrhage&lt;/li&gt;&lt;li&gt;Clinical evidence of CNS or lung leukostasis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To evaluate the efficacy and safety of doxorubicin with or without dexrazoxane</Description></Measure><Measure><Description>To determine the efficacy of hyperfractionated radiation plus standard intrathecal chemotherapy compared with intensive intrathecal chemotherapy alone in standard risk patients.</Description></Measure><Measure><Description>To compare the relative efficacy and toxicity of E.coli and Erwinia asparaginase</Description></Measure><Measure><Description>To compare the relative efficacy and toxicity of cranial radiation delivered in once-daily versus twice-daily fractions in high risk patinets.</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To compare randomized treatment groups using health-related quality of life analyses.</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to reduce the side-effects and discomfort of &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt; in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia, to attain long-term control of the disease and to hopefully eradicate it.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In Feb 2007, results were published. The estimated five-year event-free survival (EFS) for all patients was 82 +/- 2%, with a median of 5.7 years of follow-up. A prominent effect on the five-year event free survival of high-risk patients (p = 0.99) (EFS) was not shown by dexrazoxane and no prominent difference in outcome of standard-risk patients based on type of central nervous system (CNS) treatment (p = 0.26) was not observed. Erwinia asparaginase was associated with a lower incidence of toxicity (10% versus 24%) compared with E coli asparaginase, but also an inferior five-year EFS (p = 0.01) [&lt;ulink linkType="Reference" linkID="776574"&gt;776574&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, data showed that of 100 children  assigned to doxorubicin, 66 were  analyzed, and of 105 children treated with doxorubicin plus &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt;, 68 were  analyzed. The mean left ventricular fractional shortening and end-systolic dimension Z scores were significantly worse than normal for children who received doxorubicin alone after five  years of completion of doxorubicin chemotherapy, (left ventricular fractional shortening: -0.82; end-systolic dimension: 0.57) but not for those who also received &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt; (-0.41 and 0.15, respectively). At  five years, the only statistically significant characteristics were the protective effect of &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt;, relative to doxorubicin alone, on left ventricular wall thickness (difference between groups: 0.47) and thickness-to-dimension ratio (0.66). Subgroup analysis showed &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt; protection (p = 0.04) for left ventricular fractional shortening at five  years in girls (1.17), but not in boys (-0.10). Similarly, subgroup analysis showed &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt; protection (p = 0.046) for the left ventricular thickness-to-dimension ratio at five years in girls (1.15), but not in boys (0.19). With a median follow-up for recurrence and death of 8.7 years, event-free survival was 77 and 76% for  children in the doxorubicin-alone and doxorubicin plus decrazoxane groups, respectively (p = 0.99)  [&lt;ulink linkType="Reference" linkID="1146216"&gt;1146216&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;For this study, patients would be            classified into standard risk; High Risk; Infant/High Risk. The treatment for patients in the Standard Risk and High Risk  groups would consist  of           three phases of therapy: induction treatment; prevention of brain and spinal cord           leukemia (CNS treatment); and intensification/continuation chemotherapy.The treatment for patients in the Infant/High Risk group would consist of four phases of           therapy: induction treatment; infant intensification therapy;           intensification/continuation chemotherapy; and CNS treatment.The induction treatment would consist of a combination of chemotherapy drugs whose purpose is           to kill all detectable leukemia cells. This process would usually requires a least 1 month           and includes six anti-leukemia drugs.  These drugs were: vincristine, doxorubicin,           methotrexate, cytosine arabinoside, asparaginase and steroids (methylprednisolone or           prednisone).&lt;/para&gt;&lt;para&gt;After the induction phase Infant/High Risk patients would receive a highly intensive           month of treatment (infant intensification) .  Drugs used during this month would include           high-dose methotrexate, asparaginase, 6-mercaptopurine and high dose cytosine           arabinoside (ARA-C). CNS treatment would begin during induction therapy but is intensified during the second and           third month after diagnosis.  Treatment for all patients would include a series of spinal           taps with the instillation of anti-leukemia drugs, including cytosine arabinoside and           methotrexate and with or without hydrocortisone (depending upon randomization).&lt;/para&gt;&lt;para&gt;All high risk patients (those in both High Risk and Infant/High Risk) as well as           some standard risk patients would receive radiation treatment to the brain.  Radiation           therapy would either be given in either conventional treatments (once daily for 10           days), or hyperfractionated treatments (twice daily at half doses for 10 days).  Total           dose of radiation would be 1800 cGy.&lt;/para&gt;&lt;para&gt;Intensification and continuation therapy, would begin 4 to 5 weeks after diagnosis for Standard           Risk and High Risk groups and 4 to 5 weeks after infant intensification in Infant/High           Risk group.  This phase of treatment would continue until the completion of two years of           treatment.  Patients in the Standard Risk group would receive five anti-leukemia drugs           (vincristine, prednisone, methotrexate, asparaginase, and 6-mercaptopurine).  Patients           in High Risk and Infant/High Risk would receive six anti-leukemia drugs (vincristine,           prednisone, doxorubicin, methotrexate, asparaginase and 6-mercaptopurine).&lt;/para&gt;&lt;para&gt;All patients would be able to participate in a randomization comparing two types of           asparaginase, E.coli and Erwinia.  Patients would be randomized to receive either once           weekly E.coli or once-weekly Erwinia during the Intensification phase, each given for a           total of 20 weeks.&lt;/para&gt;&lt;para&gt;Patients in the Standard Risk group would    participate in an additional           randomization.  Standard risk patients would be randomized to receive one of two           different regimens designed to prevent central nervous system leukemia, either           radiation therapy (given twice daily) with chemotherapy in the spinal fluid every 18           weeks, or  intensive chemotherapy in the spinal fluid alone without radiation.&lt;/para&gt;&lt;para&gt;Patients in the High Risk and Infant/High Risk&amp;amp;quot; groups were able to participate in two           randomizations in addition to the asparaginase randomization.  The first would be to           assess whether the drug &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt; prevents heart damage caused by doxorubicin without           affecting risk of relapse. Patients would be randomized to receive either doxorubicin           alone or doxorubicin with &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt; during the induction, CNS and intensification           phases. The second randomization would compare the relative efficacy and toxicity of           different cranial radiation schedules.  Patients would be randomized to receive radiation           in either once daily or twice daily fractions.&lt;/para&gt;&lt;para&gt;Blood and bone marrow samples would be collected to learn more about the biology of           leukemia.  These samples would also be used to test minimal residual disease levels to           learn if these levels help predict risk of relapse.&lt;/para&gt;&lt;para&gt;Quality of life questionnaires would also be performed by the parents of patients, by           children over eight, and by the child's clinician.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were assigned by block randomisation to receive ten doses of 30 mg/m2 doxorubicin alone or the same dose of doxorubicin preceded by 300 mg/m2 &lt;ulink linkType="Drug" linkID="7126"&gt;dexrazoxane&lt;/ulink&gt;. Treatment assignment was obtained through a telephone call to a centralised registrar to conceal allocation. Investigators were masked to treatment assignment but treating physicians and patients were not; however, investigators, physicians, and patients were masked to study serum cardiac troponin-T concentrations and echocardiographic measurements [&lt;ulink linkType="Reference" linkID="1146216"&gt;1146216&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients were included in randomized comparisons of: doxorubicin given with or without dexrazoxane (high-risk patients), intensive intrathecal chemotherapy and cranial radiation (standard-risk patients), and Erwinia and Escherichia coli asparaginase (all patients) [&lt;ulink linkType="Reference" linkID="776574"&gt;776574&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Regimens&gt;</Regimens><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;Terminated by IRB for continuing review&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="175561">dexrazoxane</Intervention><Treatments><Treatment><Dose>300 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="175562">doxorubicin</Intervention><Treatments><Treatment><Dose>30 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>McMaster University</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Sainte Justine Hosptial</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Laval University</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Puerto Rico"><Sites><Site><Name>San Jorge Children's Hospital</Name><Address1>Santurce</Address1><Address3>00912</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Ochsner Clinic</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70121</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>Maine Medical Center</Name><Address1>Lewiston</Address1><Address2>Maine</Address2><Address3>04240</Address3><CountrySubDivision code="ME">Maine</CountrySubDivision><Contacts/></Site><Site><Name>Dana-Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Children's Hospital Boston</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>University of Rochester</Name><Address1>Rochester</Address1><Address2>New York</Address2><Address3>14627</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Mt. Sinai Medical Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10029</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3975">Subjects with Acute Leukemia Unspecified Type</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3979">Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3986">Pediatric Leukemia Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier>NCT00004034</Identifier><Identifier type="NCT">NCT00165087</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8136"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8140">Assessment of Clinical Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="7952"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7963">Assessment by Health Related Quality of Life (HRQOL)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Leukemia" id="7897"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7898">Assessment of event free survival (EFS)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="7921"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8109"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8110">Assessment of all cause mortality</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="4973"><Criterion>Subjects with Acute Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4985"><Criterion>Subjects with Acute Lymphocytic Leukemia (ALL)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Leukemia" id="6527"><Criterion>Leukemia Subjects with Advanced Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6530">Subjects with central nervous system involvement of leukemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6636">Subjects with history of/scheduled to receive hormone therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateFirstReceived>2005-09-09T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-11-12T07:43:37Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="78584"><TitleDisplay>A phase IV, randomized, double-blind, placebo-controlled, parallel group, four perimenstrual period (PMP) to evaluate naratriptan as prophylactic treatment for menstrually-associated migraine</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">S2WA4006</Identifier></Identifiers><Indications><Indication id="210">Migraine</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>naratriptan</Name><Drug id="3235">naratriptan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3235">naratriptan</Drug><IndicationsPioneer/><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3235" type="Drug"><TargetEntity id="148862" type="siDrug">Naratriptan hydrochloride</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"/><TargetEntity id="10027599" type="MEDDRA"/><TargetEntity id="D008881" type="MeSH"/><TargetEntity id="-672899670" type="omicsDisease"/><TargetEntity id="27" type="siCondition"/></SourceEntity><SourceEntity id="10" type="Action"><TargetEntity id="222" type="Mechanism">5-HT1D Agonists</TargetEntity></SourceEntity><SourceEntity id="8" type="Action"><TargetEntity id="221" type="Mechanism">5-HT1B Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10">5-HT 1d receptor agonist</Action><Action id="8">5-HT 1b receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>220</PatientCountEnrollment><PatientCountEvaluable>210</PatientCountEvaluable><DateStart>1998-04-22T00:00:00Z</DateStart><DateChangeLast>2011-06-27T11:20:53Z</DateChangeLast><DateAdded>2011-06-27T11:20:53Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Nonpregnant female subjects using adequate contraception   at least 18 years of age&lt;/li&gt;&lt;li&gt;Had at least a 6-month history of migraine with or without aura as defined by the 1988 International Headache Society criteria, and had at least one migraine during her last PMP (days 2 to  4 relative to the onset of menses) prior to Visit 1 (screening) at a predictable time relative to the onset of flow&lt;/li&gt;&lt;li&gt;Subjects were also to have regularly occurring menstrual cycles and to be able to predict within 1 to 2 days the onset of menstrual flow&lt;/li&gt;&lt;li&gt;To be able to distinguish migraine attacks as discreet attacks from other headaches (eg, tension-type headache)&lt;/li&gt;&lt;li&gt;To be able to read and write English, comprehend, and record information on subject questionnaires and diary cards. In order to be randomized the subject had to document a MAM during the qualifying PMP&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Had confirmed or suspected ischemic heart disease (angina pectoris, history of myocardial infarction, documented silent ischemia), Prinzmetals angina, or signs/symptoms consistent with any of the above&lt;/li&gt;&lt;li&gt;Had cardiac arrhythmias requiring medication or a clinically significant electrocardiogram abnormality&lt;/li&gt;&lt;li&gt;Had a history of congenital heart disease&lt;/li&gt;&lt;li&gt;Had a history of cerebrovascular pathology including stroke&lt;/li&gt;&lt;li&gt;In the investigators opinion, likely to have unrecognized cardiovascular or cerebrovascular disease&lt;/li&gt;&lt;li&gt;Had evidence or history of ischemic abdominal syndromes, peripheral vascular disease or Raynaud syndrome&lt;/li&gt;&lt;li&gt;Had uncontrolled hypertension at screening (sitting systolic pressure &gt;/= 160 mmHg, diastolic pressure &gt;/= 95 mmHg)&lt;/li&gt;&lt;li&gt;Had a history of epilepsy&lt;/li&gt;&lt;li&gt;Had basilar or hemiplegic migraine&lt;/li&gt;&lt;li&gt;Had tension-type headaches &gt; 15 days/month in either of the 2 months prior to screening&lt;/li&gt;&lt;li&gt;Had migraine headaches &gt; 6 attacks /month in either of the 2 months prior to screening&lt;/li&gt;&lt;li&gt;Had impaired hepatic or renal function&lt;/li&gt;&lt;li&gt;Had evidence of alcohol or substance abuse within the last year which, in the investigators judgment, was likely to interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results&lt;/li&gt;&lt;li&gt;Had evidence or history of ergotamine abuse in the past year&lt;/li&gt;&lt;li&gt;Had hypersensitivity, intolerance, or contraindication to the use of&lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt;, any of its components, or any other 5-hydroxytryptamine (5-HT1) receptor agonist&lt;/li&gt;&lt;li&gt;Had participated in an investigational drug study within the previous 4 weeks, or planned to participate in another study at any time during this study&lt;/li&gt;&lt;li&gt;Had any concurrent medical or psychiatric condition which, in the investigators opinion, may have affected the interpretation of efficacy and safety data or which otherwise contraindicated participation in a clinical study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of menstrually associated migraines</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Total migraine days</Description></Measure><Measure><Description>Peak headache severity</Description></Measure><Measure><Description>Lost work/activity time</Description></Measure><Measure><Description>Migraine-related quality of life</Description></Measure><Measure><Description>Incidence of adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Safety data   demonstrated that the incidence and severity of adverse events (AEs) was similar across treatment groups. For any measure, naratriptan 2.5 mg was not statistically superior to placebo. No serious AEs were reported during the study   [&lt;ulink linkType="Reference" linkID="1203259"&gt;1203259&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was deigned to evaluate &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; as prophylactic treatment for menstrually-associated migraine [&lt;ulink linkType="Reference" linkID="1203257"&gt;1203257&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1203259"&gt;1203259&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Data published in March 2001 showed that   the intent-to-treat population comprised 206 women (&lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; 1 mg, n = 70; &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; 2.5 mg, n = 70, and placebo, n = 66); 171 women treated four perimenstrual periods. Significantly more perimenstrual periods per subject treated with &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt;, 1 mg, were headache-free compared with placebo (50 versus 25%, p = 0.003). There was a significant reduction in the number of menstrually associated migraines with &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt;, 1 mg  (2.0 versus 4.0, p &amp;lt; 0.05) and menstrually associated migraine days (4.2 versus 7.0, P &amp;lt; 0.01) compared with placebo. More patients treated with &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt;, 1 mg, were headache-free across all treated perimenstrual periods compared with placebo (23 versus 8%). No difference in headache severity was observed in breakthrough headaches  [&lt;ulink linkType="Reference" linkID="1203259"&gt;1203259&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results published in August 2005 showed that the median number of MAMs over four  PMPs 4, 2 and 3 for placebo, &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; 1 and 2.5 mg groups, respectively. Treatment difference between placebo and &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt;  1.0 mg, p-value = 0.011 and treatment difference placebo and &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; 2.5 mg, p-value = 0.098. The median number of MAM days were 7.0, 4.0 and 4.0 for placebo, &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; 1 and 2.5 mg groups, respectively. There was no significant difference in the migraine-related quality of life in &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; 1 and 2.5 mg groups [&lt;ulink linkType="Reference" linkID="1203257"&gt;1203257&lt;/ulink&gt;]&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects received two dose strengths of &lt;ulink linkType="Drug" linkID="3235"&gt;naratriptan&lt;/ulink&gt; (1 and 2.5 mg po bid) or  placebo tablets (1:1:1)   twice daily during four perimenstrual periods (PMPs) or 6 months, whichever came first. Subjects began   treatment 2 days prior to the expected onset of their menstrually-associated migraine (MAM) and continued for a total of 5 days during each of four PMPs [&lt;ulink linkType="Reference" linkID="1203257"&gt;1203257&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1203259"&gt;1203259&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>naratriptan</Name><Drug id="3235">naratriptan</Drug><Dose unit="milligram dose">1.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1061">Sinusitis</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1485">Viral respiratory tract infection</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2469">Paresthesia</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="50">Bronchitis</Indication><CountPatientsAffectedPercentage>4.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="82">Cough</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>naratriptan</Name><Drug id="3235">naratriptan</Drug><Dose unit="milligram dose">2.5</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1485">Viral respiratory tract infection</Indication><CountPatientsAffectedPercentage>6.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2469">Paresthesia</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="50">Bronchitis</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="82">Cough</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="192294">naratriptan</Intervention><Treatments><Treatment><Dose>1 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>2.5 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-06-27T11:20:53Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="78815"><TitleDisplay>SOM-230 and Gemcitabine in Advanced Pancreatic Cancer</TitleDisplay><TitleOfficial>Phase I Study of Combination of SOM-230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MCC-16456</Identifier><Identifier type="NCT">NCT01385956</Identifier><Identifier type="Secondary Organisational">CSOM230CUS16T</Identifier></Identifiers><Indications><Indication id="3669">Metastatic pancreas cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="378" role="Therapeutic effect marker" type="Genomic;Proteomic">Insulin-like growth factor binding protein 3</BiomarkerName><BiomarkerName id="506" role="Therapeutic effect marker" type="Genomic;Proteomic">Insulin-like growth factor binding protein 1</BiomarkerName><BiomarkerName id="2387" role="Toxic effect marker" type="Biochemical">Bilirubin</BiomarkerName><BiomarkerName id="23331" role="Therapeutic effect marker" type="Genomic;Proteomic">Insulin growth factor-like family member 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>gemcitabine + pasireotide</Name></Intervention><Intervention type="InterventionPrimary"><Name>pasireotide diaspartate</Name><Drug id="40061">pasireotide diaspartate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="40061">pasireotide diaspartate</Drug><IndicationsPioneer><Indication id="3669">Metastatic pancreas cancer</Indication></IndicationsPioneer><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="40061" type="Drug"><TargetEntity id="305198" type="siDrug">Pasireotide diaspartate</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="29603" type="Company"><TargetEntity id="4298207159" type="organizationId">H Lee Moffitt Cancer Center and Research Institute Inc</TargetEntity></SourceEntity><SourceEntity id="3669" type="ciIndication"><TargetEntity id="631" type="siCondition"/></SourceEntity><SourceEntity id="2559" type="Action"><TargetEntity id="307" type="Mechanism">Somatostatin Receptor Type 1 (SSTR1) Agonists</TargetEntity></SourceEntity><SourceEntity id="2562" type="Action"><TargetEntity id="308" type="Mechanism">Somatostatin Receptor Type 2 (SSTR2) Agonists</TargetEntity></SourceEntity><SourceEntity id="2565" type="Action"><TargetEntity id="309" type="Mechanism">Somatostatin Receptor Type 3 (SSTR3) Agonists</TargetEntity></SourceEntity><SourceEntity id="2571" type="Action"><TargetEntity id="311" type="Mechanism">Somatostatin Receptor Type 5 (SSTR5) Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23137">Novartis AG</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="2559">Somatostatin 1 receptor agonist</Action><Action id="2562">Somatostatin 2 receptor agonist</Action><Action id="2565">Somatostatin 3 receptor agonist</Action><Action id="2571">Somatostatin 5 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2946">Analgesic</Class><Class id="3272">Growth hormone release inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><PatientCountEvaluable>16</PatientCountEvaluable><DateStart>2011-06-30T00:00:00Z</DateStart><DateEnd type="actual">2014-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-12T09:01:12Z</DateChangeLast><DateAdded>2011-07-05T07:44:57Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute; Tampa; Florida; 33612; United States</Affiliation><Email>helen.jump@moffitt.org</Email><Name>Helen Jump</Name><Phone>813-745-4834</Phone></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute; Tampa; Florida; 33612; United States</Affiliation><Name>Mokenge Malafa</Name></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute; Tampa; Florida; 33612; United States</Affiliation><Name>Gregory Springett</Name></Contact><Contact type="Scientific contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute</Affiliation><Email>richard.kim@moffitt.org</Email><Name>Richard Kim</Name><Phone>813-745-1277</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Cytologically or histologically confirmed evidence of epithelial cancer             (adenocarcinoma) of the exocrine pancreas&lt;/li&gt;&lt;li&gt;Metastatic or locally advanced disease&lt;ul&gt;&lt;li&gt;Patients with measurable and with non             measurable disease, as per RECIST criteria are eligible&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Minimum of 4 weeks since any major surgery, completion of radiation&lt;/li&gt;&lt;li&gt;Prior treatment with&lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; alone or 5-fluorouracil (5-FU) with radiation as an             adjuvant therapy will be allowed if &amp;gt; 6 months&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status&amp;lt;/=  2&lt;/li&gt;&lt;li&gt;Life expectancy &gt;/= 12 weeks&lt;/li&gt;&lt;li&gt;Adequate bone marrow function as shown by: absolute neutrophil count (ANC) &gt;/= 1.0 x             10(9)/l, platelets &gt;/= 100 x 10(9)/l, hemoglobin (Hgb)&amp;gt; 9 g/dl&lt;/li&gt;&lt;li&gt;Adequate liver function as shown by: serum bilirubin&amp;lt;/= 2 x upper limit of normal             (ULN), and serum transaminases activity &amp;lt;/= 3 x ULN, with the exception of serum             transaminases (&amp;lt; 5 x ULN) if the patient has liver metastases&lt;/li&gt;&lt;li&gt;Adequate renal function as shown by serum creatinine&amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;li&gt;Fasting serum cholesterol&amp;lt;/= 300 mg/dl or &amp;lt;/= 7.75 mmol/l and fasting triglycerides &amp;lt;/= 2.5             x ULN&lt;ul&gt;&lt;li&gt;Note: in case one or both of these thresholds are exceeded, the patient can             only be included after initiation of appropriate lipid lowering medication&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy             test within 14 days of the administration of the first study treatment. Women must             not be lactating&lt;ul&gt;&lt;li&gt;Both men and WOCBP must be advised of the importance of using             effective birth control measures during the course of the study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Signed informed consent to participate in the study must be obtained from patients             after they have been fully informed of the nature and potential risks by the             investigator (or his/her designee) with the aid of written information&lt;/li&gt;&lt;li&gt;Screening electrocardiogram (ECG) with a time from electrocardiogram Q-wave to the end of the T-wave corresponding to             electrical systole (QT) corrected for heart rate (QTc)&amp;lt; 450 ms&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Prior treatment with any cytotoxic chemotherapy except as an adjuvant therapy&lt;/li&gt;&lt;li&gt;Have undergone major surgery within 4 weeks prior to study enrollment&lt;/li&gt;&lt;li&gt;Chronic treatment with steroids or any other immunosuppressant drugs&lt;/li&gt;&lt;li&gt;Should not receive immunization with attenuated live vaccines during study period or             within 1 week of study entry&lt;/li&gt;&lt;li&gt;Untreated brain or leptomeningeal metastases, including patients who continue to             require glucocorticoids for brain or leptomeningeal metastases&lt;/li&gt;&lt;li&gt;Patients with uncontrolled diabetes mellitus or a fasting plasma glucose&amp;gt; 1.5 x ULN or             glycosylated hemoglobin (HbA1c) &amp;gt; 8%&lt;ul&gt;&lt;li&gt;Note: At the principle investigator's             discretion, non-eligible patients can be re-screened after adequate medical therapy             has been instituted&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with symptomatic cholelithiasis&lt;/li&gt;&lt;li&gt;QT related exclusion criteria:&lt;ul&gt;&lt;li&gt;Fridericia Correction Formula (QTcF) at screening &gt; 450 ms&lt;/li&gt;&lt;li&gt;History             of syncope or family history of idiopathic sudden death&lt;/li&gt;&lt;li&gt;Sustained or clinically             significant cardiac arrhythmias&lt;/li&gt;&lt;li&gt;Risk factors for Torsades de Pointes such as             hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic             bradycardia, or high-grade AV block&lt;/li&gt;&lt;li&gt;Concomitant medication(s) known to prolong the             QT interval (patient must be off the drug for 2 weeks to be eligible)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients who have congestive heart failure (New York heart association [NYHA] class             III or IV), unstable angina, sustained ventricular tachycardia, ventricular             fibrillation, clinically significant bradycardia, advanced heart block or a history             of acute myocardial infarction within the 6 months preceding enrollment&lt;/li&gt;&lt;li&gt;Known history of human immunodeficiency virus (HIV)&lt;/li&gt;&lt;li&gt;Patients who have any severe and/or uncontrolled medical conditions or other             conditions that could affect their participation in the study such as any active             (acute or chronic) or uncontrolled infection/ disorders; non-malignant medical             illnesses that are uncontrolled or whose control may be jeopardized by the treatment             with the study therapy&lt;/li&gt;&lt;li&gt;Women who are pregnant or breast feeding, or women/men able to conceive and unwilling             to practice an effective method of birth control&lt;ul&gt;&lt;li&gt;WOCBP must have a negative serum             pregnancy test within 14 days prior to administration of pasireotide&lt;/li&gt;&lt;li&gt;Oral,             implantable, or injectable contraceptives may be affected by cytochrome P450             interactions, and are therefore not considered effective for this study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Known hypersensitivity to somatostatin analogues or any component of the pasireotide             or octreotide LAR formulations&lt;/li&gt;&lt;li&gt;History of noncompliance to medical regimens&lt;/li&gt;&lt;li&gt;Patients unwilling to or unable to comply with the protocol&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of patients with serious adverse events: safety/tolerability (type, frequency, severity, and relationship of adverse events to study drug)</Description><Timeframe>The end of each participant's 28 day cycle</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of patients with progression free survival (PFS): frequency counts and percentage will be used to summarize the progression-free survival (PFS)</Description><Timeframe>3 months</Timeframe></Measure><Measure><Description>Number of patients with tumor response: tumor response according to response evaluation criteria in solid tumors (RECIST); objective tumor response will be summarized using frequency counts and percentage</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Number of patients with overall survival (OS): frequency counts and percentage will be used to summarize the overall survival (OS) in 6 months period</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Expanded cohort: plasma levels of IGF-I, IGFBP (insulin growth factor binding protein)-1, and IGFBP-3</Description><Timeframe>At baseline and with each restaging CT scan</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In 2013, results were published.Dose limiting toxicities related to &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; were not observed at any dose level.  Hyperglycemia (n = 5), increased bilirubin (n = 2), neutropenia (n = 1), thrombocytopenia (n = 1) and fatigue (n = 1) most common grade 3 or 4 toxicities [&lt;ulink linkType="Reference" linkID="1520670"&gt;1520670&lt;/ulink&gt;]. Similar results were published in January 2014   [&lt;ulink linkType="Reference" linkID="1520682"&gt;1520682&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, results showed that of 16 evaluable patients, there were no DLTs. Common grade 3/4 adverse events were hyperglycemia (n = 5), increased bilirubin (n = 2), neutropenia (n = 1), thrombocytopenia (n = 1) and fatigue (n = 1) [&lt;ulink linkType="Reference" linkID="1517523"&gt;1517523&lt;/ulink&gt;]. Similar results were published [&lt;ulink linkType="Reference" linkID="1697163"&gt;1697163&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this clinical research study was to learn if   &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; (pasireotide) in combination with standard therapy of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (Gemzar) could shrink or slow the growth of pancreatic cancer. The      safety and tolerability of different doses of &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; would also be studied. Patients physical state, changes in the size of the tumor, and laboratory findings      taken while on-study would help to decide if &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; was safe and effective. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In 2013, results were published. Confirmed partial responses (PR) was seen in 2 of 16 evaluable patients (12%) and 9 had stable disease (56%) as best response.Median PFS  and overall survival for all patients were 4.1  and  8.0 months, respectively. MTD was not reached; the cohort at 60 mg was expanded to 10 patients to assess efficacy  [&lt;ulink linkType="Reference" linkID="1520670"&gt;1520670&lt;/ulink&gt;]. Similar results were published in January 2014. Further results showed that, median overall survival was 6.8 months. The median baseline IGF-1 level was lower in patients with stable disease than in progressive disease (63 versus71 ng/ml), the median drop in the level of IGF-1 between the first cycle and the last cycle was more prominent in the stable disease than progressive disease (16 versus 28 ng/ml)  [&lt;ulink linkType="Reference" linkID="1520682"&gt;1520682&lt;/ulink&gt;]. Similar results were published in September 2015 [&lt;ulink linkType="Reference" linkID="1697163"&gt;1697163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, results showed that the higher dose cohort was expanded to 10 patients for efficacy evaluation. The median progression-free and overall survivals were 4.1 and 6.9 months. The median baseline IGF-1 level was lower in patients with stable disease (63 ng/ml) compared with that in progressive disease (71 ng/ml) [&lt;ulink linkType="Reference" linkID="1517523"&gt;1517523&lt;/ulink&gt;]. Similar results were published [&lt;ulink linkType="Reference" linkID="1561099"&gt;1561099&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a single-arm, open-label, phase I study of combination therapy with &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; LAR (long acting release) and      standard treatment with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;. A staggered, sequential dose-escalation      design would be utilized to define the maximum tolerated dose (MTD) of &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; LAR when combined with standard      doses of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;. A cycle would be for  28 days.Treatment would be administered on an outpatient basis. The dose should be based on the patient's actual baseline body weight; the dose      would be recalculated if there is a weight change of &amp;gt; 10% from baseline.&lt;/para&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (1000 mg/m2, iv, over 30 min, weekly, for q3w followed by a 1-week rest      period) and intramuscular dose of &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; (dose determined by the dosing design-dose escalation starting at a lower level 1 of 40 mg), every month.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  received &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; 1000 mg/m2 (30 min, once-weekly iv infusion for 3 out of 4 weeks [days 1, 8 and 15]) and &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; intramuscularly, monthly, according to dose escalation.A 3 + 3 dose escalation design was used and two dose levels (DL) were planned (40 and 60 mg im once a month). Following MTD determination the plan was to expand the cohort to ten more patients to assess efficacy [&lt;ulink linkType="Reference" linkID="1520670"&gt;1520670&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1520682"&gt;1520682&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1697163"&gt;1697163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 20) with previously untreated metastatic pancreatic cancer received &lt;ulink linkType="Drug" linkID="40061"&gt;SOM-230&lt;/ulink&gt; (40 and 60 mg, im, q4w) and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (1000 mg/m2, iv, 3 of 4 weeks) [&lt;ulink linkType="Reference" linkID="1517523"&gt;1517523&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>gemcitabine + pasireotide</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1821">Hyperglycemia</Indication><CountPatientsTotal>16</CountPatientsTotal><CountPatientsAffected>5</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsTotal>16</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication><CountPatientsTotal>16</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsTotal>16</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="192882">gemcitabine</Intervention><Treatments><Treatment><Dose>1000 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="192881">pasireotide diaspartate</Intervention><Treatments><Treatment><Dose>40 milligram</Dose><Route>Intramuscular</Route></Treatment><Treatment><Dose>60 milligram</Dose><Route>Intramuscular</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>H. Lee Moffitt Cancer Center and Research Institute</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8072">Subjects with Locally Advanced Pancreatic Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8073">Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11424">Subjects with Adenocarcinoma of Pancreas</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01385956</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13434">Assessment of serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13352"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pancreas tumor" id="13352"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13359">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Pancreas tumor" id="13361">Assessment of Stable Disease</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13441">Assessment of dose limiting toxicity</SubEndpoint><SubEndpoint disease="Pancreas tumor" id="13444">Assessment of treatment induced toxicity</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pancreas tumor" id="8816"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8817"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8822"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8824">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8827"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8830">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8834"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8835">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Pancreas tumor" id="8836">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Pancreas tumor" id="8837">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8845"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8846">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8854"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8855">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Pancreas tumor" id="8856">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="13485"><Criterion>Subjects with Non-measurable Disease</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="13495"><Criterion>Subjects with Histological Subtypes of Pancreatic Cancer</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="13496">Subjects with Pancreatic adenocarcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="34028"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8857">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pancreas tumor" id="10377"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10378"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10388"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10397"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10399">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>17.06 Months</EnrollmentPeriod><EnrollmentRate>1.17 Patients/Month</EnrollmentRate><DateFirstReceived>2011-06-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-07-05T07:44:57Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-02-03T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2014-12-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="85151"><TitleDisplay>Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma</TitleDisplay><TitleOfficial>Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">11-462</Identifier><Identifier type="NCT">NCT01534078</Identifier></Identifiers><Indications><Indication id="161">Hodgkins disease</Indication></Indications><BiomarkerNames><BiomarkerName id="649" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 17</BiomarkerName><BiomarkerName id="1211" role="Toxic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="2527" role="Toxic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName><BiomarkerName id="5666" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor receptor superfamily member 8</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET scan</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>adriamycin</Name></Intervention><Intervention type="InterventionPrimary"><Name>brentuximab vedotin</Name><Drug id="39172">brentuximab vedotin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>dacarbazine</Name></Intervention><Intervention type="InterventionPrimary"><Name>vinblastine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="39172">brentuximab vedotin</Drug><IndicationsPioneer/><Companies><Company><Company id="15615">Dana-Farber Cancer Institute Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21569">Massachusetts General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="24877">Beth Israel Deaconess Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="25554">Seattle Genetics Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="39172" type="Drug"><TargetEntity id="324218" type="siDrug">Brentuximab vedotin</TargetEntity></SourceEntity><SourceEntity id="15615" type="Company"><TargetEntity id="5000369732" type="organizationId">Dana-Farber Cancer Institute Inc</TargetEntity></SourceEntity><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="24877" type="Company"><TargetEntity id="4295966482" type="organizationId">Beth Israel Deaconess Medical Center Inc</TargetEntity></SourceEntity><SourceEntity id="25554" type="Company"><TargetEntity id="4295901424" type="organizationId">Seattle Genetics Inc</TargetEntity></SourceEntity><SourceEntity id="29603" type="Company"><TargetEntity id="4298207159" type="organizationId">H Lee Moffitt Cancer Center and Research Institute Inc</TargetEntity></SourceEntity><SourceEntity id="161" type="ciIndication"><TargetEntity id="C81" type="ICD10"/><TargetEntity id="201" type="ICD9"/><TargetEntity id="10020206" type="MEDDRA"/><TargetEntity id="D006689" type="MeSH"/><TargetEntity id="98293" type="ORPHANET"/><TargetEntity id="-1008729809" type="omicsDisease"/><TargetEntity id="701" type="siCondition"/></SourceEntity><SourceEntity id="541" type="Action"><TargetEntity id="2493" type="Mechanism">Tubulin Polymerization Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="15615">Dana-Farber Cancer Institute Inc</Company><Company id="24877">Beth Israel Deaconess Medical Center</Company><Company id="25554">Seattle Genetics Inc</Company><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5110">CD30 modulator</Action><Action id="541">Tubulin receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2575">Microtubule inhibitor</Class><Class id="539">Immunotoxin</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="1164">Antibody drug conjugate</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="537">Chimeric antibody</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="171">Monoclonal antibody conjugated</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>34</PatientCountEnrollment><PatientCountEvaluable>34</PatientCountEvaluable><DateStart>2012-03-31T00:00:00Z</DateStart><DateEnd type="actual">2018-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-02-07T13:21:41Z</DateChangeLast><DateAdded>2012-02-29T13:34:51Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Beth Israel Deaconess Medical Center; Boston; Massachusetts; 02215; United States</Affiliation><Name>Jon Arnason</Name></Contact><Contact type="Public contact"><Affiliation>Moffitt Cancer Center/CRU; Tampa; Florida; 33612; United States</Affiliation><Name>Celeste Bello</Name></Contact><Contact type="Public contact"><Affiliation>Massachusetts General Hosptial; Boston; Massachusetts; 02114; United States</Affiliation><Email>JBROWN56@PARTNERS.ORG</Email><Name>Jami Brown</Name><Phone>617-724-9190</Phone></Contact><Contact type="Public contact"><Affiliation>Dana-Farber Cancer Insitute; Boston; Massachusetts; 02215; United States</Affiliation><Email>alacasce@partners.org</Email><Name>Ann Lacasce</Name><Phone>617-632-5959</Phone></Contact><Contact type="Public contact"><Affiliation>H. Lee Moffitt Cancer Center and Research Institute; Tampa; Florida; 33612; United States</Affiliation><Email>elyce.turba@moffitt.org</Email><Name>Elyce Turba</Name><Phone>813-745-1706</Phone></Contact><Contact type="Scientific contact"><Affiliation>Massachusetts General Hospital</Affiliation><Email>jabramson@partners.org</Email><Name>Jeremy Abramson, M.D.</Name><Phone>617-724-4000</Phone></Contact><Contact type="Public contact"><Affiliation>Massachusetts General Hosptial; Boston; Massachusetts; 02114; United States</Affiliation><Email>jabramson@partners.org</Email><Name>Jeremy S Abramson, M.D.</Name><Phone>617-724-4000</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Previously untreated stage IA, IB, IIA or IIB classical Hodgkin lymphoma&lt;/li&gt;&lt;li&gt;Non-bulky disease defined as&amp;lt; 10 cm in maximal diameter&lt;/li&gt;&lt;li&gt;Measurable disease &gt;/= 1.5 cm&lt;/li&gt;&lt;li&gt;ECOG performance status of zero or two&lt;/li&gt;&lt;li&gt;Willing to use two effective forms of birth control&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;No prior chemotherapy or radiotherapy for Hodgkin lymphoma&lt;/li&gt;&lt;li&gt;Not receiving any other investigational agents&lt;/li&gt;&lt;li&gt;No history of allergic reactions attributed to compounds of similar chemical or             biological composition to adriamycin, vinblastine, dacarbazine or&lt;ulink linkType="Drug" linkID="39172"&gt;brentuximab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;No pre-existing &gt;/= grade 3  neuropathy&lt;/li&gt;&lt;li&gt;No uncontrolled intercurrent illness&lt;/li&gt;&lt;li&gt;Not pregnant or breastfeeding&lt;/li&gt;&lt;li&gt;No history of a different malignancy unless disease free for at least one year&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Complete Response Rate: complete response rate at the end of therapy as measured by Positron emission tomography-computed tomography (PET/CT). Response is evaluated using Revised International Working Group Criteria. Complete response is defined as disappearance of all evidence of disease</Description><Timeframe>End of Therapy (median duration of 4 months)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Overall Response Rate After One Cycle of Brentuximab: the number of participants achieving a Partial Response (PR) or Complete Response (CR) after one cycle of Brentuximab monotherapy as measured via PET/CT response. Response is evaluated using the Revised International Working Group Criteria. CR: Disappearance of all evidence of disease. PR: Regression of measurable disease and no new sites</Description><Timeframe>28 days</Timeframe></Measure><Measure><Description>Overall Response Rate: tthe number of participants achieving a Partial Response (PR) or Complete Response (CR) at the end of therapy as measured via PET/CT response. Response is evaluated using the Revised International Working Group Criteria. CR: Disappearance of all evidence of disease. PR: Regression of measurable disease and no new sites</Description><Timeframe>End of Therapy (median duration of 4 months)</Timeframe></Measure><Measure><Description>Grade III or IV Adverse Events: A summary of the grade 3 or 4 adverse events experienced by participants as determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The data is shown as the number of participants that experienced at least one grade 3 or 4 adverse event for each of the specified toxicities</Description><Timeframe>Two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In 2013, results were published. Nausea/vomiting (n = 9), fatigue (n = 7), peripheral neuropathy (n = 6), abdominal pain (n = 6), hepatic transaminitis (n = 5), constipation (n = 5), diarrhea (n = 5), and arthralgias (n = 4) were the most common grade 1-2 adverse events. Neutropenia (n = 7), febrile neutropenia (n = 6) including one case of grade 5 sepsis, and peripheral neuropathy (n = 5) were the most common grade 3 to 4 events. Peripheral neuropathy prompted dose-reduction of &lt;ulink linkType="Drug" linkID="39172"&gt;brentuximab&lt;/ulink&gt; and vinblastine in four patients [&lt;ulink linkType="Reference" linkID="1533949"&gt;1533949&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, results were presented. Due to toxicity one patient was removed. At the end of treatment, due to toxicity two patients were removed. Peripheral neuropathy (74%), fatigue (71%), nausea (24%), neutropenia (68%), anemia (56%), constipation (56%), diarrhea (35%), abdominal pain (32%), ALT increased (29%) and febrile neutropenia (29%) were the most common adverse events (AEs) observed. Grade 3 to 4 AEs including neutropenia, febrile neutropenia and peripheral neuropathy were observed in 56, 29 and 24% of patients, respectively. Death occurred in one patient due to neutropenic sepsis in the first A-AVD cycle. One patient was removed for grade 2 hypersensitivity despite premedication. Brentuximab dose reductions due to AEs were reported in 38% of patients [&lt;ulink linkType="Reference" linkID="1663501"&gt;1663501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, results were presented. Most common adverse events (any grade/grade 1 to 2) reported were nausea (79/76%), peripheral sensory neuropathy (56/56%), fatigue (50/50%), constipation (38/38%), alopecia (35/35%) and neutropenia (24/18%), ALT increased (18/18%), oral mucositis (18 and 18%), rash (18 and 18%), vomiting (18 and 15%), anorexia (15 and 15%), AST increased (15 and 15%), dyspepsia (15 and 15%), anemia (12 and 12%) and headache (12 and 12%), respectively. Grade 3 toxicity included nausea (3%), neutropenia (6%), vomiting (3%). There were no grade 4 or 5 toxicities. Adverse events of special interest were peripheral sensory neuropathy (PSN) and neutropenia. In concern with PSN, a total of 56% of patients had any PSN, and was grade 1 and grade 2 in 50 and 6% of patients and no grade 3 to 4 toxicity was reported; PSN was resolved completely in 13 patients at a median of 1.8 months though follow-up remained brief. In concern with neutropenia, 24% of patients had any neutropenia, grade 3 neutropenia was seen in 6% patients and no grade 4 neutropenia was reported; there was no neutropenic fever and no patients required growth factor support  [&lt;ulink linkType="Reference" linkID="2098827"&gt;2098827&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This open-label study was to evaluate whether &lt;ulink linkType="Drug" linkID="39172"&gt;brentuximab&lt;/ulink&gt; in      combination with AVD (adriamycin, vinblastine and dacarbazine) would be effective and safer in treating limited stage Hodgkin lymphoma.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2015, results were presented. The best complete response (CR) rate was found to be 100%. There were 53% of patients who showed CR following the monotherapy lead in cycle; and 97% of patients showed CR following two cycles of A-AVD. At the end of treatment, 88% of patients were in CR. At a median follow-up of 14 months, the progression free survival and overall survival were found to be 90 and 97%, respectively. At the end of treatment, two patients showed progressive disease, among which one received two more cycles of AVD alone and  returned to complete response [&lt;ulink linkType="Reference" linkID="1663501"&gt;1663501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, results were presented. At interim (post cycle 2) and end of treatment, overall response rate was 100 and 100%, complete response rate was 94 and 100% (primary endpoint), and partial response rate was 6 and 0%, respectively. At a median follow-up of 15 months, the progression-free survival and overall survival were 100% [&lt;ulink linkType="Reference" linkID="2098827"&gt;2098827&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Each treatment cycle would be 28 days. Patients  would receive &lt;ulink linkType="Drug" linkID="39172"&gt;brentuximab&lt;/ulink&gt; (1.2 mg/kg) alone on days 1 and 15 of the      first cycle (lead-in cycle). After cycle 1,  patients  would receive &lt;ulink linkType="Drug" linkID="39172"&gt;brentuximab&lt;/ulink&gt; combined with AVD      (adriamycin [25 mg/m2],  vinblastine [6 mg/m2] and  dacarbazine on [375 mg/m2]) days 1 and 15 for four  to six cycles, depending on patient response to therapy. &lt;ulink linkType="Drug" linkID="39172"&gt;Brentuximab&lt;/ulink&gt; and AVD      would be given  by intravenous  infusion.&lt;/para&gt;&lt;para&gt;The following test and procedures would be performed on days 1 and 15 of each cycle:&lt;/para&gt;&lt;para&gt;Review of any side effects   experienced and all medications taken by patients.&lt;br/&gt;Performance status.&lt;br/&gt;Physical exam and vital signs.&lt;br/&gt;Routine blood tests.&lt;br/&gt;Questionnaire to evaluate symptoms of neuropathy.&lt;br/&gt;Research blood sample to look at markers to see how patient body would respond to study           medication.&lt;br/&gt;PET-CT scan prior to completing cycle 2 of combination &lt;ulink linkType="Drug" linkID="39172"&gt;brentuximab&lt;/ulink&gt;/AVD.&lt;/para&gt;&lt;para&gt;After the final dose of the study drug, the following assessments would be performed within      1 month of patient's last dose of study medication:&lt;br/&gt;Review of any side effects experienced and all medications  taken by patients.&lt;br/&gt;Performance status.&lt;br/&gt;Physical exam and vital signs.&lt;br/&gt;Routine blood tests.&lt;br/&gt;Questionnaire to evaluate symptoms of neuropathy&lt;br/&gt;Research blood sample to look at markers to see how patient's body is responding to study           medication.&lt;/para&gt;&lt;para&gt;PET-CT scan follow-up would include the following:&lt;br/&gt;Review of any side effects  experienced and all medications  taken patient.&lt;br/&gt;Performance status.&lt;br/&gt;Review and physical exam.&lt;br/&gt;Routine blood tests.&lt;br/&gt;Questionnaire to evaluate symptoms of neuropathy.&lt;br/&gt;CT scans.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received brentuximab (1.2 mg/kg) on days 1 and 15 (lead in cycle) followed by a PET scan, and then received four to six cycles of brentuximab plus AVD (A-AVD), based on interim PET CT [&lt;ulink linkType="Reference" linkID="1663501"&gt;1663501&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 34) received brentuximab  1.2 mg/kg plus standard dose adriamycin and dacarbazine on days 1 and 15 of each 28-day cycle. Patients received 4 or 6 cycles of brentuximab - adriamycin and dacarbazine based on the results of an interim PETCT scan performed following cycle 2 [&lt;ulink linkType="Reference" linkID="2098827"&gt;2098827&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="210409">adriamycin</Intervention><Treatments><Treatment><Dose>25 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="210408">brentuximab vedotin</Intervention><Treatments><Treatment><Dose>1.2 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="210731">dacarbazine</Intervention><Treatments><Treatment><Dose>375 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="210730">vinblastine</Intervention><Treatments><Treatment><Dose>6 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Beth Israel Deaconess Medical Center</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02215</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Dana-Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Massachusetts General Hosptial</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Moffitt Cancer Center</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3467">Subjects with Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3468">Subjects with classical hodgkin lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="23733">Subjects with specific Ann Arbor stage</PatientSegment><SubSegments><SubSegment id="3495">Subjects with Ann Arbor Stage I Lymphoma</SubSegment><SubSegment id="3496">Subjects with Ann Arbor Stage II Lymphoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01534078</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7569">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7651"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="30186">Assessment by Peripheral Neuropathy Questionnaire</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7680"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lymphoma" id="7614"><Endpoint>Assessment of Remission</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7615">Assessment of complete remission</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="7669"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="9415"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3442"><Criterion>Subjects with Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3443">Subjects with classical hodgkin lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3469"><Criterion>Subjects with Specific (Ann Arbor) Stage of Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3470">Subjects with stage I lymphoma</SubCriterion><SubCriterion disease="Lymphoma" id="3471">Subjects with stage II lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3497"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3537">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lymphoma" id="3539">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4742"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4756">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4762">Subject with history of radiotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4769">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4783">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26917"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4808">Subjects co-morbid with peripheral neuropathy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-01-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>31.03 Months</EnrollmentPeriod><EnrollmentRate>1.10 Patients/Month</EnrollmentRate><DateFirstReceived>2012-02-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-02-29T13:34:51Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-10-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-02-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-02-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2019-02-08T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-02-08T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-02-08T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-02-08T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="92141"><TitleDisplay>The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases</TitleDisplay><TitleOfficial>The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">770172</Identifier><Identifier type="NCT">NCT00005660</Identifier><Identifier type="Secondary Organisational">77-C-0172</Identifier><Identifier type="Other">NCT00020956</Identifier><Identifier type="Other">CDR0000068733</Identifier><Identifier type="Other">NCI-77-AR-0172</Identifier></Identifiers><Indications><Indication id="1764">Basal cell carcinoma</Indication><Indication id="281">Psoriasis</Indication><Indication id="2960">Keratoderma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>acitretin</Name><Drug id="2417">acitretin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2417">acitretin</Drug><IndicationsPioneer><Indication id="1764">Basal cell carcinoma</Indication><Indication id="281">Psoriasis</Indication><Indication id="2960">Keratoderma</Indication></IndicationsPioneer><Companies><Company><Company id="1069368">National Institutes of Health Clinical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2417" type="Drug"><TargetEntity id="90739" type="siDrug">Acitretin</TargetEntity></SourceEntity><SourceEntity id="1069368" type="Company"><TargetEntity id="5037434896" type="organizationId">National Institutes of Health Clinical Center</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="1764" type="ciIndication"><TargetEntity id="10004146" type="MEDDRA"/><TargetEntity id="D002280" type="MeSH"/><TargetEntity id="-1901373975" type="omicsDisease"/><TargetEntity id="670" type="siCondition"/></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="753" type="Action"><TargetEntity id="952" type="Mechanism">Retinoid RAR Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20519">National Cancer Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1069368">National Institutes of Health Clinical Center</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="753">Retinoic acid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Prospective</Term><Term>Interventional</Term><Term>Observational</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>130</PatientCountEnrollment><DateStart>1977-10-31T00:00:00Z</DateStart><DateEnd type="actual">2001-11-01T00:00:00Z</DateEnd><DateChangeLast>2016-09-23T06:01:41Z</DateChangeLast><DateAdded>2012-09-25T08:26:52Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with widespread involvement (eg, psoriasis patients with 10% or more of        body surface area involved) or with severe, recalcitrant localized involvement with a        cutaneous disorder (eg, keratoderma palmaris et plantaris)&lt;/li&gt;&lt;li&gt;Patients (and parents of patients who are&amp;lt; 18 years old) must be advised of        presently available alternative forms of therapy&lt;/li&gt;&lt;li&gt;Patient must be available for and agreeable to regular follow up examinations in the clinic        for clinical evaluation, blood tests, diagnostic X-rays and possibly skin biopsies&lt;/li&gt;&lt;li&gt;The patient (and parent, guardian, or surrogate where appropriate) must give written        informed consent after protocol, including its limitations and risks, are thoroughly        discussed with the patients (and parents)&lt;/li&gt;&lt;li&gt;Patients who have multiple skin cancers because of xeroderma pigmentosum (XP)&lt;/li&gt;&lt;li&gt;No patients with persistently abnormal (SGOT or SGPT &gt; 3 x the upper limit        of normal) liver function tests&lt;/li&gt;&lt;li&gt;No patients with persistent pre-treatment hypertriglyceridemia (&gt; 300 mg/dl)&lt;/li&gt;&lt;li&gt;No patients with persistently abnormal (creatinine &gt; 3 x the upper limit of        normal) renal function tests&lt;/li&gt;&lt;li&gt;No patients with presence of a significant neurological, musculoskeletal or other internal        medical disorder which may be aggravated by the addition of retinoid therapy&lt;/li&gt;&lt;li&gt;Patient must not be pregnant or anticipate such an event.  Because of the long-term storage        of etretinate, a known teratogen, fertile women who may be treated in this protocol, must        have skin disease that is severe and recalcitrant to all other standard modalities.  These        women must also use an effective form of contraception (oral contraceptives or an        intrauterine device) while on treatment and at least for three years post-treatment&lt;/li&gt;&lt;li&gt;No patients with chronic intake of excessive dietary vitamin A (&gt; 25,000 IU/day)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was an observational  , continuing study which evaluates the long-term safety and efficacy of oral      &lt;ulink linkType="Drug" linkID="2417"&gt;acitretin&lt;/ulink&gt; in an open manner in the treatment of psoriasis, cutaneous disorders of      keratinization, multiple basal cell carcinomas and other retinoid responsive diseases.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive oral &lt;ulink linkType="Drug" linkID="2417"&gt;acitretin&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>National Cancer Institute (NCI)</Name><Address1>Bethesda</Address1><Address2>Maryland</Address2><Address3>20892</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3438">Subjects with Localized Psoriasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3451">Subjects with Moderate Psoriasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3452">Subjects with Severe Psoriasis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Melanoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3656">Subjects at risk of developing disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00005660</Identifier><Identifier>NCT00020956</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6597"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Psoriasis" id="6638"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6652">Therapy/Intervention Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Basal cell carcinoma" id="13102"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Basal cell carcinoma" id="13111">Assesment of Efficacy Parameter</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Melanoma" id="7025"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Melanoma" id="7036"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Melanoma" id="7038">Assessment of Efficacy End Points</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="3289"><Criterion>Subjects with Localized Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3296"><Criterion>Subjects with Moderate Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3297"><Criterion>Subjects with Severe Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3348"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="3359">Subjects co-morbid with cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="4114"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Melanoma" id="4164"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4165">Subjects with other skin cancers</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Basal cell carcinoma" id="12909"><Criterion>Subjects with Multiple Basal Cell Carcinoma (BCC)</Criterion></Inclusion><Inclusion disease="Basal cell carcinoma" id="12916"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Basal cell carcinoma" id="12944"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Basal cell carcinoma" id="12946">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Basal cell carcinoma" id="34036"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Basal cell carcinoma" id="12947">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Basal cell carcinoma" id="34265"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Basal cell carcinoma" id="12904">Subjects at High Risk for Basal Cell Carcinoma (BCC)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Psoriasis" id="35063"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="22333">Subjects with Protocol Specified Body Surface Area Involvement</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Psoriasis" id="4532"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4536"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4538"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4586"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4588">Subjects with abnormal renal function tests</SubCriterion><SubCriterion disease="Psoriasis" id="4589">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Melanoma" id="5456"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Melanoma" id="5463"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Melanoma" id="5547"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Basal cell carcinoma" id="10520"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Basal cell carcinoma" id="10521"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Basal cell carcinoma" id="10556"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Melanoma" id="20280"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="5450">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Basal cell carcinoma" id="26351"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Basal cell carcinoma" id="10532">Subjects with abnormal/unacceptable liver function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Government</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-09-25T08:26:52Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="93495"><TitleDisplay>A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis</TitleDisplay><TitleOfficial>A Double-Blind, Randomized, Single-Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving 2 Weeks of Treatment</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">122-0551-203</Identifier><Identifier type="NCT">NCT01700985</Identifier></Identifiers><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>steroid therapy (topical lotion, psoriasis, TPM), Phosphagenics/Therapeutics</Name><Drug id="70259">steroid therapy (topical lotion, psoriasis, TPM), Phosphagenics/Therapeutics</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="70259">steroid therapy (topical lotion, psoriasis, TPM), Phosphagenics/Therapeutics</Drug><IndicationsPioneer/><Companies><Company><Company id="1019957">Therapeutics Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1019957" type="Company"><TargetEntity id="5035941850" type="organizationId">Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1019957">Therapeutics Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="15183">Topical antipsoriatic product</Class><Class id="2954">Steroidal anti-inflammatory</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>44</PatientCountEnrollment><DateStart>2012-05-31T00:00:00Z</DateStart><DateEnd type="actual">2013-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-27T05:17:25Z</DateChangeLast><DateAdded>2012-10-08T12:51:37Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Therapeutics, Inc.</Affiliation><Name>Syd Dromgoole, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has a clinical diagnosis of stable plaque psoriasis&lt;/li&gt;&lt;li&gt;Subject has an ODS score for the Treatment Area of 3 or 4 at study start&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject has spontaneously improving or rapidly deteriorating plaque psoriasis&lt;/li&gt;&lt;li&gt;Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis&lt;/li&gt;&lt;li&gt;Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid             therapy within 30 days prior to study start&lt;/li&gt;&lt;li&gt;Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous             products within 90 days prior to study start&lt;/li&gt;&lt;li&gt;Subject has used any systemic biological therapy for the treatment of psoriasis within              five half-lives of the biological prior to study start&lt;/li&gt;&lt;li&gt;Subject had prolonged exposure to natural or artificial sources of ultraviolet             radiation within 30 days prior to study start&lt;/li&gt;&lt;li&gt;Subject has used topical body (excluding the scalp) psoriasis therapy including coal             tar, anthralin, steroids, retinoids, vitamin D analogs (eg, Dovonex) within 14             days prior to study start&lt;/li&gt;&lt;li&gt;Subject has used emollients/moisturizers on areas to be treated within 4 h             prior to clinical evaluation at study start&lt;/li&gt;&lt;li&gt;Subject is currently using lithium or plaquenil (hydroxychloroquine)&lt;/li&gt;&lt;li&gt;Subject is currently using a beta-blocking medication (eg, propanolol) or ACE             (eg, lisinopril) inhibitor at a dose that has not been stabilized&lt;/li&gt;&lt;li&gt;Subject is pregnant, lactating, or is planning to become pregnant during the study&lt;/li&gt;&lt;li&gt;Subject is currently enrolled in an investigational drug or device study&lt;/li&gt;&lt;li&gt;Subject has used an investigational drug or investigational device treatment within             30 days prior to study start&lt;/li&gt;&lt;li&gt;Subject has been previously enrolled in this study and treated with a test article&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in Overall Disease Severity (ODS) score: the percentage of subjects with ODS 'treatment success' at EOS where EOS is the subject's last completed visit. 'Treatment success' is defined as an ODS of 0 or 1. ODS is measured on a 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe/very severe</Description><Timeframe>Baseline and day 15 (End of Study - EOS)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>ODS 'treatment success' at days 8 and 15: the proportion of subjects with ODS 'treatment success' at day 8 and day 15</Description><Timeframe>Baseline, days 8 and 15</Timeframe></Measure><Measure><Description>ODS 'improved' at days 8 and 15: the proportion of subjects rated 'improved' with respect to ODS at days 8 and 15.  'Improved' is defined as at least a 2 grade decrease in ODS score relative to baseline</Description><Timeframe>Baseline, days 8 and 15</Timeframe></Measure><Measure><Description>'Treatment success' for clinical signs and symptoms of psoriasis: the proportion of subjects rated 'treatment success' for each of the clinical signs and symptoms of psoriasis (scaling, erythema, plaque elevation) at days 8 and 15</Description><Timeframe>Baseline, days 8 and 15</Timeframe></Measure><Measure><Description>'Improved' for clinical signs and symptoms of psoriasis: the proportion of subjects rated 'improved' for each of the clinical signs and symptoms of psoriasis (scaling, erythema, plaque elevation, pruritus) at days 8 and 15</Description><Timeframe>Baseline, days 8 and 15</Timeframe></Measure><Measure><Description>Change in % body surface area (BSA) with psoriasis: changes in % BSA with active psoriasis in the Treatment Area at days 8 and 15</Description><Timeframe>Baseline, days 8 and 15</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was designed to      determine and compare the efficacy and safety of a formulation of 122-0551 (&lt;ulink linkType="Drug" linkID="70259"&gt;steroid therapy&lt;/ulink&gt;) versus the      corresponding vehicle in subjects with stable plaque psoriasis after twice daily dosing for      14 consecutive days.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either vehicle or 122-0551 (&lt;ulink linkType="Drug" linkID="70259"&gt;steroid therapy&lt;/ulink&gt;) twice-daily for 2 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Therapeutics Clinical Research</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92123</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>DermResearch, Inc.</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78759</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3434">Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01700985</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6492"><Endpoint>Disease Severity Assessment by Other Scales</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6495">Overall disease severity score (ODSS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Psoriasis" id="6492"><Endpoint>Disease Severity Assessment by Other Scales</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6495">Overall disease severity score (ODSS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6540"><Endpoint>Changes in Characteristics of Skin/Lesion</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6594">Body surface area (BSA%) involvement</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6638"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6652">Therapy/Intervention Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="3285"><Criterion>Subjects with Plaque Psoriasis/Psoriasis Vulgaris</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3298"><Criterion>Subjects with Specific Disease Activity</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="3302">Subjects with stable/stationary psoriasis</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Psoriasis" id="4509"><Criterion>Subjects with Other Specific Forms of Psoriasis</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4564"><Criterion>Subjects with History of/Scheduled for Psoriasis Treatment</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4572">Subjects with history of/scheduled for phototherapy/photochemotherapy</SubCriterion><SubCriterion disease="Psoriasis" id="4573">Subjects with history of/scheduled for topical therapy</SubCriterion><SubCriterion disease="Psoriasis" id="5041">Subjects with history of/scheduled for biologics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Psoriasis" id="25154"><Criterion>Subjects with specific disease subtype</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4510">Subjects with Erythrodermic Psoriasis</SubCriterion><SubCriterion disease="Psoriasis" id="4511">Subjects with Guttate Psoriasis</SubCriterion><SubCriterion disease="Psoriasis" id="4512">Subjects with Pustular Psoriasis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-09-27T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-08T12:51:37Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>